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Preface 
 
Despite significant advances in the treatment of various types of cancer over the past 
decades, there is still a fundamental need to improve tumour response rates and survival in 
patients with advanced cancer. Besides development of new chemotherapeutic agents, 
existing therapies could be modified to achieve these goals. The intensity of cancer treatment 
is of paramount importance for the response of the patient. Nowadays, in most therapies 
systemic exposure is solely calculated on the basis of drug-dose administered per unit time 
(dose-intensity). This does not take into account pharmacokinetic variability. Anticancer drugs 
generally display significant pharmacokinetic variability and systemic exposure can differ 
several-fold amongst patients given an equivalent dosage possibly resulting in differences in 
success of treatment.[1]  
The anticancer agent ifosfamide is a prodrug that requires metabolic activation to exert its 
cytotoxic activity. The first step in the bioactivation pathway occurs mainly in the liver by action 
of the cytochrome P450 producing 4-hydroxyifosfamide. This intermediate is subject to further 
activation to yield the alkylating metabolite ifosforamide mustard with concomitant release of 
the urotoxic metabolite acrolein. Ifosfamide is also deactivated to 2- and 3-
dechloroethylifosfamide, which is accompanied by an equimolar formation of the neurotoxic 
chloroacetaldehyde.[2] Ifosfamide pharmacokinetics is further characterized by a time-
dependent increase in metabolic clearance explained by a mechanism of autoinduction of the 
hepatic oxygenase system.  
Pharmacokinetics of ifosfamide and metabolites show a large inter- and intraindividual 
variability. The determinants (patient characteristics, concomitant medication, autoinduction, 
infusion schedule, dose, etc.) of this variability were not yet known in detail. Furthermore, 
relationships between pharmacokinetics and pharmacodynamics were scanty. Particularly 
correlations between plasma levels of metabolites and toxicity and/or antitumour activity were 
lacking. On the one hand this may be due to the lack of tools for the investigation the 
determinants of varibility and on the other hand the lack of relatively complex methodologies 
necessary for the analysis of metabolites in biological matrices. The analysis is also 
hampered by the limited stability of the analytes in plasma and urine. Therefore, new sensitive 
and validated assay, which can be routinely used, needed to be developed for the quantitative 
determination of ifosfamide, 2- and 3-dechloroethylifosfamide, 4-hydroxyifosfamide and 
ifosforamide mustard in biological matrices. These methods were based on the techniques of 
gas chromatography, either with nitrogen-phosphorous detection or ion-trap mass 
spectrometry and liquid chromatography (after derivatization). 
The implementation of pharmacokinetic monitoring of ifosfamide and metabolites in clinical 
studies offers a unique possibility to study pharmacokinetic variability and pharmacokinetic-
pharmacodynamic relationships in ifosfamide therapy. However, for practical and ethical 
reasons extensive pharmacokinetic and pharmacodynamic studies in a large number of often 
critically ill patients are not possible. Therefore, there was a need for an approach with the 
help of which description of the relevant pharmacokinetic and pharmacodynamic relationships 
and of their variability is possible on the basis of sparse data (few data points-per patient) 
collected under unbalanced designs. A population approach also allows therapeutic drug 
monitoring of ifosfamide. Therapeutic drug monitoring can help in further tailoring ifosfamide 
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treatment to the specific needs of the individual patient.  
The aims of the research described in this thesis were to develop bioanalytical methods for 
determination of ifosfamide and its metabolites, to build population pharmacokinetic models 
for these compounds and to apply the techniques in various clinical studies on ifosfamide. 
New insights in the pharmacokinetics of ifosfamide and its metabolites may contribute to the 
development of new ifosfamide therapies with increased efficacy and/or decreased toxicities. 
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Clinical pharmacokinetics and pharmacodynamics of  
ifosfamide and its metabolites 
 
 
Summary 
 
This review will discuss several issues in the clinical pharmacology of the anti-tumour agent 
ifosfamide and its metabolites. Ifosfamide is effective in a large number of malignant 
diseases. Its use, however, can be accompanied by haematological, neuro- and 
nephrotoxicities. Since its development in the middle of the 1960’s, most of its extensive 
metabolism has been elucidated. Identification of specific isoenzymes responsible for 
ifosfamide metabolism may lead to an improved efficacy/toxicity ratio by modulation of the 
metabolic pathways. Whether ifosfamide is specifically transported by erythrocytes and 
which activated ifosfamide metabolites play a key role in this transport is currently being 
debated. In most clinical pharmacokinetic studies the phenomenon of autoinduction has been 
observed, but the mechanism is currently not completely understood. Assessment of the 
pharmacokinetics of ifosfamide and metabolites has long been impaired by the lack of 
reliable bioanalytical assays. The recent development of improved bioanalytical assays has 
changed this dramatically allowing extensive pharmacokinetic assessment, identifying key 
issues like population differences in pharmacokinetic parameters, differences in elimination 
dependent upon route and schedule of administration, implications of the drug chirality and 
interpatient pharmacokinetic variability. The mechanisms of action of cytotoxicity, 
neurotoxicity, urotoxicity and nephrotoxicity have been pivotal issues in the assessment of 
the pharmacodynamics of ifosfamide. Correlations between the new insights into ifosfamide 
metabolism, pharmacokinetics and pharmacodynamics rationalize the further development of 
therapeutic drug monitoring and dose individualization of ifosfamide treatment. 
Development 
 
The oxazaphosphorines ifosfamide, N,3-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxaza-
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phosphorin-2-amine 2-oxide (HoloxanÒ), cyclophosphamide and to a lesser extent, 
trofosfamide, mafosfamide, sufosfamide and glufosfamide play an important role in the 
treatment of various tumours.[1-3] Oxazaphosphorines are nitrogen mustard derivatives, as 
depicted in figure 1. During World War I chemical warfare with mustard gasses had produced 
leukocytopenia, bone marrow aplasia and lymphatic tissue dissolution. Gilman, Goodman and 
Dougherty evaluated these effects of nitrogen mustard on transplanted lymphosarcoma in 
murine models during the early 1940’s.[4,5] Shortly after, the first modern clinical testing of 
chemotherapy led to the discovery of cyclophosphamide. Ifosfamide has been developed in 
the middle of the 1960’s as structural isomer of cyclophosphamide and introduced as an anti-
cancer agent in the early 1970’s.[6,7]  
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Figure 1. Oxazaphosphorines 
 
Early pre-clinical testing of ifosfamide proved superior activity over cyclophosphamide, but 
initial trials in the 1970’s resulted in severe dose-limiting haemorrhagic cystitis.[8] Although 
urotoxicity could be minimized by fractionated dosage regimens and increased hydration, it 
remained the main dose-limiting toxicity. In the 1980’s it became clear that the ifosfamide 
metabolite acrolein was responsible for the urotoxicity.[2] The antidotes sodium 2-
mercaptoethane sulphonate (mesna, UromitexanÒ) and acetylcysteine were developed, 
which specifically react with acrolein in the urinary tract thereby preventing haemorrhagic 
cystitis without hampering ifosfamide cytotoxicity in blood and tissue.[9] Co-administration of 
mesna enabled further (high dose) regimen development with ifosfamide in clinical trials.[10] 
 
Metabolism 
 
Ifosfamide is a prodrug which needs activation via the cytochrome P450 enzymatic system in 
the liver to 4-hydroxyifosfamide. 4-Hydroxyifosfamide exists in equilibrium with its tautomeric 
form aldoifosfamide. Aldoifosfamide can be converted into the final alkylating agent 
ifosforamide mustard with concurrent acrolein formation, as depicted in figure 2. After ß-
elimination of acrolein from 4-hydroxyifosfamide, the cytotoxic ifosforamide mustard is 
formed.[11] Acrolein is held responsible for the urotoxic effects of ifosfamide. Alkylation of DNA 
by ifosforamide mustard can cause cross-links, resulting in cytotoxicity. Ifosforamide mustard 
is also known to yield the metabolites chloroethylamine and 1,3-oxazolidine-2-one.[12]  
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Figure 2. Ifosfamide metabolism 
 
Furthermore, 4-hydroxyifosfamide is metabolized to the inactive metabolites 4-ketoifosfamide 
and 4-thioifosfamide, and its tautomer aldoifosfamide to carboxy-ifosfamide and 
alcoifosfamide. Ifosfamide is also subject to deactivation routes that involve  removal of a 
chloroethylgroup from either the exo- or endocyclic nitrogen atom to form non-toxic 2-
dechloroethylifosfamide and 3-dechloroethylifosfamide, respectively. Dechloro-ethylation is 
achieved by a side-chain oxidation, releasing an equimolar amount of the potentially 
neurotoxic chloroacetaldehyde[13], as represented in figure 2. Chloroacetaldehyde may also 
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be involved in the urotoxicty observed in ifosfamide treatment.[14] 
 
Cytochrome P450  
 
Much research has been devoted to the metabolism of ifosfamide in the rat. Activation and 
deactivation of ifosfamide in vivo and in rat liver microsomes proved to be mediated by 
different cytochrome P450 isoenzymes 3A (CYP3A) plus CYP2B1/CYP2C11 and CYP3A, 
respectively.[15-18] Proof of differential enantioselective metabolism in rats was given, the 
specific isoenzymes responsible for metabolism in rats, however, differed significantly from 
humans.[19] Furthermore, corresponding P450 enzymes may perform different metabolic 
functions in different species, which hampers extrapolation of results obtained from laboratory 
animals to humans. In humans both activation (hydroxylation) and deactivation 
(dechloroethylation) demonstrated to be mediated by the CYP3A4.[20-22] Paradoxically, the 
mixed function CYP3A4 performs both desired hydroxylation and undesired 
dechloroethylation, making it a target for development of specific inhibition or hetero-induction 
regimens and thereby directing ifosfamide metabolism to a more favourable toxicity-efficacy 
profile. Other isoenzymes have also been implicated with ifosfamide metabolism. Human liver 
microsomes have demonstrated enantioselective metabolism.[23] This in vitro study 
supported the conclusion that CYP2B6 and not CYP3A4 were responsible for the formation of 
(S)-3- and (S)-2-dechloroethylifosfamide. Another study suggested that (R)-ifosfamide might 
have a more favourable efficacy/toxicity profile, due to enantioselective differences of CYP3A4 
and CYP2B6.[24] The activity of CYP2B6 in the in vitro metabolization of ifosfamide was also 
demonstrated in isolated cDNAs.[25] Furthermore, CYP2B1 has also proven to metabolize 
ifosfamide, yielding a cytotoxic effect in human cell lines in vitro.[26] There is no definite 
answer, whether CYP3A4 is the only in vivo relevant enzyme in the metabolism of ifosfamide, 
or if other isoenzyme contribute. Secondary isoenzyme metabolism may also be important, 
because a blockade of the main metabolic isoenzyme of ifosfamide by for instance co-
administrated drugs could render lower affinity isoenzymes into relevant metabolic pathways. 
Modulation of metabolism of ifosfamide, however, has not been successful till now.[27] Failure 
of modulation could be explained by the simultaneous administration of phenobarbital with 
ifosfamide, which did not allow for enzyme induction to develop. 
Another way to direct metabolism of ifosfamide is gene transfer of CYP in tumour cells.[26,28] 
Especially, the tumour bystander effect has been identified as a possible effective strategy. 
The tumour bystander effect will result in more widespread cytotoxicity in the tumour. 
Although only a small subset of tumour cells will be successfully transfected, their CYP 
upregulation will provide local elevated metabolism of ifosfamide, thus spreading the 
diffusable cytotoxic metabolites to adjacent and more distant non-transfected tumour cells 
and greatly enhancing the anti-tumour effect.[29] 
The different isoenzymes that have been identified demonstrate the need to consider 
interaction with co-administered drugs that are also CYP3A4 substrates. Concomitant 
therapy with inducers of CYP3A4 (e.g. rifampicin, carbamazepine, phenobarbitone and 
phenytoin) enhances the expression of this enzyme and may increase metabolic activation, 
possibly resulting in enhanced efficacy and toxicity.[30] Phenytoin induced a shift in 
enantioselective dechloroethylation in children, possibly increasing ifosfamide efficacy.[31] In 
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contrast inhibitors and substrates of CYP3A4 (e.g. erythromycin, ketoconazole, itraconazole, 
diltiazem, verapamil and cyclosporin) could interfere with the activation of ifosfamide.[32] Vice-
versa, ifosfamide could also be able to influence other co-administered drugs, possibly 
reducing the therapeutic effect of the latter.[33] However, the clinical significance of the 
changes in pharmacokinetics of or caused by ifosfamide resulting from CYP3A4 inhibition and 
induction are not well established yet. 
 
Autoinduction 
 
Metabolism of ifosfamide is an autoinducible enzymatic process, resulting in an increased 
clearance over time.[34] The exact physiological mechanism of the autoinduction of ifosfamide 
is unknown, but several mechanisms of drug induced metabolic changes have been reported 
for other compounds. For most of these drugs the amount of enzymes performing the 
metabolic breakdown is increased via de novo synthesis. For instance, the barbiturate 
pentobarbital induces nortriptyline metabolism by increasing translation of the DNA coding for 
the enzyme and thereby increasing clearance of systemic nortriptyline. De novo synthesis of 
CYP by pentobarbital was observed after two days.[35] Rapid autoinduction of carbamazepine 
due to de novo synthesis was already demonstrated after 12-24 hours with a maximum after 
six weeks.[36] Autoinduction of ifosfamide has been observed within 24 hours after start of 
treatment.[37] However, it is unlikely that an alkylating agent like ifosfamide (which reduces 
DNA/RNA and protein synthesis) would increase enzyme protein synthesis of CYP. On the 
other hand, non-transcriptional induction mechanism has also been demonstrated to produce 
drug induced metabolic changes. Troleandomycin decreased the rate of the CYP3A4 protein 
degradation by interacting with specific catalytic enzymes, which resulted in an increased 
pool of CYP3A4 protein.[38] An uncommon interaction of a drug with its metabolising enzyme 
has been demonstrated for phenobarbital, as it achieved a direct influence on the enzyme.[39] 
By binding of the drug to a non-catalytic site of the enzyme, the catalytic ability increased due 
to an altered spin state of the haemoprotein of the CYP. Ifosfamide has been shown to reduce 
protein synthesis[40] and as such may reduce synthesis of proteins responsible for CYP3A4 
degradation/inactivation, which resulted in decreased ifosfamide clearance. The protein 
reducing ability of ifosfamide and the high rate of autoinduction suggest that this mechanism 
of autoinduction is the most viable option, but further research is warranted to prove this 
hypothesis.  
 
Metabolite distribution 
 
In general, pharmacokinetics are mainly assessed using plasma, urine and/or erythrocytes. 
Erythrocytes are of special interest in the pharmacokinetics of ifosfamide, because they have 
been proposed to act as transporters of activated ifosfamide and cyclophosphamide.[41-44] 
Plasma concentrations of 4-hydroxycyclophosphamide, the activated metabolite of 
cyclophosphamide, could be detected in low but persistent levels. This led to the theory that, 
4-hydroxycyclophosphamide is trapped intracellularly and in this way act as the transport form 
of activated cyclophosphamide.[45,46] This hypothesis was confirmed by comparing 
hypothetical total cell-kill percentages of 4-hydroxy-cyclophosphamide and phosphoramide 
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mustard, based upon plasma levels in mice, rats and humans and anti-tumour sensitivity of 
mice and human cell cultures to these compounds.[11] Extracellular 4-hydroxy-
cyclophosphamide exhibits a more profound cytotoxicity than phosphoramide mustard, 
caused by its higher penetration capacity of the tumour cell membranes. In contrast to these 
findings other groups have argued that the ifosforamide mustard is the major transport form 
of ifosfamide, since the anti-tumour activity and selectivity of extracellular delivered 
ifosforamide mustard was comparable to 4-hydroxyifosfamide.[47] It has also been suggested 
that ifosfamide is bioactivated in the liver to ifosforamide mustard. Subsequently, ifosforamide 
mustard is loaded onto or into the erythrocyte.[43] The erythrocyte will transport ifosforamide 
mustard to the target tissue by interacting with the capillary endothelium and consequently 
releasing ifosforamide mustard into the target tissue. Furthermore, it was demonstrated that 
erythrocytes from five ifosfamide treated patients contained as much as 77% of the total 
whole blood concentration of ifosforamide mustard, resulting in a ratio of the area under the 
curve of erythrocytes over plasma of 2.7.[43] At present, the implications whether 4-hydroxy-
ifosfamide or ifosforamide mustard is the activated transport form of ifosfamide are not clear. 
 
Bioanalysis 
 
Pharmacokinetic assessment of ifosfamide and its metabolites have long been hampered by 
the lack of reliable, specific and selective bioanalytical methods.[48,49] During the last decade 
validated assays have been developed enabling quantitative determination of ifosfamide and 
its metabolites using various techniques, as represented in table 1.[13,50-80] Modern, 
bioanalytical methods require high sample-throughput, accuracy and precision in a clinically 
relevant concentration range, when applied in clinical pharmacokinetic studies. Furthermore, 
activated oxazaphosphorine metabolites have relati-vely short elimination half-lives, which 
necessitates stabilization steps to prevent undesired (auto-catalytic) degradation.  
Table 1. Methods for the analysis of ifosfamide and its metabolites in various biological matrices, 
applicable for clinical pharmacokinetic studies. 
 
Method Analyte Matrix Derivatization Clean-up LLQ Reference 
TLC-PD IF U - SPE 1 µg/ml Lind et al.[50] 
TLC-VIS IF U PBH -  Norpoth et al.[13] 
TLC-PD IF, DCE, CI, KI, 4OH, IFM U, C, P NBP SPE 1 µg/ml Boddy et al.[51] 
31P-NMR IF in vivo - -  Payne et al.[52] 
31P-NMR IF, 2DCE, 3DCE, CI, IFM U - SPE  Gillard et al.[53] 
31P-NMR IF, 2DCE, 3DCE, KI, 4OH U - -  Martino et al.[54] 
HPLC-UV IF P - SPE 1 µg/ml Burton et al.[55] 
HPLC-UV IF P - LLE 0.1 µg/ml Margison et al.[56] 
HPLC-UV IF P - SPE 6 µg/ml Zolezzi et al.[57] 
HPLC-UV 2DCE, 3DCE U - LLE 2-5 µM Goren et al.[58] 
HPLC-UV r/s-IF P - SPE 2.50 µg/ml Corlett et al.[59] 
HPLC-UV r/s-IF P - LLE 10 µg/ml Masurel et al.[60] 
HPLC-UV CA P TU SPE 1 nM Kaijser et al.[61] 
HPLC-UV 4OHIF P 3AP - 50 nM Kaijser et al.[62] 
HPLC-UV 4OHIF WB 3AP - 0.1 µM Kurowski et al.[63] 
HPLC-UV 4OHIF P, E SCZ LLE 0.1 µg/ml Kerbusch et al.[64] 
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HPLC-UV IFM P DDTC SPE 0.45 µM Kaijser et al.[65] 
HPLC-UV IFM, IF P DDTC LLE 0.1 µg/ml Kerbusch et al.[66] 
GC-NPD IF P - LLE 0.5 µg/ml Mehta et al.[67] 
GC-NPD IF P - LLE 1 µg/ml Talha et al.[68] 
GC-NPD IF, 2DCE, 3DCE P, U - LLE 0.05 µg/ml Kaijser et al.[69] 
GC-NPD IF, 2DCE, 3DCE P - LLE 0.5, 5, 5 µM Kurowski et al.[63] 
GC-NPD IF, 2DCE, 3DCE P - LLE 0.05 µg/ml Kerbusch et al.[70] 
GC-NPD r/s-IF, r/s-2DCE, r/s-3DCE P, U, C - LLE 0.02, 0.1, 0.05 
µg/ml 
Kaijser et al.[71] 
GC-NPD IF, 2DCE, 3DCE, 4OHIF P PFBHA LLE 0.8-3.25 µg/ml Gourmel et al.[72] 
GC-NPD IFM P TFAA SPE 0.25 µg/ml Bryant et al.[73] 
GC-FID IF P - LLE 1 µg/ml Allen et al.[74] 
GC-ECD CA WB - LLE 0.2 µM Kurowski et al.[63] 
FAB-MS IF-mesna U - LLE  Manz et al.[75] 
GC-MS IF P - LLE 0.01 µg/ml Lambrechts et al.[76] 
GC-MS IF, 2DCE, 3DCE, KI, CI, IFM, 
CEA, OXAZ 
P TFAA SPE 
LLE 
3 ng/ml Momerency et al.[77] 
GC-MS r/s-IF P - SPE 0.25 µg/ml Young et al.[78] 
GC-MS r/s-IF, r/s-2DCE, r/s-3DCE P, U - LLE 0.25, 0.5, 0.5 µg/ml Granville et al.[79] 
GC-MS IF, 2DCE, 3DCE, 4OH, IFM P CH, MSTFA, 
BSTFA, TMSI 
LLE 
SPE 
0.1-0.5 µg/ml Wang et al.[80] 
 
TLC=thin layer chromatography, PD=photography-densitometry, VIS=visible light spectroscopy, 31P-NMR=31P nuclear magnetic 
resonance spectroscopy, HPLC=high-performance liquid chromatography, UV=ultraviolet detection, GC=gas chromatography, 
NPD=nitrogen phosphorus selective detection, FID=flame ionization detection, ECD=electron capture detection, FAB=fast atom 
bombardment, MS=mass spectrometry, IF=ifosfamide, 2DCE=2-dechloroethylIF, 3DCE=3-dechloroethylIF, CI=carboxyIF, 
KI=ketoIF, 4OH=4-hydroxyIF, IFM=ifosforamide mustard, CEA=chloroethylamine, OXAZ=1,3-oxazolidine-2-one, P=plasma, 
U=urine, E=erythrocytes, C=cerebro-spinal fluid, WB=whole blood, PBH=4-pyridinealdehyde-2-benzothiazolylhydrazone, 
NPB=4-(4-nitro-benzyl)pyridine, TU=thiourea, 3AP=3-aminophenol, SCZ=semicarbazide, DDTC=diethyldithiocarbamate, 
TFAA=trifluoroacetic anhydride, PFBHA=O-(2,3,4,5,6-pentafluorobenzyl)hydroxylamine, CH=cyanohydrin, MSTFA=N-methyl-
N-trimethylsilyltrifluoro-acetamide, BSTFA=N,O-bis(trimethylsilyl)trifluoroacetamide, TMSI=N-trimethylsilylimidazole, LLE=liquid-
liquid extraction, SPE=solid-phase extraction. 
 
Nowadays several types of analytical separation are used. Thin layer chromatography with 
various detection methods is easy to apply, but is hampered by cross-selectivity and low 
sensitivity. A more elaborate and expensive method is nuclear magnetic resonance 
spectroscopy (NMR), which has been used to identify new metabolites of oxazaphosphorines 
and determination of ifosfamide concentrations in vivo.[52] 
More established techniques are high-performance liquid chromatography and gas 
chromatography. High-performance liquid chromatography is easy to use, but due to its 
undiscriminating detection at lower wavelengths (200-300 nm) a labour-intensive sample 
preparation is required to separate the analytes from interfering plasma components. The 
problems of the rapid auto-catalytic degradation of ifosforamide mustard and 4-hydroxy-
ifosfamide and their lack of a suitable chromophore was solved by immediate controlled 
derivatization.[66,64] Gas chromatography, on the other hand, quantifies volatile analytes. Gas 
chromatography can be very selective and sensitive, but the analytes need to be thermally 
stable, excluding 4-hydroxyifosfamide and ifosforamide mustard.[81] Due to its selectivity, for 
gas chromatography with nitrogen-phosphorus detection a simple liquid-liquid extraction is 
sufficient.[82] Possible chiral differences in ifosfamide metabolism are suspected, warranting 
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determination of the enantiomers of ifosfamide and its 2- and 3-dechloroethylifosfamide 
metabolites.[71,79] During the last decade, the use of mass spectrometric detection (MS) has 
increased due to its theoretical increased selectivity.[77] A major drawback of these 
hyphenated techniques is their use of non-commercially available derivatization agents and 
elaborate sample pre-treatment procedures. In summary, gas chromatography with nitrogen-
phosphorus detection is the method of preference for ifosfamide, 2- and 3-dechloroethyl-
ifosfamide and high-performance liquid chromatography with ultra-violet detection for the 
derivatized products of 4-hydroxyifosfamide and ifosforamide mustard.[64,66,70] 
 
Pharmacokinetics 
 
Despite large patient variability in the metabolism of ifosfamide, a general pattern can be 
observed. Dechloroethylation can account for 25 to 60% of the metabolism of 
ifosfamide.[11,83] This in contrast to cyclophosphamide, which has only minor oxidative side-
chain metabolism. Since both dechloroethylation and hydroxylation are competing metabolic 
pathways, plasma concentrations of activated metabolites will be lower than with 
cyclophosphamide. Following intravenous administration, the volume of distribution of 
ifosfamide approximates total body-water volume, suggesting that distribution takes place 
with minimal tissue binding. Various pharmacokinetic studies on ifosfamide have been 
conducted in both regular patient populations, as depicted in table 2,[34,40,50,63,84-106] and 
specific patient groups, as depicted in table 3.[107-117]  
These studies demonstrated a large effect of autoinduction on the pharmacokinetics of 
ifosfamide. Clearances observed are difficult to compare, because different approaches were 
used to calculate this parameter. Paediatric patients are a specific group, due to their distinct 
pharmacokinetics of ifosfamide. Their differences in body surface area lead to larger 
variability of ifosfamide doses, making comparison between pharmacokinetic parameters 
more difficult. Since the volume of distribution also approximates that of body-water, their 
volumes of distribution are significantly lower than in adults. Ifosfamide can penetrate the 
blood-brain barrier as concentrations of ifosfamide, 4-hydroxy-ifosfamide and ifosforamide 
mustard in the cerebrospinal fluid of children were almost equal to concentrations in 
plasma.[118,119] 
 
Table 2. Clinical pharmacokinetic parameters of ifosfamide in patients.  
 
Dose regimen Patients T½  
(h) 
T½ini  
(h) 
T½max  
(h) 
V  
(L) 
Cltot  
(L/h) 
Clini 
(L/h) 
Clmax 
(L/h) 
Clr  
(L/h) 
UE 
% 
Reference 
1.6-2.4 g/m² x3 3 6.9 8.3 6.3       Nelson et al.[84] 
5 g/m²/1 h 
2.4 g/m²/1 h x 3 
5 
3 
15.2 
6.9 
        Allan et al.[85] 
 
0.5 g po 
1.5 g iv 
    48.4 
37.0 
8.9 
6.7 
   4.3 
9.4 
McNiel et al.[86] 
1.8 g/m² x5 10  8.6 4.8       Piazza et al.[87] 
1 g/d 
2 g/d 
7 
7 
5.9 
5.3 
  30.1 
32.2 
3.6 
4.3 
    Cerny et al.[88] 
 
12-18 g/m²/120 h 27     4.24     Cerny et al.[89] 
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6 g/m²/72 h 9    25.6 5.1     Pearcey et al.[90] 
5 g/m²/0.5 h  6 5.85   31.5 3.9     Lewis et al.[91] 
1.5 g/m²/0.5 h x 5 15  7.2 4.6 44.8  4.0 6.9   Lewis et al.[40] 
5 g/m²/0.5 h 
5 g/m²/24 h 
6 
4 
5.4 
4.5 
  27.2 
39.4 
3.60 
4.74 
    Lewis et al.[92] 
 
1.5 g/m²/0.5 h x5 7 cy 1 
7 cy 2 
 7.0 
7.6 
3.9 
3.9 
43.8 
44.5 
 3.85 
3.55 
7.27 
7.02 
0.40 
0.48 
 Lewis et al.[93] 
1 g/m² po 
1 g/m² iv 
2 g/m² po 
2 g/m² iv 
12 
 
6 
5.89 
5.76 
5.71 
5.33 
   5.18 
5.02 
5.92 
6.20 
    Wagner et al.[89] 
1.5 g/m²/1 h x5 10 iv  
10 po  
 6.2 
5.8 
3.8 
3.5 
39.4 
23.7 
 4.15 
3.08 
7.39 
5.15 
0.85 
0.67 
2.6 Lind et al.[34,50] 
1.2 g/m² x5 7  6.8 3.9 20.4  2.4 4.2  17.2 Benvenuto et al.[95] 
1.5 g/m²/1 h x5 11   6.4 4.1      13.9 Kurowski et al.[63,96] 
5 g/m² at 41.8°C 6 5.78    8.02     Wiedermann et al.[97] 
6-9 g/m²/72 h 21         19 Hartley et al.[98] 
4.2 g/1 h (r/s) 12 6.57   42.7 4.55     Corlett et al.[99] 
5 g/m²/24 h 15 4.68   39.1 6.02   0.71 14.4 Boddy et al.[100] 
7.5-15 g/m²/240 h 22   7.6 58.5  4.76 9.78 0.72 8.5 Kaijser et al.[101] 
Various (r/s) 10     ER     Kaijser et al.[102] 
3 g/m²/3 h (r/s) 14 6.58    4.84   1.33  Granvil et al.[103] 
3 g/m²/3 h (r/s) 11         8.7r 
7.2s 
Wainer et al.[104] 
1.8 g/m² x5 8  5.26 3.58 46.2  5.96 13.9   Comandone et al.[105] 
6 g/m²/48 h/1 h x2 11         23.0 Singer et al.[106] 
 
If parameter was specified in kg or m² and average weight or body surface area were give, an average weight of 70 kg and 
an average body surface area of 1.73 m² was used to recalculate. T½=elimination half-life of ifosfamide, T½ini=initial T½, 
T½max=maximum T½, V=volume of distribution of ifosfamide, Cltot=total clearance of ifosfamide, Clini=initial clearance, 
Clmax=maximum clearance, Clr=renal clearance, UE=urinary excretion of unmetabolized ifosfamide dose, (r/s)=pharmacokinetic 
assessment of enantiomers of ifosfamide, cy=cycle, ER=enantiomeric ratios 
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Table 3. Clinical pharmacokinetic parameters of ifosfamide in obese, elderly or paediatric patients. 
 
Dose regimen Population Patients T½  
(h) 
V  
(L) 
Cltot  
(L/h) 
Clini Clmax Clr  
(L/h) 
UE 
% 
Reference 
1.5 g/m²/0.5 h 
x5 
obese 
normal 
4 
12 
6.36 
4.95 
42.8 
33.7 
4.56 
4.33 
    Lind et al.[107] 
1.5 g/m²/0.5 h 
x5 
>60 y 
< 60 y 
11 
9 
6.03 
3.85 
40 
38 
4.83 
4.47 
  0.65 
0.60 
 Lind et al.[108] 
6 g/m²/120 h Paediatric 12 5.2 18.8  3.20 6.79   Passe et al.[109] 
9 g/m²/72 h Paediatric 16 2.12 12.2 4.10   0.54 13.7 Boddy et al.[110] 
9 g/m²/72 h 
3 g/m²/1h x3 
Paediatric 
Paediatric 
17 
17 
2.1 
3.2 
 4.43 
3.12 
 
3.12 
 
5.20 
 6.4 
6.2 
Boddy et al.[111] 
9 g/m²/72 h Paediatric 11 cy 1 
11 cy 2 
2.06 
3.10 
18.2 
27.2 
5.21 
5.40 
    Boddy et al.[112] 
9 g/m²/72 h Paediatric 21    3.27 7.50   Boddy et al.[113] 
0.4-3 g/m² Paediatric 22       23.0 Silies et al.[114] 
0.4-3 g/m² Paediatric 14       56.0r 
44.0s 
Boos et al.[115] 
2 g/m²/1 h x3 
3 g/m²/3 h x3 
9 g/m²/72 h 
Paediatric 5 
 
 
3.63   4.49 6.25   Prasad et al.[116] 
2.8 g/m²/1 h Paediatric   30 2.4     Ducharme et al.[117] 
 
T½=elimination half-life of ifosfamide, V=volume of distribution of ifosfamide, Cltot=total clearance of ifosfamide, Clini=initial 
clearance, Clmax=maximum clearance, Clr=renal clearance, UE=urinary excretion of unmetabolized ifosfamide dose, 
(r/s)=pharmacokinetic assessment of enantiomers of ifosfamide 
 
Administration 
 
Various ways of administration of ifosfamide and their impact on the metabolism and toxicities 
have been studied. The pharmacokinetic differences observed after fractionation of the 
administered ifosfamide dose seem to be largely caused by differences in 
autoinduction.[34,40,92,93] Autoinduction was typically seen between day 1 and day 5, but was 
always reset to initial values at the start of a consecutive course.[93] However, a recent study 
did not demonstrate any differences in ifosfamide or metabolite areas under the 
concentration-time curve (AUC) between bolus and continuous ifosfamide infusion.[106] In 
studies with continuously infused ifosfamide, autoinduction was maximal after three to 10 
days.[101] As the decrease in elimination half-life of ifosfamide could not be explained by an 
increase in renal clearance, a metabolic difference was implicated. A shift towards more 
hepatic metabolism was observed by monitoring the dechloroethyl and 4-hydroxyifosfamide 
metabolites.[63,110] No preference in shift was observed between activation and deactivation. 
Oral versus intravenous infusion of ifosfamide has also been compared. Oral bioavailability of 
ifosfamide was close to 100%, but oral administration resulted in unacceptable neurotoxicity. 
This may be due to a shift in metabolism towards dechloroethylation compared to intravenous 
infusion.[34,94,120] Subcutaneous admini-stration and portable pumps were also successful for 
outpatient treatment.[101,121,122] High-dose regimens are of special interest since high-dose 
chemotherapy should be more effective due to the steep dose-response relationship 
observed in pre-clinical models[123] and clinical studies.[124] The AUC appeared to increase in 
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a linear fashion with increasing doses (up to at least 16 g/m²) of continuously administered 
intravenous ifosfamide, but saturation was observed in doses over 16 g/m².[89] Saturation was 
observed only in ifosforamide mustard and not ifosfamide. Since data showed wide 
interpatient variability and the bioanalytical method used had a relatively large reproducibility 
error, thus far saturation has not been demonstrated conclusively. 
 
Chirality 
 
Ifosfamide is a chiral drug with an asymmetric phosphorus atom and is always administrated 
as a racemic mixture.[125] The last decade, various clinical studies have been conducted to 
estimate the effect of this chirality on the pharmacokinetics of ifosfamide and its 
metabolites.[99,102-104,114-117] Urinary excretion of unchanged (R)-ifosfamide was significantly 
higher than (S)-ifosfamide, what could be due to different affinities for CYP of the 
enantiomers. (S)-ifosfamide could also preferentially be converted to the dechloroethyl 
metabolites. The chirality for the dechloroethylation route during induction by phenobarbital, 
resulted in a specific metabolic shift, possibly due to interspecies differences in CYP 
isoenzymes in rats compared to humans.[126] A difference was also found in human liver 
microsomes.[23,24] In theory, pure (R)-ifosfamide administration in humans could lead to less 
development of neurotoxicity, since (R)-ifosfamide is less dechloroethylated and more 
activated than (S)-ifosfamide, but the clinical relevance needs to be investigated in controlled 
clinical trials.  
 
Variability 
 
Large interpatient variability in clinical toxicity and response rates have been observed in 
patients treated with ifosfamide[124], which may be explained by differences in pharmaco-
kinetics of ifosfamide. Interindividual variations in drug disposition can be caused by genetic or 
environmental factors.[127] Genetic factors are rather easily identifiable, such as 
(over)expression of specific metabolic enzymes. For instance, the presence of CYP3A in 
pulmonary carcinomas may lead to local activation of ifosfamide in the tumour, which may 
result in situ cytotoxic activity.[128] CYP3A upregulation has been identified in several tumour 
types.[128] Intratumoural CYP3A4 may therefore be a predictive marker for the effectiveness of 
ifosfamide therapy.[21] Another co-variate for ifosfamide pharmacokinetic variability is age. 
Elderly non-small cell lung cancer patients demonstrated doubling of elimination half-life, 
apparently due to an increased volume of distribution. Total body, renal and nonrenal 
clearance were unaltered.[108] Obesity also doubled the elimination half-life, due to an 
increased volume of distribution.[107] Renal impairment has few implications for ifosfamide 
disposition, since renal clearance is only minor.[129] However, renal insufficiency might 
increase the risk of neurotoxicity, due to more extensive deactivation of ifosfamide as a result 
of decreased renal excretion of ifosfamide. Dose reduction in patients with renal failure was 
suggested.[130] Ifosfamide metabolism is mainly hepatic indicating an possible effect of liver 
impairment. Liver impairment is known to slow the metabolism of ifosfamide without shifting 
the metabolization towards more activation or deactivation.[131] Complete hepatic failure 
resulted in a total blockage of metabolism and first-order (renal) pharmacokinetics of 
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ifosfamide.[132] Further, insights into factors influencing ifosfamide pharmacokinetics may 
lead to improved dosing of ifosfamide and thus improve the anti-tumour efficacy and toxicity of 
ifosfamide treatment. 
 
Modelling 
 
The observed variability in pharmacokinetic parameters also arise from application of different 
approaches in pharmacokinetic evaluations. During the last decades several methods have 
been proposed for the description of the pharmacokinetics of ifosfamide and its 
metabolites.[109] Allen et al. and Lind et al. used a two-compartment pharmacokinetic 
model.[85,34] Nelson et al. proved a one-compartment pharmacokinetic model to be superior 
for lower doses but not for higher doses.[84] Boddy et al. used a model independent approach 
for describing ifosfamide pharmacokinetics.[110] These methods were developed to describe 
concentration-time profiles of infusions of short duration (1-3 hours) and did not take into 
account the effects of autoinduction on the pharmacokinetics of ifosfamide. Prasad et al. and 
Boddy et al. were the first to report models, which enabled more adequate description of the 
concentration-time data for ifosfamide infusions of longer duration of up to 72 hours.[116,112] 
Their models included a lag time before the development of autoinduction and described the 
increase of clearance of ifosfamide over time. Recently, a new model was published that 
simultaneously described both cyclophosphamide and 4-hydroxycyclophosphamide 
pharmacokinetics using a population approach. This mechanism-based model used a 
hypothetical enzyme compartment to estimate the effects of autoinduction on the 
pharmacokinetics of cyclophosphamide and its metabolite.[131] Recently, a similar approach 
was used for ifosfamide.[132] This population pharmacokinetic model did not require a lag time 
to describe the concentration-time profile of ifosfamide. A population approach is preferred to 
single-subject pharmacokinetics, because it will allow assessment of interindividual and 
residual variability, necessary for therapeutic drug monitoring. 
 
Pharmacodynamics 
 
Cytotoxicity 
 
The cytotoxic effect of ifosfamide is believed to be caused by its ultimate alkylating metabolite, 
ifosforamide mustard. After intracellular activation, the two chloroethyl-groups of ifosforamide 
mustard will be converted to reactive electrophilic alkyl-groups (R-CH2
+), which in turn react 
with the nucleophilic moieties of the bases in DNA, such as N-7-guanine. Due to its bi-
functional character, ifosforamide mustard is able to form two reactive alkylgroups. 
Attachment of these alkylgroups to two bases can result in an intrastrand link, if the two bases 
are in the same DNA strand, or in an interstrand cross-link or if the two bases are on different 
DNA strands. Especially, the latter will impair DNA replication by inhibition of double-strand 
separation prior to cell division.[134] Impairment of function of duplex DNA will result in 
cytotoxicity. Since tumour cells have a higher rate of cellular divisions, they will be affected at 
a higher rate than normal cells by this cytotoxic effect. Ifosforamide mustard is an analogue of 
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the phosphoramide mustard of cyclophosphamide. In contrast to phosphoramide mustard, 
which has two exocyclic 2-chloroethylgroups, ifosforamide mustard has one 2-chloroethyl 
group on the exo- and one on the endocyclic oxazaphosphorine nitrogen atom.[136] This 
apparently provides a more effective DNA cross-linking distance between the two 
independent functional alkylating moieties. DNA cross-linking will be an increasingly important 
pharmacodynamic endpoint in clinical trials. Cross-linking may possess a more direct 
relationship to clinical outcome like toxicity and efficacy than pharmacokinetics. Recent 
development of analytical methods for assessing DNA cross-linking enabled thorough 
pharmacodynamic monitoring of chemotherapeutic trials.[137] Irreparable cross-linking of DNA 
strands, depurination and chain-scission can induce permanent alterations in the DNA 
structure, resulting in mutagenesis and carcinogenesis. A second mechanism of anti-tumour 
activity has been proposed as chloroacetaldehyde-induced depletion of intracellular sulfhydryl 
agents, such as gluthatione. Normal gluthatione levels have been shown to protect DNA 
against alkylation by reacting with ifosforamide mustard.[138] For instance, cytotoxicity was 
increased in lymphocytes after gluthatione depletion.[139] Furthermore, gluthatione regulated 
multi-drug resistance could be overcome by chloroacetaldehyde-induced depletion.[140] These 
findings were confirmed by the in vitro cytotoxicity of chloroacetaldehyde observed in human 
stem cells, solid tumour cells and leukaemia cell lines.[141,142] Beside gluthatione depletion, 
inhibition of aldehyde dehydrogenase could also increase cytotoxicity (or overcome multi-drug 
resistance), because it can metabolize 4-hydroxyifosfamide to inactive compounds.[138] A 
third cytotoxic effect could be achieved by acrolein. Acrolein was able to cause single-strand 
DNA breaks, which possibly adds to the cytotoxic effects.[143] Co-administration of mesna 
may, however, prevent this cytotoxic effect.  
 
Efficacy 
 
Ifosfamide therapy has anti-tumour activity against small and non-small cell lung carcinoma, 
testicular tumours, soft tissue sarcomas and osteosarcomas, breast cancer, ovarian cancer, 
cervix carcinomas, malignant lymphomas, acute leukaemias, multiple myelomas, plasma cell 
leukaemia head and neck cancer, melanoma, prostatic cancer, renal cell carcinoma, bladder 
cancer and gastrointestinal tumours. Ifosfamide is also active against a wide range of 
paediatric tumours, such as rhabdomyosarcoma, soft tissue sarcoma, Ewing sarcoma and 
osteosarcoma, neuroblastoma, Wilms’ tumour, childhood leukaemia and paediatric 
lymphomas. Anti-tumour activity of ifosfamide is reached in both single agent and 
combination therapy with many other cytotoxic agents, such as platinum compounds, vinca 
alkaloids, etoposide, mitomycin and adriamycin. Efficacy expressed as tumour response, 
time to relapse and survival rates vary strongly dependent on tumour type, pre-treatment and 
dosing. Due to its single agent activity ifosfamide has been added to various combination 
regimens. Combination therapy aims at additive or synergistic non-cross-resistant efficacy 
with non-overlapping toxicity, based upon different mechanisms of action. The wide range of 
malignant diseases in which ifosfamide is effective is markedly different from its isomer, 
cyclophosphamide, due to differences in pharmacology. The difference in the rate of 
metabolic transformation results in different clinical pharmacokinetic profiles for the two final 
alkylating mustard metabolites. The extensive inactivation by dechloroethylation of ifosfamide 
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is responsible for the fact that ifosfamide is dosed three to tenfold higher than 
cyclophosphamide.[144,145] This also explains the more neurotoxic character of ifosfamide 
compared to cyclophosphamide. However, in comparison to phosphoramide mustard, 
ifosforamide mustard was able to alkylate DNA with a higher affinity and had its effects over a 
longer period of time, due to the stereochemical orientation of its alkylating moieties.[146]  
 
Haematological toxicity 
 
The principal dose-limiting toxicity of ifosfamide is myelosuppression, especially 
leukocytopenia. White blood cell nadirs usually occur between days eight to 13 of the 
treatment cycle. Haematological recovery in most patient groups will usually be complete by 
day 17 or 18 of the treatment cycle, facilitating chemotherapeutic retreatment in four week 
cycles. Recovery can be accelerated by treatment with cytokines, e.g. granulocyte colony-
stimulating factor, granulocyte-macrophage colony-stimulating factor or interleukine-3.[147] 
The incidence of leukocytopenia is dose-related[148] and fractionated dosage schedules of 
ifosfamide tend to produce less myelosuppression than single high-dose schedules.[149] A 
white blood cell count below 3 x 109/L is expected in approximately 50% of patients treated 
with single agent ifosfamide treatment at doses of 1.2 g/m²/day for 5 days, while at this dose 
level thrombocytopenia with platelets below 100 x 109/L can be expected in about 20% of 
patients.[149] 
 
Neurotoxicity 
 
Encephalopathy 
Central neurotoxicity is the non-haematological dose-limiting toxicity of oral and high-dose 
ifosfamide treatment. Encephalopathy caused by ifosfamide is characterized by confusion, 
sleepiness, drowsiness, hallucinations, amnesia and clear dreams.[150,151] Epileptic insults 
and coma have also been described.[152] Changes in the electro-encephalogram of patients 
suffering from ifosfamide-induced encephalopathy have been reported.[153,154] Although in 
most cases encephalopathy was only temporary and reversible, deadly outcome has been 
reported mainly in children.[155-158] Acute symptoms have been observed between two and 96 
hours after the start of ifosfamide administration, but reversed within 48 to 72 hours after 
cessation of administration.[159,155] Onset of acute symptoms after 12 to 146 hours and a 
duration of 3 days has also been described.[160] Some long-term sometimes irreversible 
effects have been reported such as mild symptoms of emotional instability, apathy, short-
term memory problems and mental focusing problems.[160] 
 
Encephalopathy mechanisms 
Various predisposing factors exist for ifosfamide-induced encephalopathy. Factors identified 
were oral ifosfamide therapy, decreased hepatic and renal function, previous chemotherapy 
with cisplatin, low serum albumin levels, pelvic abnormalities (obstruction of tractus 
urogenitalis) and brain metastases (irradiation of central nervous system). A higher incidence 
was also observed in women and elderly patients.[161,162] The irreversible renal toxicity 
caused by cisplatin predisposed for ifosfamide-induced encephalopathy and not the exposure 
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to cisplatin itself.[155,163] Drug-drug interaction may also lead to an altered ifosfamide 
metabolism through enzyme induction or competition. Oral therapy and short duration 
intravenous infusions have a higher risk of encephalopathy than continuous infusions, 
suggesting a relation with maximal plasma concentrations. Most predisposing factors could 
be correlated to clearance of ifosfamide and its metabolites. For instance, renal insufficiency 
could decrease unchanged ifosfamide excretion, possibly resulting in more extensive 
metabolism. Mesna which is always co-administered with ifosfamide therapy, does not cause 
encephalopathy when administered as single agent.[164] No differences were observed in 
pharmacokinetic parameters, such as elimination half-life and clearance of excreted 
unchanged ifosfamide between patients with and without encephalopathy.[165] Thus it was 
proposed that, an abnormal high concentration of a specific metabolite of ifosfamide would be 
the most likely candidate to cause encephalopathy and not the alkylating activity of ifosfamide 
in the cerebrospinal fluid as was suggested earlier.[166,167] Cyclophosphamide does not 
exhibit neurotoxicity. Thus, metabolic differences between ifosfamide and cyclophosphamide 
can yield further insights into the mechanism. For the greater part cyclophosphamide is 
metabolized by ring-oxidation yielding 4-hydroxycyclophosphamide and phosphoramide 
mustard and only 1-2% of cyclophosphamide is dechloroethylated. In contrast, ifosfamide is 
metabolized for 25-60% by dechloroethylation, which results in approximately a tenfold 
increase of chloroacetaldehyde concentrations.[159] Oral administration of ifosfamide results 
in a metabolic shift towards increased dechloroethylation compared to intravenous 
administration. Moreover, ifosfamide is administered at 10 times higher doses than 
cyclophosphamide, which gives rise to a hundredfold increase of chloroacetaldehyde 
concentrations. Chloroacetaldehyde and structural closely related metabolites of ethanol 
(acetaldehyde) and the hypnotic chloral hydrate (trichloroacetalde-hyde) all exhibit central 
nervous activity.[168] Chloroacetaldehyde serum concentrations in two paediatric patients 
suffering from encephalopathy were markedly increased, compared to four asymptomatic 
paediatric patients. These findings suggest induction of encephalopathy by chloro-
acetaldehyde and not by dechloroethyl metabolites, as was proposed earlier.[169] Only few 
clinical pharmacokinetic studies have been performed on chloroacetaldehyde, because of 
bioanalytical stability problems. Chloroacetaldehyde has an elimination half-life of only 2-3 
minutes, which necessitates stabilization directly after sample collection.[170] Furthermore, 
due to its rapid elimination half-life, caution must be taken in extrapolating serum 
concentrations of chloroacetaldehyde to cerebrospinal fluid concentrations, which will have 
the best relationship with the site of action. As chloroacetaldehyde is formed equimolarly with 
each dechloroethyl metabolite of ifosfamide, pharmacokinetics of 2-dechloroethyl-ifosfamide 
and 3-dechloro-ethylifosfamide could provide further insights into the risk of central 
neurotoxicity. Elevated concentrations of 2-dechloroethylifosfamide and 3-dechloroethyl-
ifosfamide were observed in patients with encephalopathy receiving a 10-day continuous 
infusion of 1500-1750 mg/m² ifosfamide.[101] Chloroacetaldehyde (and 4-hydroxyifosfamide) 
cause a rapid depletion of gluthatione in lymphocytes, both in vivo and in vitro.[139] Gluthatione 
depletion in the brain could also result in neurotoxicity because detoxification is impaired.[171] 
Acetylcysteine administration could theoretically normalize the gluthatione depletion by acting 
as a gluthatione precursor. Cerebral gluthatione depletion in mice treated with ifosfamide and 
CYP3A enzyme inducers phenobarbital or dexamethason was correlated with the severity of 
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neurotoxic symptoms.[172] The gluthatione regeneration capacity of the liver is much higher 
than that of the brain. This elucidates the fact that hepatotoxicity has a lower incidence than 
encephalopathy. Beside gluthatione depletion in the brain, inhibition acetyl-CoA-
dehydrogenase dependent processes in the mitochondrial terminal respiration chain by 
chloroacetaldehyde may result in neurotoxicity. Several studies have demonstrated elevated 
levels of urinary excreted glutaric acid and sarcosine in patients with ifosfamide-induced 
encephalopathy.[173] These observations are similar to symptoms seen in glutaricaciduria 
type II, a syndrome caused by a shortage of electron-transporting flavoproteins (type I) or a 
shortage of acetyl-CoA-dehydrogenases (type II). The latter enzyme is essential in the 
regeneration of reduced acetyl-CoA in the mitochondrial terminal respiration chain. Reduced 
acetyl-CoA is unable to transfer electrons. This will result in an accumulation of toxic 
intermediaries of the Krebs-cyclus possibly resulting in neurotoxicity.[162] Therefore, 
chloroacetaldehyde may interfere with the oxidative phosphorylation in the mitochondria and 
thereby disturbing the acetyl-CoA-dehydrogenase dependent processes.  
 
Treatment of encephalopathy 
Methylene-blue (methylthionine) has been used successfully in the treatment of 
glutaricaciduria type II. The mechanism of action of methylene-blue is based upon its ability to 
act as a non-physiological electron-acceptor, thereby regenerating the reduced acetyl-CoA. 
Methylene-blue was also able to compensate the chloroacetaldehyde effect on the long-chain 
fatty acid oxidation, thus preventing encephalopathy and fatigue.[174] Methylene-blue inhibits 
several mono-amino-oxidases in vitro. Besides hepatic CYP dependent metabolism of 
ifosfamide, extrahepatic oxidation of ifosfamide in the mitochondria in the brain by these 
mono-amino-oxidases may also lead to chloroacetaldehyde. Prophylactic methylene-blue 
may therefore not only counter the effect of chloroacetaldehyde, but may also prevent its 
formation.[171,175] If encephalopathy (CTC-grade II/III) is observed due to ifosfamide, cessation 
of infusion, regaining a correct electrolyte balance, use of neuroleptics or benzodiazepines for 
symptom fighting (exclusion of brain metastases is essential) and use of methylene-blue may 
be indicated. Haemodialysis has also been successful in reversing neurotoxicity.[129] Although 
few randomized studies have been conducted, several case reports have shown that 
encephalopathy can be treated successfully and prevented with 50 mg methylene-blue p.o. 
every 4 hours in a 5%-glucose solution. Treatment must continue until full recovery is 
observed.[162,173,176,177] Glucose solution is used because analogous to glutaricaciduria type II 
treatment glucose compensates for the disturbed fatty acid oxidation and decreased 
gluconeogenesis. One randomized study with effective methylene-blue treatment showed 
that the pharmacokinetics and metabolism of ifosfamide were not altered.[178] 
 
Urotoxicity 
 
During the middle of the 1960’s urotoxicity was the dose-limiting toxicity of ifosfamide, which 
often manifested as haemorraghic cystitis. Urotoxicity can be prevented by co-administration 
of mesna as it reacts specifically with acrolein in the urinary tract.[9] Specificity of the 
detoxification-reaction is based upon the pH-dependent moieties of mesna.[179,180] After oral 
or intravenous administration the thiol-compound mesna is rapidly auto-oxidized in plasma at 
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pH 7.4 to dimesna, which is inactive. Dimesna is highly hydrophilic resulting in a poor tissue 
distribution and a rapid renal clearance, but also in prevention of penetration of tumour cell 
membranes. Hence, no impairment of cytotoxicity of ifosfamide can be expected.[181,182] In 
the renal tubular epithelial dimesna is converted back to mesna by gluthatione reductase 
enzymes. The free sulfhydryl groups of mesna will react with the double bond of the urotoxic 
acrolein or with the potentially urotoxic 4-hydroxyoxazaphosphorine metabolites to form stable 
and non-toxic compounds. In contrast to acrolein-mesna, 4-hydroxyoxazaphosphorine-mesna 
has been detected in urine. From this it was concluded that the main anti-urotoxicity activity of 
mesna is prevention of acrolein formation from 4-hydroxyoxazaphosphorines rather than 
derivatization of acrolein itself.[75] In order to maintain optimal urothelial protection, mesna 
should be given continuously before, during and after ifosfamide administration.[183] Outdoor 
patient oral administration of mesna proved to be equally effective against urotoxicity of 
ifosfamide if patient compliance is sufficient.[184,185] Some concern has been raised over co-
administration of platinum agents and mesna (e.g. cis- and carboplatin), because in vitro cell 
lines were protected from platinum cytotoxicity by mesna.[186] Since these agents are 
frequently administered in combination chemotherapy with ifosfamide, a decreased efficacy 
of the platinum agents may be expected.  
 
Nephrotoxicity 
 
Another non-haematological toxicity of ifosfamide is its nephrotoxicity. Especially children are 
at risk. Predictive risk factors are age, cumulative ifosfamide dose, concurrent administration 
of cis- or carboplatin, unilateral nephrectomy and ifosfamide administration.[187] Ifosfamide-
induced nephrotoxicity may lead to Fanconi Syndrome (FS) which has been reported in over 
60 cases, predominantly in paediatric populations. Incidence ranged from 1.4 to 5% of all 
ifosfamide-treated patients. Fanconi Syndrome is a global impairment of the proximal tubule 
function including glucose, protein, phosphate, bicarbonate and amino acid transport. Fanconi 
Syndrome is generally irreversible, long-lasting and potentially progressive. Damage clinically 
manifested itself as polyuria, metabolic acidosis and renal phosphate wasting, resulting in 
hypophosphatemia induced rickets. Phosphate suppletion and vitamin D may then be 
indicated.[188] Another 15% of patients developed subclinical tubular dysfunction.[189] Renal 
dysfunction can be tested by determining urinary retinol binding protein or ß2-
microglobulin.[190] The cause of ifosfamide-induced Fanconi Syndrome is unclear. 
Cyclophosphamide does not cause nephrotoxicity. Extensive dechloroethylation is only 
observed with ifosfamide. Chloroacetaldehyde has been mentioned as possible causative of 
Fanconi Syndrome.[191] In vitro renal cells have been able to metabolize ifosfamide to 2- and 
3-dechloroethylifosfamide, thus locally providing chloroacetaldehyde.[14,192] Furthermore, 
chloroacetaldehyde binds to carnitine. Carnitine depletion impairs the energy production in 
mitochondria resulting in a local energetic failure in the proximal tubules.[193,194] However, no 
clinical studies have shown correlation between systemic production of chloroacetaldehyde 
and nephrotoxicity.[195] Secondly, a difference in rate and extent of alkylation compared to 
cyclophosphamide may be a cause. Fanconi Syndrome may also be caused by local 
gluthatione depletion in the proximal tubules due to recirculating mesna, but this does not 
explain the difference in the development of nephrotoxicity between ifosfamide and 
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cyclophosphamide.[196,197] 
 
Miscellaneous toxicities 
 
Alopecia occurs in almost all patients treated with ifosfamide.[198] Nausea and/or vomiting can 
occur within a few hours of ifosfamide administration and incidence is dose-related. Standard 
anti-emetic drugs administered prior or simultaneously with ifosfamide can control these 
symptoms.[199] Hypersensitivity to ifosfamide is rare but has been reported, consisting of 
redness in the face, left arm, back and chest and bronchoconstriction.[200] Case-reports 
mentioned cardiotoxicity and interstitial pneumonitis but no predisposing factors were 
identified.[201,202]  
 
Pharmacokinetics-pharmacodynamics 
 
During the development of ifosfamide therapy assessment of pharmacokinetic-
pharmacodynamic relationships was not part of the standard drug development as it is 
now.[203] Ifosfamide development focused on identification of metabolites and their roles in 
efficacy and toxicity. Lack of reliable bioanalytical methodology has long hampered these 
attempts. Thus far, only some ambiguous pharmacokinetic-pharmacodynamic relationships 
of ifosfamide and its metabolites were identified. Since ifosfamide is a prodrug, no correlation 
between plasma levels of the parent drug and toxicity and/or response was expected. In 
contrast, it has been demonstrated that increased cyclophosphamide clearance resulted in 
less relapse but increased risk of cardiac toxicity.[204,205] Increased clearance of 
cyclophosphamide may have lead to increased formation of activated metabolite. Ifosfamide 
demonstrated a relationship between the area under the plasma alkylating activity curve and 
the nadir leukocyte count.[206] Furthermore, high ifosfamide concentrations were related to 
renal toxicity.[207] Markedly, a negative relationship has been found between both progression 
free interval and survival, and ifosforamide mustard area under the plasma curve.[100] In the 
same study a positive correlation of urinary recovery of the dechloroethylated metabolites of 
ifosfamide was found with survival.[100] Both findings are in contrast with the assumed 
relationship of ifosforamide mustard and ifosfamide efficacy and the assumption of lack of 
activity of 2- and 3-dechloroethylifosfamide. Possibly plasma alkylating activity as determined 
with thin layer chromatography does not necessarily reflect intratumoural DNA alkylation. 
Furthermore, the equimolarly formed chloroacetaldehyde could well posses anti-tumour 
activity.[140] Prolonged low exposure of 4-hydroxycyclophosphamide was more efficacious 
than short infusions in an animal model.[208] Thus far, the complex process of activation and 
detoxification of ifosfamide, lack of reliable bioanalytical methodology and its infrequent use as 
single agent, hampered the definition of unambiguous pharmacokinetic-pharmacodynamic 
relationships between systemic exposure of the relevant metabolites and their anticipated 
beneficial or toxic effects.[209] 
Since high dose therapy is generally close to the maximum tolerated dose, the concept of 
pharmacokinetic variability is very important. Wide interpatient pharmacokinetic or exposure 
variability could result in sub-therapeutic treatment and at the same time in possibly lethal 
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overdosing. By choosing a population approach in quantifying the pharmacokinetics of 
ifosfamide, the observed large interpatient variability could be taken into account. A second 
step should be the identification of co-variables correlating with abnormal pharmacokinetic 
profiles. Then correlations between the pharmacokinetics of chloroacetaldehyde or the 
equimolar 2- and 3-dechloroethylifosfamide and the neurotoxicity of ifosfamide have to be 
made. Also, activated ifosfamide metabolites either 4-hydroxyifosfamide or ifosforamide 
mustard must be correlated with clinical efficacy and haematological toxicity. Recently, even 
toxicity was used to evaluate efficacy by correlating leukocyte nadir with distant disease-free 
survival.[210,211] By combining all pharmacokinetic-pharmacodynamic relationships, including 
variability on both pharmacokinetic and pharmacodynamic population parameters, therapeutic 
drug monitoring of ifosfamide may become essential. Therapeutic drug monitoring can be 
done after assessment of the pharmacokinetics of a first course of ifosfamide followed by a 
dose alteration in subsequent courses tailored to the patient. Secondly, therapeutic drug 
monitoring could be achieved a priori by assessing specific co-variables correlating with 
pharmacokinetics or pharmacodynamics. Both methods require an extensive database of 
pharmacokinetic and pharmacodynamic data with a wide range of variability. 
Conclusions 
 
Although ifosfamide has successfully been used for over 30 years in the treatment of various 
malignant diseases, there is still a need for a mechanism-based understanding of the 
autoinducible metabolism, transport through the body, pharmacokinetics and its variability, 
cytotoxicity, neurotoxicity, urotoxicity and nephrotoxicity of ifosfamide. The lack of high-
throughput validated bioanalytical methods has long been the limiting factor in ifosfamide 
research. Now that these methods have finally been developed, the underlying mechanisms 
of above mentioned phenomena will be better understood and a superior ifosfamide therapy 
can be developed, better tailored to the individual patient.  
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Determination of ifosfamide,  
2- and 3-dechloroethylifosfamide using gas 
chromatography with nitrogen-phosphorous 
or mass spectrometry detection 
 
 
 
 
 
Summary 
 
A comparison was made between methods for determining ifosfamide, 2- and 3-
dechloroethylifosfamide using gas chromatography with nitrogen-phosphorous detection 
(GC-NPD) versus positive ion electron-impact ion-trap mass spectrometry (GC-MS2). 
Sample pretreatment involved liquid-liquid extraction with ethyl acetate after adding 
trofosfamide as internal standard and alkalinization. The GC-NPD was linear, specific and 
sensitive for all analytes in the range of 0.0500-100 µg/ml with lower limits of quantification 
(LLQ) of 0.0500 µg/ml using a 50-µl plasma sample. The GC-MS2 was linear specific, and 
sensitive for ifosfamide, 2- and 3-dechloroethylifosfamide in the ranges of 0.250-100, 0.500-
25.0 and 0.500-25.0 µg/ml, respectively, with LLQs of 0.250, 0.500 and 0.500 µg/ml. The 
ranges of accuracy, within-day precision and between-day precision for analysis of all 
compounds with GC-NPD did not exceed 93.3-105.4%, 8.0% and 9.8%, respectively. The 
ranges of accuracy, within-day precision and between-day precision for analysis of all 
compounds with GC-MS2 did not exceed 86.5-99.0%, 9.0% and 12.7%, respectively. In 
conclusion, GC-NPD proved to be superior to GC-MS² in sensitivity, detection range, 
accuracy and precisions. Therefore, GC-NPD is the method of choice for fast underivatized 
determination of ifosfamide, 2- and 3-dechloroethyl-ifosfamide in human plasma and can 
readily be used for clinical pharmacokinetic studies and routine monitoring of ifosfamide 
treated patients in a hospital setting. 
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Introduction 
 
Ifosfamide, N,3-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide 
(Holoxanâ, Ifexâ), is commonly used to treat various solid tumours, soft tissue sarcomas 
and hematological malignancies in adults and children. Ifosfamide is a member of the 
oxazaphosphorine class of cytotoxic drugs along with cyclophosphamide and trofosfamide, 
as shown in figure 1.[1] 
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Figure 1. Structures of ifosfamide, cyclophosphamide and trofosfamide. 
 
Ifosfamide is a prodrug which needs activation via the cytochrome P450 enzymatic system in 
the liver.[2] It is also subject to deactivation routes that involve removal of a chloroethylgroup 
from either the exo- or endocyclic nitrogen atom to form 2- and 3-dechloroethylifosfamide, 
respectively. An equimolar amount of the neurotoxic chloroacetaldehyde is formed, as 
represented in figure 2.[3]  
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Figure 2. Dechloroethylation of ifosfamide. 
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Ifosfamide is a chiral compound. Possible chiral differences are suspected, but their effect on 
the efficacy and toxicity of ifosfamide is not clear. Central neurotoxicity is the dose-limiting 
toxicity of high-dose ifosfamide treatment and can vary from mild hallucinations to coma and 
death.[4] Hence, 2- and 3-dechloroethylifosfamide pharmacokinetics are crucial for insight into 
the risk of central neurotoxicity during ifosfamide treatment. By monitoring these metabolites 
during ifosfamide treatment, dose adjustments could be suggested for following treatment 
courses. Modern, bioanalytical methods require high sample-throughput, accuracy and 
precision in a clinically relevant concentration range, when applied in clinical pharmacokinetic 
studies. To support our clinical studies, we aimed to develop a fast, new, direct method that 
fulfilled these criteria for monitoring ifosfamide, 2- and 3-dechloroethylifosfamide using gas 
chromatography. In the past various bioanalytical methods have been reported for quantifying 
ifosfamide and its dechloroethylated metabolites. Thin layer chromatography with various 
detection methods is easy to apply, but is hampered by cross-selectivity and low sensitivity.[5] 
A more elaborate and expensive method is nuclear magnetic resonance (NMR) 
spectroscopy, which has been used to identify new metabolites of oxazaphosphorines.[6] 
High-performance liquid chromatography is easy to use but because of its undiscriminating 
detection at lower wavelengths (200-300 nm), labour-intensive sample preparation is required 
to separate the analytes from interfering plasma components.[7] Previously published 
enantiomer-selective methods were less robust and high sample-throughput was not 
feasible.[8,9] In the last decade the use of bioanalytical methods with mass spectrometric (MS) 
detection has increased enormously. These techniques are usually preferred due to 
theoretical increased selectivity.[10] To justify the choice for detection we compared ion-trap 
mass spectrometry (GC-MS2) with a more conventional method using gas chromatography 
with nitrogen-phosphorous selective detection (GC-NPD), without the use of a derivatization 
agent.[11,12] 
 
Materials and methods 
 
Chemicals  
 
Ifosfamide, 2- and 3-dechloroethylifosfamide and trofosfamide were kind gifts of Dr J. Pohl, 
ASTA Medica AG (Frankfurt, Germany). Ethyl acetate (p.a. grade) was obtained from Merck 
(Darmstadt, Germany). Distilled water was used throughout. Blank, drug-free plasma was 
obtained from the Central Laboratory of the Blood Transfusion Service (Amsterdam, The 
Netherlands). 
 
Instrumentation 
 
A gas chromatograph (HP 5890 series II, Hewlett Packard, Amstelveen, The Netherlands) 
equipped with a split/splitless injector, a model HP 7360 autosampler (Hewlett Packard, 
Amstelveen, The Netherlands) and a flame ionization nitrogen-phosphorous selective 
detection system (NPD) were used. Separation was achieved on a capillary CP Sil 8 CB 25 
m ´ 0.25 mm column coated with 5% phenyl-groups and 95% dimethylpolysiloxane-groups 
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with a film thickness of  0.25 mm (Chrompack, Middelburg, The Netherlands). Data were 
recorded with a Spectra Physics model 4270 integrator (Spectra Physics, Santa Clara, CA, 
USA) and reprocessed using the PC1000 system (Thermo Separation Products, Breda, The 
Netherlands). A combined Finnigan MAT GCQ gas chromatograph/mass spectrometer with 
an ion-trap (Thermo Quest, Breda, The Netherlands) was used with a split/splitless injector 
and a model A200S autosampler (Thermo Quest, Breda, The Netherlands). Detection was 
achieved in positive ion electron-impact mode followed by parent-daughter fragmentation (EI-
MS2) with mass selective detection. Separation was achieved on a capillary DB-5MS low-
bleed 30 m x 0.25 mm column, also coated with 5% phenyl-groups 95% 
dimethylpolysiloxane-groups with a film thickness of 0.25 µm (J&W Scientific, Folsom, CA, 
USA). The characteristics of the analytical columns used in both systems were identical, but 
the DB-5MS was specifically adapted for low-bleed MS2-applications. Data were analyzed 
using GCQ software on a Gateway 2000 P5-75 personal computer (Gateway, NJ, USA). 
 
Chromatographic conditions 
 
Both the injector and detector temperatures of the GC-NPD system were 275°C. A straight 
inlet-liner with a funnel-shaped collection chamber (without glasswool) was installed. Split 
flow was set at 1:10. Helium was used as a carrier gas at a flow-rate of 3.0 ml/min. The flow-
rates of the detection gases hydrogen, air and auxiliary (helium) were 2.6, 95 and 25 ml/min, 
respectively. The starting temperature of the column oven (200°C) was maintained for 7 min. 
and then ramped to 225°C at 40°C/min. and kept at 225°C for 2.88 min., resulting in a total 
run time of 10.5 min. The injector temperature of the GC-MS2 system was 275°C, the transfer 
line temperature was 275°C and the ion source temperature was 200°C. A straight inlet-liner 
(without glasswool) was installed. Split flow was set at 1:10. The column flow had a constant 
linear velocity of 40.00 cm/sec. The oven temperature programme started at 120°C and was 
ramped directly to 225°C at 20°C/min. and kept at 225°C for 9.75 min, resulting in a total run 
time of 15.00 min. MS-detection was performed in positive ion electron-impact mode with an 
ion current of 70 eV, an ion-trap and refragmentation with a collision energy 0.8 V. From 0 to 
5.00 min., the MS detector was switched off. From 5.00 to 8.00 min. daughter-fragments at 
m/z 149.0 were refragmented yielding the quantification-fragments for 2- and 3-
dechloroethylifosfamide at m/z 56.0. From 8.00 to 10.00 min. daughter-fragments at m/z 
211.0 were refragmented yielding the quantification-fragment for ifosfamide at m/z 70.0. From 
10.00 to 15.00 min. daughter-fragments at m/z 273.0 were refragmented yielding the 
quantification-fragment for trofosfamide at m/z 118.0.  
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Calibration standards and quality control samples 
 
Samples for the standard calibration curves were obtained by adding ifosfamide, 2- and 3-
dechloroethylifosfamide solutions in distilled water to 50 µl drug-free human plasma in a 1.5-
ml Eppendorf cup. The stock solutions were prepared fresh prior to the preparation of 
calibration and quality control samples. The resulting concentrations of the standard 
calibration curve for each of the analytes were 0, 0.0500, 0.100, 0.250, 0.500, 1.00, 2.50, 5.00, 
10.0, 25.0, 50.0 and 100 µg/ml. A final volume of 100 µl was obtained by adding water. A 
volume of 50 µl of a 2.5 µg/ml trofosfamide solution in distilled water, 10 µl of a 0.5 M sodium 
hydroxide solution and 500 µl of ethyl acetate was then added. The solutions were whirlmixed 
for 30 sec. and centrifuged for 10 min. at 3,000 g at ambient temperature. Extraction 
recoveries from plasma for ifosfamide, 2- and 3-dechloroethylifosfamide of 86, 44 and 69% 
have been reported.[11,12] There is a lower extraction recovery of 2-dechloroethylifosfamide, 
because it has a higher polarity than 3-dechloroethylifosfamide. A 450-µl volume of the 
organic layer was transferred to a 1.5 ml Eppendorf cup and evaporated under a gentle 
stream of nitrogen at 40°C. No degradation was observed for the analytes compared to 
ambient temperature evaporation. Operating at 40°C sped up the evaporation step. The 
residue was reconstituted in 25 µl ethyl acetate. The injected volume in the GC-NPD and GC-
MS2 was 1 µl. Quality control samples, containing 0.0500, 0.100, 0.250, 10.0 and 100 µg/ml 
ifosfamide, 2- and 3-dechloroethylifosfamide in plasma were prepared independently from the 
standard calibration curve as described above. Five replicate quality control samples of each 
concentration were analyzed simultaneously with the calibration curves in three different 
analytical runs on both the GC-NPD and GC-MS2 systems. 
 
Selectivity and specificity 
 
Interference by endogenous compounds was investigated by analysis of six different blank 
plasma samples. Regular co-medication of ifosfamide treatment and other anti-cancer drugs 
(granisetron, dexamethasone, acetaminophen, oxazepam, temazepam, MESNA, 
ketoconazole, caffeine, topotecan, paclitaxel, etoposide, cisplatin and carboplatin) were 
investigated for interference with the analytical methods. 
 
Limit of quantification  
 
The lower limit of quantification (LLQ) was investigated by determining five quality controls at 
the LLQ in three analytical runs. Each analytical run was made with plasma from a different 
donor. For the concentration to be accepted as the LLQ, the percentage of deviation from the 
nominal concentration (measure of accuracy) and the relative standard deviation (measure of 
precision) were required to be less than 20%. The upper limit of quantification (ULQ) was 
defined as 100 µg/ml in accordance with expected clinical concentrations. 
Accuracy, precisions and linearity 
 
Accuracy, between-day precision and within-day precision of the methods were determined 
by assaying five replicate standard samples in plasma at five different concentrations (0.0500, 
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0.100, 0.250, 10.0 and 100 µg/ml) in three different analytical runs. Accuracy was measured 
as the percentage of the nominal concentration. The within-day and between-day precisions 
were obtained by analysis of variance for each test concentration using the analytical run as a 
grouping variable. For the construction of each calibration curve 12 spiked plasma samples 
were analyzed in duplicate. Optimization of their weighting factors was investigated. Linearity 
of the three plasma calibration curves was tested with the F-test for lack of fit. 
 
Statistics 
 
All statistical calculations were performed with the Statistical Product and Service Solutions 
(SPSS) for Windows, version 6.1 (SPSS, Chicago, IL, USA). Correlations were considered 
statistically significant if calculated p-values were 0.05 or less. 
 
Results and discussion 
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Figure 3. Left panel: Typical chromatogram by gas chromatography with nitrogen-phosphorous detection 
of a plasma sample spiked with 10.0 µg/ml 2- (2-DCE) and 3-dechloroethylifosfamide (3-DCE) and 
ifosfamide (IF), with trofosfamide (TF) as internal standard (top) and blank plasma (bottom). Right panel: 
Typical chromatogram of a plasma sample spiked with 0.100 µg/ml 2-DCE, 3-DCE and IF with TF as 
internal standard (top) and blank plasma (bottom). 
 
The GC-NPD chromatogram of a 10.0 and a 0.100 µg/ml spiked plasma sample in figure 3 
demonstrated retention times of 2.8, 3.3, 5.9 and 9.5 min. for 2- and 3-dechloroethyl-
ifosfamide, ifosfamide and trofosfamide, respectively. The peak with a retention time of 3.6 
min. was identified as caffeine. The GC-MS2 chromatogram in figure 4 demonstrated 
retention times of 6.0, 6.5, 8.6 and 12.7 min. for 2- and 3-dechloroethylifosfamide, ifosfamide 
and trofosfamide, respectively. 
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Figure 4. Typical chromatogram by gas chromatography with mass spectrometry with daughter-ion 
fragmentation of a plasma sample spiked with 10.0 µg/ml 2- (2-DCE) and 3-dechloroethylifosfamide (3-
DCE) and ifosfamide (IF), with trofosfamide (TF) as internal standard. From top to bottom: total ion-
current, 2-DCE and 3-DCE quantification-fragments at m/z 56, IF quantification-fragment at m/z 70 and 
TF quantification-fragment at m/z 118 
 
Detection  
 
The NPD system used a rubidium-salt detector with a high sensitivity for nitrogen and 
phosphorous atoms producing a high selectivity for ifosfamide and its metabolites. GC-MS2 
operated with selected reaction monitoring (SRM) in which the analyte (parent ion) is 
fragmented and a specific daughter-ion is selected in the ion-trap and subsequently 
refragmented. The mass spectra observed are represented in figure 5. Ifosfamide has a 
molecular weight (Mw) of 261.1 g/mol.  
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Figure 5. Mass-spectra of 2- (2-DCE) and 3-dechloroethylifosfamide (3-DCE), ifosfamide (IF) and 
trofosfamide (TF) fragmentation. Refragmentation of daughter fragments at m/z 149, m/z 149, m/z 211 
and m/z 273, respectively yielded quantification-fragments at m/z 56, m/z 56, m/z 70 and m/z 118, 
respectively. 
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After EI+ the parent-ion (M+) with mass-to-charge ratio (m/z) of 261 was fragmented. The 
base peak at m/z 211 with its typical isotope peak at m/z 213 contains 1 Cl-atom. The base 
peak of ifosfamide at m/z 211 can be explained by a loss of a CH3Cl. CH3Cl could be split off 
from either the exo- or endocyclic chloroethylgroup of ifosfamide. The isomers 2- and 3-
dechloroethyl-ifosfamide with Mw 198.6 yielded M+s with m/z 199. Fragmentation lead to the 
base peak at m/z 149, due to a loss of CH3Cl. No M
+ peak was observed with trofosfamide. 
Trofosfamide has a Mw 323.6. The base peak m/z 273 with two isotope peaks, could be 
explained by a loss of CH3Cl. For all analytes the M-CH3Cl fragment was selected for further 
fragmentation. Daughter-ion fragmentation of the ifosfamide M-CH3Cl fragment (m/z 211) 
yielded a base peak at m/z 70, which could be explained by (CH2NHCH2CHCH2)
+. Daughter-
ion fragmentation of the 2- and 3-dechloroethyl-ifosfamide M-CH3Cl fragments (m/z 149) 
yielded both a base peak at m/z 56, which could be explained by (CH2NHCHCH2)
+. Daughter-
ion fragmentation of the trofosfamide M-CH3Cl fragment (m/z 118) yielded a base peak at m/z 
118, which could be explained by NPNHCH2CH2CH2O. In theory, the selectivity of the SRM 
mode used, should be much greater than that obtained in single ion monitoring (SIM) mode. 
To produce a false positive result, the interfering compound must fragment to a daughter-
fragment of the same m/z and refragment identically to a quantification-fragment of the same 
m/z. This advantage of SRM over SIM resulted in a relatively higher sensitivity due to 
increased selectivity (data not reported). A major disadvantage of SRM, however, is the lower 
absolute sensitivity, because refragmentation results in wasting mass. Due to the second 
fragmentation only 40, 48, 40 and 54% of the daughter-fragments of ifosfamide, 2- and 3-
dechloroethyl-ifosfamide and trofosfamide was retreived as final quantification-fragment. 
Therefore, although very selective the GC-MS2 system was inappropriate for sensitive 
determination of 2- and 3-dechloroethylifosfamide. Furthermore, non-linearity in response was 
observed at concentrations higher than 25 µg/ml. This resulted in underestimated responses 
and non-linear calibration curves at higher concentrations. This non-linearity could possibly be 
explained by column-overloading or non-linearity in detector response.  
 
Specificity and selectivity 
 
After sample pretreatment with liquid-liquid extraction, plasma samples spiked with 
granisetron, dexamethasone, acetaminophen, oxazepam, temazepam, MESNA, 
ketoconazole, topotecan, paclitaxel, etoposide, cisplatin and carboplatin did not display any 
interference with either the GC-NPD or GC-MS2 method. Caffeine was detected by GC-NPD 
but did not interfere due to its retention time of 3.6 min. Blank plasma samples of six different 
individuals showed no interfering endogenous substances. A typical chromatogram of blank 
spiked plasma by GC-NPD is shown in figure 3. 
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Limit of quantification 
 
The LLQs using GC-NPD for all analytes were 0.0500 µg/ml each. The percentages of 
deviation from the nominal concentration of ifosfamide, 2- and 3-dechloroethylifosfamide by 
GC-NPD at these concentrations were less than 15.5%, 19.4% and 18.2%, respectively. The 
relative standard deviations of ifosfamide, 2- and 3-dechloroethyl-ifosfamide with GC-NPD 
were less than 5.7%, 5.3% and 5.7%, respectively. The LLQs using GC-MS2 for ifosfamide, 
2- and 3-dechloroethylifosfamide were 0.250, 0.500 and 0.500 µg/ml, respectively. Because 
of the insufficient sensitivity of the GC-MS2 system, the LLQ concentrations of 2- and 3-
dechloroethylifosfamide could not be tested using the quality control samples prepared. The 
percentage of deviation from the nominal concentration of ifosfamide using GC-MS2 was less 
than 11.4%. The relative standard deviation of ifosfamide using GC-MS2 was less than 9.8%. 
Thus, 0.0500 µg/ml was defined as the LLQ for ifosfamide, 2- and 3-dechloroethylifosfamide 
using GC-NPD and 0.250, 0.500 and 0.500 µg/ml using GC-MS2, respectively. 
 
Accuracy, precisions and linearity 
 
The use of the weighting factor of 1/(conc.)2 resulted in a minimal sum of deviations from the 
nominal concentrations, and prevented the relative standard deviations of the duplicates and 
the deviations from the nominal concentrations from exceeding 15% or, in case of the LLQ, 
20%. Removal of the weighting factor and using a weighting of 1/conc. both resulted in 
deviations from the nominal concentration for the LLQ of greater than 30%. This could 
possibly be explained by non-linearity in detection or column-overloading. Intercepts, slopes 
and correlation coefficients (r2) describing the calibration curves of all analytes measured 
using GC-NPD and GC-MS2 are represented in table 1. 
 
Table 1. Standard calibration curves of ifosfamide (IF), 2- (2DCE) and 3-dechloroethyl-
ifosfamide (3DCE) for validation of GC-NPD and GC-MS2 (n=3). 
 
Analyte Method Range 
(µg/ml) 
Slope±S.D. Intercept±S.D. Correlation  
coefficient±S.D. 
IF NPD 0.0500-100 0.4073±0.0220 0.0024±0.0009 0.9986±0.0003 
2DCE NPD 0.0500-100 0.0824±0.0029 -0.0002±0.0006 0.9992±0.0007 
3DCE NPD 0.0500-100 0.1448±0.0126 0.0004±0.0014 0.9975±0.0012 
IF MS2 0.250-100 0.1471±0.0072 0.0102±0.0009 0.9954±0.0017 
2DCE MS2 0.500-25.0 0.0350±0.0134 -0.0010±0.0014 0.9945±0.0016 
3DCE MS2 0.500-25.0 0.0331±0.0151 -0.0054±0.0025 0.9901±0.0062 
 
Abbreviations: S.D.= standard deviation 
 
Correlation coefficients determined using GC-NPD and GC-MS2 were always greater than 
0.995 and 0.990, respectively, as determined by least squares analysis. All calibration curves 
by GC-NPD were linear in the range of 0.0500-100 µg/ml with use of the F-test for lack of fit. 
Ifosfamide, 2- and 3-dechloroethylifosfamide determined by GC-MS2 were linear only for 
ranges of 0.250-100, 0.500-25.0 and 0.500-25.0 µg/ml. GC-NPD was more accurate and 
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more precise (within-day and between-day) than GC-MS2 in the concentration ranges 
specified for ifosfamide, 2- and 3-dechloroethylifosfamide, as represented in tables 2 and 3. In 
addition to being superior to GC-MS2 in accuracy and precisions, GC-NPD used a less 
expensive detection system. 
 
Table 2. Accuracy, within-day and between-day precisions of ifosfamide (IF), 2- (2DCE) and 3-
dechloroethylifosfamide (3DCE) analysis in human plasma determined by GC-NPD, calculated using 
one-way ANOVA (p<0.05) (n=5). 
 
Analyte Concentrations Accuracy (%) Precision (%) 
 (µg/ml) Mean ± S.D. 95% C.I. Within-day Between-day 
IF 0.0500 103.2 ± 6.5 99.6-106.8 5.5 3.5 
IF 0.100 99.9 ± 2.5 98.5-101.3 0.8 2.9 
IF 0.250 104.5 ± 3.7 102.4-106.6 1.8 3.6 
IF 10.0 102.0 ± 3.0 100.3-103.7 2.0 2.6 
IF 100 93.3 ± 4.8 90.6-95.6 2.9 5.1 
2DCE 0.0500 103.2±7.7 98.9-107.4 5.1 6.4 
2DCE 0.100 98.9±9.0 94.0-103.9 3.8 9.8 
2DCE 0.250 96.4±5.5 93.4-99.5 3.2 5.7 
2DCE 10.0 100.4±1.9 99.3-101.5 1.9 0.4 
2DCE 100 100.6±2.5 99.3-102.0 2.1 1.6 
3DCE 0.0500 103.6±8.7 98-9-108.4 5.1 7.8 
3DCE 0.100 93.6±9.3 88.5-98.8 8.0 6.8 
3DCE 0.250 97.9±6.8 94.1-101.6 5.0 5.7 
3DCE 10.0 105.4±6.1 102.0-108.8 4.5 4.4 
3DCE 100 102.5±5.5 99.5-105.6 3.0 5.3 
 
Abbreviations: S.D.= standard deviation, C.I.= confidence interval. 
 
Table 3. Accuracy, within-day and between-day precisions of ifosfamide (IF), 2- (2DCE) and 3-
dechloroethylifosfamide (3DCE) analysis in human plasma determined by GC-MS2, calculated using one-
way ANOVA (p<0.05) (n=5). 
 
Analyte Concentrations Accuracy (%) Precision (%) 
 (µg/ml) Mean ± S.D. 95% C.I. Within-day Between-day 
IF 0.250 94.6±9.0 89.6-99.6 7.8 6.4 
IF 10.0 99.0±11.0 92.9-105.1 2.9 12.7 
IF 100 86.5±5.7 83.3-89.7 3.8 6.4 
2DCE 10.0 95.9±9.0 90.9-100.9 8.0 5.7 
3DCE 10.0 96.3±11.0 90.2-102.4 9.0 8.4 
 
Abbreviations: S.D.= standard deviation, C.I.= confidence interval. 
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Analysis of patient samples 
 
The applicability of the selected GC-NPD assay for pharmacokinetic studies in patients was 
demonstrated, as depicted in figure 6. The assay allowed monitoring of plasma levels of 
ifosfamide, 2- and 3-dechloroethylifosfamide in a patient receiving 1.5 g/m² ifosfamide in 1 
hour for two days. 
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Figure 6. Plasma concentrations of ifosfamide (IF), 2- (2DCE) and 3-dechloroethylifosfamide (3DCE) in 
a patient receiving 1.5 g/m² ifosfamide in 1 hour for two days. 
 
Conclusions 
 
Two GC methods for quantification of underivatized ifosfamide, 2- and 3-dechloroethyl-
ifosfamide were compared. The more conventional method using GC-NPD proved to have a 
better detection range, accuracy and precisions than a recently developed method using GC-
MS2. The GC-NPD assay meets the current requirements for the validation of a bioanalytical 
methodology and can be used for pharmacokinetic studies of ifosfamide treated patients. It is 
our experience that the described GC-NPD assay can readily be used in a hospital laboratory 
environment for routine monitoring of ifosfamide, 2- and 3-dechloroethylifosfamide 
concentrations. Thus far, we have analyzed more than 5,000 samples without major 
problems. 
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Summary 
 
A method using reversed-phase high-performance liquid chromatography is described for the 
measurement of the stabilized activated metabolite of ifosfamide, 4-hydroxyifosfamide, in 
human plasma and erythrocytes. Immediately after sample collection and plasma-
erythrocyte separation at 4°C, 4-hydroxyifosfamide was stabilized by derivatization with 
semicarbazide. The sample pretreatment involves liquid-liquid extraction with ethyl acetate. 
Reversed-phase high-performance liquid chromatography was executed with a C8 column 
and acetonitrile-0.025 M potassium dihydrogen phosphate buffer (pH 7.40)-triethylamine 
(13.5:86:0.5 v/v) as mobile phase. The analyte was determined with UV-detection at 230 nm. 
Complete validation, optimization and stability studies were performed and the method proved 
to be specific, sensitive and with a stable analyte in the range of clinically relevant 
concentrations (0.1-10 µg/ml) after conventional dosing. The lower limit of quantitation was 
100 ng/ml using a 1.00 ml of sample. Accuracy was between 94.1 and 107.0%. Within-day 
and between-day precisions were less than 6.2% and 7.2%, respectively. 4-
Hydroxyifosfamide-semicarbazide was found to be stable in the biological matrix at -20°C for 
at least 1 month. A pharmacokinetic study conducted in a patient receiving 9 g/m2 in 3 days 
by means of a continuous infusion demonstrated the applicability of this method. 
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Introduction 
 
Ifosfamide, N,3-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide 
(HoloxanÒ, IfexÒ), is commonly used for the treatment of various solid tumours, soft tissue 
sarcomas and haematological malignancies in adults and children. Ifosfamide is a prodrug 
which needs activation via the cytochrome P450 enzymatic system in the liver to 4-
hydroxyifosfamide. 4-Hydroxyifosfamide exists in equilibrium with its tautomeric form 
aldoifosfamide. Aldoifosfamide can be converted into the final alkylating agent ifosforamide 
mustard with concurrent acrolein formation. Since 4-hydroxyifosfamide/aldo-ifosfamide is the 
activated form of the prodrug ifosfamide and because 4-hydroxy-ifosfamide/aldoifosfamide in 
contrast with ifosforamide mustard is capable of penetrating a (tumour)cell, systemic 4-
hydroxyifosfamide/aldoifosfamide concentrations may yield the most relevant and easily 
accessible reflection of a concentration-therapeutic effect correlation. Erythrocytes are of 
special interest, because it was proposed that they act as transporters of 4-hydroxyifosfamide 
and 4-hydroxycyclophosphamide the activated metabolite of cyclophosphamide, an isomer of 
ifosfamide.[1,2] 
Various laborious methods for the determination of 4-hydroxyifosfamide in whole blood, 
plasma and erythrocytes have been developed. An indirect method widely used is based on 
the release of acrolein from 4-hydroxyifosfamide, followed by trapping with 3-aminophenol 
yielding 7-hydroxyquinoline which is amenable to fluorometric analysis.[3,4] The acrolein that is 
generated in vivo could interfere with this method, but due to the unstable character of 
acrolein in blood this is not likely. Another technique applies thin-layer chromatography 
combined with fluorometric detection.[5] The lower limit of detection with this method is 1 
mg/ml and therefore this method is not useful for patient plasma analysis using small volume 
samples. Furthermore, no stability data were presented. An elaborate method using gas 
chromatography with mass spectrometric detection was also developed but its use of self-
synthesized deuterium labelled analogues as internal standards renders it less favourable. 
This method stabilizes 4-hydroxyifosfamide to a cyanohydrin adduct, followed by 
dichloromethane extraction and silyl derivatization.[6] New methods were developed using 31P 
nuclear magnetic resonance (NMR) [7] and 1H-NMR-high-performance liquid 
chromatography.[8] Thus far, no relatively simple, repro-ducible validated method using high-
performance liquid chromatography has been developed. The highest hurdle in the analysis of 
4-hydroxyifosfamide is its instability in biological fluids. However, by adding semicarbazide the 
tautomeric equilibrium of 4-hydroxyifosfamide/aldo-ifosfamide is stabilized with subsequent 
formation of a stable semicarbazone derivative, as depicted in figure 1. This prevents 
spontaneous decomposition to ifosforamide mustard.[9] An analogous method for the 
quantitative analysis of 4-hydroxycyclophosphamide was published recently.[10] 
Our aim was to develop a novel selective and sensitive high-performance liquid 
chromatographic method for 4-hydroxyifosfamide analysis in biological samples, which offers 
sufficient robustness to investigate 4-hydroxyifosfamide pharmacokinetics in patients 
receiving high dose ifosfamide treatment. The mentioned requirements can be met by 
stabilizing 4-hydroxyifosfamide with semicarbazide and by using the resulting semicarbazone 
derivative for high-performance liquid chromatographic analysis. 
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Figure 1. Stabilization of 4-hydroxyifosfamide by reaction of semicarbazide with the tautomeric aldo-
ifosfamide yielding the derivative 4-hydroxyifosfamide-semicarbazone. 
 
Materials and methods 
 
Equipment 
 
The high-performance liquid chromatographic system consisted of a Thermo Separation 
Products (TSP) Spectraseries System with a model AS3000 automated injector with a 100 µl 
loop and a model P1000 pump connected to a model UV1000 detector with ultra-violet 
detection at 230 nm. Data were collected by the TSP system and transferred by model 
SN4000 analog-digital convertor to a Dell optiplex Gs Pentium personal computer. A 5-µm 
Merck Hibar Lichrosorb C8 RP-Select B (25 cm x 4.0 mm I.D.) column was equipped with a 
10-µm Chrompack pre-column. 
 
Chemicals 
 
4-Hydroperoxyifosfamide (Lot 033.6496) and all other ifosfamide and cyclophosphamide 
metabolites were a kind gift of Dr J Pohl, ASTA Medica AG (Frankfurt, Germany). Acetonitrile 
and ethanol (HPLC supra-gradient) were purchased from Biosolve (Valkenswaard, The 
Netherlands). Ethyl acetate (p.a. grade), triethylamine (p.s. grade) and anhydrous potassium 
dihydrogen phosphate (suprapure grade) were obtained from Merck (Darmstadt, Germany). 
Semicarbazide hydrochloride (p.a. grade) was purchased from Acros (Geel, Belgium). A 2 M 
semicarbazide solution was made and adjusted to pH 7.40 with 1 M HCl and 1 M NaOH, prior 
to use. Distilled water was used throughout. Blank, drug-free plasma was obtained from the 
Central Laboratory of Blood Transfusion Service (Amsterdam, The Netherlands). Blank 
erythrocytes were collected from volunteers in the Slotervaart Hospital (Amsterdam, The 
Netherlands). 
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Preparation of standards 
 
4-Hydroperoxyifosfamide was used as a substitute for 4-hydroxyifosfamide. In aqueous 
solution, 4-hydroperoxyifosfamide rapidly liberates 4-hydroxyifosfamide/aldoifosfamide and 
hydrogen peroxide. Fresh solutions of 4-hydroxyifosfamide were prepared immediately prior 
to use by dissolving an equimolar amount of 4-hydroperoxyifosfamide in distilled water. 
Dissolution was accelerated by ultra-sonification. Standard concentration curves were 
obtained by adding 1 ml drug-free plasma of 4°C to known amounts of unstabilized 4-
hydroxyifosfamide in the range 0, 0.10, 0.25, 0.50, 1.0, 5.0 and 10.0 µg/ml in 5 ml 
polypropylene reaction tubes. Immediately after vortexing for 15 s. 100 µl 2 M semicarbazide 
(pH 7.40) was added and vortexed rigorously for 1 min.  
 
Patient sample collection 
 
Venous blood samples of a patient receiving intravenous ifosfamide treatment (9 g/m2/72 
hours) were taken at 0, 3, 10, 20, 24, 48, 68, 72, 73, 76, 80 hours after start of the infusion. 
The samples were collected in 5 ml polypropylene reaction tubes and immediately cooled by 
placing them in ice water. The samples were then centrifuged without delay for 5 min. with 
1,000 g at 4°C. Two 1 ml plasma samples were collected and added to 100 µl 2 M 
semicarbazide (pH 7.40). The left-over plasma was collected for ifosfamide analysis 
according to the method as described by Kaijser et al.[11] The white blood cell layer was 
discarded with sufficient margins. 1 ml erythrocytes was collected from the erythrocyte-layer 
and added to 100 µl 2 M semicarbazide (pH 7.40). The left-over erythrocytes were also 
collected for ifosfamide analysis. All semicarbazide-stabilized samples were vortexed 
rigorously for 1 min. and stored at -70°C pending analysis. The sample collection and 
stabilization procedure was performed within a 10 min. time-period. 
 
Sample pretreatment 
 
After thawing 3 ml ethyl acetate was added to all patient and standard samples. After 
vortexing for 1 min. the samples were centrifuged for 10 min. with 1,000 g. The organic layer 
was separated and evaporated to dryness under a gentle nitrogen flow at 40°C. The samples 
were reconstituted in 150 µl mobile phase. Total reconstitution was achieved by ultra-
sonificating the sample for 15 min. followed by vortexing for 1 min. The injected volume into 
the high-performance liquid chromatography system was 100 µl. 
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Chromatography 
 
The mobile phase consisted of acetonitrile-0.025 M potassium dihydrogen phosphate buffer-
triethylamine (13.5:86:0.5 v/v) adjusted to pH 7.40 with 2 M hydrochloric acid. The UV 
wavelength for detection was 230 nm. The flow-rate was 0.8 ml/min. The analytical column 
was operated at ambient temperature. 
 
Mass spectrometric identification of 4-hydroxyifosfamide-semicarbazide 
 
A solution containing 5.7 mg 4-hydroxyifosfamide was derivatized with 9.2 mg semicarbazide 
(an approximately four times equimolar semicarbazide amount). After ex-traction with ethyl 
acetate the derivative was evaporated to dryness. Also, a 1-ml aliquot of eluted 4-
hydroxyifosfamide-semicarbazide was collected after high-performance liquid 
chromatographic analysis and extracted with ethyl acetate. The residues were recon-stituted 
in a 50% acetonitrile solution and injected into an electron spray VG Platform (Fissons 
instrument) electron impact mass spectrometry system for identification. 
 
Specificity and selectivity 
 
The interference from endogenous compounds was investigated by the analysis of six 
different blank plasma and erythrocytes samples. The following related compounds were 
investigated for interference with the analytical method: ifosfamide, 4-ketoifosfamide, 
carboxyifosfamide, 2-dechloroethylifosfamide, 3-dechloroethylifosfamide, ifosforamide 
mustard and 4-hydroxycyclophosphamide-semicarbazide. Possible co-medication was also 
tested for interference. Tested substances were granisetron, dexamethasone, 
acetaminophen, oxazepam, temazepam, topotecan and sodium 2-mercaptoethane 
sulphonate (MESNA). 
 
Limit of quantification and limit of detection 
 
The lower limit of quantification (LLQ) was investigated in plasma samples from three 
different donors, by a five-fold determination in three analytical runs. For the concentration to 
be accepted as the LLQ, the percent deviation from the nominal concentration (measure of 
accuracy) and the relative standard deviation (measure of precision) were to be less than 
20%. The limit of detection (LOD) in plasma was defined by the concentration with a signal-
to-noise ratio of 3. The upper limit of quantification (ULQ) was arbitrarily defined as 10 µg/ml. 
 
Validation: accuracy, precision, linearity and recovery 
 
Accuracy, between-day and within-day precisions of the method were determined by 
assaying six replicate standard samples in plasma at four different 4-hydroxyifosfamide 
concentrations (0.1, 0.5, 5 and 10 µg/ml) in three different analytical runs. These quality 
control samples were made independent of standard curve concentrations. Accuracy was 
measured as the percent deviation from the nominal concentration. The within-day and 
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between-day precision were obtained by analysis of variance (ANOVA) for each test 
concentration using the analytical run as grouping variable. For the construction of each 
calibration curve seven spiked plasma samples were analyzed in duplicate. After optimization 
of their weight factors, linearity of the three plasma and three erythrocyte calibration curves 
was tested with the F-test for lack of fit. Recovery of 4-hydroxy-ifosfamide-semicarbazide 
after sample pretreatment procedure was determined by comparing observed 4-
hydroxyifosfamide-semicarbazide in extracted plasma and erythrocytes samples to those of 
non-processed standard solutions made of 4-hydroxy-ifosfamide-semicarbazide diluted in 
mobile phase and direct injection. 
 
Optimization 
 
The possible breakdown of 4-hydroxyifosfamide before stabilization with semicarbazide was 
determined. This was carried out by exposing standard plasma samples of 0.5 and 5 µg/ml 4-
hydroxyifosfamide in duplicate (unprotected by semicarbazide) to 4°C, room temperature and 
37°C for 0, 10, 20, 30, 60 and 90 min. Directly after exposure the standards were stabilized 
with semicarbazide and stored at -20°C pending standard analysis. Optimization of 
incubation was tested by using standard plasma samples of 0.5 and 5 µg/ml 4-
hydroxyifosfamide in triplicate, stabilized with semicarbazide and exposing them to 4°C, room 
temperature, 40°C and 60°C for 0, 10, 20 and 60 min. The influence of the amount of 
semicarbazide on the stability and chromatography was tested by adding various amounts of 
semicarbazide (100 µl of 0.125, 0.25, 0.5, 1.0 and 2.0 M) to standard plasma samples of 0.5 
and 5 µg/ml 4-hydroxyifosfamide in duplicate, followed by sample pretreatment as described.  
 
Stability during storage 
 
Stability during storage was tested by storing standard plasma samples of 0.5 and 5 µg/ml 4-
hydroxyifosfamide in triplicate, stabilized with semicarbazide, at 37°C and 60°C for one hour 
and 24 hours, at room temperature for one hour, 24 hours, three days and seven days, and at 
-20°C and -70°C (including three additional freeze-thawing cycles) for one hour, 24 hours, 
three days, seven days and one month. After the storage period the samples were treated as 
described and after organic layer evaporation stored as dry samples at -70°C pending further 
analysis. Analysis was always done within one month. 
 
Statistics 
 
All statistical calculations were performed with the Statistical Product and Service Solutions 
(SPSS) for Windows, version 6.1 (SPSS, Chicago, IL, USA). Correlations were considered 
statistically significant if calculated p-values were 0.05 or less. 
 
Results and discussion 
 
Chromatography and detection 
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A new bioanalytical assay was developed for the determination of 4-hydroxyifosfamide. 
Recently, a bioanalytical assay was described for 4-hydroxycyclophosphamide.[10] Although 
some parallels exist between the two methods we did change the chromato-graphy 
substantially. Furthermore, a detailed optimization and stability study was performed in order 
to validate every step in the handling of the samples from collection in the clinic to bioanalysis 
in the laboratory. The spectral analysis of 4-hydroxyifosfamide-semicarbazide displayed a 
maximal chromophoric activity at 230 nm. The reversed-phase chromatography was 
investigated at different mixtures of acetonitrile in order to find the optimal combination of good 
separation and a practicable retention time for the analyte. By raising the pH to 7.40 full 
separation of interfering peaks and the analyte was achieved. Peak shape was further 
optimized by addition of 0.5% triethylamine.  
 
Sample pretreatment 
 
For 4-hydroxycyclophosphamide-semicarbazide a two-step liquid-liquid extraction (LLE) with 
ethyl acetate : chloroform (3:1 v/v) is described in order to separate the analyte from 
interfering substances.[10] Since no interfering peaks were found for 4-hydroxyifosfamide-
semicarbazide with the chromatography as described above, extraction could be reduced to 
a single step. Furthermore, the extraction efficacy could be increased by using ethyl acetate 
alone. Optimal balance between extraction of 4-hydroxyifosfamide-semicarbazide and 
efficient removal of interfering endogenous compounds was found to be at pH 7.40. 
Alkalinization to pH 12 resulted in a higher extraction efficacy, but this coincided with 
increased levels of interfering substances. Since 4-hydroxycyclophos-phamide-
semicarbazide is also detectable its usefulness as an internal standard was investigated. 
However, 4-hydroxycyclophosphamide is not commercially available thus rendering it a less 
preferable internal standard. Furthermore, accuracy, within-day and between-day precisions 
were far within accepted limits, thus an internal standard was not considered essential. By 
adding 100 µl semicarbazide of pH 7.40 to 1 ml plasma with an approximate pH of 7.4 
sufficient buffering capacity during LLE was accomplished. LLE of 1 ml plasma resulted in 
turbid reconstituted samples. However, by ultra-sonificating clear solutions were obtained with 
no chromatographic complications when 100 µl of the 150 µl reconstituted sample was 
injected. 
 
Mass spectrometric identification of 4-hydroxyifosfamide-semicarbazide 
 
The directly derivatized preparation and the eluted preparation of 4-hydroxyifosfamide-
semicarbazide were both tested on the high-performance liquid chromatographic system as 
described in this article, before mass spectrometric analysis. No evidence of impurity could 
be detected with high-performance liquid chromatography, but the eluted preparation 
contained relatively high amounts of various salts originating from the mobile phase, which 
interfered with the mass spectrometric analysis. The mass-spectrogram of the preparative 
sample of 4-hydroxyifosfamide-semicarbazide is shown in figure 2. 
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Figure 2. Mass spectrogram of the derivative 4-hydroxyifosfamide-semicarbazone (M+ 334) by means of 
electron spray electron impact mass spectrometry. 
 
At increasing ionization strengths more fragmentation was observed, but all spectra 
contained the parent peak with m/z of 334.1 (M+) with its characteristic chlorine isotopes. The 
sodium adduct at m/z 356 (M++Na) and the potassium adduct at m/z 374 (M++K) confirmed 
the parent peak. Furthermore, a dimer (M2
+) and trimer (M3
+) with similar fragmentation 
patterns were observed albeit at 10 and 100 times lower intensities. The major fragmentation 
peaks were at m/z 80 (NH3
+CH2CH2Cl), 249 (M
+-CNNHCONH2), 259 (M
+-NH2NHCONH2), 
275 (M+-NHCONH2). The peak at m/z 293 (M
+-NHCONH2+H2O) could be explained by 
addition of water (at the C-atom bonded to N-atom of semicarbazide) and subsequent 
fragmentation. The characteristic chlorine isotope fragmentation pattern suggested 
preservation of both chloroethyl-groups. Subsequently, the peak at m/z 315 (M++Na-NHCN) 
was the sodium adduct of the rearranged fragment. 
 
Specificity and selectivity 
 
After normal sample pretreatment with semicarbazide and LLE, plasma samples spiked with 
ifosfamide, carboxyifosfamide, 2-dechloroethylifosfamide, 3-dechloroethylifosfamide, 
ifosforamide mustard, granisetron, dexamethasone, acetaminophen, oxazepam, temazepam, 
topotecan and MESNA did not display any interference with the chromatography. Blank 
plasma and erythrocytes samples of six different individuals showed no interfering 
endogenous substances in the analysis of 4-hydroxyifosfamide-semicarbazide. Typical 
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chromatograms of blank erythrocyte and plasma samples and erythrocyte and plasma patient 
samples of 1.0 µg/ml are shown in figure 3. 
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Figure 3. Chromatograms of a 1-ml blank erythrocyte sample (lower curve of lower set of curves), a 1 ml 
patient erythrocyte sample containing 1.0 µg/ml 4-hydroxyifosfamide (upper curve of lower set of curves), 
a 1 ml blank plasma sample (lower curve of upper set of curves) and a 1 ml patient plasma sample 
containing 1.0 µg/ml 4-hydroxyifosfamide (upper curve of upper set of curves). 
 
However, the semicarbazide derivative of 4-ketoifosfamide did appear in the chromatogram 
(tR 16.5 min.), well separated from 4-hydroxyifosfamide-semicarbazide (tR 13.0 min.). Limited 
analysis of 4-ketoifosfamide revealed that the lower limit of quantification was approximately 5 
µg/ml from a 1 ml plasma sample. Furthermore, 4-hydroxycyclophosphamide-semicarbazide 
(tR 15.5 min.) can be detected, well separated from 4-hydroxyifosfamide-semicarbazide. 
 
Limit of quantification and limit of detection 
 
In three analytical runs the LLQ was determined in five-fold. The percent deviation from the 
nominal concentration (100 ng/ml) and the relative standard deviation were less than 18.1% 
and 7.5%, respectively. Thus, 100 ng/ml was defined to be the LLQ. The LOD in plasma was 
10 ng/ml, with a signal-to-noise ratio of 3. 
 
Validation: accuracy, precision, linearity and recovery 
 
The results from the validation of the method in human plasma are listed in table 1. The use 
of the weight factor of 1/(conc.)2 resulted in a minimal sum of deviations from nominal 
concentrations. The method proved to be accurate (average accuracy at four different 
concentrations between 94.1 and 107.0% of the real concentrations) and precise (within-day 
precision ranged from 2.2 to 6.8% and between-day precision ranged from 2.6 to 7.2%). 
Correlation coefficients (r2) of calibration curves were always higher than 0.995 as 
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determined by least squares analysis. Calibration curves proved to be linear in the range of 
0.1-10 µg/ml with use of the F-test for lack of fit as an indicator of linearity of the regression 
model. Extraction recoveries from plasma were 96.0 ± 11.2 and 99.8 ± 3.7% for a 0.5 and 1.0 
µg/ml 4-hydroxyifosfamide spiked sample (n=3), respectively. Similar, 4-hydroxyifosfamide 
was extracted from erythrocytes with 108.6 ± 9.5 and 118.8 ± 4.3% recovery, respectively. 
Since extraction recovery of erythrocytes were equal to that of plasma, a limited validation of 
the analysis in erythrocytes is sufficient. 
 
Table 1. Accuracy, within-day and between-day precision of the analysis of the 4-
hydroxyifosfamide-semicarbazone derivative in human plasma, calculated using one-way 
ANOVA (p<0.05). Total number of different runs, total number of replicates per run for 
accuracy and total number of replicates per run for precision were respectively 3, 5 and 4. 
 
Concentrations Accuracy (%) Precision (%) 
(µg/ml) Mean ± S.D. 95% C.I. Mean ± S.D. Within-day Between-day 
0.1 94.1±7.3 90.1-98.2 94.4±7.9 6.0 6.8 
0.5 100.0±10.3 94.3-105.7 110.4±8.8 6.2 7.2 
5.0 107.0±4.2 104.7-109.3 108.3±3.4 2.2 2.6 
10.0 101.8±4.1 99.6-104.1 102.6±4.0 2.3 3.7 
 
Abbreviations: S.D.= standard deviation, C.I.= confidence interval. 
 
Optimization 
 
Degradation during sample collection of underivatized 4-hydroxyifosfamide determined under 
various conditions is shown in table 2. With higher temperature and increasing time, 
breakdown is observed at both concentrations. Most relevant is the observation that at 4°C 
during the first 20 min. 4-hydroxyifosfamide is stable. The sample collection process in the 
clinic was always at 4°C and within 10 min., starting directly after collecting the blood until 
semicarbazide derivatization and storage. Optimal incubation during derivatization of 4-
hydroxy-ifosfamide with semicarbazide is shown in table 3. 
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Table 2. Effect of temperature and exposure time on degradation of 4-hydroxyifosfamide 
without semicarbazide protection in human plasma during sample collection. 
 
Temp. Conc. Degradation (% nominal conc.) ± C.V. (%) N 
 (µg/ml) 10 min. 20 min. 30 min. 60 min. 90 min.  
4°C 0.5 
5.0 
100.0±0.8 
100.0±2.7 
94.5±4.1 
94.4±1.7 
76.7±0.3 
93.8±3.0 
85.2±1.5 
93.0±0.5 
87.9±4.6 
83.0±0.6 
3 
3 
25°C 0.5 
5.0 
98.0±1.5 
87.2±0.8 
94.3±1.6 
76.4±4.3 
75.7±3.6 
64.3±7.2 
57.9±2.0 
40.0±2.8 
56.5±2.4 
23.3±15.0 
3 
3 
37°C 0.5 
5.0 
69.9±6.7 
67.0±4.6 
64.3±3.1 
39.8±4.9 
40.6±1.3 
18.1±13.4 
44.2±8.6 
9.9±6.5 
28.1±6.4 
7.8±14.9 
3 
3 
 
Abbreviations: N=total number of replicates, C.V.=coefficient of variation. 
 
Table 3. Effect of temperature and incubation duration on derivatization of 4-
hydroxyifosfamide with semicarbazone in human plasma during sample pretreatment. 
 
Temp. Conc. Recovery (%) ± C.V. (%) N 
 (µg/ml) 10 min. 20 min. 60 min.  
4°C 0.5 
5.0 
100.0±20.2 
77.7±6.3 
82.7±2.1 
100.0±11.4 
73.3±0.4 
89.1±1.2 
2 
2 
25°C 0.5 
5.0 
65.0±0.4 
92.5±7.1 
51.0±10.7 
79.5±2.5 
40.4±5.5 
87.1±9.8 
2 
2 
40°C 0.5 
5.0 
17.9±1.0 
52.3±4.1 
18.6±6.1 
46.1 
18.1±2.0 
47.2±1.2 
2 
2 
60°C 0.5 
5.0 
22.1±3.4 
51.1±0.8 
15.9±9.0 
41.1±3.7 
19.6±0.7 
39.2±6.8 
2 
2 
 
Abbreviations: N=total number of replicates, C.V.=coefficient of variation. 
 
Belfayol et al. reported optimal incubation for the formation of 4-hydroxy-cyclophosphamide-
semicarbazide at 60°C for 60 min.[10] Our investigations on the formation of 4-
hydroxyifosfamide-semicarbazide show an optimal incubation at 4°C with minimal exposure. 
At 60°C for 60 min. a 60% reduction of 4-hydroxyifosfamide-semicarbazide can be observed. 
Although the reaction of 4-hydroxyifosfamide with semicarbazide might be maximized at 
higher temperatures, the still underivatized 4-hydroxyifosfamide is susceptible to breakdown 
in non-cooled circumstances. Therefore, the best method of derivatization appears to be a 
fast and cooled incubation with semicarbazide. This guarantees full albeit slow derivatization, 
but without unwanted degradation of 4-hydroxyifosfamide. Alteration of the amount of added 
semicarbazide (0.125-2 M) did not influence the intensity of the 4-hydroxyifosfamide-
semicarbazide or the non-interfering endogenous peaks. 
 
Stability during storage 
 
The stability during storage of 4-hydroxyifosfamide-semicarbazide in biological matrix is 
represented in table 4. During the first month the degradation of 4-hydroxyifosfamide-
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semicarbazide in biological matrix was less than 3% at -70°C and 10.6% at -20°C. Storage of 
pretreated 4-hydroxyifosfamide-semicarbazide samples (dry residues after LLE and solvent 
evaporation) was also stable for at least one month. By storing biological samples containing 
4-hydroxyifosfamide-semicarbazide at most for one month at -20°C before analysis sample 
stability is not jeopardized. 
 
Table 4. Stability during storage of human plasma samples spiked with 4-hydroxyifosfamide-
semicarbazone derivative. 
 
Storage Conc. Recovery (%) ± C.V. (%) N 
 (µg/ml) 1 hr. 24 hrs. 3 days  7 days  1 month  
60°C 0.5 
5.0 
100±1.7 
100±0.5 
52.6±1.4 
47.4±0.7 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
3 
3 
37°C 0.5 
5.0 
100±2.0 
100±2.9 
81.0±0.5 
84.2±1.0 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
3 
3 
25°C 0.5 
5.0 
100±1.3 
100±2.4 
91.9±3.9 
89.7±0.7 
74.4±1.4 
79.5±3.1 
73.0±4.8 
77.6±1.5 
n.d. 
n.d. 
3 
3 
-20°C* 0.5 
5.0 
100.0±5.5 
100.0±2.6 
n.d. 
n.d. 
105.5±4.1 
104.9±0.8 
101.8±5.5 
93.2±2.3 
100.6±3.1 
89.4±1.7 
3 
3 
-70°C* 0.5 
5.0 
100.0±6.6 
100.0±2.2 
n.d. 
n.d. 
100.1±5.9 
104.0±1.6 
100.3±5.8 
100.8±2.5 
97.0±5.2 
104.5±0.5 
3 
3 
 
Abbreviations: N=total number of replicates, C.V.=coefficient of variation, *=including three freeze-thaw cycles, 
n.d.=not determined. 
 
Analysis of patient samples 
 
The applicability of the 4-hydroxyifosfamide assay for pharmacokinetic studies in patients 
receiving ifosfamide treatment was demonstrated, as depicted in figure 4. The assay allowed 
monitoring of plasma and erythrocytes levels of 4-hydroxyifosfamide. In addition, the 
erythrocytes can be used to investigate preferential transport routes of 4-hydroxyifosfamide 
throughout the body.[1] Since, 4-hydroxyifosfamide is the transport form directly prior in the 
cascade to the ultimate active metabolite ifosforamide mustard and the latter is unable to 
penetrate cell walls, it is the most relevant metabolite in blood to monitor ifosfamide 
pharmacokinetics and metabolism in relation to efficacy of ifosfamide treatment.  
 
Conclusions 
 
A validated assay for the quantitative determination of 4-hydroxyifosfamide in human plasma 
and erythrocytes has been described. The assay meets the current requirements as to the 
validation of a bioanalytical methodology and can be used for the pharmacokinetic studies 
with ifosfamide treated patients. It is our experience that the currently described high-
performance liquid chromatographic assay can readily be used in a hospital laboratory 
environment for monitoring 4-hydroxyifosfamide concentrations. 
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Figure 4. 4-Hydroxyifosfamide concentrations in plasma and erythrocytes (solid and dashed line, 
respectively) in a patient receiving a 72-hour intravenous infusion of 9 g/m2 ifosfamide. 
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Simultaneous determination of ifosfamide 
and its metabolite ifosforamide mustard in 
human plasma by high-performance liquid 
chromatography 
 
 
 
 
 
 
Summary 
 
Because ifosforamide mustard is the active alkylating metabolite of ifosfamide, it is of 
particular interest in the pharmacokinetic analysis of patients undergoing ifosfamide 
treatment. This paper presents an assay for the simultaneous determination of ifosforamide 
mustard and ifosfamide after derivatization with diethyldithiocarbamate (DDTC), subsequent 
liquid-liquid extraction of the plasma with acetonitrile and using reversed phase high-
performance liquid chromatography with ultra-violet detection at 276 nm. Structural 
confirmation of the analytes was accomplished using mass spectrometry (MS). Reaction 
conditions such as incubation duration, temperature and concentration of derivatization agent 
were investigated; 30 min at 70°C with 100 mg/ml DDTC was optimal. The presented 
analytical method proved to be accurate, precise and linear for ifosforamide mustard and 
ifosfamide concentrations, ranging from 0.100-50.0 and 0.100-100 µg/ml, respectively, and 
with lower limits of quantification of 0.100 µg/ml for both analytes. A typical patient 
pharmacokinetic profile is presented to demonstrate the applicability of the assay in clinical 
samples. The analytical method could be employed in high-throughput clinical analysis of 
ifosforamide mustard and ifosfamide patient samples.  
Introduction 
 
Ifosfamide, N,3-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide 
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(HoloxanÒ, IfexÒ) is commonly used for the treatment of various solid tumours, soft tissue 
sarcomas and haematological malignancies in adults and children. Ifosfamide is a prodrug, 
which needs activation via the cytochrome P450 enzymatic system in the liver to exert its 
alkylating activity.[1] First, ifosfamide is hydroxylated to 4-hydroxyifosfamide as represented in 
figure 1.  
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Figure 1. Metabolism of ifosfamide. 
4-Hydroxyifosfamide exists in equilibrium with its tautomeric form aldoifosfamide. 
Aldoifosfamide can be converted into the final alkylating agent ifosforamide mustard with 
concurrent acrolein formation. Besides activation de-activation occurs, yielding 2-
dechloroethylifosfamide and 3-dechloroethylifosfamide with equimolar release of neurotoxic 
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chloroacetaldehyde. In the (tumour)cell ifosforamide mustard reacts with DNA causing 
interstrand cross-links, leading to cell death.[2] Ifosfamide is known to increase its own 
metabolism (autoinduction).[3] 
P
O
HO
NH-CH2-CH2-Cl
NH-CH2-CH2-Cl
+ C
S
N
C2H5
C2H5HS
NH-CH2-CH2-S
NH-CH2-CH2-Cl
O
CH2
CH2
CH2
O
P
C N
C2H5
C2H5
Ifosforamide mustard DDTC
C2H5
C2H5
NC
P
O
HO
NH-CH2-CH2-S
NH-CH2-CH2-S
S
S
C
S
N
C2H5
C2H5
Endocyclic mono-derivatised ifosfamide IFO(DDTC)
di-derivatised ifosforamide mustard IFM(DDTC)2
Exocyclic mono-derivatised ifosfamide IFO(DDTC)
S
C2H5
C2H5
NC
P
O
NH-CH2-CH2-Cl
NH-CH2-CH2-S
Ifosfamide
NH-CH2-CH2-Cl
NH-CH2-CH2-Cl
O
CH2
CH2
CH2
O
P
CH2
CH2
CH2
O
DDTC
HS C2H5
C2H5
N
S
C
DDTC
HS C2H5
C2H5
N
S
C
2
+
+
 
 
Figure 2. Derivatization of ifosforamide mustard and ifosfamide with diethyldithiocarbamate (DDTC). 
 
Recently, an assay was reported for ifosforamide mustard.[4] This method consisted of direct 
derivatization of ifosforamide mustard in plasma with diethyldithiocarbamate (DDTC) and 
subsequent solid phase extraction (SPE) of the resulting derivative. The samples were 
stabilized by adding semicarbazide and sodium chloride, which prevent auto-catalytic 
breakdown of 4-hydroxyifosfamide to ifosforamide mustard and further ifosforamide mustard 
breakdown, respectively. During large scale implementation of this method various problems 
were encountered. These were mainly clogging of the SPE columns, low analytical column 
half-life, and late co-eluting peaks, preventing rapid use in clinical investigations with high 
sample throughput. A faster more reproducible method has now been developed for 
ifosforamide mustard, which also permitted simultaneous determination of ifosfamide. No 
easy applicable assay for both ifosforamide mustard and ifosfamide by high-performance 
liquid chromatography has been described thus far. Derivatization of ifosforamide mustard 
(IFM) and ifosfamide (IFO) with DDTC leads to IFM(DDTC)2 and IFO(DDTC) as depicted in 
figure 2. Structural confirmation of the analytes and assay validation were performed for both 
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ifosforamide mustard and ifosfamide. 
 
Materials and Methods 
 
Equipment 
 
The high-performance liquid chromatographic equipment consisted of an integrated system 
with a model SCM1000 in-line degassing unit, a model P1000 pump, a model AS3000 
automated injector with a 100-µl loop, a model UV150 ultra-violet (UV) detector operated at 
276 nm and a DataJet integrator (Thermo Separation Products, Breda, The Netherlands). 
Data were analysed using PC1000 software (Thermo Separation Products, Breda, The 
Netherlands) using a Dell optiplex Gs Pentium personal computer. A 250 x 40 mm I.D. RP8 5 
µm particle size Prodigy 5 C8 column with a Security Guard C8 pre-column (Phenomenex, 
Torrance, CA, USA) was operated at ambient temperature. The analytical column was 
washed monthly with 1-propanol in order to maintain high separation efficiency. The mobile 
phase consisted of acetonitrile (AcN):water (32:68 v/v) containing 25 mM K2HPO4 buffer pH 
8.0. For identification of the derivatives a mass spectrometer (MS) was used operating with 
direct continuous split-injection (Sciex, Thornhill, ON, Canada). Electrospray ionization (1500 
V) was achieved using a TurboIonä sample inlet. Ions were created at atmospheric pressure 
and were transferred to a model API 365 triple quadrupole mass spectrometer (LC/ESI-
MS/MS) with a dwell-time of 0.1-1 msec. The channel electron multiplier was set at 1900 V. 
For optimising the wavelength of detection, the UV-absorption spectrum was recorded on-line 
using a Waters model 996 Photodiode-Array (PDA) detector (Waters Chromatography, 
Milford,  Ma, USA). 
 
Chemicals 
 
Ifosforamide mustard (D-18847, Lot 034.5333) and all other ifosfamide and 
cyclophosphamide metabolites were a kind gift of Dr J. Pohl, ASTA Medica AG (Frankfurt, 
Germany). Sodium diethyldithiocarbamate was obtained from Sigma (St. Louis, Mo, USA). 
AcN and methanol (HPLC supra-gradient) were purchased from Biosolve (Valkenswaard, The 
Netherlands). K2HPO4, sodium chloride, hydrochloric acid and sodium hydroxide (suprapure 
grade) were obtained from Merck (Darmstadt, Germany). Semicarbazide hydrochloride (p.a. 
grade) was purchased from Acros (Geel, Belgium). Distilled water was used throughout.  
Preparation of standards 
 
Blank, drug-free plasma was obtained from the Central Laboratory of the Blood Transfusion 
Service (Amsterdam, The Netherlands). Plasma was centrifuged at 1,000 g for 5 min and the 
pellet was discarded. To the supernatant a solution containing 2 M semicarbazide, 1 M 
sodium chloride pH 7.40 (SCZ*) was added, yielding a mixture of plasma:SCZ* 10:1 v/v 
(plasma*). After storage of at least one hour at -70°C the plasma* was thawed and 
centrifuged again at 1,000 g for 5 min. The supernatant was used as blank plasma in the 
assay. Ifosforamide mustard was dissolved as a 1 mg/ml solution in a phosphate buffer (1 M 
sodium chloride, 0.1 M K2HPO4, pH=8.00)(PPB) immediately prior to preparation of the 
Bioanalysis of Ifosforamide Mustard        73 
standards. Ifosfamide was also dissolved as a 1 mg/ml solution in PPB. 350 µl Ifosforamide 
mustard and ifosfamide solutions in PPB were added to 500 µl plasma* in a 2.0 ml Eppendorf 
cup, resulting in combined calibration curves of 0, 0.100, 0.250, 0.500, 1.00, 2.50, 5.00, 10.0 
and 50.00 µg/ml ifosforamide mustard and 0, 0.100, 0.500, 1.00, 5.00, 10.0, 25.0, 50.0 and 
100 µg/ml ifosfamide. Quality control samples were prepared similarly but from different stock 
solutions and separate weighting of the standards at 0.100, 0.250, 5.00 and 50.0 µg/ml 
ifosforamide mustard and 0.100, 0.500, 50.0 and 100 µg/ml ifosfamide.  
 
Sample pretreatment 
 
The derivatising agent was added as a 50-µl volume of 100 mg/ml DDTC in PPB to 500 µl 
plasma* and 350 µl PPB. After whirl-mixing for 15 sec the samples were placed for 30 min at 
70°C in a thermostatically controlled waterbath. After incubation the samples were placed on 
ice water in order to stop the derivatization reaction. Liquid-liquid extraction was performed by 
adding 1,000 µl AcN. After whirl-mixing thoroughly three times for 1 min and subsequent 
centrifugation at 3,000 g for 10 min at 4°C, a 700-µl volume of the AcN fraction was 
transferred to a clean 1.5 ml Eppendorf cup and evaporated to dryness under a gentile 
stream of nitrogen at 40°C. The samples were reconstituted by adding 150 µl mobile phase. 
After whirl-mixing for 1 min and subsequent centrifugation at 3,000 g for 5 min at ambient 
temperature, the supernatants of the samples were transferred to 200 µl inserts in vials. The 
injected volume was 50 µl. 
 
Patient sample collection and pretreatment 
 
Whole blood samples were collected and immediately placed on ice water, centrifuged at 
1,000 g for 5 min at 4°C and 1 ml plasma was transferred to a 2-ml Eppendorf cup containing 
100 µl SCZ*, yielding plasma*. After thorough vortex mixing the samples were stored at -
70°C. The entire sample handling was always performed within 10 min. After thawing, a 500-
µl volume of patient plasma* was prepared in duplicate, identical to standard sample 
pretreatment. 
 
Identification 
 
Identification of derivatized ifosforamide mustard was achieved by derivatising an 850 µl 
volume of 5 mg/ml ifosforamide mustard in PPB with 50 µl 500 mg/ml DDTC in water and 
incubation and extraction with AcN as described for the plasma samples. After evaporation of 
the organic extract, the sample was reconstituted in 100 µl mobile phase and injected in the 
high-performance liquid chromatographic system. The analyte was isolated by collecting the 
fraction containing the ifosforamide mustard-derivative. The eluate was again extracted with 
2:1 (v/v) AcN after addition of 1 g sodium chloride. After whirl-mixing and centrifugation the 
AcN-layer was transferred and evaporated as described above. Since, the residue could be 
contaminated by sodium chloride dissolved in co-extracted water in the AcN-layer, the dry 
residue was again extracted with 1 ml AcN. After transfer of the AcN-layer and subsequent 
evaporation the clean residue was stored at -70°C pending identification by MS. Derivatization 
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of ifosfamide yields two products as represented in figure 2, with two corresponding peaks in 
the high-performance liquid chromatographic chromatogram. The ifosfamide-derivatives were 
isolated similarly by collecting both peaks separately. Partial re-injection of the final AcN-layer 
on the high-performance liquid chromatographic system confirmed the purity of the isolated 
ifosforamide mustard and ifosfamide-derivatives. The isolated derivatives were reconstituted 
in 80% methanol solution and analysed by MS for identification.  
 
Optimization of derivatization  
 
Derivatization conditions were changed to find the optimal incubation temperature, duration 
and DDTC concentration. Variations in conditions were tested with 0.500 and 5.00 µg/ml 
ifosforamide mustard spiked plasma in duplicate. Derivatization temperature was investigated 
at ambient temperature (20°C), 40°C and 70°C for 5, 10, 30 and 60 min and the reaction 
duration at 70°C for 0, 5, 10, 20, 30, 60 and 120 min. To find the optimal derivatization reagent 
concentration tests were performed at 70°C for 30 min with 0, 0.100, 0.500, 1.00, 5.00, 10.0, 
50.0, 100 and 500 mg/ml DDTC. 
 
Specificity and selectivity 
 
Potential interference from endogenous compounds was investigated by analysing six 
different blank plasma samples. The following compounds were investigated for interference 
with the analytical method: 2-dechloroethylifosfamide, 3-dechloroethyl-ifosfamide, 
didechloroethylifosfamide, 4-ketoifosfamide, carboxyifosfamide, 4-hydroxy-ifosfamide with 
and 4-hydroxyifosfamide without semicarbazide stabilization. Possible co-medication was 
also tested for interference. Tested substances were topotecan, paclitaxel, ketoconazole, 
granisetron, dexamethasone, acetaminophen, oxazepam, temazepam, caffeine, furosemide 
and sodium 2-mercaptoethane sulphonate (MESNA). All compounds were tested at a 
concentration of 20 µg/ml. 
Limit of quantification 
 
The lower limits of quantification (LLQ) of ifosforamide mustard and ifosfamide were 
investigated in plasma samples from three different donors by a five-fold determination in 
three analytical runs. For the concentration to be accepted as the LLQ, the percentage 
deviation from the nominal concentration (measure of accuracy) and the relative standard 
deviation (measure of precision) were to be less than 20%. The upper limits of quantification 
(ULQ) of ifosforamide mustard and ifosfamide were defined as 50.0 and 100 µg/ml, 
respectively, based upon the expected clinical concentration range. 
 
Validation: accuracy, precision and linearity 
 
Accuracy, between-day and within-day precisions of the method were determined by 
assaying five replicate quality control samples in plasma at four different ifosforamide 
mustard and ifosfamide concentrations (0.100, 0.250, 5.00 and 50.0 µg/ml and 0.100, 0.500, 
50.0 and 100 µg/ml, respectively) in three different analytical runs. Accuracy was measured 
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as a percentage of the nominal concentration. The within-day and between-day precisions 
were obtained by analysis of variance (ANOVA) for each test concentration using the 
analytical run as grouping variable. For the construction of each calibration curve eight spiked 
plasma samples were analysed in duplicate. After optimization of their weighting factors, 
linearity of the plasma calibration curves was tested with the F-test for lack of fit.  
 
Extraction recovery 
 
Recovery of extraction of the ifosforamide mustard-derivative was determined by dissolving 
the isolated ifosforamide mustard-derivative in PPB, resulting in theoretical 1.00 and 10.0 
µg/ml solutions which were diluted further. Full recovery (without sample extraction) was 
achieved by addition of AcN to the derivative solution in PPB (68:32 v/v), producing a solution 
identical to the mobile phase, which was injected directly into the high-performance liquid 
chromatographic system. Spiked plasma samples were extracted, transferred, evaporated 
and subsequently reconstituted in mobile phase and injected on the high-performance liquid 
chromatographic system as described above. Furthermore, 25 mM K2HPO4 pH 8.00 was 
also added to the AcN-layer after extraction (68:32 v/v) of additional samples, producing a 
solution identical to the mobile phase. Recoveries were calculated by comparing the directly 
injected ifosforamide mustard-derivative to the extracted samples with and without the 
evaporation-step. 
 
Statistics 
 
All statistical calculations were performed with the Statistical Product and Service Solutions 
(SPSS) for Windows, version 6.1 (SPSS, Chicago, IL, USA). Correlations were considered 
statistically significant if calculated p-values were 0.05 or less. 
 
Results and discussion 
 
Chromatography and detection 
 
The chromatographic method enabled sufficient separation of the analytes. No ion-exchange 
modifier was used since it did not prove to be essential and better column endurance could 
be obtained without it. Figure 3 represents typical chromatograms of a blank sample, a patient 
sample of 3.20 and 14.9 µg/ml ifosforamide mustard and ifosfamide, respectively, and a 
spiked sample of 5.00 and 25.0 µg/ml ifosforamide mustard and ifosfamide, respectively.  
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Figure 3. Typical chromatograms of a blank (bottom), a patient (middle) and a spiked (top) plasma 
sample with 0, 3.20 and 5.00 µg/ml ifosforamide mustard (11.0 min) and 0, 14.9 and 25.0 µg/ml 
ifosfamide (29.8 and 31.5 min), respectively. 
 
The patient sample was taken at the end of a 1-hour 1.2 g/m² ifosfamide intravenous (i.v.) 
infusion. Noteworthy are the large injection peak consisting of non-retained DDTC and 
(derivatized) matrix components, the IFM(DDTC)2 peak at 11.0 min and the IFO(DDTC) 
peaks at 29.8 and 31.5 min, respectively. Since the ratio of the exo- and endocyclic 
ifosfamide-derivative peaks was always equal to 5:1 and it can be expected that the molar 
absorptivities of the compounds are identical, the sum of both peaks was used in the 
quantification of ifosfamide. 
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Sample pretreatment 
 
Besides stabilization of underivatized ifosforamide mustard,[4] the addition of sodium chloride 
in PPB to the plasma sample also prevented mixing of the aqueous and organic-phases 
during the liquid-liquid extraction enabling easy transfer of the organic-layer and preventing 
undesired co-extraction of water-soluble plasma components. SCZ* addition prevented 
autocatalytic degradation of 4-hydroxyifosfamide. After a freeze-thaw cycle and subsequent 
centrifugation, addition of SCZ* to blank or patient plasma resulted in a clear plasma layer and 
a pellet. If the plasma was not subjected to this procedure no reproducible separation of the 
aqueous and organic-layer could be obtained. The pellet possibly contained plasma 
components that otherwise prevent a clear separation of the phases. 
 
Identification  
 
The peak of the ifosforamide mustard-derivative was identified as double derivatized 
IFM(DDTC)2, as depicted in figure 4. The molecular weight of IFM(DDTC)2 is 446.1, as 
depicted in figure 2. Consequently, the parent-peak (MH+) can be observed at a mass-to-
charge ratio (m/z) of 447. The sodium and potassium-adducts were observed at m/z 469 and 
485, respectively. A dimer (M+2) was observed at m/z 892 with its typical sodium-adduct at 
m/z 915. The fragment at m/z 116 and m/z 176 may be explained by CSN(C2H5)2 and 
C2H5SCSN(C2H5)2 fragments, respectively. The two ifosfamide peaks were identified as 
isomeric monomers of IFO(DDTC), as depicted in figure 2. The DDTC could react with either 
the chloroethylgroup attached to the exo- or endocyclic nitrogen atom. The molecular weight 
of IFO(DDTC) is 373.1. Figures 5 and 6 demonstrate similar MS patterns for both isomers. 
Although differences in relative intensity between fragments were observed, no unique 
fragments could be distinguished between the two isomers. The MH+ was observed at m/z 
374 with its typical Cl atom isotope peaks. The sodium and potassium-adducts were 
observed at m/z 396 and 411. A dimer (M+2) was observed at m/z 746 with its sodium and 
potassium-adducts at m/z 769 and 785. Since none of the theoretical possible fragments of 
either the exo- or endocyclic derivatized ifosfamide were observed uniquely with MS, further 
identification was performed by refragmentation of the parent-peak (MS2). MS2 of peak 1 
yielded fragments at m/z 92 and 120. These fragments may be explained by CH2NHC2H4Cl 
and C3H6NHC2H4Cl, respectively.  
78           Chapter 2.3 
1.38e6 cps+Q1 MCA (5 scans): from IFM(DDTC)2
39
60
88
116
176
220
277
304
396
469
549
585
639
723
842
915
959
4 4 7
8 9 2
4 8 4
1 9 3
100 200 300 400 500 600 700 800 900
m/z, amu
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
%
 In
te
ns
ity
 
Figure 4. Mass-spectrum of ifosforamide mustard di-derivative (IFM(DDTC)2). IFM(DDTC)2 was 
isolated at 11.0 min. 
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Figure 5. Mass-spectrum of the exocyclic ifosfamide mono-derivative (IFO(DDTC)) isolated 
at 29.8 min.  
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Figure 6. Mass-spectrum of the endocyclic ifosfamide mono-derivative (IFO(DDTC)) isolated 
at 31.5 min. 
 
The exocyclic derivative can yield these fragments, the endocyclic derivative cannot. 
Therefore, it was concluded that ifosfamide peak 1 was the exocyclic derivatized ifosfamide 
and ifosfamide peak 2 was the endocyclic derivatized ifosfamide. The UV-absorption 
spectrum is shown in figure 7. A maximum is observed at 276 nm. 
 
 
 
Figure 7. Ultra-violet absorption spectrum of ifosforamide mustard di-derivative. 
 
276 
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Specificity and selectivity 
 
After sample pretreatment, plasma samples spiked with 2-dechloroethylifosfamide, 
didechloroethylifosfamide, carboxyifosfamide, topotecan, paclitaxel, acetaminophen, caffeine, 
furosemide and MESNA did not display any interference with the method. Non-interfering 
peaks were detected for 3-dechloroethylifosfamide (9.0 min), 4-ketoifosfamide (19.8 min), 
ketoconazole (83.5 min), granisetron (6.0 min), dexamethasone (12.5 min), oxazepam (14.5, 
21.3 and 26.4 min), temazepam (22.8 min), compared to ifosforamide mustard (11.0 min). 
Stabilized 4-hydroxyifosfamide (with semicarbazide) resulted in a peak at 11.4 min. 
Unstabilized 4-hydroxyifosfamide was spontaneously converted to ifosforamide mustard (11.0 
min). Blank plasma samples of six different individuals showed no interfering endogenous 
substances in the analysis. Addition of semicarbazide did not interfere with the 
chromatography. 
 
Optimization of derivatization 
 
The derivatization temperature did not demonstrate an optimum, but the variability with 0.500 
and 5.00 µg/ml ifosforamide mustard at 70°C was less than at 20°C and 40°C. Therefore, 
70°C was selected as derivatization temperature. Optimization of derivatization duration 
scaled to 100% is presented in figure 8.  
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Figure 8. Effect of incubation duration on derivatization of ifosforamide mustard (IFM) with 
diethyldithiocarbamate. 
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Figure 9. Effect of diethyldithiocarbamate (DDTC) concentration on derivatization of ifosforamide 
mustard (IFM). 
 
The optimum derivatization duration was set at 30 min. The effect of DDTC concentration on 
the derivatization of ifosforamide mustard is presented in figure 9. Between 0 and 5.00 mg/ml 
no ifosforamide mustard-derivative could be detected. Between 25.0 and 500 mg/ml DDTC a 
log-linear relationship between derivative response and DDTC concentration is observed. 
Although no optimum was reached, chromatographic separation between the unretained 
DDTC peak and the ifosforamide mustard-derivative deteriorated at reagent concentrations of 
500 mg/ml. Therefore, 100 mg/ml DDTC was chosen as the most optimal concentration for 
derivatization.  
 
Limit of quantification 
 
In three analytical runs the LLQs of ifosforamide mustard and ifosfamide were determined in 
five-fold. The mean percentage deviation from the nominal concentration at 0.100 µg/ml 
ifosforamide mustard and ifosfamide were 10.2 and 1.9% with a relative standard deviation of 
17.2 and 11.0%, respectively. Therefore, both LLQs were determined to be 0.100 µg/ml. 
 
Validation: accuracy, precision and linearity 
 
The results from the validation of the method in human plasma are listed in table 1. The use 
of the weighting factor of 1/(conc.)2 resulted in a minimal sum of squares of residuals from 
the nominal concentrations. The method proved to be accurate for both analytes (average 
accuracy at four different concentrations between 89.5 and 110.0% of the nominal 
concentrations) and precise (within-day precision ranged from 2.8 to 15.8% and between-day 
precision ranged from 2.0 to 10.0%). Correlation coefficients (r2) of calibration curves were 
always higher than 0.995 as determined by least sum of squares analysis. Calibration curves 
of ifosforamide mustard and ifosfamide proved to be linear in the range of 0.100-50.0 and 
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0.100-100 µg/ml, respectively, without lack of fit. Furthermore, no systematic proportional or 
additive errors were observed. 
 
Table 1. Accuracy, within-day and between-day precisions of ifosforamide mustard (IFM) and ifosfamide 
(IFO) analysis in human plasma. 
 
Analyte Concentrations Accuracy (%) Precision (%) 
 (µg/ml) Mean ± S.D. 95% C.I. Within-day Between-day 
IFM 0.100 110.0±17.0 100.6-119.7 15.8 N.A. 
IFM 0.250 107.2±15.2 98.7-115.4 11.3 10.0 
IFM 5.00 106.6±8.0 102.1-111.0 4.5 7.2 
IFM 50.0 101.4±8.3 96.8-106.0 2.8 9.2 
IFO 0.100 101.9±11.0 95.8-108.0 11.2 N.A. 
IFO 0.500 94.6±5.1 91.8-97.4 5.1 2.0 
IFO 50.0 90.6±5.3 87.6-93.5 4.2 4.9 
IFO 100 89.5±3.6 87.5-91.5 4.0 N.A. 
 
Abbreviations: S.D.= standard deviation, C.I.= confidence interval, N.A.= not applicable, between-day variation 
did not exceed within-day variation. 
 
Extraction recovery 
 
Extraction recoveries (mean ± coefficient of variation) of the ifosforamide mustard-derivative 
from plasma with the evaporation-step were 62.2 ± 6.7 and 62.4 ± 13.4% for 1.00 and 10.0 
µg/ml ifosforamide mustard (n=3), respectively. Extraction recoveries of the ifosforamide 
mustard-derivative from plasma without evaporation-step were 62.9 ± 8.4 and 59.8 ± 3.3% for 
1.00 and 10.0 µg/ml ifosforamide mustard spiked sample (n=3), respectively. It is obvious that 
there is no significant extraction-loss of ifosforamide mustard due to the evaporation-step. 
 
Analysis of patient samples 
 
Figure 10 represents a typical pharmacokinetic profile of a patient receiving 3 g/m² ifosfamide 
i.v. in three hours on two consecutive days. Ifosfamide and ifosforamide mustard 
concentrations accumulated over time, but were also eliminated faster on the second day. 
This resulted in similar maximum ifosfamide concentrations on day 1 and 2. But ifosforamide 
mustard concentrations were substantially higher on day 2, because more ifosfamide was 
metabolized to ifosforamide mustard on day 2. This phenomenon can be explained by the 
autoinduction of ifosfamide and its effect on the metabolism. 
Bioanalysis of Ifosforamide Mustard        83 
0.1
1
10
100
0 12 24 36 48
Time (h)
C
o
n
c
. (
µ
g
/m
l)
IFM
IFO
 
Figure 10. Ifosforamide mustard (IFM, lower curve) and ifosfamide (IFO, upper curve) concentrations in 
plasma in a patient receiving 3 g/m² ifosfamide i.v. in three hours on two consecutive days. 
 
Conclusions 
 
An analytical method for the simultaneous determination of ifosforamide mustard and 
ifosfamide in human plasma was described. This technique employed derivatization with 
DDTC followed by deproteinization with AcN. Quantification was achieved by reversed phase 
high-performance liquid chromatographic with UV-detection. Identification of the derivatized 
analytes was accomplished using MS and LC-PDA. Incubation settings were optimized. It is 
our experience that the presented assay can be readily used in a hospital laboratory 
environment for simultaneous monitoring of ifosforamide mustard and ifosfamide 
concentrations in patients.  
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Distribution of ifosfamide and metabolites 
between plasma and erythrocytes 
 
 
 
 
 
Summary 
 
The distribution of ifosfamide and its metabolites 2-dechloroethylifosfamide, 3-dechloro-
ethylifosfamide, 4-hydroxyifosfamide and ifosforamide mustard between plasma and erythro-
cytes was examined in vitro and in vivo. In vitro distribution was investigated by incubating 
whole blood with various concentrations of ifosfamide and its metabolites followed by 
separation of plasma and erythrocyte layers and subsequent analysis. In vivo distribution of 
ifosfamide, 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide was determined in 
seven patients receiving a 72-hour intravenous continuous infusion of 9 g/m² ifosfamide. In 
vitro distribution equilibrium between erythrocytes and plasma was obtained quickly after drug 
addition. Mean (±sem) in vitro and in vivo erythrocyte (e)-plasma (p) partition coefficients 
(Pe/p) were 0.75±0.01 and 0.81±0.03, 0.62±0.09 and 0.73±0.05, 0.76±0.10 and 0.93±0.05 and 
1.38±0.04 and 0.98±0.09 for ifosfamide, 2- and 3-dechloroethylifosfamide and 4-
hydroxyifosfamide respectively. These ratios were independent of concentration and 
unaltered with time. The ratios of the area under the erythrocyte and plasma concentration-
time curves (AUCe/p) obtained in patients were 0.96±0.03, 0.87±0.07, 0.98±0.06 and 
1.34±0.39, respectively. A time- and concentration dependent distribution-equilibrium 
phenomenon was observed during incubation with ifosforamide mustard. It was hypothesized 
that the more hydrophilic ifosforamide mustard is less capable of penetrating the erythrocyte 
compared to the other analytes. Complete spontaneous  in vitro conversion of 4-
hydroxyifosfamide to ifosforamide mustard was observed. The equivalency in red blood cell 
partitioning of ifosfamide and its metabolites under in vitro and in vivo conditions was 
corroborated by the AUCe/ps, because similar ratios were observed. It is concluded that 
ifosfamide and metabolites rapidly reach distribution equilibrium between erythrocytes and 
plasma; the process is slower for ifosforamide mustard. Drug distribution to the erythrocyte 
fraction ranged from about 38% for 2-dechloroethylifosfamide to 58% for 4-hydroxyifosfamide 
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and was stable over a wide range of clinically relevant concentrations. A strong parallelism in 
the erythrocyte and plasma concentration profiles was observed for all compounds. Thus, 
pharmacokinetic assessment using only plasma sampling yields direct and accurate insights 
into the whole blood kinetics of ifosfamide and metabolites and may be used for 
pharmacokinetic-pharmacodynamic studies. 
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Figure 1. Metabolism of prodrug ifosfamide with activation through 4-hydroxyifosfamide to the alkylating 
ifosforamide mustard and deactivation to 2- and 3-dechloroethylifosfamide. 
 
Ifosfamide, N,3-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide 
(HoloxanÒ, IfexÒ), is commonly used for the treatment of various solid tumours, soft tissue 
sarcomas and haematological malignancies in adults and children.[1] Ifosfamide is a prodrug 
which needs activation via the cytochrome P450 enzymatic system in the liver to 4-
hydroxyifosfamide. 4-Hydroxyifosfamide exists in equilibrium with its tautomeric form 
aldoifosfamide, which converts into the final alkylating agent ifosforamide mustard with 
concomitant acrolein release. Ifosfamide is also deactivated to the non-cytotoxic compounds 
2-dechloroethylifosfamide and 3-dechloroethylifosfamide with simultaneous release of the 
potentially neurotoxic chloracetaldehyde.[1] The metabolism of ifosfamide is depicted in figure 
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1. The measurement of ifosfamide and metabolites has mostly been limited to plasma.[1] 
Recently, Highley et al. reported a strong preference of ifosforamide mustard, the active anti-
tumour metabolite for the erythrocytes.[2] They observed that erythrocytes from five patients 
treated with ifosfamide contained as much as 77% of the total whole blood concentration of 
ifosforamide mustard, resulting in a ratio of the areas under the concentration-time curve of 
erythrocytes over plasma (AUCe/p) of 2.7. This indicated that the relationship between 
concentrations in the plasma compartment and associated with erythrocytes may not be fixed 
and the two compartments could behave rather differently. Consequently, drug concentration-
time profiles in whole blood and plasma could differ, thereby yielding different values for the 
pharmacokinetic parameters. To support ongoing pharmacokinetic and pharmaco-dynamic 
studies of ifosfamide, the possibility of any preferential distribution of ifosfamide and its 
metabolites to erythrocytes must be assessed.[3] The present work deals with the in vitro and 
in vivo distribution of ifosfamide, 2- and 3-dechloroethylifosfamide, 4-hydroxyifosfamide and 
ifosforamide mustard in erythrocytes. 
 
Materials and methods 
 
Chemicals 
 
Ifosfamide, 2- and 3-dechloroethylifosfamide, ifosforamide mustard and 4-hydroperoxy-
ifosfamide were a kind gift of Dr J. Pohl, ASTA Medica AG (Frankfurt, Germany). Acetonitrile 
and methanol (HPLC supra-gradient) were purchased from Biosolve (Val-kenswaard, The 
Netherlands). 0.9 % Sodium chloride solution (NaCl) was obtained from the Slotervaart 
Hospital Pharmacy (Amsterdam, The Netherlands). Ethyl acetate (p.a. grade), anhydrous 
potassium dihydrogen phosphate (suprapure grade) were obtained from Merck (Darmstadt, 
Germany). Semicarbazide hydrochloride (p.a. grade) was purchased from Acros (Geel, 
Belgium). A 2 M semicarbazide solution (SCZ) for stabilising 4-hydroxyifosfamide was made 
and adjusted to pH 7.40 with 1 M HCl and 1 M NaOH prior to use. Semicarbazide is a 
derivatising agent for 4-hydroxyifosfamide yielding an ultra-violet detectable chromophore. 
Moreover, 4-hydroxyifosfamide is trapped by this derivatization and can no longer 
spontaneously decompose to ifosforamide mustard.[4] A 2 M semicarbazide with 1 M NaCl 
solution (SCZ/NaCl) for stabilising ifosforamide mustard was made and adjusted to pH 7.40 
with 1 M HCl and 1 M NaOH, prior to use.[5] Distilled water was used throughout. Blank 
plasma, erythrocytes and heparinized whole blood were collected from healthy volunteers in 
the Slotervaart Hospital (Amsterdam, The Netherlands). 
 
Preparation of standards and solutions 
 
4-Hydroperoxyifosfamide was used as a substitute for 4-hydroxyifosfamide. In aqueous 
solution, 4-hydroperoxyifosfamide rapidly liberates 4-hydroxyifosfamide/aldoifosfamide and 
hydrogen peroxide. Fresh solutions of 4-hydroxyifosfamide were prepared immediately prior 
to use by dissolving an equimolar amount of 4-hydroperoxyifosfamide in distilled water. 
Dissolution was accelerated by ultra-sonification. Ifosforamide mustard was also prepared 
freshly for each experiment. Four separate in vitro experiments were performed. Experiment I 
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investigated the distribution of ifosfamide, 2- and 3-dechloroethylifosfamide between plasma 
and erythrocytes. 3 ml Venous blood at 37°C was added to 30 µl of a 50, 500 and 5000 µg/ml 
solution of ifosfamide, 2- and 3-dechloroethylifosfamide in a 0.9% NaCl solution. By using 
isotonic NaCl solutions undesired haemolysis of the erythrocytes by the stock solutions could 
be prevented. Next, 500 µl samples were aliquoted in six Eppendorf cups. The final drug 
concentrations in whole blood were 0.5, 5.0 and 50 µg/ml ifosfamide, 2- and 3-
dechloroethylifosfamide. Experiment II investigated the distribution of 4-hydroxyifosfamide 
between plasma and erythrocytes. 12 ml Venous blood at 37°C was added to 120 µl of a 25 
and 250 µg/ml solution of 4-hydroxyifosfamide in a 0.9 % NaCl solution. Next, 2000 µl 
samples were aliquoted in six Eppendorf cups. The final drug concentrations in whole blood 
were 0.25 and 2.5 µg/ml 4-hydroxyifosfamide. Experiment III investigated the distribution of 
ifosforamide mustard between plasma and erythrocytes. 6 ml Venous blood at 37°C was 
added to 60 µl of a 100 and 500 µg/ml solution of ifosforamide mustard in a 0.9 % NaCl 
solution. Next, 1000 µl samples were aliquoted in six Eppendorf cups. The final drug 
concentrations in whole blood were 1.00 and 5.00 µg/ml ifosforamide mustard. Experiment IV 
investigated the spontaneous conversion of 4-hydroxyifosfamide to ifosforamide mustard and 
subsequent distribution of ifosforamide mustard between plasma and erythrocytes. 6 ml 
Venous blood at 37°C was added to 60 µl of a 25 and 250 µg/ml solution of 4-
hydroxyifosfamide in a 0.9 % NaCl. Next, 2000 µl samples were aliquoted in six Eppendorf 
cups. The final drug concentrations in whole blood were 0.25 and 2.5 µg/ml 4-
hydroxyifosfamide. All venous blood samples were carefully mixed by gently tilting the tubes 
several times before they were aliquoted. All experiments were executed in triplicate. Since 
three bioanalytical methods with different stabilization and/or derivatization steps were 
applied, the in vitro experiments were not conducted simultaneously. 
 
Incubation and sample pre-treatment 
 
The samples were placed in a thermostatically controlled waterbath at 37°C. At various time-
points (0, 5, 10, 20, 30 and 60 min) samples were taken and placed on ice water followed by 
immediate centrifugation for 2 min at 3,000 g at 4°C. After centrifugation the plasma layer was 
separated from the erythrocyte layer. The buffy coat with the leukocytes was removed 
carefully with sufficient margins and discarded, followed by transferring the erythrocytes. In 
order to exclude interference of haemolysis, a 50 µl plasma sample was used to determine 
the percentage haemolysis. In experiment I the ifosfamide, 2- and 3-dechloroethylifosfamide 
spiked samples were aliquoted in three 50-µl volumes of plasma and 50-µl volumes of the 
erythrocytes. In experiment II the 4-hydroxyifosfamide samples were aliquoted in two 250-µl 
volumes of plasma and two 250-µl volumes of the erythrocytes. In experiment III the 
ifosforamide mustard spiked samples were aliquoted in a 200-µl volume of plasma and a 
200-µl volume of erythrocytes. In experiment IV the 4-hydroxyifosfamide spiked samples were 
aliquoted in a two 200-µl volume of plasma and a two 200-µl volume of erythrocytes for 
ifosforamide mustard determination. Immediately after incubation and matrix separation, 
samples containing 4-hydroxyifosfamide and ifosforamide mustard were stabilized by addition 
of 25 µl SCZ or 20 µl SCZ/NaCl, respectively, followed by vortex mixing for 15 sec. All 
samples were stored at -70°C pending analysis. 
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Determination of haemolysis 
 
Interferences due to possible haemolysis have been investigated as follows: a volume of 2.5 
ml distilled water was added to 25 µl venous blood yielding full haemolysis (100% standard 
sample) and 2.5 ml 0.9% NaCl was added to 25 µl venous blood with no haemolysis (0% 
standard sample). To check for haemolysis during the distribution experiments, a volume of 
2.5 ml 0.9% NaCl was added to 25 µl plasma samples. If haemolysis of the erythrocytes 
would have occurred, erythrocyte cell-fragments would cause increased absorbance of the 
plasma matrix. The resulting mixture was mixed by gently tilting the tube several times and 
subsequent centrifugation for 10 min at 3,000 g. The absorption of all supernatants was 
measured at 540 nm. The 0 and 100% standard samples were measured in triplicate and the 
plasma samples were measured in duplicate. The percentage haemolysis was calculated by 
the ratio of the absorbance of the plasma sample (Aplasma) corrected for the background 
absorbance of 0.9% NaCl (ANaCl) divided by the absorbance of 100% haemolysed venous 
blood (Awater) again corrected for the background absorbance of 0.9% NaCl, as described by 
equation 1. 
A A
A A
plasma NaCl
water NaCl
-
-
´ 100%        (eq. 1) 
 
Patients 
 
Venous whole blood samples of seven patients receiving 9 g/m²/72 hr intravenous ifosfamide 
treatment for soft tissue sarcoma were taken at 0, 3, 10, 20, 24, 34, 48, 58, 68, 72, 73, 76, 80 
and 92 hours after start of the infusion. The samples were collected in 10-ml heparinized 
tubes and immediately cooled by placing them on ice water. The samples were then 
centrifuged without delay for 5 min with 1,000 g at 4°C. Plasma was transferred and the buffy 
coat was discarded, followed by transferring the erythrocytes. Both plasma and erythrocytes 
were aliquoted out for ifosfamide and metabolite analysis. Stabilization followed if required. 
Samples were stored at -70°C pending analysis of ifosfamide, 2- and 3-
dechloroethylifosfamide and 4-hydroxyifosfamide. 
 
Analytical methods 
 
Ifosfamide, 2- and 3-dechloroethylifosfamide were measured using gas chromatography with 
flame ionization nitrogen/phosphorous detection.[6] The samples were prepared by alkalinized 
liquid-liquid extraction (LLE) with ethyl acetate. Lower limit of quantification (LLQ) was 0.050 
µg/ml for ifosfamide, 2- and 3-dechloroethylifosfamide. 4-hydroxyifosfamide was quantified 
using reversed phase high-performance liquid chromatography (RP-HPLC) with ultra-violet 
(UV) detection at 230 nm after LLE with ethyl acetate as reported previously.[4] LLQ was 
0.100 µg/ml 4-hydroxyifosfamide. Ifosforamide mustard was determined by using RP-HPLC 
with UV detection at 280 nm.[5] This method allowed accurate determination of ifosforamide 
mustard in plasma, but not in erythrocytes due to interfering endogenous compounds. 
Samples were pre-treated by derivatization with diethyldithiocarbamate in phosphate buffer 
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after stabilising with SCZ/NaCl, followed by LLE with acetonitrile. LLQ was 0.100 µg/ml 
ifosforamide mustard. Since separate analytical methods were used the distribution 
experiments were also performed in separate series. Furthermore, by combining ifosfamide, 
2- and 3-dechloroethylifosfamide in one experiment and 4-hydroxyifosfamide and ifosforamide 
mustard in separate experiments, specific conditions could be included for optimal 
stabilization of the latter two compounds. Concentrations of the analytes were measured in 
duplicate using standard calibration curves in the same matrix. Recovery of ifosfamide and its 
metabolites in the in vitro experiments was calculated according to equation 2, 
( ) ( )
Recovery
C H C H
C DF
p e
b
=
´ - + ´
´
´
1
100%       (eq. 2) 
in which Cp, Ce and Cb are the plasma, erythrocyte (blood cells) and nominal blood 
concentration, respectively. H is the haematocrit (volume of blood cells) and DF is the dilution 
factor (1-[volume of stock solution/volume of blood]). 
 
Pharmacokinetic analysis 
 
The mean partition coefficient value (Pe/p) of erythrocytes over plasma was used as an 
indicator for any preferential distribution to erythrocytes. Pe/p was calculated by the ratio of the 
erythrocyte and plasma concentration. Ratios of the areas under the erythrocytes and plasma 
concentration-time curves (AUCe/p) of the patients were calculated using a validated 
population approach.[3] 
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Results 
 
Analytical methods  
 
The in vitro experiments used a clinically relevant concentration range for each compound. 
The haemolysis during the distribution experiments over plasma and erythrocytes was always 
less than 3%. The haematocrit was determined at 44%. Mean (±sem) recoveries of 
ifosfamide, 2- and 3-dechloroethylifosfamide were 85.5±0.7%, 93.5±0.8% and 97.0±0.8%, 
respectively. 4-Hydroxyifosfamide was subject to autocatalytic degradation. At the beginning 
of the experiment recovery was 97.9±6.4%, but after 60 minutes recovery was only 0.7±0.2%.  
 
In vitro distribution 
 
In vitro equilibrium was obtained within 1 minute after drug addition (approximate time 
between spiking of the blood and sample collection at t=0). The mean (±sem) in vitro Pe/ps of 
ifosfamide, 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide were 0.75±0.01, 
0.62±0.09, 0.76±0.10 and 1.38±0.04, respectively (table 1).  
 
Table 1. Partition coefficients (Pe/p) and ratios of the area under the erythrocyte and plasma 
concentration-time curves (AUCe/p) of ifosfamide (IF), 2-dechloroethylifosfamide (2DCE) and 3-
dechloroethylifosfamide (3DCE) and 4-hydroxyifosfamide (4OHIF). 
 
 in vitro Pe/p in vivo Pe/p in vivo AUCe/p 
 Mean (±sem) Mean (±sem) Mean (±sem) 
IFO 0.75±0.01 0.81±0.03 0.96±0.03 
2DCE 0.62±0.09 0.73±0.03 0.87±0.07 
3DCE 0.76±0.10 0.93±0.05 0.98±0.06 
4OHIF 1.38±0.04 0.98±0.09 1.34±0.39 
 
No trends with time or in concentration were observed, as presented in figure 2. Pe/ps of 
ifosfamide, 2- and 3-dechloroethylifosfamide were always less than one. In contrast, Pe/p of 4-
hydroxyifosfamide was always higher than one. Not all 4-hydroxyifosfamide concentrations 
could be determined, because they were below the LLQ. In figure 3 the autocatalytic 
degradation of 4-hydroxyifosfamide in plasma and erythrocytes is depicted. No difference in 
degradation rate was observed between plasma or erythrocytes as the profiles decayed in 
parallel. Mean (±sem) elimination half-lives in plasma and erythrocytes were 9.0±0.3 and 
9.1±0.4 min, respectively. The plasma concentrations of ifosforamide mustard are depicted in 
figure 4. During incubation with 1.0 µg/ml ifosforamide mustard, plasma concentrations did 
not exceed 1.0 µg/ml. During incubation with 5.0 µg/ml ifosforamide mustard, plasma 
concentrations were higher than 5.0 µg/ml but declined towards 5.0 µg/ml after 20 minutes. 
No degradation of ifosforamide mustard was observed during the incubation. The formation of 
ifosforamide mustard from 4-hydroxyifosfamide is also depicted in figure 4. 
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Figure 2. Mean (±sem) in vitro partition coefficients of ifosfamide, 2- and 3-dechloroethylifosfamide and 
4-hydroxyifosfamide during incubation at 37°C.  
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Figure 3. Plasma and erythrocyte concentrations of 4-hydroxyifosfamide (4OHIF) during 
incubation at 37°C. 
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Figure 4. Plasma concentrations of ifosforamide mustard (IFM) during incubation 
of ifosforamide and 4-hydroxyifosfamide (4OHIF) at 37°C. 
 
Incubation with 0.25 µg/ml 4-hydroxyifosfamide did not yield ifosforamide mustard plasma 
concentrations above the LLQ. Incubation with 2.5 µg/ml 4-hydroxyifosfamide yielded an 
equimolar ifosforamide mustard plasma concentration of 2.0 µg/ml. Thus, complete 
conversion of 4-hydroxyifosfamide to ifosforamide mustard without further degradation of 
ifosforamide mustard was observed after incubating for 60 minutes at 37°C. The formation 
half-life of ifosforamide mustard was 28.1 min-1.  
 
Clinical pharmacokinetics 
 
Typical plasma and erythrocyte concentration-time profiles of ifosfamide, 2- and 3-
dechloroethylifosfamide and 4-hydroxyifosfamide after a 72-hour continuous infusion of 9 g/m² 
ifosfamide are depicted in figure 5. The pharmacokinetics assessment in seven patients 
receiving this infusion resulted in 85, 86, 83 and 70 samples for ifosfamide, 2- and 3-
dechloroethylifosfamide and 4-hydroxyifosfamide. Their mean (±sem) in vivo Pe/ps of 
ifosfamide, 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide were 0.81±0.03, 
0.73±0.03, 0.93±0.05 and 0.98±0.09, respectively (table 1). The plots of Pe/ps with time are 
depicted in figure 6. Pe/ps did not vary during the 72-hour ifosfamide infusion. However, during 
a brief period after cessation of the infusion a preference of ifosfamide and metabolites for the 
erythrocytes was observed. Pe/ps of ifosfamide, 2- and 3-dechloroethylifosfamide were 
always less than one, but the coefficient for 4-hydroxyifosfamide was always higher than one 
during the infusion. The mean (±sem) AUCe/ps of ifosfamide, 2- and 3-
dechloroethylifosfamide and 4-hydroxyifosfamide were 0.96±0.03, 0.87±0.07, 0.98±0.06, 
1.34±0.39, respectively (table 1). 
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Figure 5. Plasma (solid lines) and erythrocyte (dashed lines) concentrations of ifosfamide (circles), 2-
dechloroethylifosfamide (squares), 3-dechloroethylifosfamide (triangles) and 4-hydroxyifosfamide 
(diamonds) in a typical patient receiving 9 g/m² ifosfamide in a 72-hour continuous i.v. infusion. 
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Figure 6. Mean (±sem) in vivo partition coefficients of ifosfamide, 2- and 3-dechloroethylifosfamide and 
4-hydroxyifosfamide in seven patients receiving 9 g/m² ifosfamide in a 72-hour continuous i.v. infusion. 
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Discussion 
 
So far, the pharmacokinetics of ifosfamide and metabolites have mostly been defined with 
reference to drug in plasma. Considering that erythrocytes comprise about 40-50% of the 
whole blood volume, it is necessary to investigate possible differences in kinetics in plasma 
and erythrocytes. We performed in vitro and in vivo experiments to investigate possible 
kinetic differences of ifosfamide, 2- and 3-dechloroethylifosfamide, 4-hydroxy-ifosfamide and 
ifosforamide mustard in plasma and erythrocytes.  
Drug measurement studies in erythrocytes must safeguard against possible lower 
reproducibility and accuracy in handling this matrix. The method used in the current study 
involved separation of erythrocyte sediments by centrifugation at 3,000 g. Recently, a novel 
device (MESED) was introduced for erythrocyte separation.[7] The investigators pointed out 
that with regular centrifugation plasma is possibly still trapped between erythrocytes which 
could interfere with the determination of possible accumulation of a compound in 
erythrocytes. However, the reduction in trapped plasma in the erythrocyte layer using MESED 
was only 1.9% with 10,000 g (from 3.9 to 2.0%).[7] Furthermore, this labour-intensive and 
costly method required three centrifugation steps, impeding routine use in clinical studies and 
possibly allowing degradation of unstable metabolites. Since the gain in erythrocyte purity was 
not considered significant, normal centrifugation was assumed to be sufficient in matrix 
separation. 
The haemolysis during the in vitro experiments was always less than 3%. Thus, the 
erythrocytes remained intact during the experiment. This implies that Pe/p < 1 of a compound 
could not be caused by a transfer from the erythrocyte to the plasma compartment as a 
consequence of haemolysis. It was in vitro confirmed that total drug recovery of ifosfamide, 2- 
and 3-dechloroethylifosfamide and 4-hydroxyifosfamide (t=0) from erythrocyte and plasma 
fraction were within the accuracy of the analytical methods.[4-6] Lack of degradation of 
ifosforamide mustard could be assumed because equimolar conversion of 4-
hydroxyifosfamide to ifosforamide mustard was observed. The nominal blood concentration of 
2.5 µg/ml 4-hydroxyifosfamide could maximally be converted to 2.0 µg/ml ifosforamide 
mustard. This concentration was reached after 60 minutes, thus complete conversion without 
degradation was observed. 
Highley and co-workers reported differences in ifosforamide mustard distribution between 
plasma and erythrocytes in patients receiving ifosfamide.[2,8] An integrated bioanalytical 
method using gas chromatography with mass detection was applied in their studies.[9] They 
determined ifosfamide, 2- and 3-dechloroethylifosfamide, ifosforamide mustard, 
carboxyifosfamide, ketoifosfamide and two metabolites of ifosforamide mustard but not 4-
hydroxyifosfamide. The ifosforamide mustard as determined by their assay represented the 
sum of free ifosforamide mustard and 4-hydroxyifosfamide because no stabilization of 4-
hydroxyifosfamide was performed. They observed higher concentrations in the erythrocytes 
of ifosforamide mustard and carboxyifosfamide (a metabolite of 4-hydroxyifosfamide), but not 
with ifosfamide, 2- and 3-dechloroethyl-ifosfamide.  
In accordance with the findings of Highley and co-workers the present study shows that to a 
large extent ifosfamide and metabolites are located in plasma: drug distribution to the 
erythrocyte compartment ranged from about 38% for 2-dechloroethylifosfamide to 43% for 
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ifosfamide and was stable over a wide range of clinically relevant concentrations. 4-
Hydroxyifosfamide showed affinity for the erythrocytes with 58% of the total drug 
concentration associated with this fraction. Distribution to erythrocytes was very rapid 
because no change in Pe/ps was observed between the start and the end of the incubation, 
indicating that the compounds can enter the erythrocyte compartment freely. This was 
confirmed by the parallelism in in vitro erythrocyte and plasma concentration profiles. The 
pharmacokinetics of 4-hydroxyifosfamide are expected to be related with efficacy of 
ifosfamide therapy.[1] The autocatalytic degradation of 4-hydroxyifosfamide was equal in 
plasma and erythrocytes, indicating that no differences between pharmacokinetic parameters 
of 4-hydroxyifosfamide are expected when using plasma or erythrocytes.  
A concentration dependent difference in distribution of ifosforamide mustard was observed. 
Incubation with 1.0 µg/ml ifosforamide mustard did not demonstrate a particular affinity for the 
erythrocytes. However, incubation with 5.0 µg/ml ifosforamide mustard demonstrated 
increased plasma concentrations of ifosforamide mustard during the first 20 minutes. It can 
be hypothesized that the more hydrophilic ifosforamide mustard in comparison to the other 
analytes is less capable of penetrating the erythrocyte. Furthermore, ifosforamide mustard is 
highly ionized and hence does not readily cross membranes.[10] To reach a distribution-
equilibrium of ifosforamide mustard will require time due to this concentration dependent 
phenomenon. This phenomenon was not observed during the conversion of 4-
hydroxyifosfamide to ifosforamide mustard, possibly due to the lower incubation 
concentration. Furthermore, a relatively lower amount of ifosforamide mustard will be 
exposed to the erythrocytes during conversion. The in vivo experiment was evidently done 
with all compounds simultaneously, thus incorporating possible interactions between the 
metabolites that could influence their distribution between plasma and erythrocytes. The in 
vivo Pe/ps and AUCe/p were in accordance with the in vitro findings (table 1). The apparent 
shift in affinity towards the erythrocytes of ifosfamide and its metabolites during the elimination 
phase could be explained by a lack of equilibrium between plasma and erythrocytes. 
However, this transient shift was only minor and therefore probably not clinically relevant. 
The lack of in vitro affinity for the erythrocyte of ifosforamide mustard is apparently in 
disagreement with the findings in patients by Highley et al.[2] However, 4-hydroxyifosfamide 
exhibited in vitro and in vivo affinity for erythrocytes. Moreover, the pharmacokinetics of 4-
hydroxyifosfamide in the two compartments did not differ. It can be hypothesized that 
relatively more 4-hydroxyifosfamide will reside in the erythrocyte compartment. Consequently, 
relatively more ifosforamide mustard will be formed in this compartment, thus corroborating 
the findings of Highley and co-workers.[2] 
It is concluded that ifosfamide and metabolites rapidly reach distribution equilibrium between 
erythrocytes and plasma, with ifosforamide mustard being the slowest. Drug distribution to 
the erythrocyte fraction ranged from about 38% for 2-dechloroethyl-ifosfamide to 58% for 4-
hydroxyifosfamide and was stable over a wide range of clinically relevant concentrations. A 
strong parallelism in the erythrocyte and plasma concentration profiles was observed for all 
compounds, indicating that no differences will arise in the assessment of pharmacokinetic 
parameters using either matrix. Thus, pharmaco-kinetic assessment using only plasma 
sampling can yield direct, accurate and relevant relationships with efficacy and toxicity in 
patients treated with ifosfamide. 
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Evaluation of the autoinduction of ifosfamide 
metabolism by a population pharmacokinetic 
approach using NONMEM 
 
 
 
 
 
 
 
Summary 
 
This study investigated the population pharmacokinetics of ifosfamide in 15 patients treated 
for soft tissue sarcoma with 9 or 12 g/m² ifosfamide by means of a 72-hour continuous 
intravenous infusion. A model was developed using non-linear mixed effect modelling 
(NONMEM) to describe the non-linear pharmacokinetics of ifosfamide by linking the 
ifosfamide plasma concentrations to the extent of the autoinduction. The proposed model 
revealed the effect of autoinduction on the disposition of ifosfamide. The initial clearance, 
volume of distribution, rate constant for enzyme degradation, induction half-life of the enzyme 
and the ifosfamide concentration at 50% of the maximum inhibition of enzyme degradation 
were estimated at 2.94±0.27 L· h-1, 43.5±2.9 L, 0.0546±0.0078 h-1, 12.7 h and 30.7±4.8 µM, 
respectively. Interindividual variabilities of initial clearance, volume of distribution, rate 
constant for enzyme degradation were 24.5, 23.4 and 22.7%, respectively. Proportional and 
additive variability not explained by the model were 13.6% and 0.0763 µM, respectively. The 
absence of a lag time for the autoinduction of ifosfamide metabolism could be the result of an 
immediate inhibition of the enzymatic degradation of CYP3A4 by ifosfamide. By application of 
the autoinduction model individual pharmacokinetic profiles of patients were described with 
adequate precision. This model may therefore be used in the future development of a model 
to individualize dose selection in patients. 
Introduction 
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Ifosfamide (N,3-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide, 
Holoxanâ) is an alkylating oxazaphosphorine widely applied as anti-cancer agent in the 
treatment of various solid and haematological malignancies in adults and children.[1,2] 
Ifosfamide is a prodrug requiring activation to 4-hydroxyifosfamide as shown in figure 1.  
2- and 3-Dechloroethylifosfamide
               +
Chloroacetaldehyde
Ifosforamide mustard
                        +
                   Acrolein
4-Hydroxyifosfamide
Ifosfamide
Neurotoxicity
Urotoxicity
Alkylation
 
Figure 1. Metabolism of the prodrug ifosfamide. Ifosfamide is activated through 4-hydroxyifosfamide to 
the ultimate alkylating agent ifosforamide mustard by ß-elimination of urotoxic acrolein. Ifosfamide is 
deactivated to 2- and 3-dechloroethylifosfamide yielding neurotoxic chloroacetaldehyde. 
 
After ß-elimination of the urotoxic acrolein from 4-hydroxyifosfamide, the alkylating 
ifosforamide mustard is formed.[3] Deactivation of ifosfamide leads to 2- and 3-
dechloroethylifosfamide and the release of the potentially neurotoxic chloroacetaldehyde. Both 
activation (hydroxylation) and deactivation (dechloroethylation) are mediated by the 
cytochrome P450 3A4 (CYP3A4) iso-enzyme.[4,5] Metabolism of ifosfamide is an 
autoinducible enzymatic process, resulting in increased clearance over time.[6] 
During the last decades several methods have been proposed for the description of the 
pharmacokinetics of ifosfamide and its metabolites.[7] Allen & Creaven and Lind et al. used a 
two-compartment pharmacokinetic model for describing the pharmacokinetics of 
ifosfamide.[8,6] Nelson et al. proved a one-compartment pharmacokinetic model to be superior 
for 1.5 to 2.4 g/m2 in 30 min. intravenous (i.v.) infusion but not when dosed 3.8 to 5 g/m2.[9] 
Boddy et al. used a model independent approach for describing ifosfamide 
pharmacokinetics.[1] All these methods were developed to describe concentration-time 
profiles of infusions of short duration (1-3 hours) and did not take into account the effect of the 
autoinduction on the pharmacokinetics of ifosfamide. Prasad et al. and Boddy et al. were the 
first to report models, enabling an adequate description of the concentration-time data for 
ifosfamide infusions of long duration of up to 72 hours.[10,11] Their models included a lag time 
before the development of autoinduction started and described the increase of clearance of 
ifosfamide over time. 
Large interpatient variability in clinical toxicity and response rates is observed during 
ifosfamide treatment.[12] This could possibly be explained by interpatient differences in 
ifosfamide pharmacokinetics e.g. autoinduction. In this study we aimed to develop a non-
linear pharmacokinetic model for ifosfamide, by which all relevant pharmacokinetic 
parameters including the rate and extent of autoinduction over time could be estimated. Our 
future aim is to investigate the possibility of therapeutic drug monitoring (TDM) of ifosfamide. 
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Therefore, a population pharmacokinetic approach was selected because this allowed 
assessment of interindividual and residual variability necessary for TDM. Furthermore, a 
simulation was performed to assess the influence of autoinduction on the pharmacokinetics 
of ifosfamide.  
 
Methods 
 
Patient population and treatment 
 
Patients treated for various types of soft tissue sarcoma with single agent high-dose 
ifosfamide in an open non-randomized phase II trial, were subjected to pharmacokinetic 
sampling after written informed consent was obtained. Six patients received 12 g/m² 
ifosfamide as a 72-hour continuous i.v. infusion once every 4 weeks. Due to unacceptable 
central neurotoxicity in this group the following nine patients received a decreased dose of 9 
g/m²/72 h. This resulted in individual total doses ranging from 10.3 to 23.5 g ifosfamide. 
Supportive care consisted of mesna and extensive hydration to prevent haemorrhagic cystitis 
and bicarbonate to prevent acidosis. Anti-emetics and methylene blue (a neurotoxicity 
antidote) were given when indicated. Additional co-medication consisted of 21 different drugs 
with a mean of seven per patient, including anti-coagulants, H2 receptor antagonists, 
glucocorticosteroids and tricyclic anti-depressants. 
 
Pharmacokinetic sampling and analysis 
 
Whole blood samples were drawn at 0, 3, 10, 20, 24, 34, 48, 58, 68, 72, 73, 76, 80 and 92 
hours after start of the infusion. Following plasma separation the samples were stored at -
70°C pending analysis. After alkalinized liquid-liquid extraction with ethyl acetate, ifosfamide 
was determined using gas-chromatography with nitrogen-phosphorous detection.[13] The 
method was validated resulting in an accuracy of 103.2, 99.9, 104.5, 102.0 and 93.3%, an 
intra-assay precision of 5.5, 0.8, 1.8, 2.0 and 2.9% and an inter-assay precision of 3.5, 2.9, 
3.6, 2.6 and 5.1% at concentrations of 0.192, 0.383, 0.958, 38.3 and 383 µM ifosfamide, 
respectively.  
 
Model development 
 
Ifosfamide plasma concentration-time profiles were described by a one-compartment model 
as depicted in figure 2. The change of the amount of ifosfamide in the central compartment 
(A1, µmol) over time was described by equation 1, 
 ( )dAdt R CLapp Cp1 = - ´         (eq. 1) 
in which R (µmol· h-1) is the infusion rate of ifosfamide, CLapp (L· h
-1) is the apparent 
ifosfamide clearance and Cp (µmol· L
-1) is the plasma concentration in compartment 1, 
which is equal to A1/V with V (L) as the volume of distribution of ifosfamide. CLapp is defined 
by equation 2.  
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 CL CL Aapp = ´ 2         (eq. 2) 
In this equation CL (L· h-1) is the initial clearance of ifosfamide and A2 is an amount of 
enzyme in the hypothetical compartment 2 as depicted in figure 2. The change in A2 over time 
is described by equation 3, 
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in which Kenz,in (mol· h
-1) is the zero-order rate constant for enzyme formation/activation, 
Kenz,out (h
-1) is the first-order rate constant for enzyme degradation/inactivation and IC50 (µM) 
is the ifosfamide concentration at 50% of the maximum inhibition of enzyme degradation. 
Before treatment with ifosfamide (t=0) steady-state levels of the enzyme were assumed. 
Hence, the change in enzyme amount was zero. Kenz,in was equal to Kenz,out times the 
amount of enzyme at t=0 (A2 t=0). By defining A2,t=0 at a value of 1, Kenz,in could be substituted 
for Kenz,out, yielding equation 4, 
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in which A2 is the relative amount of enzyme. The induction half-life of the enzyme (T½,enz, h) 
was calculated by dividing ln(2) by Kenz,out.  
A1
Kenz,in
Kenz,outCLapp/V
Dose
A2
 
Figure 2. Pharmacokinetic model of ifosfamide with autoinduction of its metabolism. The time profile of 
ifosfamide amount (A1, µmol) in compartment 1 was described by an influx of dose and an efflux 
calculated by an apparent clearance (CLapp, L· h
-1) divided by volume of distribution (V, L). The time 
profile of the relative amount of enzyme (A2) in the hypothetical compartment 2 was determined by a rate 
constant for enzyme formation (Kenz,in) and a rate constant for enzyme degradation (Kenz,out). The dashed 
arrows represent the effect of the enzyme (A2) on the elimination rate of ifosfamide (CLapp/V) and the 
effect of ifosfamide (A1) on the degradation rate (Kenz,out) of the enzyme. 
Data analysis was performed using the non-linear mixed effect modelling programme 
(NONMEM) (double precision, version V, level 1.0) operated on an MS-DOS computer under 
FORTRAN90 Powerstation (version 4.0).[14] Population and individual estimates for CL, V, 
Kenz,out and IC50 were obtained using a general non-linear population pharmacokinetic 
programme of NONMEM with first-order processes and non-stiff differential equations 
(ADVAN6 TOL=5).[15] The interindividual variability for all pharmacokinetic parameters was 
estimated with a proportional error model. The residual variability was modelled using a 
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combined additive plus proportional error model. The POSTHOC function of NONMEM 
enabled estimation of the individual pharmacokinetic parameters using a Bayesian approach 
taking both individual observations and population effects into account. The predictive 
performance of the model was assessed by plotting the population predicted (PRED) and 
individual Bayesian predicted estimates (IPRED) versus the observed concentrations (OBS). 
The effect of autoinduction on the dose-area under the curve (AUC) relationship was 
investigated by simulation. The profiles were simulated based upon the population 
parameters found. 
 
Results 
 
The patient population consisted of nine males and six females with a mean age of 49 years 
(ranging from 23 to 72) and a mean weight of 59 kg (ranging from 49 to 82). Tumour types 
were rhabdomyosarcoma (n=3), neurofibrosarcoma (n=1), osteosarcoma (n=3), 
synoviumsarcoma (n=2), leiomyosarcoma (n=4) and endometriumsarcoma (n=2). 
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Figure 3. The relationships between estimates (PRED) and individual Bayesian estimates (IPRED) 
versus observed (OBS) ifosfamide concentrations. 
 
Pharmacokinetic assessment of the 15 patients resulted in 176 concentration-time points. 
The predictive performance is represented in figure 3. By including individual estimates the 
predictive performance was increased. The individual predictions (IPRED) were 
symmetrically distributed around the line of unity, suggesting adequate model prediction. No 
outliers or trends could be observed in the concentration range or time range. The observed 
and Bayesian estimated pharmacokinetic profiles of all patients are represented in figure 4. 
Most patients received 72-hour infusions and showed initial build-up of ifosfamide plasma 
concentrations in the first 24 hours (reaching maximum concentrations), followed by a 
gradual decrease due to autoinduction. After 72 hours the infusion was stopped and 
elimination pharmacokinetics could be observed. The infusion in one patient was stopped 
after 48 hours, due to acute severe neurotoxicity. Therefore, the patient receiving only 66% of 
6           Chapter 3.1 
the planned dose (open circles).  
 
Figure 4. The observed (dots) and Bayesian estimated (lines) ifosfamide concentrations vs. time for all 
patients (n=15). The open circles represent a patient who suffered from a neurotoxicity episode. The drug 
infusion for this patient was stopped after 48 hours. 
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Figure 5. Individual time profiles of the relative amount of enzyme (A2) for all patients (n=15). The 
profiles were obtained on basis of the individual Bayesian parameter estimates provided by NONMEM. 
At the initiation of the therapy A2 was 100%. 
 
The predicted relative amount of enzyme in the hypothetical compartment 2 is described in 
figure 5. The relative amount of enzyme increased over time during the infusion and 
decreased after cessation. Notably, during the first 24 hours for all patients the model 
predicted an average doubling of the relative enzyme amount. Estimates of pharmacokinetic 
population parameters, their standard error, their interindividual variability and the residual 
variability are presented in table 1.  
Table 1. Estimates of pharmacokinetic population parameters for ifosfamide with their standard error, 
interindividual variability and residual variability. 
 
Parameter Mean Standard  
Error 
Interindividual 
Variability 
Residual  
Variability 
CL (L· h-1) 2.94 0.27 24.5%  
V (L) 43.5 2.9 23.4%  
Kenz,out (h
-1) 0.0546 0.0078 22.7%  
T½,enz (h) 12.7     
IC50 (µM) 30.7 4.8   
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P.E.    13.6% 
A.E. (µM)    0.0763 
 
CL=initial ifosfamide clearance, V=volume of distribution of ifosfamide, Kenz,out=first-order rate constant for 
enzyme degradation, T½,enz=induction half-life of the enzyme, IC50=ifosfamide concentration at 50% of the 
maximum inhibition of enzyme degradation, P.E.=proportional residual error, A.E.=additive residual error. 
 
The effect of autoinduction on the AUC after doubling of the dose is simulated in figure 6 and 
represented in table 2. This simulation shows that after increasing the dose from 10 to 20 g 
ifosfamide, the AUC was only 56% larger. 
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Figure 6. The simulated pharmacokinetic profiles of ifosfamide after 10 g (dashed line) and 20 g (solid 
line) ifosfamide in a patient receiving a 72-hour continuous intravenous infusion, based upon population 
parameters found. 
 
Table 2. The simulated effect of different doses of ifosfamide on the area under the plasma 
concentration-time curve (AUC). 
 
Ifosfamide dose  
(g/72 hr) 
AUC 
(µM· h)  
10 1.7 
20 2.7 
increase 56 % 
 
Discussion 
 
A population model of the pharmacokinetics of ifosfamide has been presented in which 
autoinduction was modelled by inhibition of the degradation of the enzyme responsible for 
ifosfamide metabolism. The exact physiological mechanism of the autoinduction of ifosfamide 
is unknown, but several mechanisms of drug induced metabolic changes have been reported 
for other compounds. For most of these drugs the amount of enzymes performing the 
metabolic breakdown is increased via de novo synthesis. For instance, the barbiturate 
pentobarbital induces nortriptyline metabolism by increasing translation of the DNA coding for 
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the enzyme and thereby increasing clearance of systemic nortriptyline. De novo synthesis of 
cytochrome P450 (CYP) by pentobarbital was observed after two days.[16] Rapid 
autoinduction of carbamazepine due to de novo synthesis was already demonstrated after 
12-24 hours with a maximum after six weeks.[17] Autoinduction of ifosfamide has been 
observed within 24 hours after the start of the treatment.[18] However, it is unlikely that an 
alkylating agent like ifosfamide (which reduces DNA/RNA and protein synthesis) increases 
enzyme protein synthesis of CYP. Non-transcriptional induction mechanisms have been 
demonstrated to produce drug induced metabolic changes as well. Troleandomycin produced 
no increase in the rate of CYP3A4 protein synthesis, but it decreased the rate of the CYP3A4 
protein degradation by interacting with specific catalytic enzymes.[19] This resulted in an 
increased pool of the CYP3A4 protein. An uncommon interaction of a drug with its 
metabolizing enzyme has been demonstrated for phenobarbital.[20] This interaction did not 
result in an increased synthesis of the enzyme, but was achieved by direct influence of the 
drug on the enzyme. By binding of the drug on a non-catalytic site of the enzyme, the catalytic 
ability increased due to an altered spin-state of the haemoprotein of the CYP.  
Ifosfamide has been shown to reduce protein synthesis and could have a similar effect on the 
enzymes responsible for CYP3A4 degradation/inactivation, thus increasing ifosfamide 
clearance.[21] CYP3A4 performs both a desired hydroxylation and an undesired 
dechloroethylation of ifosfamide, making it a target for the development of a specific inhibition 
or heteroinduction regimens and thereby directing ifosfamide metabolism to a more 
favourable toxicity-efficacy profile. Although co-medication consisted of a total of 24 different 
drugs, none have been shown to be inhibitors or inducers of CYP3A4. Furthermore, no 
metabolic interactions between ifosfamide and any of these drugs have been reported. 
Figures 3 and 4 indicate that the proposed population pharmacokinetic model was precise 
and without misspecifications and thus described the observed data well. Although population 
programmes such as NONMEM were designed to describe populations using sparse data, 
the development of population models requires fewer subjects if the pharmacokinetic data are 
rich. Figure 4 indicates that the patient suffering from severe neurotoxicity had the highest 
AUC between 0 to 48 hours. The CL and Kenz,out of this patient were 2.25 L/h and 0.0471 h
-1, 
respectively. Population values ranged from 2.22 to 4.96 L/h and from 0.0439 to 0.0697 h-1, 
respectively. Curiously, this patient had the second lowest Kenz,out (a slow onset of 
autoinduction) and the second lowest CL of the subjects receiving a dose of 12 g/m². The 
relative low clearance of ifosfamide in this patient should theoretically result in a lower AUC of 
neurotoxic metabolites and less neurotoxicity. The latter is in contrast with our observations. It 
can therefore be concluded that the development of neurotoxicity cannot be predicted or 
explained on the basis of the pharmacokinetic parameters of ifosfamide alone. 
Previously reported models of ifosfamide pharmacokinetics used a lag time before the start of 
autoinduction, because it was first noticed only after 24 hours.[10,11] Our model described the 
autoinduction as a gradually developing effect with a half-life of 12.7 hours. Figure 5 shows 
that our data could be modelled without a lag time. The absence of a lag time for the 
autoinduction of ifosfamide metabolism could be the result of direct inhibition of the enzymatic 
degradation of CYP3A4 by ifosfamide, rather than its de novo synthesis, which requires time. 
However, activation of CYP3A4 activity cannot be excluded. The use of a lag time model 
results in overestimation of the initial CL of ifosfamide compared to our model. Thus, an initial 
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CL of 3.48±0.88 L/h/m2 was reported in 15 breast cancer patients after 5 g/m2/24 h 
continuous i.v. infusion using a model with a lag time, compared to our findings of 1.77 L/h/m2 
(2.94 L/h) after 9 and 12 g/m2/72 h continuous i.v. infusion.[2] 
The observed interindividual variability in population parameters was small (less than 24.5%). 
For IC50, the inclusion of interindividual variability did not improve the fit. This should not be 
interpreted as an absence of interindividual variability in this parameter, but only that the data 
did not contain sufficient information to estimate it. The proportional error of 13.6% and the 
additive error of 0.0763 µM described the residual variability not explained by the model. The 
residual variability may in part be explained by errors in the bioanalytical assay and errors in 
patient treatment (e.g. infusion duration) and sampling times.  
In clinical studies with ifosfamide large variability has been observed in treatment 
effectiveness and toxicity.[12] Interpatient pharmacokinetic variability could be one of the 
factors that contributes to this variability in response. Our observations demonstrate that 
pharmacokinetic variability in our population was only modest. However, since the metabolites 
of ifosfamide are responsible for the treatment effectiveness and toxicity, interpatient 
pharmacokinetic variability of these compounds should also be characterized when studying 
dose response relationships. The increase in AUC of ifosfamide after doubling of the dose 
was only 56%. This emphasizes the importance of the integrating autoinduction into the 
modelling of non-linear ifosfamide pharmacokinetics. 
In conclusion, the proposed model allowed quantification of the effect of autoinduction on the 
concentrations-time profiles of ifosfamide. The model demonstrated no necessity for a lag 
time in onset of induction. Although the small number of patients studied prevented the use of 
techniques such as data-splitting, cross-validation and bootstrapping for testing the predictive 
performance, the model was able to describe the individual pharmacokinetic profile of patients 
with adequate precision. Future utilization of this model may include investigating the 
relationship between the pharmacodynamics (e.g. bone marrow suppression, neurotoxicity) 
and the pharmacokinetics of ifosfamide. In order to achieve this plasma 2- and 3-
dechloroethylifosfamide and 4-hydroxyifosfamide metabolite data will have to be included in 
the model, since they are thought to be responsible for specific toxicities. Secondly, co-
variables could also be studied for their possible predictiveness of the pharmacokinetics and 
pharmacodynamics of ifosfamide.  
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Chapter 3.2 
 
 
 
 
 
 
Population pharmacokinetics of ifosfamide  
and its 2- and 3-dechloroethylated and  
4-hydroxylated metabolites in resistant  
small-cell lung cancer patients 
 
Summary 
 
This study aimed to develop a population pharmacokinetic model that could describe the 
pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide and 4-hydroxy-ifosfamide 
and calculate their plasma exposure and urinary excretion. Fourteen patients with small cell 
lung cancer received a 1-hour intravenous infusion of 1.0-3.0 g/m² ifosfamide for 1 or 2 days 
in combination with 175 mg/m² paclitaxel and carboplatin at AUC=6. A comparison was made 
between three population pharmacokinetic models without and with a time- or concentration-
dependent development of autoinduction of ifosfamide. The latter model described the 
concentration-time profiles of ifosfamide best. Population values were estimated for 
clearance, volume of distribution, rate constant for enzyme degradation and the ifosfamide 
concentration at 50% of the maximum inhibition of the enzyme degradation at 2.49±0.47 L/h, 
46.2±2.8 L, 0.114±0.040 h-1 and 21.4±2.6 µM, respectively. The Bayesian estimates of the 
pharmacokinetic parameters were used to evaluate the systemic exposure of ifosfamide and 
its metabolites in four ifosfamide schedules. Modest interindividual differences were observed 
in systemic exposure. Both ifosfamide and 4-hydroxyifosfamide exhibited a steeper dose-
exposure relationship than the dechloroethylated metabolites. Dose-fractionation over two 
days compared to one day resulted in increased metabolite formation especially for 2-
dechloroethylifosfamide, probably due to increased autoinduction. Renal recovery was only 
minor with 6.6% of the administered dose excreted unchanged and 9.8% as 
dechloroethylated metabolites. In conclusion, ifosfamide pharmacokinetics were best 
described by a model with ifosfamide concentration-dependent development of autoinduction. 
Population pharmacokinetics of the metabolites of ifosfamide and their exposures were 
estimated. 
Introduction 
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Small cell lung cancer (SCLC) is highly sensitive to chemotherapy, but cure rates remain low 
with 5-year survival rates of 20-25%.[1] Responses may be followed by a rapid relapse within 
a few months and this usually goes along with development of tumour resistance against 
chemotherapy. Since salvage treatment rarely results in long-lasting disease control, most 
patients die from locally progressive or metastatic disease. A paclitaxel with carboplatin 
regimen has already proven activity with a tumour response rate of 73% in resistant SCLC.[2] 
Brain metastases are regularly observed in SCLC patients.[3] Therefore, ifosfamide, which is 
also active in SCLC was added to this regimen, because its activated metabolites are able to 
penetrate the blood brain barrier for 38-49% of the plasma concentrations.[4]  
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Figure 1. Metabolism of ifosfamide. 
 
Ifosfamide (HoloxanÒ) is a prodrug, which needs activation by cytochrome P450-3A4 
(CYP3A4) to 4-hydroxyifosfamide, as depicted in figure 1. Intracellular spontaneous 
decomposition of 4-hydroxyifosfamide yields the ultimate alkylating metabolite ifosforamide 
mustard.[5] Ifosfamide is deactivated to the non-cytotoxic metabolites 2- and 3-dechloro-
ethylifosfamide. Dechloroethylation yields an equimolar amount of chloroacetaldehyde, which 
was held responsible for neurotoxicity observed in about 10% of all patients receiving conven-
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tional single-agent dosing of ifosfamide.[6] Activation is mainly conducted by CYP3A4 and 
deactivation by CYP3A4 and possibly CYP2B6.[7] Ifosfamide metabolism is subject to 
autoinduction, which will increase metabolism of ifosfamide in time. In order to evaluate 
ifosfamide pharmacokinetics in relation to pharmacodynamic outcome, the pharmacokinetics 
of metabolites emerging from both the activation and deactivation routes need to be included 
in the evaluation. Historically, systemic exposure, particularly the area under the plasma 
concentration-time profile (AUC), is used in oncology in the development of these 
relationships.[8-10] Large interpatient variability in clinical toxicity is observed in ifosfamide 
treatment.[11] This could possibly be explained by interpatient differences in ifosfamide 
pharmacokinetics due to autoinduction. A population pharmacokinetic approach allows 
assessment of this variability. In this study we aimed to compare the applicability and 
goodness-of-fit of three population pharmacokinetic models without or with a time-dependent 
or ifosfamide concentration-dependent development of autoinduction. The superior model will 
be applied to describe the ifosfamide concentration-time profiles of patients, who participated 
in a phase I study of the combination ifosfamide, paclitaxel and carboplatin. The Bayesian 
estimated pharmacokinetic parameters of ifosfamide were used to estimate the population 
pharmacokinetic parameters of the ifosfamide metabolites. The pharmacokinetics will be 
used to discuss ifosfamide and metabolite systemic exposure in four different ifosfamide 
treatment schedules. 
 
Methods  
 
Patients 
 
Patients with resistant SCLC were hospitalized for administration of ifosfamide, paclitaxel and 
carboplatin in a phase I study. Inclusion criteria were: last chemotherapy given within 3 
months, WHO performance status  2, white blood cell counts  > 3 x109/L, platelets > 100 
x109/L and normal renal and liver function tests. The study protocol was approved by the 
Ethics Board of the University Hospital Groningen. Written informed consent was obtained 
from each patient before entering the study protocol.  
 
Drug administration 
 
Ifosfamide (HoloxanÒ, ASTA Medica, Diemen) was delivered in vials with dry powder and was 
dissolved in distilled water and administered as an intravenous infusion in glucose 5%. 
Paclitaxel (TaxolÒ, Bristol-Myers Squibb, Woerden, The Netherlands) was delivered as a 
concentrated sterile solution, 6 mg/ml in 5 ml ampoules in polyoxyethylated castor oil 
(Cremophor EL) and dehydrated alcohol (1:1, v/v). Paclitaxel was diluted in a minimum 
volume of 250 ml and a maximum volume of 1000 ml of dextrose 5% or normal saline. 
Carboplatin (ParaplatinÒ, Bristol-Myers Squibb, Woerden, The Netherlands) was supplied as 
a lyophilized product that contained 150 mg carboplatin and 150 mg of mannitol as bulking 
agent. Immediately before use, the content of each vial was reconstituted with 15 ml water for 
injection and the total dose was added to 250 ml dextrose 5%. The dose of carboplatin in mg 
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was calculated according to the formula: dose (mg) = carboplatin clearance (ml/min) x AUC 
(min· mg/ml). Carboplatin clearance was calculated according to the Chatelut formula.[12]  
Four different dose levels for ifosfamide were investigated in the phase I study. At the first 
dose level sampling was performed in four patients receiving ifosfamide 1,500 mg/m² on days 
1 and 2 by means of a 1-hour intravenous infusion. At the second dose level four patients 
received ifosfamide 1,000 mg/m² on days 1 and 2. At the third dose level two patients 
received ifosfamide 2,000 mg/m² on day 1 by means of a 1-hour intravenous infusion. At the 
fourth dose level four patients received ifosfamide 3,000 mg/m² on day 1. At each dose level 
after the last ifosfamide administration, paclitaxel 175 mg/m² by means of a 3-hour 
intravenous infusion and carboplatin at AUC=6 min· mg/ml by means of a 30-minute 
intravenous infusion were administered. 
To prevent bladder toxicity, mesna (UromitexanÒ, ASTA Medica, Diemen) was administered 
in a total dose equal to the ifosfamide dose. Administration was partitioned equally over the i.v. 
infusion and twice orally three and seven hours, thereafter. To avoid acute allergic reactions 
all patients received dexamethasone 8 mg orally every 12 hours and 30 minutes before 
paclitaxel, clemastine 2 mg i.v. push 30 minutes before paclitaxel and ranitidine 50 mg i.v. 
push 30 minutes before paclitaxel. Anti-emetics used were ondansetron twice daily for the 
first three days and additionally dexamethasone and metoclopramide when needed.  
 
Pharmacokinetic sampling 
 
Pharmacokinetic sampling was performed during the first dosing cycle. The pharmacokinetic 
sampling at 0, 0.5, 1, 1.5, 2, 4, 8, 24, 24.5, 25, 25.5, 26, 28, 32 and 48 hours after start of the 
first ifosfamide infusion by means of an intravenous dwelling catheter was performed in 
patients receiving ifosfamide over two days (dose levels 1 and 2) and at 0, 1, 2, 5 and 24 
hours in patients receiving ifosfamide for one day (dose levels 3 and 4). First 2 ml whole blood 
was drawn and discarded, followed by collection of 5 ml whole blood in a lithium heparin-
coated Vacutainer® (Becton-Dickinson, Plymouth, UK) and placed on ice water. The plasma 
was immediately separated by centrifugation at 1,000 g for 5 min at 4°C. The plasma was 
aliquoted in three volumes of which two were precisely 1-ml volumes. To these 1-ml volumes, 
100 µl 2 M semicarbazide solution at pH 7.40 were added to stabilize 4-hydroxyifosfamide. 
The remaining plasma was used for ifosfamide, 2- and 3-dechloroethylifosfamide analysis. 
Furthermore, urine was collected for up to 24 hours after the end of the last ifosfamide 
infusion and a representative sample of the collected urine was analysed for ifosfamide, 2- 
and 3-dechloroethylifosfamide. Both plasma and urine samples were stored at -20°C up to 1 
month pending analysis. 
 
Bioanalysis 
 
Gas chromatography with selective nitrogen phosphorous detection was used for the 
determination of ifosfamide, 2- and 3-dechloroethylifosfamide in urine and plasma.[13] Sample 
pre-treatment consisted of alkalinized liquid-liquid extraction with ethyl acetate, transfer of the 
organic extract, evaporation to dryness and subsequent reconstitution in ethyl acetate. This 
method proved to be specific, sensitive, accurate (93.3-104.5%) and precise (<5.5%) from 
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0.192 to 383 µM, with a lower limit of quantification (LLQ) of 0.192 µM for ifosfamide, 2- and 3-
dechloroethylifosfamide. 
High-performance liquid chromatography (HPLC) was used for determination of 4-
hydroxyifosfamide pharmacokinetics.[14] In brief, this method determined the 4-
hydroxyifosfamide-semicarbazone derivative in plasma. The HPLC column used was 
reversed phase C8 with acetonitrile-0.025 M potassium dihydrogenphosphate (32:68 v/v) as 
mobile phase. Detection was performed at 230 nm. Sample pre-treatment consisted of liquid-
liquid extraction with ethyl acetate. This method was specific, sensitive, accurate (94.1-
107.9%) and precise (<7.2%) from 0.361 to 361 µM, with a LLQ of 0.361 µM 4-
hydroxyifosfamide. 
 
Data evaluation 
 
Pharmacokinetic models were fitted to the data from l4 individuals using the population 
pharmacokinetic programme NONMEM (Non-linear Mixed Effects Modelling).[15,16] NONMEM 
estimates population parameters as typical parameter values with corresponding 
interindividual variability, usually as its S.D., denoted as w. This is accomplished by allowing 
each individual’s data to be described by subject specific pharmacokinetic parameters Pi; this 
parameter is assumed to come from the distribution of parameters in the population 
according to equation 1. 
P Pi pop i= ´ exp( )h          (eq. 1) 
In which Ppop is the parameter value of a typical individual and h is the symmetrically 
distributed zero-mean variable with the S.D. denoted as w. For mixed effects models the 
residual error corresponds to the difference between observed (Cobs) and predicted (Cpred) 
concentration by individual parameters (Pi). The residual or intraindividual error was 
described by a proportional and additive component according to equation 2, 
C Cobs pred= ´ + +( )1 1 2e e         (eq. 2) 
in which e1 and e2 are zero-mean random variables with S.D.s s1 and s2. Either component 
of the residual error could be omitted if it did not provide an improvement of the fit of the data. 
Model accuracy was evaluated using goodness-of-fit plots and precision of the parameters 
estimates. For the graphical goodness-of-fit analysis extensive plotting was available through 
the use of X-pose, a purpose-built set of subroutines in S-PLUS (Mathsoft, 1997).[17] In 
comparison between models the objective function value (which was minus two times the 
log-likelihood) provided by NONMEM was used. For hierarchical models the difference in 
objective function value is approximately c-squared distributed and formal testing between 
models can be performed using the log-likelihood ratio test.[15] For non-hierarchical models 
the objective function value cannot be used for formal testing, but we considered a difference 
of 9 units between models of the same number of parameters and identical databases to 
present a real difference in description of the data.[18] Three models (model 1-3) for the 
description of the plasma concentration-time profiles of ifosfamide were compared. 
Furthermore, a model describing the pharmacokinetics of the metabolites was developed. 
 
Model 1 
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Model 1 is a one-compartment model describing the change of the amount of ifosfamide (Aifo, 
µmol) in the central compartment over time by equation 3, 
t T< inf  : 
dA
dt
R CL A V
ifo ifo
ifo
= - ´æèç
ö
ø÷  
t T> inf  : 
dA
dt
CL A V
ifo ifo
ifo
= - ´æèç
ö
ø÷        (eq. 3) 
in which Tinf (h) is the infusion duration, R (µmol· h
-1) is the infusion rate of ifosfamide, CL 
(L· h-1) the ifosfamide clearance and Vifo (L) the volume of distribution. The concentration of 
ifosfamide Cifo (µM) is the ratio of Aifo and Vifo. Thus in model 1, CL is a constant parameter. 
 
Model 2 
 
In model 2, CL has been replaced by a clearance of ifosfamide which changes over time 
(CL(t), L· h
-1), thus yielding equation 4. 
t T< inf  : 
dA
dt
R CL A V
ifo
t
ifo
ifo
= - ´æèç
ö
ø÷( )  
t T> inf  : 
dA
dt
CL A V
ifo
t
ifo
ifo
= - ´æèç
ö
ø÷( )        (eq. 4) 
In turn, CL(t) can be described by defining a hypothetical enzyme compartment. CL(t) can then 
be described by an initial clearance (CLinit, L· h
-1) multiplied by the relative amount of enzyme 
(Aenz) in the hypothetical enzyme compartment as given in equation 5.   
CL CL At init enz( ) = ´          (eq. 5) 
The change of Aenz over time in the enzyme compartment is dependent on Cifo as follows, 
dA
dt
K K A
C
C IC
enz
enz in enz out enz
ifo
ifo
= - ´ ´ -
+
æ
è
ç
ö
ø
÷, , 1
50
     (eq. 6) 
in which Kenz,in (mol· h
-1) is the zero-order rate constant for enzyme formation/activation, 
Kenz,out (h
-1) is the first-order rate constant for enzyme degradation/inactivation and IC50 (µM) 
is the ifosfamide concentration at 50% of the maximum inhibition of enzyme degradation. 
Before treatment with ifosfamide (t=0) steady-state levels of the enzyme were assumed. 
Hence, the change in enzyme amount was zero. Kenz,in was equal to Kenz,out times the 
amount of enzyme at t=0 (Aenz, t=0). By scaling Aenz, t=0 to a value of 1 (without a dimension), 
Kenz,in could be substituted for Kenz,out yielding equation 7. 
dA
dt
K K A
C
C IC
enz
enz out enz out enz
ifo
ifo
= - ´ ´ -
+
æ
è
ç
ö
ø
÷, , 1
50
     (eq. 7) 
In which Aenz is the relative amount of enzyme (no dimension). The induction half-life of the 
enzyme (T½ enz, h) was calculated by the ratio of ln(2) and Kenz,out.
[19]  
 
Model 3 
 
In model 3 a concentration independent increase of CL(t) over time during steady-state 
infusions was used. Boddy et al. described a similar model but with an exponential increase 
after a lag time from an initial clearance to a maximum clearance.[20] This model described 
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CL(t) with a time dependent increase from CLinit as described by equation 8. 
( )CL CL K tt ini enz( ) = ´ + ´1         (eq. 8) 
In which Kenz (L· h
-2) was the enzyme induction rate constant and t (h) the time. 
 
Model 4 
 
After obtaining the individual pharmacokinetic parameters CL(t) and Vifo from the superior 
model, these parameters were used in the modelling of the metabolite pharmacokinetics. The 
change in the amount of a metabolite (Am) over time could be described by equation 9. 
( )dA
dt
F
V
CL
A
V
K Am m
m
t
ifo
ifo
m m= ´ ´
æ
è
ç
ö
ø
÷ - ´( )       (eq. 9) 
In which Km (h
-1) is the elimination rate constant of the metabolite and Fm is the fraction of 
ifosfamide metabolized to the metabolite. The values for Fm and the volume of distribution of 
the metabolite (Vm, L) cannot be estimated separately in this model. Therefore, the ratio of Fm 
over Vm was estimated: F
* (L-1). The ratio was used to calculate the area under the 
concentration-time curve (AUCm) of the metabolite, as described by equation 10. 
AUC
D
K
V
F
m
m
m
m
=
´
         (eq. 10) 
In which D (mol) was the ifosfamide dose administered to the patient. The interindividual 
variability of each pharmacokinetic parameter was estimated using a proportional error model 
according to equation 1. The residual or intraindividual variability of ifosfamide and metabolites 
kinetics were described separately with a proportional and additive term according to equation 
2. The Bayesian estimates of the areas under the concentration-time curves (AUC) of 
ifosfamide and its metabolites were obtained by describing the cumulative concentrations of 
these compounds over a given time. AUCs were obtained with extrapolation of ifosfamide and 
metabolite concentration-time profiles to 144 hours after the start of the infusion, where 
concentrations were below the LLQ. The urinary excretions (UE) for ifosfamide and 2- and 3-
dechloroethylifosfamide were calculated as the equimolar amount of the administered 
ifosfamide dose recovered in urine over 96 hours.  
 
Results 
 
Fourteen patients were evaluable for plasma pharmacokinetics and ten patients for urine 
recovery measurements. The pharmacokinetic data-base consisted of 122 ifosfamide, 120 2-
dechloroethylifosfamide, 122 3-dechloroethylifosfamide and 117 4-hydroxy-ifosfamide plasma 
concentrations. The observed ifosfamide and metabolite concentration-time profiles are 
shown in figure 2. The pharmacokinetic parameters for ifosfamide and a comparison of the 
three population pharmacokinetic models are represented in table 1. 
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Figure 2. Observed concentrations of ifosfamide and metabolites in 14 patients treated with four 
different schedules of ifosfamide, followed by paclitaxel and carboplatin. 
Table 1. Estimates of pharmacokinetic population parameters for ifosfamide (IFO) with their relative 
standard error, interindividual variability and residual variability by model 1, 2 and 3. 
 
Parameter Mean estimate Relative error Interindividual variability 
MODEL 1 obj f=975    
CL (L· h-1) 5.30 22% 29% 
Vifo (L) 42.4 3% 17% 
P.E. IFO 13.9%   
A.E. IFO (µM) 16.2   
MODEL 2 obj f=934    
CLinit (L· h
-1) 2.49 19% 41% 
Vifo (L) 46.2 6% 17% 
Kenz,out (h
-1) 0.114 35% - 
T½ ,enz (h) 6.1 - - 
IC50 (µM) 21.4 12% - 
P.E. IFO 17.4%   
A.E. IFO (µM) -   
MODEL 3 obj f=954    
CLinit (L· h
-1) 3.39 26% 30% 
Vifo (L) 46.9 6% 19% 
Kenz (h
-1) 0.0269 38% - 
T½ ,enz (h) 25.8   
P.E. IFO 14.9%   
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A.E. IFO (µM) 10.5   
 
Obj f=objective function, CL=ifosfamide clearance, Vifo=volume of distribution of ifosfamide, P.E.=proportional 
intraindividual error, A.E.=additive intraindividual error, CLini,ifo=initial CL, Kenz,out=first-order rate constant for 
enzyme degradation, T½ ,enz=induction half-life of the enzyme, IC50=ifosfamide concentration at 50% of the 
maximum inhibition of enzyme degradation, Kenz=zero-order rate constant for enzyme degradation. 
 
The goodness-of-fit of a model was described by its objective function. The objective 
functions of  model 1 and 3 were 41 and 20 points, respectively, higher than that of model 2. 
We therefore conclude that model 2 is the most appropriate model to describe the observed 
data. The residual error represents the remaining variability not explained by the structural 
model; it is described by an additive and proportional component. Model 1 has the lowest 
proportional error, but with the highest additional error. On the other hand, model 2 only 
required a proportional error. Overall, model 2 had the lowest residual variability with 17.4%. 
The relative error in the estimate of a population parameter is a measure of precision of 
estimation. These precisions in all three models for ifosfamide were less than 38% and 
considered good. All three models estimated Vifo similar. Vifo was estimated between 42.4 
and 46.9 L, with an interindividual variability of 17-19%. CLinits of model 2 and 3 were also 
similar with 2.49±0.47 and 3.39±0.88 L· h-1 and an interindividual variability of 41 and 30%, 
respectively. For the parameters describing the increase in CL(t), such as Kenz,out, IC50 and 
Kenz, inclusion of interindividual variability did not improve the fit. This should not be interpreted 
as an absence of interindividual variability in these parameters, but only that the data do not 
contain sufficient information to estimate these. The CL(t) as function of time and calculated 
by model 2 for each patient is shown in figure 3.  
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Figure 3. Individual ifosfamide clearance-time (CL(t)) profiles in 14 patients with an ifosfamide 
concentration-dependent increase of ifosfamide clearance (model 2). The profiles were obtained on 
basis of the individual Bayesian parameter estimates provided by NONMEM. 
 
The population pharmacokinetic parameters of the metabolites are given in table 2. The 
model predictions and individual Bayesian predictions versus observed ifosfamide and 
metabolite concentrations with their distribution around the line of identity are shown in figure 
4. Accuracy of the estimates was reasonable (relative errors ranged from 14 to 66%). Modest 
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interindividual variability was observed in the population parameters (29 to 52%). In contrast to 
3-dechloroethylifosfamide and 4-hydroxyifosfamide, 2-dechloroethyl-ifosfamide was best 
estimated by a residual error model with only an additive error. 
 
Table 2. Estimates of pharmacokinetic population parameters for 2-dechloroethylifosfamide (2DCE), 3-
dechloroethylifosfamide (3DCE) and 4-hydroxyifosfamide (4OHIF) with their relative standard error, 
interindividual variability and residual variability based upon the Bayesian parameter estimates of model 
2. 
 
Parameter Mean estimate Relative error Interindividual variability 
F*2DCE (L
-1) 0.0426 40% 52% 
K2DCE (h
-1) 2.22 36% - 
F*3DCE (L
-1) 0.00771 14% 36% 
K3DCE (h
-1) 0.138 16% 47% 
F*4OHIF (L
-1) 0.0180 60% - 
K4OHIF (h
-1) 9.90 66% 29% 
P.E. 2DCE -   
A.E. 2DCE (µM) 6.89   
P.E. 3DCE 33.1%   
A.E. 3DCE (µM) 0.366   
P.E. 4OHIF 30.5%   
A.E. 4OHIF (µM) 0.218   
 
F*=ratio of the fraction of ifosfamide metabolized to the metabolite and the volume of distribution of the 
metabolite, K=first-order elimination rate constant of metabolite, P.E.=proportional residual error, A.E.=additive 
residual error. 
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Figure 4. The relationships between model predictions, individual Bayesian estimates and observed 
ifosfamide (IFO), 2-dechloroethylifosfamide (2DCE), 3-dechloroethylifosfamide (3DCE) and 4-
hydroxyifosfamide (4OHIF) concentrations. 
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The pharmacokinetic parameter estimates for the metabolites were used to estimate the 
AUCs. Figure 5 depicts the relationship between the systemic exposures of ifosfamide and 
metabolites and the absolute dose. Linearity was observed in the relationship of the absolute 
ifosfamide dose and AUC with ifosfamide (p<0.001) and 4-hydroxyifosfamide (p=0.003), but 
not 2-dechloroethylifosfamide (p=0.458) and 3-dechloroethylifosfamide (p=0.065). The urinary 
excretion of unchanged ifosfamide and its dechloroethylated metabolites are represented in 
table 3. The relationships between the urinary excretion of ifosfamide (p=0.238) and the 
dechloroethylated metabolites (p=0.015), and the absolute ifosfamide doses are represented 
in figure 6. Considerable interindividual variability is observed in the urinary recoveries. 
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Figure 5. The relationship between the systemic exposure of ifosfamide (IFO) and 2-dechloroethyl-
ifosfamide (2DCE), 3-dechloroethylifosfamide (3DCE) and 4-hydroxyifosfamide (4OHIF) after four 
different dosing schedules in 14 patients. Systemic exposure was based on the area under the plasma 
concentration-time curve (AUC).  
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Table 3. Percentage of dose excreted in urine either unchanged as ifosfamide (IFO) or as metabolite 2-
dechloroethylifosfamide (2DCE) and  3-dechloroethylifosfamide (3DCE) in 10 patients. 
 
Patient IFO Dose  
(g) 
IFO 
(%) 
2DCE 
(%) 
3DCE 
(%) 
Total 
(%) 
1 6.30 4.0 1.6 6.0 11.6 
2 6.00 3.9 1.6 5.4 10.9 
3 5.25 6.3 1.4 4.4 12.1 
4 5.85 7.8 1.7 4.2 13.7 
5 4.00 2.8 1.3 6.9 11.0 
6 3.60 13.6 3.6 7.5 24.7 
7 4.20 9.8 3.4 7.9 21.1 
8 3.08 4.6 7.6 15.4 27.6 
13 6.00 5.1 2.8 4.9 12.8 
14 6.20 8.4 2.4 8.4 19.2 
Mean±SD  6.6±3.3 2.7±1.9 7.1±3.3 16.5±6.2 
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Figure 6. The relationship between the urinary recovery of ifosfamide and the dechloroethylated 
metabolites and the absolute ifosfamide dose in 10 patients. 
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Discussion 
 
Three different population models were compared to describe pharmacokinetics of ifosfamide 
in patients treated with the combination ifosfamide, paclitaxel and carboplatin. The Bayesian 
estimates of the ifosfamide parameters provided by the superior model were used in the 
modelling of the metabolite pharmacokinetics. All population models for ifosfamide were 
based on one-compartment models. Introduction of a peripheral compartment did not 
significantly increase the goodness-of-fit of the model. Urinary recovery of unchanged 
ifosfamide and its dechloroethylated metabolites was minor. As a result, splitting the 
ifosfamide clearance into an inducible metabolic clearance and a non-inducible renal 
clearance also did not improve the goodness-of-fit of the model. 
Model 3 was based on a model by Boddy et al. describing autoinduction by an exponential 
increase of the initial clearance to a maximum value.[20] This model was developed on a 
population of patients receiving a 72-hours continuous infusion schedule. The application of 
this model in our patient population resulted in a linear increase of clearance over time from 0 
to 48 hours, thus a more simple linear increase with time could be used without estimation of 
the maximum value of clearance. 
Model 2 described autoinduction of ifosfamide best using a dynamic hypothetical enzyme 
compartment. This enzyme amount could be increased by inhibition of enzyme degradation 
and/or inactivation by ifosfamide. Ifosfamide reduces protein synthesis.[21] Ifosfamide could, 
therefore, also reduce catalytic enzymes responsible for CYP degradation and/or inactivation, 
resulting in an increased ifosfamide clearance. An increased amount of enzyme could also be 
achieved by an increase in synthesis of the enzyme itself. Such a model has been proposed 
for cyclophosphamide, an isomer of ifosfamide.[22] Whatever the physiological mechanism, 
all will result in an increased amount of enzyme and both modelling approaches will yield the 
same result.[22]  
The ifosfamide concentration dependent autoinduction model (2) describes an increase in the 
clearance of ifosfamide during the first 24 hours with an observed maximum on the second 
day followed by a decrease. In one patient an increased CLinit was observed. This patient 
metabolized ifosfamide more rapidly than other patients, but without an altered rate of 
autoinduction, which was reflected in elevated levels of dechloroethylated and hydroxylated 
metabolites. Although the ifosfamide and metabolite concentrations were outlyers compared 
to other patients, the population approach with estimation of interindividual variability still 
provided an adequate Bayesian pharmacokinetic description of this patient.  
The metabolite model adequately described the pharmacokinetics of the metabolites. The 
fraction of the ifosfamide dose converted to a metabolite (Fm) was less than one for all 
metabolites. Thus according to equation 9, Vm of all metabolites was always smaller than Vifo. 
This is in accordance with the expectation that the metabolism of an exogenous compound 
like ifosfamide will lead to more hydrophilic compounds.  
Pharmacokinetics of 4-hydroxyifosfamide are formation rate-limited as reflected in the high 
value for K4OHIF. Therefore, elimination of 4-hydroxyifosfamide could also be estimated by 
fixing the K4OHIF to 100 times the elimination of ifosfamide. Nevertheless, fixing of K4OHIF did 
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not improve the objective function significantly. Therefore, it was decided to estimate K4OHIF, 
although the imprecision of the estimation was relatively high. 
Both ifosfamide and 4-hydroxyifosfamide exhibited a more steep dose-exposure relationship 
than dechloroethylated metabolites, as represented in figure 5. The lack of a distinct dose-
exposure relationship of the dechloroethylated metabolites could be explained by their 
relatively high interindividual differences in exposure. Although the four different treatment 
schedules of ifosfamide administration did not result in a wide dose range, some trends in the 
exposures due to dose-fractionating could be observed. The AUC of 3 g/m² ifosfamide given 
over one or two days did not differ significantly. However, administration over two days 
resulted in relatively higher metabolite formation. The AUC of 2-dechloroethylifosfamide, 
particularly, was increased after administration of ifosfamide over two subsequent days. This 
can be explained by autoinduction resulting in increased metabolite formation. 
Renal excretion of unchanged ifosfamide was 6.6±3.3% and of the dechloroethylated 
metabolites 9.8±5.1% of the administered dose. The urinary excretions are in accordance 
with previously reported data in patients receiving fractionated dosing of single agent 
ifosfamide.[5] Previous stability studies indicated no degradation of ifosfamide, 2- and 3-
dechloroethylifosfamide during the 24-hour collection interval.[13] 
The relationship between the ifosfamide dose and the percentage excreted as 
dechloroethylated metabolites (figure 6) were largely determined by patient no. 8 (table 3). 
Markedly, in this patient the second lowest dose-corrected exposure to ifosfamide was 
observed in combination with the highest and second highest dose-corrected exposure to 2- 
and 3-dechloroethylifosfamide, respectively. This was also reflected in the clearance values 
(approximately 8 L/h) of this patient.  
In conclusion, ifosfamide concentration-time profiles were best described by modelling the 
development of autoinduction with an ifosfamide concentration-dependent increase in 
ifosfamide clearance. Systemic exposures to ifosfamide and metabolites were calculated 
using Bayesian estimated pharmacokinetic parameters. 
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Influence of infusion duration on the 
pharmacokinetics of ifosfamide and 
metabolites 
 
 
Summary 
 
The anticancer drug ifosfamide is a prodrug requiring activation through 4-hydroxyifosfamide 
to ifosforamide mustard to exert cytotoxicity. Deactivation of ifosfamide leads to 2- and 3-
dechloroethylifosfamide and the release of potentially neurotoxic chloroacetaldehyde. The 
aim of this study was to quantify and to compare the pharmacokinetics of ifosfamide, 2- and 
3-dechloroethylifosfamide, 4-hydroxyifosfamide and ifosforamide mustard in short (1-4 h), 
medium (24-72 h) and long infusion durations (96-240 h) of ifosfamide. An integrated 
population pharmacokinetic model was used to describe the autoinducible pharmacokinetics 
of ifosfamide and its four main metabolites in 56 patients. The rate by which autoinduction of 
the metabolism of ifosfamide developed and the fractions metabolized to 2- and 3-
dechloroethylifosfamide were found to be significantly dependent on the infusion schedule. 
The observed differences in the parameters were, however, comparable to their interindividual 
variability and were, therefore, considered to be of minor clinical importance. Autoinduction 
caused a less than proportional increase in the area under the ifosfamide plasma 
concentration-time curve (AUC) and more than proportional increase in metabolite exposure 
with increasing ifosfamide dose. During long infusion durations dose-corrected exposures 
(AUC/D) were significantly decreased for ifosfamide and increased for 3-
dechloroethylifosfamide when compared with short infusion durations. No differences in dose-
normalized exposure to ifosfamide and metabolites were observed between short and 
medium infusion durations. This study demonstrates that the duration of ifosfamide infusion 
influences the exposure to the parent and its metabolite 3-dechloroethylifosfamide. The 
observed dose and infusion duration dependency should be taken into account when the 
pharmacodynamics of different infusion schedules are evaluated. 
Introduction 
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Ifosfamide (HoloxanÒ, IfexÒ) is an alkylating agent which has been proven to be active 
against a number of solid tumours and haematological malignancies in adults and children. 
Currently, ifosfamide is mostly used in combination with other anticancer drugs, but also as 
single agent. Many different infusion schedules are in use, e.g. continuous infusion over either 
24, 72 or 240 hours with doses of 5, 9 or 7.5-15 g/m² ifosfamide, respectively.[1,2] 
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Figure 1. Metabolism of ifosfamide. 
 
Ifosfamide is a prodrug, which needs activation by cytochrome P450-3A4 (CYP3A4) to 4-
hydroxyifosfamide as depicted in figure 1. Spontaneous decomposition of 4-
hydroxyifosfamide yields the ultimate alkylating metabolite ifosforamide mustard and 
acrolein.[3] The alkylating activity of ifosforamide mustard is responsible for both the anti-
tumour activity and haematological toxicity. Acrolein causes haemorrhagic cystitis, which can 
generally be prevented by mesna co-administration. Ifosfamide is deactivated to the non-
cytotoxic metabolites 2- and 3-dechloroethylifosfamide. Each dechloroethylation reaction 
yields an equimolar amount of chloroacetaldehyde, which is held responsible for neurotoxicity 
observed in about 10% of all patients receiving conventional single-agent dosing of 
ifosfamide.[4] In addition, observed renal tubular abnormalities may also be correlated with the 
formation of chloroacetaldehyde.[3] Chloroacetaldehyde is very unstable. Therefore, 
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assessment of 2- and 3-dechloroethylifosfamide exposure is preferred when quantifying the 
relationship between the pharmacokinetics and neurotoxicity after ifosfamide infusion. 
Ifosfamide is subject to autoinduction leading to an increase in metabolism of ifosfamide over 
time.[5] Several comparative studies observed that fractionation of the ifosfamide dose leads 
to increased autoinduction.[3] Pharmacokinetic studies can provide further insight into the 
effect of the infusion schedule on the autoinduction of ifosfamide metabolism. Aim of this 
study is to quantify and compare the pharmacokinetics of ifosfamide, 2- and 3-
dechloroethylifosfamide, 4-hydroxyifosfamide and ifosforamide mustard in short (1-4 h), 
medium (24-72 h) and long infusion durations (96-240 h) of ifosfamide. Assessment of 
pharmacokinetics will indicate whether the development of autoinduction is dependent on the 
dose and/or infusion duration and may further aid in the design of ifosfamide infusion 
schedules. 
 
Methods 
 
Eligibility criteria 
 
Thirty-three patients received ifosfamide (HoloxanÒ, ASTA Medica, Diemen, The Netherlands) 
as intravenous (i.v.) infusion as part of the regular therapy with ifosfamide as single agent or 
as combination chemotherapy with cisplatin, carboplatin, etoposide, adriamycine, vincristine 
or methotrexate, during the period of March 1997 to April 2000. Typical infusion schedules 
used for ifosfamide were 1.2 g/m² once daily over 1, 3 or 4 hours for three consecutive days, 
1.5 g/m² once daily in 22.5 hours for two consecutive days, 5 g/m² in 24 hours once and 9 
g/m² by means of a 72-hours continuous infusion. The study protocol was approved by the 
Ethics Board of the Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute. 
Another group of 23 patients received a 10-day continuous infusion of single-agent ifosfamide 
using an ambulatory pump. This group was treated at the Leiden University Medical Center, in 
a study that was approved by the hospital Ethics Board.[2] Supportive care consisted of 
mesna and extensive hydration to prevent haemorrhagic cystitis and bicarbonate to prevent 
acidosis. Standard 5-HT3 blockers as anti-emetics and methylene blue (a neurotoxicity 
antidote) were given when indicated.[4] Pharmacokinetic sampling was performed after written 
informed consent was obtained from the patients.  
  
Pharmacokinetic sampling 
 
Blood samples were drawn before the start of, during, and after the end of the infusion at 
selected time points, depending on the infusion schedule. Ten ml of whole blood was 
collected in a lithium heparin-coated Vacutainer® (Becton-Dickinson, Plymouth, UK) and 
placed on ice water. The plasma was immediately separated by centrifugation at 1,000 g for 5 
min at 4°C. The plasma was aliquoted in four volumes of which three were precisely 1-ml 
volumes. 100 µl 2 M semicarbazide solution pH 7.4 were added to two 1-ml volumes to 
stabilize 4-hydroxyifosfamide. 100 µl 1 M sodium chloride, 2 M semicarbazide solution pH 8.0 
were added to another 1-ml volume to prevent 4-hydroxyifosfamide degradation to 
ifosforamide mustard and to stabilize the latter. The remaining plasma was used for 
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ifosfamide, 2- and 3-dechloroethylifosfamide analysis. Urine was collected from the start of 
the (first) infusion until 24 hours after the end of the (last) ifosfamide infusion and was 
analysed for ifosfamide, 2- and 3-dechloroethylifosfamide. Both plasma and urine samples 
were stored at -70°C pending analysis.  
 
Bioanalysis 
 
Gas chromatography with selective nitrogen-phosphorous detection was used for the 
determination of ifosfamide, 2- and 3-dechloroethylifosfamide in urine and plasma.[6] Sample 
pre-treatment consisted of alkalinized liquid-liquid extraction with ethyl acetate, transfer of the 
organic extract to another tube, evaporation to dryness and subsequent reconstitution in ethyl 
acetate. This method was validated and proved to be specific, sensitive, accurate (93.3-
104.5%) and precise (within and between-day <5.5%) within the concentration range of 0.192 
to 383 µM, with a lower limit of quantification (LLQ) of 0.192 µM for ifosfamide, 2- and 3-
dechloroethylifosfamide. High-performance liquid chromatography (HPLC) was used for 
determination of 4-hydroxyifosfamide plasma levels.[7] In brief, this method determined the 4-
hydroxyifosfamide-semicarbazone derivative in plasma. Sample pre-treatment consisted of 
liquid-liquid extraction with ethyl acetate. The HPLC column used was reversed phase C8 with 
acetonitrile-0.025 M potassium dihydrogenphosphate (32:68 v/v) as mobile phase. Detection 
was performed at 230 nm. This method was specific, sensitive, accurate (94.1-107.9%) and 
precise (within and between-day <7.2%) in the concentration range of 0.361 to 361 µM, with a 
LLQ of 0.361 µM 4-hydroxyifosfamide (measured as semicarbazone derivative). Plasma 
concentrations of ifosforamide mustard were determined using a validated HPLC method.[8] 
In brief, this method determined the ifosforamide mustard-diethyldithio-carbamate derivative in 
plasma. Sample pre-treatment consisted of derivatization followed by liquid-liquid extraction 
with acetonitrile. Derivatization was achieved by incubating 500 µl plasma with 350 µl 1 M 
sodium chloride 0.1 M potassium dihydrogenphosphate buffer pH 8.0 and 50 µl 
diethyldithiocarbamate for 30 min at 70°C. The HPLC column used was a reversed phase C8 
column with acetonitrile-0.025 M potassium dihydrogenphosphate pH 8.0 (32:68 v/v) as 
mobile phase. Detection was performed at 276 nm. This method was specific, sensitive, 
accurate (101.4-110.0%) and precise (<15.8%) in the concentration range of 0.452 to 226 µM, 
with a LLQ of 0.452 µM ifosforamide mustard (measured as diethyldithiocarbamate 
derivative). 
 
Data evaluation 
 
Pharmacokinetic models were fitted to the plasma concentration data from the individuals 
using the population pharmacokinetic programme NONMEM (Non-linear Mixed Effects 
Modelling, version V 1.1, double precision, first order estimation).[9,10] The population 
pharmacokinetic models resulted in model predictions and Bayesian individual predictions for 
the concentrations of ifosfamide and metabolites. The non-linear pharmacokinetics of 
ifosfamide were described using a recently developed model, which incorporated the 
development of autoinduction.[5] According to this recent study the time dependent 
pharmacokinetics of ifosfamide can be described by a one-compartment model (figure 2).  
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Figure 2. Pharmacokinetic model for ifosfamide metabolism describing the autoinducible 
pharmacokinetics of ifosfamide (IFO), 2-dechloroethylifosfamide (2DCE), 3-dechloroethylifosfamide 
(3DCE), 4-hydroxyifosfamide (4OHIF) and ifosforamide mustard (IFM). Autoinduction is modelled with a 
hypothetical enzyme compartment described by an enzyme formation rate (Kenz,in) and elimination rate 
(Kenz,out). The amount of enzyme increases the clearance of IFO (CLIFO). The amount of IFO, described 
by the IFO concentration and IFO volume of distribution (V IFO), inhibits Kenz,out. Metabolite compartments 
are described by metabolite formation (F) and elimination rates (K). 
 
The change of the amount of ifosfamide (Aifo, µmol) in the central compartment over time is 
described by equation 1, 
t T< inf  : 
dA
dt
R CL A V
ifo ifo
ifo
= - ´æèç
ö
ø÷ and    
t T> inf  : 
dA
dt
CL A V
ifo ifo
ifo
= - ´æèç
ö
ø÷        (eq. 1) 
in which Tinf (h) is the infusion duration, R (µmol· h
-1) is the infusion rate of ifosfamide, CL 
(L· h-1) the ifosfamide clearance, which changes over time and Vifo (L) the volume of 
distribution. The predicted concentration of ifosfamide Cifo (µM) is the ratio of Aifo and Vifo. The 
development of autoinduction is described using a hypothetical enzyme compartment. CL is 
expressed as initial clearance (CLini,ifo, L· h
-1) multiplied by the relative amount of enzyme 
(Aenz) in the hypothetical enzyme compartment, as given in equation 2.   
CL CL Aini ifo enz= ´,          (eq. 2) 
The change of Aenz (a relative measure with no dimension) over time in the enzyme 
compartment is dependent on Cifo as follows, 
dA
dt
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+
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50
     (eq. 3) 
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in which Kenz,out (h
-1) is the first-order rate constant for enzyme degradation/inactivation and 
IC50 (µM) is the ifosfamide concentration at 50% of the maximum inhibition of enzyme 
degradation. At t=0 and Aenz=1, the enzyme formation rate (Kenz,in) is equal to Kenz,out (figure 
2). The induction half-life of the enzyme (T½enz, h) was calculated by the ratio of ln(2) and 
Kenz,out.  
The pharmacokinetics of ifosfamide and metabolites were described sequentially: Bayesian 
estimations (posthocs) of the pharmacokinetic parameters of ifosfamide were used during 
the assessment of the pharmacokinetics of the metabolites. The change in the amount of a 
metabolite (Am) over time for 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide could 
be described by equation 4,  
( )dA
dt
F CL
A
V
K Am m
ifo
ifo
m m= ´ ´
æ
è
ç
ö
ø
÷ - ´        (eq. 4) 
in which Km (h
-1) is the elimination rate constant of the metabolite and Fm is the fraction of 
ifosfamide metabolized to the metabolite. The values for Fm and the volume of distribution of 
the metabolite (Vm, L) cannot be estimated separately in this model. Therefore, the ratio of Fm 
over Vm was estimated: F
* (L-1). The change in the amount of ifosforamide mustard (Aifm) 
over time could be described by equation 5,  
( ) ( )dA
dt
F K A K Aifm ohif ohif ifm ifmifm= ´ ´ - ´4 4       (eq. 5) 
in which Kifm (h
-1) is the elimination rate constant of ifosforamide mustard and Fifm is the 
fraction of 4-hydroxyifosfamide metabolized to ifosforamide mustard. Equation 5 can be 
rearranged to equation 6, 
( ) ( )dA
dt
F V K C K Aifm ohif ohif ohif ifm ifmifm= ´ ´ ´ - ´4 4 4      (eq. 6) 
in which V4ohif (L) is the volume of distribution of 4-hydroxyifosfamide and C4ohif (µM) is the 4-
hydroxyifosfamide concentration. The values for Fifm and the volumes of distribution of 4-
hydroxyifosfamide and ifosforamide mustard (Vifm, L) cannot be estimated separately in this 
model and were, therefore, replaced by one parameter: F**ifm, which has no dimension. 
The residual or intraindividual variability of the pharmacokinetics of ifosfamide and metabolites 
were described separately with a combined proportional and additive term. The interindividual 
variability of each pharmacokinetic parameter was estimated using a proportional error 
model. 
The posthocs of the areas under the concentration-time curves (AUC) of ifosfamide and its 
metabolites were obtained by describing the cumulative concentrations of these compounds 
over a given time. AUCs were obtained with extrapolation of ifosfamide and metabolite 
concentration-time profiles up to 72 hours after the end of the (last) ifosfamide infusion, where 
concentrations were below the LLQ. The effect of the infusion duration on the autoinduction of 
ifosfamide metabolism and its effect on the metabolite exposures was investigated by 
calculating dose-corrected AUCs. The dose-corrected AUC was obtained by dividing the AUC 
by the administered ifosfamide dose. A non-parametric test was conducted to determine 
significant differences in dose-corrected AUCs between the infusion schedules. The 
pharmacokinetics of each group of infusion schedules were compared with the other two 
groups using the Kolmogorov-Smirnov test for two independent samples. The influence of the 
independent variable infusion duration was tested on the estimation of each population 
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parameter of ifosfamide, 2- and 3-dechloroethylifosfamide according to equation 7, 
Ppop
short medium long= ´ ´q q q1 2 3         (eq. 7) 
in which Ppop is a population parameter, q1 is the typical value of that parameter with short 
duration infusions, q2 is the change in q1 with medium infusion duration, q3 is the change in q1 
with long infusion duration. If the 95% confidence interval (95%-CI) of the estimate of q2 and 
q3 incorporated 1, no significant difference between the short infusion durations with medium 
or long infusion durations was observed. The urinary excretions (UE) for ifosfamide and 2- 
and 3-dechloroethylifosfamide were calculated as the equimolar amount of the administered 
dose recovered in urine. Differences between the urinary excretions of the different infusion 
durations were tested for significance using the non-parametric Mann-Whitney test. Statistical 
analysis was performed using SPSS software (Version 6.1 for Windows; SPSS, Inc., 
Chicago, IL, USA). The level of significance (p) was set at 0.05. All tests for significance were 
two-tailed. 
 
Results 
 
A total of 56 patients was divided into three sub-populations with 12 patients receiving short 
(1-4 h), 21 patients receiving medium (24-72 h) and 23 patients receiving long (96-240 h) 
infusion durations of ifosfamide (table 1). The number of patients in which 4-
hydroxyifosfamide and ifosforamide mustard were analysed were insufficient for the separate 
estimation of the pharmacokinetics of these metabolites for each infusion schedule. The 
pharmacokinetic population parameters with their standard error and interindividual variability 
and the residual variability of ifosfamide and 2- and 3-dechloroethylifosfamide are presented in 
table 2.  
Table 1. Number of patients pharmacokinetically assessed for ifosfamide (IFO), 2-
dechloroethylifosfamide (2DCE), 3-dechloroethylifosfamide (3DCE), 4-hydroxyifosfamide (4OHIF) and 
ifosforamide mustard (IFM) for each infusion schedule. 
 
 All infusions Short (1-4 h) Medium (24-72 h) Long (96-240 h) 
 patients samples  patients samples  patients samples  patients samples  
 n n n n n n n n 
IFO 56 598 12 143 21 184 23 271 
2DCE 53 502 12 141 21 180 20 181 
3DCE 53 513 12 140 21 181 20 192 
4OHIF 15 135 2 27 13 108 0 0 
IFM 8 70 2 20 6 50 0 0 
 
Table 2. Estimates of population pharmacokinetic parameters of ifosfamide (IFO) 2-
dechloroethylifosfamide (2DCE) and 3-dechloroethylifosfamide (3DCE) with their relative standard error of 
the mean, interindividual variability and residual variability. 
 
Parameter Mean RE IIV Parameter Mean RE IIV 
CLini,ifo (L/h) 3.01 7% 26% F
*
2DCE (L
-1) 0.0161 24% 43% 
Vifo (L) 45.9 10% 28%        q
medium 0.487 34%  
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Kenz,out (h
-1) 0.0815 13% 22% K2DCE (h
-1) 0.385 19% 39% 
       qlong 0.48 39%  P.E.2DCE 1.73   
T½enz (h) 8.5   A.E.2DCE (µM) 20.6%   
IC50 (µM) 24.4 33% 55% F
*
3DCE (L
-1) 0.0109 20% 35% 
P.E.IFO 2.84          q
medium 0.666 23%  
A.E.IFO (µM) 12.6   K3DCE (h
-1) 0.124 18% 19% 
    P.E.3DCE 3.31   
    A.E.3DCE (µM) 17.0%   
 
RE=Relative error of the mean, IIV=interindividual variability, CLini,ifo=initial ifosfamide clearance, Vifo=volume of 
distribution of ifosfamide, Kenz,out=autoinduction formation rate, q=difference in parameter estimation due to long 
or medium infusion duration, IC50=ifosfamide concentration at 50% of the maximum inhibition of enzyme 
degradation, P.E.=proportional intraindividual error, A.E.=additive intraindividual error, F*=ratio of fraction 
metabolized and volume of distribution of metabolite, K=first-order rate constant for metabolite elimination. 
 
Table 3. Estimates of pharmacokinetic population parameters of 4-hydroxyifosfamide (4OHIF) and 
ifosforamide mustard (IFM) with their relative standard error of the mean, interindividual variability and 
residual variability. 
 
4OHIF    IFM    
Parameter Mean RE IIV Parameter Mean RE IIV 
F*4OHIF (L
-1) 0.126 3% 30% F**IFM 0.514 16%  
K4OHIF (h
-1) 73.8 3% 8% KIFM (h
-1) 3.63 35% 73% 
P.E.4OHIF 22.8%   P.E.IFM 50.2%   
A.E.4OHIF (µM) 0.300   A.E.IFM (µM) -   
 
RE=Relative error of the mean, IIV=interindividual variability, F*=ratio of fraction metabolized and volume of 
distribution of metabolite, K=first-order rate constant for metabolite elimination, F**IFM=fraction metabolized to 
IFM, P.E.=proportional intraindividual error, A.E.=additive intraindividual error. 
 
The corresponding estimates of 4-hydroxyifosfamide and ifosforamide mustard are listed in 
table 3. The estimates of most pharmacokinetic parameters were not influenced by the 
duration of infusion. Only minor differences were found for Kenz,out, F
* of 2-
dechloroethylifosfamide (F*2dce) and 3-dechloro-ethylifosfamide (F
*
3dce). Kenz,out during long 
infusion durations was 52% lower in comparison with short and medium infusion durations. 
F*2dce and F
*
3dce decreased with 51% and 33%, respectively, after medium infusion durations 
when comparing to short and long infusion durations. No outliers or trends could be observed 
in the plots of the population predictions and individual Bayesian predictions of the 
concentrations versus the observed concentrations (plots not shown). The observed and 
individual Bayesian estimated pharmacokinetic profiles of ifosfamide of all patients are 
presented in figure 3. The urinary excretion of unchanged ifosfamide and its dechloroethylated 
metabolites are presented in table 4.  
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Figure 3. The Bayesian individual predicted plasma concentration-time profiles of ifosfamide (IFO) for all 
patients during short (1-4 h), medium (24-72 h) and long (96-240 h) infusion durations. The observations 
are represented by the dots. 
Table 4. Percentage of dose excreted in urine either unchanged as ifosfamide (IFO) or as metabolite 2-
dechloroethylifosfamide (2DCE) and  3-dechloroethylifosfamide (3DCE) in 40 patients. 
 
  IFO (%) 2DCE (%) 3DCE (%) Sum (%) 
Infusion schedule n Mean±SD* Mean±SD Mean±SD Mean±SD* 
short (1-4 h) 3 21.2±6.6 5.6±2.0 14.9±5.4 41.7±10.2 
medium (24-72 h) 14 14.7±7.2 7.1±3.6 11.6±5.0 33.4±14.7 
long (96-240 h) 23 8.6±2.6 2.9±2.6** 11.4±2.6 22.9±3.4 
 
SD=Standard Deviation, *significantly different for all infusion durations, **significantly different from medium 
infusion durations. 
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Figure 4. Individual time profiles of the clearance of ifosfamide (IFO) for all patients during short (1-4 h), 
medium (24-72 h) and long (96-240 h) infusion durations. The profiles were obtained from the individual 
Bayesian parameter estimates based on the total population. 
Increase of infusion duration resulted in a significant decrease of urinary recovery of 
unchanged ifosfamide and the sum of ifosfamide and metabolites. For ifosfamide values for 
short and long infusion durations were 21.2±6.6% and 8.6±2.6%, respectively. No clear trend 
was observed for 2- and 3-dechloroethyl-ifosfamide, although urine recovery of 2-
dechloroethylifosfamide during long infusions was slightly lower than during medium infusion 
duration. The individual profiles of the ifosfamide clearances over time of each infusion 
schedule are depicted in figure 4. Modest interindividual variability was observed. The 
clearance of ifosfamide increased during the infusion and decreased after cessation. Notably, 
during the first 24 hours for all patients the model predicted an average doubling of the 
clearance.  
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Figure 5. The relationships (with Loess-smooths) between the ifosfamide dose (mmol) and ifosfamide 
(IFO), 2-dechloroethylifosfamide (2DCE), 3-dechloroethylifosfamide (3DCE), 4-hydroxyifosfamide (4OHIF) 
and ifosforamide mustard (IFM) exposures as calculated by the area under the concentration-time curve 
(AUC) of each patient. 
Figure 5 depicts the relationships between the AUCs of ifosfamide and its metabolites and the 
ifosfamide dose for the total population. The AUC of ifosfamide increased less than 
proportional with increase in absolute ifosfamide dose. In contrast, the AUCs of the 
metabolites increased more than proportional with increase in absolute ifosfamide dose. 
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Figure 6. The relationship between the ifosfamide infusion duration (h) and ifosfamide (IFO), 2-
dechloroethylifosfamide (2DCE), 3-dechloroethylifosfamide (3DCE), 4-hydroxyifosfamide (4OHIF) and 
ifosforamide mustard (IFM) dose-standardized exposures as calculated by the ratio of the area under the 
concentration-time curve (AUC) and the ifosfamide dose of each patient. *Significantly decreased 26% 
(p<0.001) and 25% (p<0.05), respectively, compared to 1-4 h and 24-72 h infusions. **Significantly 
increased 45% (p<0.01) compared to 24-72 h infusions. 
 
The dose-corrected AUCs are depicted in figure 6. The dose-corrected exposure to 
ifosfamide during long infusions was decreased 26% (p<0.001) and 25% (p<0.05) when 
compared to short and medium infusion duration, respectively. In comparison with medium 
infusion durations dose-corrected exposure to 3-dechloroethylifosfamide during long infusion 
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durations was increased with 45% (p<0.01). 
 
Discussion 
 
This study investigated the effect of the duration of the ifosfamide infusion on the 
pharmacokinetics of ifosfamide and its metabolites. In a review on the clinical 
pharmacokinetics of ifosfamide in 1994 it was proposed that fractionation of the ifosfamide 
dose increased the metabolism of ifosfamide.[11] However, more recent studies have 
indicated that the ifosfamide infusion schedule does not influence the degree of metabolism. 
In a comparative study in paediatric patients receiving 3 g/m² ifosfamide administered as a 1-
hour infusion for three consecutive days or 9 g/m² ifosfamide administered as a 72-hour 
continuous infusion, no major differences in exposure were observed except a minor 
decrease in exposure to deactivated metabolites with the bolus infusion.[12] In addition, no 
differences in metabolic exposures were found in a similar study in adults.[13] Singer and co-
workers concluded that there is no identifiable pharmacokinetic basis for insistence on either 
bolus or infusional methods of ifosfamide administration.  
In our study a group of 56 patients was divided into three sub-populations receiving either 
short (1-4 h), medium (24-72 h) or long (96-240 h) infusion durations with ifosfamide. All 
patients studied received ifosfamide as part of standard therapy for the treatment of various 
malignancies. A previously developed autoinduction model was applied to assess the 
population pharmacokinetics of ifosfamide and metabolites.[5,14] This model describes the 
development of autoinduction with a relationship between the ifosfamide plasma 
concentration and a hypothetical, dynamic enzyme compartment, which is responsible for 
ifosfamide metabolism. Thus, clearance of ifosfamide over time changes with ifosfamide 
concentrations. From some of the patients included in the study only a limited number of 
blood samples was available for pharmacokinetic analysis. In such cases conventional non-
compartmental analysis of the concentration-time profiles does not allow accurate estimation 
of the pharmacokinetic parameters due to insufficient data. The applied population approach 
with Bayesian estimation on the other hand does not have these drawbacks. 
Statistically significant differences were found for Kenz,out between long and short infusion 
durations and for F*2dce and F
*
3dce between medium and short infusion durations. These 
differences in parameter estimates were considered to be minor (33%-52%) and not clinically 
relevant, since they were in the same order of magnitude as the interindividual variability of the 
respective parameters (22%-43%). The observed differences may be explained by different 
amounts of data within the concentration-time profiles of the various infusion schedules, 
which are necessary for the estimation of these pharmacokinetic parameters. Estimation of 
Kenz,out in long infusion durations is more accurate than in short infusion durations, because 
the effect of autoinduction is more pronounced. The relatively lower number of samples 
drawn during the first 24 hours of medium infusion durations, compared to short infusion 
durations, may have resulted in different estimations of the formation rates of the deactivated 
metabolites. All other estimates of the population parameters were not significantly influenced 
by infusion duration. This indicates that no clinically relevant differences were observed in the 
pharmacokinetics between the different infusion durations. 
The population pharmacokinetic parameters were in accordance with a recent study on the 
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pharmacokinetics of ifosfamide and metabolites after administration of 9-12 g/m² ifosfamide 
in a 72-hour continuous intravenous infusion.[15] However, in the referred study values for 
F*3dce and K3dce were 0.075±0.097 L
-1 and 1.5±2.0 h-1, respectively, which is approximately 
tenfold higher than observed in the present study (0.011±0.002 L-1 and 0.12±0.02 h-1, 
respectively, table 2). The difference may be explained by the lower accuracy of the estimates 
in the former study. Interestingly, K values of the metabolites are greater than the value 
calculated for ifosfamide (CLini,ifo/Vifo). This indicates that the observed decay in plasma of 
the metabolites is formation rate limited. 
Table 4 indicates that considerable amounts of unchanged ifosfamide are excreted in the 
urine. Separate estimation of renal clearance, however, did not improve the goodness-of-fit of 
the model. The urinary excretion data found in this study were similar to previous 
observations. Gilard et al. reported urinary excretion of 18, 16 and 7% for ifosfamide, 2- and 3-
dechloroethylifosfamide, respectively, in patients receiving 3g/m²/3 hours ifosfamide for 3 
days.[16] The decrease in excretion of ifosfamide with increasing infusion duration can be 
explained by the development of the autoinduction. The decrease in excretion of ifosfamide 
with increasing infusion durations can be explained by decreasing AUCs due to autoinduction. 
For 2- and 3-dechloroethylifosfamide increased AUCs would theoretically produce increased 
urine recovery. This was however not observed. The mechanism of this discrepancy remains 
to be elucidated. Nevertheless, the latter observation is in accordance with the previously 
reported finding that the urinary excretions of 2- and 3-dechloroethylifosfamide were 
superimposable for the different infusion schedules in paediatric patients.[17] 
The AUC of ifosfamide increased less than proportional with the absolute dose and the AUCs 
of the metabolites increased more than proportional with the absolute ifosfamide dose. This 
can be explained by a greater extent of autoinduction due to higher ifosfamide plasma 
concentrations (equations 2, 3 and 4). These findings are in accordance with a previous 
report in which the pharmacokinetic model for ifosfamide was developed.[5] The dose-
corrected exposures to ifosfamide and its metabolites changed with increasing infusion 
duration. In comparison with short infusions, a decrease of 25% in dose-corrected ifosfamide 
exposure and an increase of 45% in 3-dechloroethylifosfamide exposure were observed with 
long infusion durations. The decrease in ifosfamide exposure can be explained by an 
increased average clearance during the long infusions (figure 4). 
As a result of the increased average clearance of ifosfamide during long infusions dose 
corrected exposure to the dechloroethylated metabolites were expected to be increased. A 
significant increase was observed for 3-dechloroethylifosfamide. For 2-
dechloroethylifosfamide an increase of dose corrected exposure may be obscured by the 
large interindividual variability (figure 6). Unfortunately, the effect of infusion duration on the 
dose corrected exposure to 4-hydroxyifosfamide and ifosforamide mustard could not be 
evaluated since no samples were available for the long infusions. Nevertheless, the observed 
increased exposure to the dechloroethylated metabolites during long infusion durations 
demonstrates the importance of the assessment of the pharmacokinetics when comparing 
the pharmacodynamics during different infusion durations. 
In conclusion, a population pharmacokinetic model for ifosfamide and its metabolites was 
used to investigate any differences in ifosfamide metabolism due to the duration of the 
ifosfamide infusion. Estimates of Kenz,out, F
*
2dce and F
*
3dce were found to depend on the 
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infusion schedule. The clinical relevancy of the observed differences was however 
considered to be of minor importance. Concentration dependent development of 
autoinduction produced a less than proportional increase in ifosfamide exposure and more 
than proportional increase in metabolite exposure with increasing ifosfamide dose. Schedule 
dependency could be demonstrated for the dose-corrected exposures to ifosfamide and 3-
dechloroethylifosfamide between short and long infusion durations, which could be explained 
by the increased average clearance during infusion. No change in dose-corrected exposure to 
ifosfamide and metabolites was observed between short and medium infusion durations in 
this population. The observed dependency on dose and infusion duration should be taken into 
account when the pharmacodynamics of different infusion schedules of ifosfamide are 
evaluated. 
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Population pharmacokinetics and pharmacodynamics of ifosfamide and metabolites after a 72-hour continuous 
infusion in patients with soft tissue sarcoma  
 
 
 
 
 
 
 
Summary 
 
The population pharmacokinetics and pharmacodynamics of the cytostatic agent ifosfamide 
and its main metabolites 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide were 
assessed in patients with soft tissue sarcoma. Patients received 9 or 12 g/m² ifosfamide 
administered as a 72-hour continuous intravenous infusion. The population pharmacokinetic 
model was built sequentially, starting with a covariate-free model and progressing to a 
covariate model with the aid of generalized additive modelling. The addition of the covariates 
weight, body surface area, albumin, serum creatinine, serum urea, alkaline phosphatase and 
lactate dehydrogenase improved the prediction errors of the model. Typical pretreatment 
(mean±sem) initial clearance of ifosfamide was 3.03±0.18 L/h with a volume of distribution of 
44.0±1.8 L. Autoinduction, dependent on ifosfamide levels, was characterized by an induction 
half-life of 11.5±1.0 h with 50% maximum induction at 33.0±3.6 µM ifosfamide. Significant 
pharmacokinetic-pharmacodynamic relationships (p=0.019) were observed between the 
exposure to 2- and 3-dechloroethylifosfamide and orientational disorder, a neurotoxic side-
effect. No pharmacokinetic-pharmacodynamic relationships between exposure to 4-
hydroxyifosfamide and haematological toxicities could be observed in this population. 
Introduction 
 
Ifosfamide (HoloxanÒ) is an alkylating agent, used as a single chemotherapeutic drug or in 
combination schedules. Ifosfamide has been proven to be active against a number of solid 
tumours and haematological malignancies in adults and children.[1] Large interpatient 
variability in clinical toxicity and response rates have been observed during ifosfamide 
treatment.[2] Besides pharmacodynamic variability, this could possibly be explained by 
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interpatient differences in ifosfamide pharmacokinetics. Ifosfamide is a prodrug, which needs 
activation by cytochrome P450-3A4 (CYP3A4) to form 4-hydroxyifosfamide, as depicted in 
figure 1. 
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Figure 1. Metabolism of ifosfamide. 
 
Intracellular spontaneous decomposition of 4-hydroxyifosfamide yields the ultimate alkylating 
metabolite ifosforamide mustard.[1] Therefore, 4-hydroxyifosfamide may be used to describe 
the pharmacokinetic-pharmacodynamic relationship between the plasma concentrations and 
the anti-tumour efficacy and toxicity of ifosfamide treatment. Ifosfamide is deactivated to the 
non-cytotoxic metabolites 2- and 3-dechloroethylifosfamide. Each dechloroethylation reaction 
yields an equimolar amount of chloroacetaldehyde, which is held responsible for neurotoxicity 
observed in about 10% of all patients receiving conventional single-agent dosing of 
ifosfamide.[3] Neurotoxicity can be succesfully treated with the antidote methylene blue. Since 
chloroacetaldehyde degrades rapidly, assessment of 2- and 3-dechloroethylifosfamide may 
be preferred when quantifying the relationship between the pharmacokinetics and 
neurotoxicity after administration of ifosfamide. 
Ifosfamide metabolism has been reported to be subject to autoinduction leading to an 
increase of metabolism of ifosfamide over time.[1] Variability in the rate and the extent of this 
process may contribute to the large interpatient variability in toxicity and response. As a result 
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assessment of the population pharmacokinetics of ifosfamide and its metabolites may be 
important since this may help to interpret the variability. 
In this study pharmacokinetics and pharmacodynamics were investigated in patients 
participating in a phase II study on high dose ifosfamide in advanced soft tissue sarcoma.[4] 
Aim of our investigation was to develop a population pharmacokinetic model for ifosfamide and 
its metabolites. The correlations between the patient characteristics and pharmacokinetics 
were assessed. Furthermore, pharmacokinetic-pharmacodynamic relationships between the 
2- and 3-dechloroethylifosfamide and neurotoxicity and between the 4-hydroxyifosfamide and 
haematological toxicity were investigated.  
 
Methods 
 
Patient selection 
 
Patients were treated for various types of soft tissue sarcoma with single agent high-dose 
ifosfamide in an open non-randomized multi-centric phase II trial at the Leiden University 
Medical Center and Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute, 
Amsterdam, the Netherlands. Eligibility criteria included WHO performance status of 0-2, 
adequate bone marrow function (white blood cells  4.0 x 109/L, platelets  100 x 109/L), 
adequate hepatic function (total bilirubin  30 µmol/L), adequate renal function (serum 
creatinine 120 µmol/L), no active infection or post-surgical complications, no central 
nervous system disease and no concomitant second malignant disease. Previous 
radiotherapy or chemotherapy had to be discontinued for at least 4 weeks. The study protocol 
was approved by the Ethics Boards of both above mentioned hospitals. Patients were subjected 
to pharmacokinetic sampling after written informed consent was obtained. 
 
Patient characteristics 
 
Pre-treatment evaluation included a complete medical history and physical examination. 
These examinations yielded information on patient characteristics such as age (AGE), weight 
(WT), body surface area (BSA) and gender (SEX). Before treatment, blood chemistry and 
haematological parameters (haemoglobin, white blood cells and platelets) were evaluated. 
Blood chemistry yielded baseline levels for sodium, potassium, calcium, urea (UREA), 
creatinine (CREA), creatinine clearance (CrCL), alkaline phosphatase (AF), lactate 
dehydrogenase (LDH), alanine-aminotransferase (ALAT), aspartate-aminotransferase 
(ASAT), gamma-glutamyltransferase (g-GT), albumin (ALB) and total protein (TP). CrCL was 
estimated by the Cockcroft-Gault formula.[5] 
 
Drug administration 
 
Patients received 9 or 12 g/m² ifosfamide (HoloxanÒ, ASTA Medica, Diemen, The 
Netherlands) as a 72-hour continuous intravenous infusion once every 4 weeks. Supportive 
care consisted of mesna and extensive hydration to prevent haemo rrhagic cystitis and 
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bicarbonate to prevent acidosis. Standard 5-HT3 blockers as anti-emetics and methylene blue 
(a neurotoxicity antidote) were given when indicated. 
 
Pharmacokinetic sampling 
 
Blood samples were drawn from an indwelling intravenous cannula placed in the arm 
contralateral to the arm receiving ifosfamide at 0, 3, 10, 20, 24, 34, 48, 58, 68, 72, 73, 76, 80 
and 92 hours after start of the infusion. Ten ml of whole blood were collected in a lithium 
heparin-coated Vacutainer® (Becton-Dickinson, Plymouth, UK) and placed on ice water. The 
plasma was immediately separated by centrifugation at 1,000 g for 5 min at 4°C. The plasma 
was aliquoted in three volumes of which two were precisely 1-ml volumes. To these two 1-ml 
volumes, 100 µl 2 M semicarbazide solution at pH 7.40 were added to stabilize 4-
hydroxyifosfamide. The remaining plasma was used for ifosfamide, 2- and 3-
dechloroethylifosfamide analysis. Urine was collected for up to 96 hours after the start of the 
ifosfamide infusion and analysed for ifosfamide, 2- and 3-dechloroethylifosfamide. Both 
plasma and urine samples were stored at -70°C, pending analysis. 
 
Bioanalysis 
 
Gas chromatography with selective nitrogen-phosphorous detection was used for the 
determination of ifosfamide, 2- and 3-dechloroethylifosfamide in urine and plasma.[6] Sample 
pre-treatment consisted of alkalinized liquid-liquid extraction with ethyl acetate, transfer of the 
organic extract, evaporation to dryness and subsequent reconstitution in ethyl acetate. This 
method was validated and proved to be specific, sensitive, accurate (93.3-104.5%) and 
precise (within and between-day <5.5%) within the concentration range of 0.192 to 383 µM, 
with a lower limit of quantification (LLQ) of 0.192 µM for ifosfamide, 2- and 3-
dechloroethylifosfamide. 
High-performance liquid chromatography (HPLC) was used for determination of 4-
hydroxyifosfamide plasma levels.[7] In brief, this method determined the 4-hydroxyifosfamide-
semicarbazone derivative in plasma. Sample pre-treatment consisted of liquid-liquid 
extraction with ethyl acetate. The HPLC column used was reversed phase C8 with 
acetonitrile-0.025 M potassium dihydrogenphosphate (32:68 v/v) as mobile phase. Detection 
was performed at 230 nm. This method was specific, sensitive, accurate (94.1-107.9%) and 
precise (within and between-day <7.2%) in the concentration range of 0.361 to 361 µM, with a 
LLQ of 0.361 µM 4-hydroxyifosfamide. 
 
Data evaluation 
 
Pharmacokinetic models were fitted to the data from the individuals using the population 
pharmacokinetic programme NONMEM (Non-linear Mixed Effects Modelling, version V 1.1, 
double precision, first order estimation).[8,9] The non-linear pharmacokinetics of ifosfamide 
were described using a recently developed model, which incorporated the development of 
autoinduction.[10] According to this recent study the pharmacokinetics of ifosfamide can be 
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described by using a one-compartment model. The change of the amount of ifosfamide (Aifo, 
µmol) in the central compartment over time can be described by equation 1, 
t T< inf  : 
dA
dt
R CL A V
ifo ifo
ifo
= - ´æèç
ö
ø÷ and    
t T> inf  : 
dA
dt
CL A V
ifo ifo
ifo
= - ´æèç
ö
ø÷        (eq. 1) 
in which Tinf (h) is the infusion duration, R (µmol· h
-1) is the infusion rate of ifosfamide, CL 
(L· h-1) the ifosfamide clearance, which changes over time and Vifo (L) the volume of 
distribution. The concentration of ifosfamide Cifo (µM) is the ratio of Aifo and Vifo. In turn, 
autoinduction can be described using a hypothetical enzyme compartment. CL can then be 
expressed by an initial clearance (CLini,ifo, L· h
-1) multiplied by the relative amount of enzyme 
(Aenz) in the hypothetical enzyme compartment, as given in equation 2.   
CL CL Aini ifo enz= ´,          (eq. 2) 
The change of Aenz (no dimension) over time in the enzyme compartment is dependent on 
Cifo as follows, 
dA
dt
K K A
C
C IC
enz
enz out enz out enz
ifo
ifo
= - ´ ´ -
+
æ
è
ç
ö
ø
÷, , 1
50
     (eq. 3) 
in which Kenz,out (h
-1) is the first-order rate constant for enzyme degradation/inactivation and 
IC50 (µM) is the ifosfamide concentration at 50% of the maximum inhibition of enzyme 
degradation. The induction half-life of the enzyme (T½enz, h) was calculated by the ratio of 
ln(2) and Kenz,out.  
The pharmacokinetics of ifosfamide and metabolites were described sequentially. Bayesian 
estimations (posthocs) of the pharmacokinetic parameters of ifosfamide were used for the 
description of the pharmacokinetics of the metabolites. The change in the amount of a 
metabolite (Am) over time could be described by equation 4.  
( )dA
dt
F CL
A
V
K Am m
ifo
ifo
m m= ´ ´
æ
è
ç
ö
ø
÷ - ´        (eq. 4) 
In which Km (h
-1) is the elimination rate constant of the metabolite and Fm is the fraction of 
ifosfamide metabolized to the metabolite. The values for Fm and the volume of distribution of 
the metabolite (Vm, L) cannot be estimated separately in this model. Therefore, the ratio of Fm 
over Vm was estimated: F
* (L-1). 
The residual or intra-individual variability of ifosfamide and metabolites kinetics were 
described separately with a proportional and additive term. The interindividual variability of 
each pharmacokinetic parameter was estimated using a proportional error model. 
The posthocs of the areas under the concentration-time curves (AUC) of ifosfamide and its 
metabolites were obtained by describing the cumulative concentrations of these compounds 
over a given time. AUCs were obtained with extrapolation of ifosfamide and metabolite 
concentration-time profiles to 144 hours after the start of the infusion, where concentrations 
were below the LLQ. The urinary excretions (UE) for ifosfamide and 2- and 3-
dechloroethylifosfamide were calculated as the equimolar amount of the administered 
ifosfamide dose recovered in urine over 96 hours.  
 
Covariate model building 
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The patient characteristics and blood chemistry parameters prior to the ifosfamide infusion 
were analysed for their correlations with the pharmacokinetic parameters of ifosfamide and its 
metabolites. The influence of these covariates was tested using the Generalized Additive 
Modelling (GAM) procedure in the software programme Xpose (Xpose, version 2.0, Uppsala 
University, Sweden) as implemented in the statistical programme S-PLUS (version 2000 
Professional release I, Mathsoft).[11] Covariates that correlated significantly with the 
pharmacokinetic parameters, as indicated by the Akaike criterion, were selected for testing in 
NONMEM.[12] The selected covariates were entered stepwise into the structural NONMEM 
model.[13] Continuous variables were centred to their medians, as depicted in equation 5, 
( )P COV COVpop ind med= + ´ -q q1 2        (eq. 5) 
in which, Ppop is a population pharmacokinetic parameter, q1 the typical value of Ppop, q2 the 
influence of the covariate on Ppop, COVind the individual value of the covariate and COVmed the 
median value of that covariate. An increase in goodness-of-fit caused by the introduction of a 
covariate, is associated with a decrease in the value of the objective function. The objective 
function of the NONMEM model is approximately chi-squared distributed and a decrease of > 
3.8 upon entering a covariate was considered statistically significant (p<0.05).[9] All variables 
that caused significant decreases in objective function were entered into the intermediate 
model. A stepwise backward elimination procedure was then performed with all variables 
entered in the intermediate model. Variables were retained in the final model when elimination 
of the variable caused an increase in objective function > 7.8 (p<0.005). Individual 
pharmacokinetic parameters for ifosfamide were calculated with the final model using the 
posthoc option in NONMEM. Subsequently, identical procedures were followed for 2- and 3-
dechloroethylifosfamide and 4-hydroxyifosfamide population models. 
Pharmacodynamics 
 
Haematological assessment yielded nadirs for haemoglobin (HGB), white blood cells (WBC) 
and platelets (PLT). The haematological toxicities were evaluated using the percentage 
decrease in HGB, WBC and PLT. The percentage decrease was calculated using equation 6, 
%
Pr
Pr
 decrease
 value
 value
= - ´etreatment value of nadir
etreatment
100%   (eq. 6) 
Non-haematological toxicity such as, nausea, vomiting, anorexia, alopecia, fatigue, 
constipation, diarrhoea, fever, pain, irritation, activity score, peripheral neurotoxicity, central 
neurotoxicity, such as loss of consciousness, concentration problems, orientation disorder, 
hallucinations and coma were scored with a dichotomous scale (absent or present during the 
study period), at the discretion of the physician.  
 
Pharmacokinetic-pharmacodynamic relationships  
 
Correlations between the pharmacokinetics and pharmacodynamics were explored using 
scatter plots and Pearson´s correlation coefficients (r). Correlations between the 
pharmacokinetic parameters and categorical toxicity data were explored using the Spearman 
rank correlation test and logistic regression. Statistical analysis was performed using SPSS 
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software (Version 6.1 for Windows; SPSS, Inc., Chicago, IL, USA). The level of significance 
was set at p<0.05. All tests for significance were two-tailed.   
 
Results 
 
Patients and treatment 
 
A total of 20 patients was enrolled in the pharmacokinetic study. Six patients received 12 g/m² 
ifosfamide as a 72-hour continuous intravenous infusion once every 4 weeks. Due to 
unacceptable central neurotoxicity in this group, the following 14 patients received an adjusted 
dose of 9 g/m²/72 h. The infusion of 12 g/m² in one patient was stopped after 48 hours due to 
acute severe neurotoxicity during drug-administration. Therefore, this patient received only 
66% of the planned dose. Five patients received methylene blue after neurotoxicity had 
occurred. In addition, two patients received prophylactic methylene blue, because 
neurotoxicity occurred in the previous treatment course. Additional co-medication included 
anti-coagulants, H2 receptor antagonists, glucocorticosteroids and tricyclic anti-depressants. 
The patient characteristics and blood chemistry are summarized in table 1. 
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Table 1. Characteristics of 20 patients receiving 9 or 12 g/m² ifosfamide by means of a 72-hour 
continuous i.v. infusion and blood chemistry values prior to study entry.  
 
Characteristics mean (range) Blood chemistry median (range) reference values 
No. of patients 20 Sodium (mM) 140 (138-146) 135-148 
Sex (M/F) 14/6 Potassium (mM) 4.4 (3.8-5.1) 3.5-5 
Median age (years) 49 (24-72) Calcium (mM) 2.3 (2.2-2.4) 2.2-2.7 
Median weight (Kg) 59 (49-88) Urea (mM) 5.1 (2.6-8.7) 2.9-8.9 
Body surface area (m2) 1.75 (1.43-2.09) Creatinine (µM) 77 (53-101) 50-133 
Prior Radiotherapy 4 Creatinine clearance 
(ml/min) 
82 (51-144) > 60 
Prior Surgery 20 Albumin (g/L) 43 (36-77) 30-52 
Prior chemotherapy 14 Total protein (g/L) 73 (34-81) 60-84 
Metastases 17 AF (U/L) 147 (68-250) 100-280 
Primary tumour  LDH (U/L) 377 (166-1123) 150-300 
Rhabdomyosarcoma 3 ALAT (U/L) 26 (7-72) 10-32 
Neurofibrosarcoma 1 ASAT (U/L) 28 (14-61) 10-32 
Osteosarcoma 3 g-GT (U/L) 61 (15-143) < 40 (M)  <25 (F) 
Synoviumsarcoma 3    
Leiomyosarcoma 6    
Endometrial sarcoma 2    
Liposarcoma 2    
 
Pharmacokinetics 
 
Pharmacokinetic assessment resulted in 228, 230, 228 and 119 concentration-time points for 
ifosfamide, 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide, respectively. 
Pharmacokinetic profiles showed initial build-up of ifosfamide plasma concentrations in the 
first 24 hours (reaching maximum concentrations), followed by a gradual decrease due to 
autoinduction. After 72 hours the infusion was stopped and elimination pharmacokinetics 
were observed. A one-compartment model with a hypothetical enzyme compartment 
adequately characterized the time profiles of the ifosfamide plasma concentrations. The 
pharmacokinetic parameters of ifosfamide were related to various combinations of 
covariates. GAM-analysis indicated significant correlations between UREA (µM), CREA (µM) 
and CLini,ifo, WT (Kg) and Vifo, AF (U· L
-1) and LDH (U· L-1) and Kenz,out, and CREA (µM) and 
IC50. After forward inclusion and backward elimination of these covariates, a final population 
model for ifosfamide was obtained. Significant correlations were obtained for the covariates 
included in equations 7-9. 
( )V WTifo = + ´ -44 0 056 59. .        (eq. 7) 
( ) ( )CL UREA CREAini ifo, . . . . .= + ´ - - ´ -303 0169 51 00267 77 2    (eq. 8) 
( )K AFenz out, . .= + ´ -0 0602 00000647 147       (eq. 9) 
Conform equation 5, each population parameter was described by an estimate of the typical 
value of that parameter plus an estimate of the influence of the covariate. The covariate was 
centred to its median value, eg. for Vifo, a typical value for a patient of 59 kg is 44 L. Increase of 
WT with 1 kg results in an increase of Vifo with 0.56 L. WT ranged between 49 and 88 kg, 
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hence V will range between 38 and 60 L. Inclusion of the covariates resulted in a decrease in 
objective function of 41 in comparison with the intermediate model without covariates. Bayesian 
estimates of the pharmacokinetic parameters of ifosfamide were obtained. These parameters 
were used for the development of pharmacokinetic models for the metabolites. A sequential 
approach was used, because the data did not allow simultaneous estimation of the population 
pharmacokinetic parameters of ifosfamide and its metabolites.  
No interindividual variability could be estimated for the elimination rates of the metabolites. 
Hence, no correlations with covariates could be found for these parameters. This should not 
be interpreted as an absence of interindividual variability, but only that the data do not contain 
sufficient information to estimate the interindividual variability of the metabolite elimination 
rates.  
 
Table 2. Covariate-based estimates of population pharmacokinetic parameters for ifosfamide (IFO 
n=20), 2-dechloroethylifosfamide (2DCE n=20), 3-dechloroethylifosfamide (3DCE n=20) and 4-
hydroxyifosfamide (4OHIF n=11) with their relative standard error of the mean, interindividual variability 
and residual variability, obtained in patients receiving 9 or 12 g/m² ifosfamide by means of a 72-hour 
continuous i.v. infusion.  
 
Parameter Mean Rel. err. I.I.V. R.V. Mean Rel. err. 
CLini,ifo (L· h
-1) 3.03 6% 13% P.E. IFO 13.7% 11% 
   qUREA 0.169 32%  A.E. IFO (µM) 0.0606 43% 
   qCREA 0.0267 44%     
VIFO (L) 44.0 4% 13%    
   qWT 0.56 25%     
Kenz,out (h
-1) 0.0602 9% 37%    
   qAF 0.0000647 19%     
T½enz (h) 11.5      
IC50 (µM) 30.0 12% 10%    
F*2DCE (L
-1) 0.0140 32% 22% P.E. 2DCE -  
   qALB 0.000413 40%  A.E. 2DCE (µM) 1.95 4% 
   qBSA 0.0164 100%     
K2DCE (h
-1) 0.501 30% -    
F*3DCE (L
-1) 0.0745 130% 22% P.E. 3DCE 35.6% 37% 
K3DCE (h
-1) 1.51 130% - A.E. 3DCE (µM) 2.51 13% 
F*4OHIF (L
-1) 0.338 21% 55% P.E. 4OHIF 33.0% 30% 
   qLDH 0.000773 48%  A.E. 4OHIF (µM) 0.228 43% 
K4OHIF (h
-1) 168 26% -    
 
Rel. Err.=Relative error of the mean, I.I.V.=interindividual variability, R.V.=residual variability, CLini,ifo=initial 
ifosfamide clearance, q=covariate, UREA=urea serum concentration, CREA=creatinine serum concentration, 
VIFO=volume of distribution of ifosfamide, WT=weight, Kenz,out=autoinduction formation rate, AF=alkaline 
phosphatase, T½,enz=induction half-life of the enzyme, IC50=ifosfamide concentration at 50% of the maximum 
inhibition of enzyme degradation, P.E.=proportional intraindividual error, A.E.=additive intraindividual error, 
F*=ratio of fraction metabolized and volume of distribution of metabolite, ALB=albumin, BSA=body surface area, 
K=first-order rate constant for metabolite elimination, LDH=lactate dehydrogenase. 
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Figure 2. The relationships between the final model predictions, individual Bayesian estimates and 
observed ifosfamide, 2-dechloroethylifosfamide (2DCE), 3-dechloroethylifosfamide (3DCE) and 4-
hydroxyifosfamide (4OHIF) concentrations. 
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GAM-analysis of the Bayesian estimates of the metabolites indicated BSA (m-2) and ALB (g· L-
1) for F*2DCE, AGE (y), LDH and UREA (µM) for F
*
3DCE and LDH (U· L
-1) for F*4OHIF to be 
significant covariates. After forward inclusion and backward elimination of these covariates, a 
final population model for the metabolites was obtained. Significant correlations were obtained 
for the covariates included in equations 10-11. 
( ) ( )F ALB BSADCE* . . . .2 00140 0000413 43 00164 1749= + ´ - - ´ -     (eq. 10) 
( )F LDHOHIF* . .4 0 338 0 000773 377= + ´ -       (eq. 11) 
Inclusion of these covariates resulted in a decrease in objective function of 16 and 18 for 2-
dechloroethylifosfamide and 4-hydroxyifosfamide models compared to their respective 
intermediate models without covariates. Estimates of pharmacokinetic population parameters 
of the final model with their standard error and their interindividual variability and the residual 
variability are presented in table 2. The relationships between the observed and population 
predicted concentrations and between the observed and Bayesian individually predicted 
concentrations of ifosfamide, 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide, as 
described by the final covariate model, are depicted in figure 2.  
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Figure 3. The concentration time profiles of ifosfamide (IFO), 2-dechloroethylifosfamide (2DCE), 3-
dechloroethylifosfamide (3DCE) and 4-hydroxyifosfamide (4OHIF). The observations are represented by 
the dots and the Bayesian individual predictions are connected by the lines. 
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The observed and Bayesian estimated pharmacokinetic profiles for ifosfamide, 2- and 3-
dechloroethylifosfamide and 4-hydroxyifosfamide of all patients are represented in figure 3. No 
outliers or trends could be observed in the plots of the weighted residuals versus the 
predicted concentrations and the individual weighted residuals versus time (not shown).  
The time profile of clearance (CL) is described in figure 4. Initial clearance (CLini,ifo = 3.03 L/h) 
increased three-fold during the infusion and declined to pre-treatment levels after cessation of 
the infusion. The pharmacokinetic model described the increase in clearance as a 
progressively developing effect with a half-life of 11.5 h. The interindividual variability in 
clearance was moderate. At the start of the infusion the posthoc estimations for CLini,ifo 
ranged from 2.3 to 4.3 L/h and at the end of the infusion from 6.5 to 14.7 L/h.  
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Figure 4. Individual time profiles of the ifosfamide clearance (CL) for all patients (n=20). The profiles 
were obtained on basis of the individual Bayesian parameter estimates provided by NONMEM. 
 
Mean (and range) of the Bayesian estimates of the AUC of ifosfamide, 2- and 3-
dechloroethylifosfamide and 4-hydroxyifosfamide were 9.30 (7.11-13.62), 1.72 (0.49-3.01), 
3.18 (1.92-4.64) and 0.117 (0.036-0.290) mM· h, respectively. The plots of AUCs of 
ifosfamide and its metabolites versus ifosfamide dose are presented in figure 5. The plots 
indicate that the exposure of ifosfamide and its metabolites increases with increasing dose. 
Table 3 contains the urinary excretion data of ifosfamide and 2- and 3-dechloroethylifosfamide 
for all individuals.  
 
Table 3. Mean urinary excretion (UE) and coefficient of variation (CV) of ifosfamide (IFO), 2-
dechloroethylifosfamide (2DCE) and 3-dechloroethylifosfamide (3DCE).  
 
 UE CV 
IFO 19.9% 35% 
2DCE 9.3% 28% 
3DCE 17.0% 47% 
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Figure 5. The relationship between the absolute ifosfamide dose and ifosfamide, 2-
dechloroethylifosfamide (2DCE), 3-dechloroethylifosfamide (3DCE) and 4-hydroxyifosfamide (4OHIF) 
exposures as calculated by the area under the concentration-time curve (AUC) of each patient. 
 
Pharmacodynamics 
 
The median percentages decrease in HGB, WBC and PLT and frequencies of the non-
haematological toxicities (e.g. neurotoxicities and gastrointestinal toxicities) are represented in 
table 4. 
 
Table 4. Median percentage change in haemoglobin (HGB), white blood cells (WBC) and platelets (PLT) 
and frequencies (absent or present during treatment) of non-haematological toxicities in 20 patients 
receiving 9 or 12 g/m² ifosfamide by means of a 72-hour continuous intravenous infusion. 
 
Haematological toxicity Median % change (range) Frequency of gastrointestinal toxicity 
HGB -17% (-48% - +15%) Nausea 12/20 
WBC  -76% (-99% - +9%) Vomiting 10/20 
PLT -13% (-82% - +64%) Anorexia 10/20 
Frequency of neurotoxicity Constipation 11/20 
Central neurotoxicity 6/20 Diarrhoea 2/20 
Vision distortion 4/20 Frequency of other toxicities 
Loss of consciousness 1/20 Fever 1/20 
Concentration problems 3/20 Pain 5/20 
Hallucinations 2/20 Alopecia 9/20 
Orientational disorder 2/20   
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Pharmacokinetic-pharmacodynamic relationships 
 
All statistical significant correlations between the pharmacokinetic and pharmacodynamic 
parameters with their level of significance and correlation coefficient are represented in table 
5.  
 
Table 5. Statistical significant (p<0.05) linear correlations between pharmacokinetic and 
pharmacodynamic parameters, obtained in 18 patients receiving 9 or 12 g/m² ifosfamide by means of a 
72-hour continuous i.v. infusion. 
 
Pharmacokinetics Effect Statistical method p-value R2 
IC50 (µM)
# HGB (% decrease) Pearson´s 0.009 -0.58 
AUC2DCE (h· mM) Orientation disorder Spearman-rank 0.019 0.53 
AUC3DCE (h· mM) Orientation disorder Spearman-rank 0.019 0.53 
F*3DCE Orientation disorder Spearman-rank 0.038 0.56 
AUC2DCE (h· mM) Vision distortion Multiple logistic regression 0.013  
and Concentration 
problems 
Multiple logistic regression 0.006  
AUC3DCE (h· mM) Loss of consciousness Multiple logistic regression 0.004  
 Orientation disorder Multiple logistic regression 0.003  
 Hallucinations Multiple logistic regression 0.003  
 
#=in 20 patients, IC50=ifosfamide concentration at 50% of the maximum inhibition of enzyme degradation, 
HGB=haemoglobin, 2DCE=2-dechloroethylifosfamide, 3DCE=3-dechloroethylifosfamide, AUC=area under the 
plasma concentration-time curve, F*=ratio of fraction metabolized and volume of distribution of metabolite. 
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Figure 6. The relationship between the neurotoxic side-effect orientational disorder and the area under 
the concentration-time curve (AUC) of 2-dechloroethylifosfamide (2DCE) and 3-dechloroethylifosfamide 
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(3DCE). Level of significance calculated by Spearman-rank test. 
 
The two patients with prophylactic methylene blue treatment for neurotoxicity were excluded 
from the pharmacodynamic evaluation. Multiple logistic regression indicated correlations 
between the exposure to 2- and 3-dechloroethylifosfamide with central neurotoxic side-effects 
including vision distortion, concentration problems, loss of consciousness, orientation 
disorder and hallucinations. Except for orientational disorder, these correlations were not 
observed with either the exposure to 2- or 3-dechloroethylifosfamide alone. The 
pharmacokinetic-pharmacodynamics relationship between the exposure to the 
dechloroethylated metabolites and orientational disorder, a central neurotoxic side-effect, is 
represented in figure 6. No relationship between the exposure to ifosfamide or 4-
hydroxyifosfamide and the haematological toxicities was observed. 
 
Discussion 
 
In this study the population pharmacokinetics of ifosfamide and its metabolites and the 
pharmacokinetic-pharmacodynamic relationships were assessed in patients who participated 
in a multicentre phase II study on high dose ifosfamide in advanced soft tissue sarcomas.[4] In 
this study a partial response rate of only 16% was seen with severe toxicity resulting in a 
negative recommendation for this indication. Nevertheless, knowledge of the population 
pharmacokinetics and pharmacokinetic-pharmacodynamic relationships may be beneficial for 
other clinical applications of ifosfamide. The population pharmacokinetics of ifosfamide, 2- 
and 3-dechloroethylifosfamide and 4-hydroxyifosfamide were adequately described by the 
model (table 2, figure 4). Modest interindividual differences in the parameters were observed. 
Interindividual variability in the pharmacokinetic parameters of ifosfamide ranged between 
10% and 37%. The metabolite pharmacokinetics demonstrated larger differences with 
interindividual variability ranging between 22% and 55%, which has been observed before in 
population pharmacokinetic models which included metabolites.[14] Residual variability was 
also acceptable for ifosfamide and its metabolites.  
The inclusion of the selected covariates resulted in an improved goodness-of-fit of the 
population pharmacokinetic model. The relationship between weight and Vifo is self-
explicatory. An analogous relationship with F*2DCE and BSA was found. F
*
2DCE is the ratio of 
the fraction metabolized and the volume of distribution of 2-dechloroethylifosfamide. BSA 
depends on both the characteristics height and weight. Thus, with increasing weight V2DCE will 
increase and F*2DCE will decrease. CREA and UREA are both indicators of renal function: 
increased levels indicate reduced function. In the final model the relationship between renal 
function and CLini,ifo is not clear since correlations between CLini,ifo and CREA and UREA had 
opposite signs. Moreover, no relationship with CrCL was found. No plausible physiological 
explanation can be given for the other significant correlations between patient characteristics 
and pharmacokinetics of ifosfamide and metabolites. 
Renal excretion of unchanged ifosfamide amounted to 20%. Furthermore, a model with 
separate estimation of renal and metabolic clearance did not produce a decrease in objective 
function. This indicates that renal clearance does not constitute a major route of elimination of 
ifosfamide. Previously, similar urinary excretions were found. Gillard et al. observed renal 
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excretion of ifosfamide, 2- and 3-dechloroethylifosfamide of 18, 16 and 7%, respectively, in 
patients receiving 3g/m²/3 hours ifosfamide for 3 days.[15] 
The volumes of distribution of the metabolites (Vm) may be estimated on basis of their 
respective F* values. F* represents the ratio of Fm (fraction of ifosfamide metabolized to the 
metabolite) and Vm. On basis of the data presented in table 3 Fm of 3-dechloro-ethylifosfamide 
ranges from 0.17 to 0.708 corresponding to a Vm range of 2.3 to 9.5 L. The lower boundary of Fm 
is based on the urinary excretion of 3-dechloroethyl-ifosfamide. The upper boundary of Fm is 
based on fraction of the ifosfamide dose not excreted in the urine as 3-
dechloroethylifosfamide. Corresponding Vm values of 2-dechloroethylifosfamide range from 
6.6 to 45 L. These calculated volumes of distribution are consistent with the expectation that 
in general Vm´s will be less than V of the parent compound, because detoxification tends to 
lead to more hydrophilic compounds.  
In our study, one patient developed acute severe neurotoxicity during drug administration. 
Interestingly, the ifosfamide concentrations in this patient were the highest in the population, 
but the dechloroethylated metabolite profiles were not different from the rest of the population. 
The relatively low clearance of ifosfamide in this patient should theoretically result in a lower 
AUC of neurotoxic metabolites and less neurotoxicity. The latter is in contrast with the clinical 
observations. It can therefore be concluded that the development of neurotoxicity cannot be 
predicted or explained on the basis of the pharmacokinetic parameters of ifosfamide alone. 
In a previous study it was demonstrated that autoinduction of metabolism causes non-linear 
pharmacokinetics of ifosfamide: increase in ifosfamide dose results in a less than 
proportional increase in AUC of ifosfamide.[10] Consequently, the AUCs of the metabolites 
would increase more than proportional with an increase in ifosfamide dose. In the current 
study, however, these trends cannot be observed in the plots, possibly because of the 
interindividual variability (figure 5). 
In contrast with our findings Cerny et al. have reported a linear increase of AUC for ifosfamide 
from 9.7 to 16.6 mM· h when dose increased from 12 to 18 g/m².[16] Furthermore, AUC of the 
metabolites did not increase with dose. There is no apparent explanation for the differences in 
observations by Cerny and co-workers and our findings. However, in our study different 
structural models (linear and nonlinear) for the description of the concentration-time profiles of 
ifosfamide and its metabolites were tested. Inclusion of autoinduction in the pharmacokinetic 
model resulted in an impoved description of the data than a linear pharmacokinetic model. 
Several significant pharmacokinetic-pharmacodynamic relationships were observed (table 5). 
The significant relationship between IC50 (the ifosfamide concentration at 50% of the 
maximum inhibition of enzyme degradation) and the percentage decrease from pre-treatment 
levels of HGB may be explained physiologically. Patients with high IC50 values exhibit less 
autoinduction. Relatively less autoinduction of ifosfamide clearance will result in lower AUCs 
of 4-hydroxyifosfamide. In theory, lower AUCs of 4-hydroxyifosfamide should correlate with 
less decrease in HGB levels. However, no significant relationships between the exposure to 
4-hydroxyifosfamide and any haematological toxicity was observed, nor has this ever been 
reported before, thus far.[1] This is probably due to high interindividual variability in 
pharmacodynamic effect and an insufficient number of patients. Moreover, nadirs are 
inherently more variable, because of infrequent sampling of haematological parameters. 
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The exposures to 2- and 3-dechloroethylifosfamide were both positively correlated with the 
development of orientational problems during the infusion. The F* of 3-dechloroethyl-
ifosfamide was also positively correlated indicating that formation of dechloroethylated 
metabolites, which is accompanied by the formation of the neurotoxic chloroacetaldehyde is 
responsible for the observed neurotoxicity. Orientational disorder is characterized by transient 
lack of recognition of one’s temporal and spatial relationships and environment. This form of 
neurotoxicity can be very disturbing for patients and can have a severe impact on their 
experience of quality of life. The effect of prophylactic methylene blue administration on the 
assessment of the pharmacokinetic-pharmacodynamic relationship was taken into account, 
by excluding patients with prophylactic methylene blue treatment from this analysis. All 
patients who developed neurotoxicity during the ifosfamide infusion received methylene blue 
on the second or third day of treatment. 
In conclusion, a pharmacokinetic model for ifosfamide and metabolites was developed. The 
addition of covariates to the population model improved the prediction errors. Moderate 
interindividual variability in the pharmacokinetics and considerable interindividual variability in 
the pharmacodynamics was observed. Exposure to both dechloroethylated metabolites was 
positively and significantly correlated with orientation disorder during ifosfamide therapy. This 
may be explained by the simultaneous formation of chloroacetaldehyde. No pharmacokinetic-
pharmacodynamic relationship between exposure to 4-hydroxyifosfamide and haematological 
toxicities could be observed in this population. 
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Sparse data population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in 
children 
 
 
 
 
 
 
 
 
Summary 
 
The purpose of this study was to assess the feasibility of a sparse data approach for the 
determination of the population pharmacokinetics of ifosfamide, 2- and 3-
dechloroethylifosfamide and 4-hydroxyifosfamide in children. The sparse data population 
pharmacokinetic assessment was performed in children treated with single agent ifosfamide 
against various malignant tumours. The analysis included 32 patients aged between 1 and 18 
years receiving a total of 45 courses of 1.2, 2 or 3 g/m² ifosfamide in 1 or 3 hours on 1, 2 or 3 
days. Plasma concentrations of ifosfamide and its dechloroethylated metabolites were 
determined using gas chromatography. Plasma concentrations of 4-hydroxyifosfamide were 
described using high-performance liquid chromatography. The models were fitted to the data 
using a non-linear mixed effects model as implemented in the NONMEM programme. Cross-
validation was performed by bootstrapping the data. Pharmacokinetic assessment resulted in 
133 ifosfamide, 106 2-dechloroethylifosfamide, 116 3-dechloroethylifosfamide and 76 4-
hydroxyifosfamide observed concentrations. The model predicted all population 
pharmacokinetic parameter means, their accuracy, interindividual variability and residual 
variability. Cross-validation demonstrated no bias. In conclusion, a model to estimate 
ifosfamide and metabolite concentrations in a sparse data paediatric population was 
developed and validated. 
Introduction 
 
Ifosfamide (HoloxanÒ) is a cytostatic agent that exerts its effect through DNA alkylation. 
Phase II clinical trials in paediatric populations have demonstrated activity in a wide range of 
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tumour types. Ifosfamide is presently included in combination chemotherapy for several 
tumours, including Ewings sarcoma, osteosarcoma, rhabdomyosarcoma, and other soft 
tissue sarcomas.[1] Adverse effects of ifosfamide include myelosuppression, nausea and 
vomiting, alopecia and urotoxicity. The latter can be prevented by the co-administration of 
mesna. Although encephalopathy is more frequently observed in adults than in children, the 
consequences of encephalopathy can be more disastrous in children.[2] Ifosfamide can cause 
chronic nephrotoxicity in children, which can lead to rickets and growth retardation due to 
renal tubular acidosis. Both the efficacy of ifosfamide treatment and its side effects are highly 
unpredictable. Some patients experience treatment restricting toxicities, while others do not. 
Similarly, some tumour types are chemosensitive and curable, whereas others remain 
resistant or recur following an initial response.[3]  
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Figure 1. Metabolism of ifosfamide. 
Ifosfamide is a prodrug, which needs activation by cytochrome P450-3A4 (CYP3A4) to 4-
hydroxyifosfamide, as depicted in figure 1. Intracellular spontaneous decomposition of 4-
hydroxyifosfamide yields the ultimate alkylating metabolite ifosforamide mustard.[1] This 
means that the 4-hydroxyifosfamide is the preferred metabolite to describe the 
pharmacokinetic-pharmacodynamic relation between the conveniently obtainable plasma 
concentrations and the anti-tumour efficacy and toxicity of ifosfamide treatment. Ifosfamide is 
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deactivated to the non-cytotoxic metabolites 2- and 3-dechloroethylifosfamide. 
Dechloroethylation yields an equimolar amount of the chloroacetaldehyde, which is held 
responsible for neurotoxicity observed in approximately 10% of all patients receiving conven-
tional single-agent dosing of ifosfamide.[3] Chloroacetaldehyde is rapidly degraded in plasma 
with a half-life of 2-3 minutes. Therefore, measurement of 2- and 3-dechloroethylifosfamide is 
preferred in describing the relationship between the pharmacokinetics and the risk of 
neurotoxicity of ifosfamide treatment. The metabolism of ifosfamide is subject to extensive 
autoinduction.[1]  
Since the efficacy and specific toxicities of the treatment with the prodrug ifosfamide can be 
linked to its extensive metabolism, pharmacokinetic assessment of these metabolites are of 
special interest in helping to explain the unpredictable chances of success and failure in 
ifosfamide treatment. Nowadays, the establishment of these pharmacokinetic-
pharmacodynamic relationships are fully standardized in new drug development. 
Nevertheless, less than a dozen pharmacokinetic trials in children have been conducted to 
asses the pharmacokinetics of ifosfamide and its metabolites. Boddy et al. especially 
contributed much of the current knowledge of paediatric ifosfamide pharmacokinetics and its 
variability.[3-6] A minimal impact on the quality of life of the children can be obtained by applying 
a sparse data approach limiting the pharmacokinetic assessment to routine phlebotomies 
and indwelling catheters.[7] The aim of the current study was to assess the feasibility of a 
sparse data approach for the determination of the population pharmacokinetics of ifosfamide, 
2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide in a paediatric population. 
 
Methods 
 
Patients 
 
A group of 32 paediatric patients suffering from various malignant diseases were subjected to 
pharmacokinetic sampling during ifosfamide treatment. Inclusion and exclusion criteria were 
identical to those of the regular ifosfamide treatment. The study protocol was approved by the 
Ethics Board of the Academic Medical Center of Amsterdam. Written informed consent was 
obtained from the carer or patient (if more appropriate) before entering the study protocol.  
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Pharmacokinetic sampling 
 
The pharmacokinetic analysis included 32 patients with 16 males and 16 females aged 
between 1 and 18 years receiving a total of 45 courses of 1.2, 2 or 3 g/m² ifosfamide in 1 or 3 
hours on 1, 2 or 3 days. The Ethics Board approved the study with the understanding that no 
additional phlebotomies beyond those considered part of routine patient care would be 
performed. In most patients an already indwelling double-lumen catheter was used. Whole 
blood was drawn and immediately placed on ice water. A volume of 3 ml whole blood was 
immediately transferred to a polypropylene tube containing 300 µl 2 M semicarbazide to 
stabilize 4-hydroxyifosfamide. The whole blood was separated by centrifugation at 1,000 g for 
5 min at 4°C. Plasma was transferred and stored at -20°C up to 1 month, pending analysis.  
 
Pharmacokinetic analysis 
 
Gas chromatography with selective nitrogen phosphorous detection was used for the 
determination of ifosfamide, 2- and 3-dechloroethylifosfamide in urine and plasma.[8] Sample 
pre-treatment consisted of alkalinized liquid-liquid extraction with ethyl acetate, transfer of the 
organic extract, evaporation to dryness and subsequent reconstitution in ethyl acetate. This 
method was validated and proved to be specific, sensitive, accurate (93.3-104.5%) and 
precise (<5.5%) from 0.192 to 383 µM, with a lower limit of quantification of 0.192 µM for 
ifosfamide, 2- and 3-dechloroethylifosfamide. 
High-performance liquid chromatography was used for determination of 4-hydroxy-ifosfamide 
pharmacokinetics.[9] In brief this method determined the 4-hydroxyifosfamide-semicarbazone 
derivative in plasma. The HPLC column used was reversed phase C8 with acetonitrile-0.025 
M potassium dihydrogenphosphate (32:68 v/v) as mobile phase. Detection was performed at 
230 nm. Sample pre-treatment consisted of liquid-liquid extraction with ethyl acetate. This 
method was specific, sensitive, accurate (94.1-107.9%) and precise (<7.2%) from 0.361 to 
361 µM, with a lower limit of quantification of 0.361 µM 4-hydroxyifosfamide. 
 
Modelling 
 
Pharmacokinetic model for ifosfamide and its dechloroethylated and hydroxylated metabolites 
were fitted to the data from the individuals using the population pharmacokinetic programme 
NONMEM (Non-linear Mixed Effects Modelling).[10,11] NONMEM estimates population 
parameters as typical parameter values with their estimated interindividual variability, usually 
as its S.D., denoted as w. This is accomplished by allowing each individual’s data to be 
described by subject specific parameters Pi; this is assumed to come from the distribution of 
parameters in the population according to equation 1. 
P Pi pop i= ´ exp( )h          (eq. 1) 
In which Ppop is the parameter value of a typical individual and h is the symmetrically 
distributed zero-mean variable with the S.D. w. For mixed effects models, the residual error 
corresponds to the difference between observed (Cobs) and predicted (Cpred) concentration by 
individual parameters (Pi). The residual or intraindividual error was described by a 
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proportional and additive component according to equation 2, 
C Cobs pred= ´ + +( )1 1 2e e         (eq. 2) 
in which e1 and e2 are zero-mean random variables with S.D.s s1 and s2. Either component 
of the residual error could be omitted if it did not provide any improvement of the fit of the data. 
Model accuracy was evaluated using goodness-of-fit plots and precision of the parameters 
estimates. In comparison between models the objective function value (which was minus two 
times the log-likelihood) provided by NONMEM was used. For hierarchical models the 
difference in objective function value is approximately c-squared distributed and formal testing 
between models can be performed, using the log-likelihood ratio test. For non-hierarchical 
models the objective function value cannot be used for formal testing, but we considered a 
difference of 9 units between models with identical databases to present a real difference in 
description of the data.[12] For the graphical goodness-of-fit analysis extensive plotting was 
available through the use of X-pose, a purpose-built set of subroutines in S-PLUS (Mathsoft, 
1997).[13]  
A one-compartment model described the change of the amount of ifosfamide (Aifo, µmol) in 
the central compartment over time by equation 3, 
t T< inf  : 
dA
dt
R CL A V
ifo ifo
ifo
= - ´æèç
ö
ø÷  
t T> inf  : 
dA
dt
CL A V
ifo ifo
ifo
= - ´æèç
ö
ø÷        (eq. 3) 
in which Tinf (h) is the infusion duration, R (µmol· h
-1) is the infusion rate of ifosfamide, CL 
(L· h-1· m-2) the ifosfamide clearance over time and Vifo (L· m
-2) the volume of distribution. 
Both CL and Vifo are expressed per body surface area (m
-2) in order to accommodate the 
differences in body size within the paediatric population. The concentration of ifosfamide Cifo 
(µM) is the ratio of Aifo and Vifo. CL was described with a time dependent increase from an 
initial clearance (CLinit, L· h
-1· m-2) by equation 4. 
CL CL K tinit enz= + ´          (eq. 4) 
In which Kenz (L· h
-2· m-2) was the enzyme induction rate constant and t (h) the time. No lag-
time was used. Boddy et al. described a similar model but with an exponential increase after 
a lag time from an initial clearance to a maximum clearance.[5]  
Ifosfamide and metabolite pharmacokinetics were described simultaneously. The change in 
the amount of a metabolite (Am) over time was described by equation 5.  
( )dA
dt
F CL
A
V
K Am m
ifo
ifo
m m= ´ ´
æ
è
ç
ö
ø
÷ - ´        (eq. 5) 
In which Km (h
-1) is the elimination rate constant of the metabolite and Fm is the fraction of 
ifosfamide metabolized to the metabolite. The values for Fm and the volume of distribution of 
the metabolite (Vm, L) cannot be estimated separately in this model. Therefore, the ratio of Fm 
over Vm was estimated: F
* (L-1). The ratio was used to calculate the area under the 
concentration-time curve (AUCm) of the metabolite, as described by equation 6. 
AUC
D
K
V
F
m
m
m
m
=
´
         (eq. 6) 
In which D (mol) was the ifosfamide dose administered to the patient.  
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The interindividual variability of each pharmacokinetic parameter was estimated using a 
proportional error model according to equation 1. The residual or intraindividual variability of 
ifosfamide and metabolites kinetics were described separately with a proportional and additive 
term according to equation 2. The Bayesian estimates of the areas under the concentration-
time curves (AUC) of ifosfamide and its metabolites were obtained by describing the 
cumulative concentrations of these compounds over a given time. AUCs were obtained with 
extrapolation of ifosfamide and metabolite concentration-time profiles to 48 hours after the last 
ifosfamide infusion, where concentrations were below the LLQ. 
 
Validation 
 
In order to assess objectively the predictive capability of our model a cross-validation was 
performed using a bootstrap technique.[14] The patients were divided in 5 groups: 3 groups 
with 6 and 2 with 7 patients. The pharmacokinetic model was fitted to the data from 4 of the 5 
groups and parameter estimates were obtained. These parameter estimates were then used 
to generate concentration predictions for the remaining patients in the fifth group. This 
process was repeated four more times so that predictions could be generated for all 32 
patients.  
 
Results 
 
Pharmacokinetic assessment resulted in 133 ifosfamide, 106 2-dechloroethylifosfamide, 116 
3-dechloroethylifosfamide and 76 4-hydroxyifosfamide observed concentrations, as 
represented in figure 2. The sparse data approach model was able to estimate population 
values for the pharmacokinetic parameter of ifosfamide and its dechloroethylated and 
hydroxylated metabolites (table 1). The pharmacokinetic model also estimated the differences 
between patients (interindividual variability) and within the patient (intraindividual variability). 
Table 1 also contains the accuracy of parameter estimation as described by the relative error. 
The relationship between the model predictions, Bayesian predictions, cross-validated 
predictions and the observed ifosfamide, 2- and 3-dechloroethylifosfamide and 4-
hydroxyifosfamide concentrations are represented in figure 3. In general, no trends or extreme 
outlyers were observed, although one patient evidently had different 4-hydroxyifosfamide 
concentrations of about 10 µM.  
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Figure 2. Plots of all observed ifosfamide, 2-dechloroethylifosfamide (2DCE), 3-dechloroethyl-ifosfamide 
(3DCE) and 4-hydroxyifosfamide (4OHIF) concentrations over time. 
 
Table 1. Estimates of pharmacokinetic population parameters for ifosfamide (IFO), 2-
dechloroethylifosfamide (2DCE), 3-dechloroethylifosfamide (3DCE) and 4-hydroxyifosfamide (4OHIF) with 
their relative standard error of the mean, interindividual variability and residual variability. 
 
Parameter Mean Rel. err. I.I.V. R.V. Mean 
IFO      
CLinit (L· h
-1· m -2) 2.36 14% 43% P.E. IFO 48% 
Vifo (L· m
-2) 20.6 8% 32% A.E. IFO (µM) 3.18 
Kenz (L· h
-2· m -2) 0.0493 21%    
2DCE      
F* (L-1) 0.0976 57% 23% P.E. 2DCE 41% 
K (h-1) 3.64 56%  A.E. 2DCE (µM) 2.24 
3DCE      
F* (L-1) 0.0328 31% 34% P.E. 3DCE 40% 
K (h-1) 0.445 39%  A.E. 3DCE (µM) 1.98 
4OHIF      
F* (L-1) 0.0230 36% 53% P.E. 4OHIF 47% 
K (h-1) 7.67 37%  A.E. 4OHIF (µM) 0.448 
 
Rel. Err.=Relative error of the mean, I.I.V.=interindividual variability, R.V.=residual variability, CLinit=initial 
ifosfamide clearance, Vifo=volume of distribution of ifosfamide, Kenz=autoinduction formation rate, F
*=ratio of 
fraction metabolized and volume of distribution of metabolite, K=first-order rate constant for metabolite 
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elimination, P.E.=proportional intraindividual error, A.E.=additive intraindividual error. 
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Figure 3. The relationships between model predictions (left panel), individual Bayesian estimates 
(middle panel), cross-validated predictions (right panel) and observed ifosfamide, 2-dechloroethyl-
ifosfamide (2DCE), 3-dechloroethylifosfamide (3DCE) and 4-hydroxyifosfamide (4OHIF) concentrations. 
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The relationship between the ifosfamide clearance and time is represented in figure 4. Modest 
interindividual variability is observed in clearance. The relationships between the area under 
the concentration-time curve (AUC) of ifosfamide, 2- and 3-dechloroethyl-ifosfamide and 4-
hydroxyifosfamide and the ifosfamide dose administered are represented in figure 5. The AUC 
is a measure of exposure to the compound. 
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Figure 4. The relationship between the ifosfamide clearance (CL(t), L/h/m²) and the time for all 
individuals. The profiles were obtained on basis of the individual Bayesian parameter estimates provided 
by NONMEM. 
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Figure 5. The relationship between the ifosfamide dose (g/m²) and ifosfamide, 2-dechloroethylifosfamide 
(2DCE), 3-dechloroethylifosfamide (3DCE) and 4-hydroxyifosfamide (4OHIF) exposures as calculated by 
the area under the concentration-time curve (AUC) of each patient. 
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Discussion 
 
Only limited information is available on the pharmacokinetics of ifosfamide and its metabolites 
in paediatric patients.[15] The lack of adequate pharmacokinetic research can be explained by 
both the lack of reliable and sensitive bioanalytical assays for ifosfamide and its metabolites 
and due to the problems involving paediatric studies. Paediatric studies have always been 
plagued by ethical issues. Due to these concerns drugs used in paediatric population have 
been less assessed compared to those used in adult populations. Especially 
pharmacokinetic studies are difficult to execute, because children and their parents may find 
blood sampling very distressing. It is therefore essential that the number of blood samples is 
kept to the minimum required. An opportunistic limited sampling approach only allows 
assessment of fairly straightforward pharmacokinetics and excludes for instance multi-
compartment modelling. A solution to this problem is a population approach. A population 
approach pools all observed concentrations in a population of patients, yielding population 
values for the pharmacokinetic parameters. Bayesian estimates are then used to calculate 
individual pharmacokinetic parameters. Nevertheless, a reduced number of samples will 
result in an increase in the minimum number of patients required.[16] An additional problem in 
young children relates to the volume of blood sample collected, necessitating the use and 
development of micro-assays.  
A minimal impact on the quality of life of the children was obtained by applying a sparse data 
approach, which limited the pharmacokinetic assessment to routine phlebotomies and 
indwelling catheters. This approach allowed pharmacokinetic assessment of all parameters 
for each individual. In contrast, conventional non-population based methods are not able to 
estimate these parameters based only on one or two observations. The Bayesian estimation 
step was based on the information obtained from the sparse individual observations 
supplemented with information from the population values. The model is adequate in 
describing the ifosfamide and metabolite concentration-time (profiles including autoinduction) 
in this paediatric population (figure 3). The description of these concentration-time profiles 
enabled calculation of the exposures to these compounds (figure 5).  
During the development of the model a comparison was made between a pharmacokinetic 
model with time-dependent autoinduction and a model with ifosfamide concentration-
dependent autoinduction.[5,17] The sparse data necessitated the use of a simplified model with 
a linear increase of clearance over time with time-dependent autoinduction. 
Boddy et al. also described the pharmacokinetics of ifosfamide and its metabolites after 3 
g/m² ifosfamide in one-hour infusions for three consecutive days.[3] Their model did not 
include autoinduction, but rather the pharmacokinetics were estimated separately each 
consecutive day. They observed the clearance of ifosfamide to increase from 3.81±1.08 to 
6.34±1.81 L· h-1· m-2 over three days with a volume of distribution of 21.8±6.5 L· m-2, based 
on an average body surface area of 0.82 m2 and weight of 22.1 kg. Our model resulted in 
similar values (figure 4 and table 1). The initial CL ranged from 1.40 to 6.20 and increased 
maximally to 9.75 L· h-1· m-2. The volume of distribution ranged between 8.73 and 33.5 L· m-
2. 
The sparse data were not sufficient to estimate possible interindividual differences in the 
enzyme induction rate Kenz. A similar pharmacokinetic model without estimation of 
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autoinduction was also tested. The inclusion of the Kenz in the model, however, resulted in an 
improved goodness-of-fit as calculated by the objective function of the model. The objective 
function increased significantly from 3035 to 3056. The exclusion of Kenz resulted in an 
increase of CLinit, but also decreased the accuracy of the estimation of the metabolite 
parameters. The relative errors of the metabolite parameters without estimation of Kenz 
ranged from 51 to 91%. 
Besides simultaneous estimation (‘one-step approach’) of the pharmacokinetic parameters of 
ifosfamide and its metabolites, a ‘two-step approach’ was also investigated. This ‘two-step 
approach’ estimated the individual pharmacokinetic parameters of ifosfamide first, 
independently from the metabolites. Then these individual estimations were fixed in a second 
estimation step of the metabolite pharmacokinetics. The objective function of the two 
approaches cannot be compared, because the models use to describe the pharmacokinetics 
of ifosfamide and metabolites were not hierarchical. The ‘two-step approach’ estimated a 
relatively low residual proportional variability for ifosfamide (27.1%), but the additive 
component was higher with 39.8 µM. Furthermore, the relative errors of all parameters were 
higher with the two-step approach. The simultaneous approach resulted in more precise 
estimates, because then the metabolites had an influence on the estimation of the 
pharmacokinetics of the parent-compound. This resulted in optimal use of all information in 
this sparse data approach. 
The cross-validation was performed using the predicted concentrations and not the individual 
Bayesian predictions, because of the large differences in number of samples of each patient. 
Normally, bootstrapping-techniques are repeated more than 200 times, but due to extensive 
calculation-time this was not feasible.[14] The residual error model of ifosfamide and those of 
the metabolites assume a larger imprecision with lower concentrations. This was modelled 
with the additive and proportional residual error. Thus no bias or precision could be 
calculated, because this would not take into account the different precisions per 
concentration. The best indication of lack of bias is seen in the scatterplot of figure 3 when 
comparing the left with the right panel.  
The ifosfamide dose and the ifosfamide and metabolite exposures (AUC) exhibit linear 
relationships (figure 5). Modest interpatient differences in exposure are observed. Since 
ifosfamide was typically given as short duration (1-3 h) infusions no interindividual differences 
in effect of autoinduction on the metabolic routes were expected. This explains also why no 
interindividual variability in autoinduction could be estimated in this population.  
The sparse data approach for describing the pharmacokinetics of ifosfamide and its 
metabolites can be used to investigate the pharmacokinetic-pharmacodynamic relationships 
of the specific metabolites with the efficacy and toxicities of ifosfamide treatment in children, 
based on opportunistic sampling. These pharmacokinetic-pharmacodynamic relationships 
can assist in improving ifosfamide treatment in a paediatric setting, tailoring the treatment to 
the specific needs of the individual child. 
In conclusion, the application of a sparse data approach for the determination of the 
population pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide and 4-
hydroxyifosfamide in a paediatric population was feasible. A bootstrap technique 
demonstrated the validity of the population pharmacokinetic model.  
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Modulation of the cytochrome P450- 
mediated metabolism of ifosfamide  
by ketoconazole and rifampicin 
 
 
Summary 
 
The autoinducible metabolic transformation of the anti-cancer agent ifosfamide involves 
activation through 4-hydroxyifosfamide to the ultimate cytotoxic ifosforamide mustard and 
deactivation to 2- and 3-dechloroethylifosfamide with concomitant release of the neurotoxic 
chloroacetaldehyde. Activation is mediated by the cytochrome P450-3A4 (CYP3A4) and 
deactivation by CYP3A4 and 2B6. The aim of this study was to investigate modulation of the 
CYP-mediated metabolism of ifosfamide with ketoconazole and rifampicin, a potent inhibitor 
of CYP3A4 and inducer of CYP3A4/2B6, respectively. In a double randomized, two-way 
cross-over study a total of 16 patients received 3 g/m²/24 hours ifosfamide i.v., either alone 
or in combination with 200 mg ketoconazole bid (1 day pre-treatment and 3 days concomitant 
administration) or 300 mg rifampicin bid (3 days pre-treatment and 3 days concomitant 
administration). Plasma pharmacokinetics and urinary excretion of ifosfamide, 2- and 3-
dechloroethylifosfamide and 4-hydroxy-ifosfamide were assessed in both courses. Data 
analysis was performed with a population pharmacokinetic model with description of 
autoinduction of ifosfamide. Rifampicin increased the clearance of ifosfamide at the start of 
therapy with 102%. The fraction of ifosfamide metabolized to the dechloroethylated 
metabolites was increased, whereas exposure to the metabolites was decreased due to 
increased elimination. The fraction metabolized and exposure to 4-hydroxyifosfamide were 
not significantly influenced. Ketoconazole did not affect the fraction metabolized or exposure 
to the dechloroethylated metabolites, whereas both parameters were reduced with 4-
hydroxyifosfamide. As a result co-administration of ifosfamide with ketoconazole or rifampicin 
did not produce changes in the pharmacokinetics of the parent or metabolites that may result 
in increased benefit of ifosfamide therapy. 
Introduction 
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Ifosfamide (HoloxanÒ, IfexÒ) is an alkylating agent used as a single chemotherapeutic or in 
combination schedules. It has been proven to be active against a number of solid tumours 
and haematological malignancies in adults and children.[1] Ifosfamide is a prodrug, which 
needs activation by cytochrome P450-3A4 (CYP3A4) to form 4-hydroxyifosfamide. 
Spontaneous decomposition of 4-hydroxyifosfamide yields the ultimate alkylating metabolite 
ifosforamide mustard and acrolein.[1] The alkylating activity of ifosforamide mustard is both 
responsible for the anti-tumour activity and haematological toxicity. Acrolein causes 
haemorrhagic cystitis, which can generally be prevented by sodium-2-
mercaptoethanesulfonate (MESNA) co-administration.[1] Ifosfamide is also deactivated by 
CYP3A4 and possibly CYP2B6 to the non-cytotoxic metabolites 2- and 3-dechloroethylifosfa-
mide. Dechloroethylation, however, yields an equimolar amount of chloroacetaldehyde, which 
is held responsible for neurotoxicity observed in about 10% of all patients receiving conven-
tional single-agent dosing of ifosfamide.[2] Renal tubular abnormalities have been observed as 
well and may also be correlated with the extent of metabolic formation of chloroacetaldehyde. 
Chloroacetaldehyde is very unstable and therefore, assessment of 2- and 3-
dechloroethylifosfamide is preferred when quantifying the relationship between the 
pharmacokinetics and neurotoxicity after ifosfamide treatment. Ifosfamide metabolism is 
subject to autoinduction, which leads to an increase in metabolism of ifosfamide over time.[1] 
Both activation and deactivation routes are mainly mediated by CYP3A4, making this 
isoenzyme a suitable target for development of specific inhibition or hetero-induction 
regimens and thereby directing ifosfamide metabolism to a more favourable toxicity-efficacy 
profile: minimized risk of neurotoxicity (deactivation) and maximized anti-tumour activity 
(activation) of ifosfamide treatment.[3] 
Ketoconazole is a broad spectrum anti-fungal agent. It has been shown to reduce the 
metabolism of other drugs sharing the CYP3A4 pathway.[4] The in vitro inhibition constants 
(Ki) for ketoconazole towards CYP3A4 index substrates are usually in the nanomolar range.
[4] 
Therapeutic concentrations of ketoconazole significantly inhibited the formation of N-
dechloroethylated metabolites of ifosfamide by human liver microsomes in vitro.[5] Rifampicin 
(rifampin) is a semi-synthetic macrocyclic antibiotic and a highly potent, albeit non-specific, 
inducer of CYP.[6] Induction is achieved through activation of de novo synthesis of CYP and 
typically requires several days to develop.[7] In a recent in vitro study it was demonstrated that 
rifampicin was capable of inducing ifosfamide metabolism in cultured human hepatocytes.[8] 
Hydroxylation of ifosfamide was increased 200-400% and CYP2B6, 2C8, 2C9 and 3A4 levels 
were elevated in the cell culture. 
The aim of this study was to investigate modulation of the CYP-mediated metabolism of 
ifosfamide by ketoconazole a potent inhibitor of CYP3A4 and rifampicin a potent inducer of 
CYP. The activation and deactivation routes of ifosfamide were monitored using the 
pharmacokinetic profiles of 4-hydroxyifosfamide and 2- and 3-dechloroethyl-ifosfamide, 
respectively. 
Methods 
 
Patients 
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Eligible patients had incurable malignancies, no major organ disturbances, no active infection, 
no major medical illness or signs of CNS involvement or leptomeningal disease, a life 
expectancy of 3 months or more and were at least 6 and 4 weeks chemotherapy- and 
radiotherapy-free, respectively. Other eligibility criteria were: age between 18 and 75 years, 
adequate contraception, white blood cells  3.5 x 109/L and platelets  100 x 109/L, serum 
bilirubin  25 µmol/L, serum creatinine  125 µmol/L and creatinine clearance  60 ml/min, 
serum ASAT  50 U/L and serum ALAT  60 U/L. The study protocol was approved by the 
Ethical Board of the University Hospital of Maastricht. The study was conducted at the 
department of Internal Medicine of the above mentioned hospital between April 1998 and April 
2000. All patients gave written informed consent.  
 
Study design  
 
The study was designed as a double randomized, cross-over study. Sixteen patients received 
two courses of palliative treatment with ifosfamide, at a three week interval. Ifosfamide 
(HoloxanÒ, ASTA Medica B.V., Diemen, The Netherlands) was administered at 3 g/m² by 
means of 24-hour continuous intravenous (i.v.) infusion. No dose reductions were allowed, 
but the second course could be delayed by one week if the eligibility criteria for the white blood 
cells and platelets counts were not met.  
Eight patients were randomized to the co-administration of twice daily 200 mg ketoconazole 
orally for four days starting one day prior to the ifosfamide infusion. Four patients received 
ketoconazole during their first course of ifosfamide treatment and four patients received 
ketoconazole during their second course of ifosfamide treatment. The other eight patients 
were randomized to the co-administration of twice daily 300 mg rifampicin orally for 6 days, 
starting 3 days prior to the ifosfamide infusion. Four patients received rifampicin during their 
first course of ifosfamide treatment and four patients received rifampicin during their second 
course of ifosfamide treatment.  
Supportive care consisted of MESNA (UromitexanÒ, ASTA Medica B.V., Diemen, The 
Netherlands) at 0.75 g/m² in 1 hour prior to the ifosfamide infusion. This was followed by 1.5 
g/m² mesna in 24 hours during the ifosfamide infusion and 0.75 g/m² mesna in 12 hours 
thereafter. Extensive hydration to prevent haemorrhagic cystitis was achieved by 
administration of 500 ml 0.9% NaCl in 1 hour prior to the ifosfamide infusion, 3000 ml 0.9% 
NaCl in 24 hours during the ifosfamide infusion and 2000 ml 0.9% NaCl in 24 hours after the 
ifosfamide infusion. Eight mg of the anti-emetic ondansetron was given intravenously every 
eight hours during the ifosfamide infusion. No use of dexamethasone, barbiturates, 
cimetidine, macrolide antibiotics and lorazepam was allowed, because of possible CYP3A4 
interactions. 
 
Pharmacokinetic sampling 
 
Blood samples were drawn from an indwelling intravenous cannula placed in the arm 
contralateral to the arm receiving ifosfamide prior to the start of the ifosfamide infusion and 6, 
12, 18, 24, 25, 27, 30, 36 and 48 hours thereafter. A 10 ml volume of whole blood was 
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collected in a lithium heparin-coated Vacutainer® (Becton-Dickinson, Plymouth, UK) and 
placed on ice water. The plasma was immediately separated by centrifugation at 1,000 g for 5 
min at 4°C. The plasma was aliquoted in three volumes of which two were precisely 1-ml 
volumes. To these two 1-ml volumes, 100 µl 2 M semicarbazide solution at pH 7.40 were 
added to stabilize 4-hydroxyifosfamide. The remaining plasma was used for ifosfamide, 2- 
and 3-dechloroethylifosfamide analysis. Urine was collected for up to 72 hours after the start 
of the ifosfamide infusion and an aliquot was analysed for ifosfamide, 2- and 3-
dechloroethylifosfamide. No 4-hydroxyifosfamide can be detected in urine due to rapid 
degradation. Both plasma and urine samples were stored at -70°C, pending analysis. 
 
Bioanalysis 
 
Gas chromatography with selective nitrogen-phosphorous detection was used for the 
determination of ifosfamide, 2- and 3-dechloroethylifosfamide in urine and plasma.[9] Sample 
pre-treatment consisted of alkalinized liquid-liquid extraction with ethyl acetate, transfer of the 
organic extract, evaporation to dryness and subsequent reconstitution in ethyl acetate. This 
method was validated and proved to be specific, sensitive, accurate (93.3-104.5%) and 
precise (within- and between-day precision <5.5%) within the concentration range of 0.192 to 
383 µM, with a lower limit of quantification (LLQ) of 0.192 µM for ifosfamide, 2- and 3-
dechloroethylifosfamide. 
High-performance liquid chromatography (HPLC) was used for the determination of 4-
hydroxyifosfamide plasma concentrations.[10] In brief, this method determined the 4-
hydroxyifosfamide-semicarbazone derivative in plasma.  Sample pre-treatment consisted of 
liquid-liquid extraction with ethyl acetate. The HPLC column used was a reversed phase C8 
column with acetonitrile-0.025 M potassium dihydrogenphosphate (32:68 v/v) as mobile 
phase. Detection was performed at 230 nm. This method was specific, sensitive, accurate 
(94.1-107.9%) and precise (within- and between-day precision <7.2%) within the 
concentration range of 0.361 to 361 µM, with a LLQ of 0.361 µM 4-hydroxyifosfamide. 
  
Data evaluation 
 
Pharmacokinetic models were fitted to the data from the sixteen individuals using the 
population pharmacokinetic programme NONMEM (Non-linear Mixed Effects Modelling, 
version V 1.1, double precision, first order estimation).[11,12]  
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Figure 1. Pharmacokinetic model for ifosfamide metabolism describing the autoinducible 
pharmacokinetics of ifosfamide (IFO) and the pharmacokinetics of 2-dechloroethylifosfamide (2DCE), 3-
dechloroethylifosfamide (3DCE), 4-hydroxyifosfamide (4OHIF) and ifosforamide mustard (IFM). 
Autoinduction is modelled with a hypothetical enzyme compartment described by an enzyme formation 
rate (Kenz,in) and elimination rate (Kenz,out). At t=0 Kenz,in equalled Kenz,out. A higher amount of enzyme 
increases the clearance of IFO (CLIFO). The amount of IFO described by the IFO concentration and IFO 
volume of distribution (V IFO), inhibi ts  Kenz,out. Metabolite compartments are described by fraction of 
ifosfamide metabolized to the metabolite (F) and elimination rates (K). 
 
The non-linear pharmacokinetics of ifosfamide were described using a recently developed 
model (figure 1), which incorporated the development of autoinduction.[13,14] According to 
these recent studies the time-dependent pharmacokinetics of ifosfamide can be described by 
a one-compartment model. The change of the amount of ifosfamide (Aifo, µmol) in the central 
compartment over time can be described by equation 1, 
t T< inf  : 
dA
dt
R CL A V
ifo ifo
ifo
= - ´æèç
ö
ø÷ and    
t T> inf  : 
dA
dt
CL A V
ifo ifo
ifo
= - ´æèç
ö
ø÷        (eq. 1) 
in which Tinf (h) is the infusion duration, R (µmol· h
-1) is the infusion rate of ifosfamide, CL 
(L· h-1) the ifosfamide clearance, which changes over time and Vifo (L) the volume of 
distribution. The concentration of ifosfamide Cifo (µM) is the ratio of Aifo and Vifo. In turn, 
autoinduction can be described using a hypothetical enzyme compartment. CL can then be 
expressed by an initial clearance (CLini,ifo, L· h
-1) multiplied by the relative amount of enzyme 
(Aenz) in the hypothetical enzyme compartment, as given in equation 2.   
CL CL Aini ifo enz= ´,          (eq. 2) 
The change of Aenz (no dimension) over time in the enzyme compartment is dependent on 
Cifo as follows, 
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dA
dt
K K A
C
C IC
enz
enz out enz out enz
ifo
ifo
= - ´ ´ -
+
æ
è
ç
ö
ø
÷, , 1
50
     (eq. 3) 
in which Kenz,out (h
-1) is the first-order rate constant for enzyme degradation/inactivation and 
IC50 (µM) is the ifosfamide concentration at 50% of the maximum inhibition of enzyme 
degradation. The induction half-life of the enzyme (T½enz, h) was calculated by the ratio of 
ln(2) and Kenz,out.  
The pharmacokinetics of ifosfamide and metabolites were described sequentially: Bayesian 
estimations (posthocs) of the pharmacokinetic parameters of ifosfamide were used for the 
description of the pharmacokinetics of the metabolites. The change in the amount of a 
metabolite (Am) over time could be described by equation 4.  
( )dA
dt
F CL
A
V
K Am m
ifo
ifo
m m= ´ ´
æ
è
ç
ö
ø
÷ - ´        (eq. 4) 
in which Km (h
-1) is the elimination rate constant of the metabolite and Fm is the fraction of 
ifosfamide metabolized to the metabolite. The values for Fm and the volume of distribution of 
the metabolite (Vm, L) cannot be estimated separately in this model. Therefore, the ratio of Fm 
over Vm was estimated: F
* (L-1). 
The residual or intraindividual variability of ifosfamide and metabolites were described 
separately with a proportional and additive term. The interindividual variability of each 
pharmacokinetic parameter was estimated using a proportional error model. 
The posthocs of the areas under the concentration-time curve (AUC) of ifosfamide were 
obtained by describing the cumulative concentrations of these compounds over a given time. 
AUCs of ifosfamide were obtained by extrapolation of concentration-time profiles to 144 hours 
after the start of the infusion, where ifosfamide concentrations were below the LLQ. The 
AUCs of the metabolites were calculated using equation 5, 
AUC
D F
Km m
= ´
*
         (eq. 5) 
in which D represents the ifosfamide dose (µmol).  
The effect of ketoconazole and rifampicin on the pharmacokinetics of ifosfamide, 2-
dechloroethylifosfamide, 3-dechloroethylifosfamide and 4-hydroxyifosfamide was estimated 
simultaneously, as described by equation 6.  
( )Ppop control ketoconazo le rifampicin= ´ + +q q q 1       (eq. 6) 
in which Ppop is the population pharmacokinetic parameter, qcontrol is the estimate for this 
parameter without modulation, qketoconazole is the change in this parameter due to 
ketoconazole co-administration and qrifampicin is the change in this parameter due to rifampicin 
co-administration. Significant differences due to modulation were tested by calculating the 
95%-confidence intervals of qketoconazole and qrifampicin using the relative error of the respective 
mean. If the 95%-confidence interval did not include zero, the observed difference was 
significant (p<0.05). The percentage change in AUCs of the metabolites was also tested 
according to equation 6 after reparametrization of the model according to equation 5. A non-
parametric test (Kolmogorov-Smirnov test for two independent samples) was conducted to 
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determine significant differences in AUC of ifosfamide with a modulator compared to control. 
The urinary excretions (UE) for ifosfamide and 2- and 3-dechloroethylifosfamide were 
calculated based on the equimolar amount of the dose administered. Differences in urinary 
excretion were tested with a paired samples t-test using SPSS software (Version 6.1 for 
Windows; SPSS, Inc., Chicago, IL, USA). 
 
Results 
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Figure 2. Mean (±SD) observed concentration-time profiles of ifosfamide (IFO), 2-dechloroethyl-
ifosfamide (2DCE), 3-dechloroethylifosfamide (3DCE) and 4-hydroxyifosfamide (4OHIF) in 16 patients 
receiving 3 g/m²/24 hours ifosfamide i.v., either alone or in combination with 200 mg ketoconazole bid 
(one day pre-treatment and three days concomitant administration) or 300 mg rifampicin bid (three days 
pre-treatment and three days concomitant administration). 
 
All 16 patients were evaluable for the determination of the plasma pharmacokinetics of 
ifosfamide and its metabolites and their excretion in urine. The mean observed ifosfamide and 
metabolite concentration-time profiles are shown in figure 2. The pharmacokinetic parameters 
of ifosfamide and its metabolites and changes due to CYP modulation with ketoconazole and 
rifampicin are presented in table 1.  
The pharmacokinetic data contained insufficient information to estimate the interindividual 
variability on the enzyme induction parameters Kenz,out and IC50. The influence of modulation 
on these parameters could therefore not be evaluated. Autoinduction of ifosfamide developed 
with an average value for T½,enz (ln(2)/Kenz,out) of 25.9 h. It was assumed that the volumes of 
distribution of the ifosfamide and the metabolites were not affected by the modulation. The 
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changes in exposure to ifosfamide and its metabolites due to modulation are depicted in 
figure 3. 
 
Table 1. Pharmacokinetic parameters of ifosfamide (IFO), 2-dechloroethylifosfamide (2DCE), 3-
dechloroethylifosfamide (3DCE) and 4-hydroxyifosfamide (4OHIF) and changes (%) after CYP3A4-
modulation with ketoconazole (n=8) or rifampicin (n=8) in 16 patients receiving 3 g/m²/24 hours 
ifosfamide i.v.. 
 
 Control  Ketoconazole  Rifampicin  
Parameter Mean±sem I.I.V. Mean change significance Mean 
change 
significance 
CLini,ifo (L· h
-1) 3.44±0.33 20% -11% p<0.05 +102% p<0.05 
Vifo (L) 42.7±2.52 19%     
Kenz,out (h
-1) 0.0268±0.0056      
IC50 (µM) 13.2±9.8      
AUCifo (µM· h) 5263±947  +14% ns -49% p<0.05 
UEifo 17% 47% +26% ns -43% p<0.05 
F*2dce (L
-1) 0.00241±0.00043 83% +17% p<0.05 +23% p<0.05 
K2dce (h
-1) 0.131±0.092 150% -5% ns +82% p<0.05 
AUC2dce (µM· h) 867±92  +23% p<0.05 -32% p<0.05 
UE2dce 7% 40% +39% ns +17% ns 
F*3dce (L
-1) 0.00469±0.00075 61% -10% ns +15% ns 
K3dce (h
-1) 0.0475±0.0128 52% -4% ns +320% p<0.05 
AUC3dce (µM· h) 1950±245  -6% ns -72% p<0.05 
UE3dce 8% 30% -3% ns +11% ns 
F*4ohif (L
-1) 0.000295±0.000062 42% -48% p<0.05 +1200% ns 
K4ohif (h
-1) 0.179±0.068 33% -26% ns +1370% ns 
AUC4ohif (µM· h) 32±4  -30% ns -11% ns 
 
I.I.V.=interindividual variability, CLini,ifo=initial ifosfamide clearance, Vifo=volume of distribution of ifosfamide, 
Kenz,out=autoinduction formation rate, IC50=ifosfamide concentration at 50% of the maximum inhibition of enzyme 
degradation, F*=ratio of fraction metabolized and volume of distribution of metabolite, K=first-order rate constant 
for metabolite elimination, AUC=area under the concentration-time curve, UE=urinary excretion, ns=not 
significant. 
 
Table 1 demonstrates that CLini,ifo was decreased by ketoconazole. Concomitant increases 
in AUCifo (figure 3) and UEifo were observed although not significantly different from the 
control values. When assuming that the volume of distribution of the metabolites is not 
affected by concomitant administration of the modulators, it can be concluded that 
ketoconazole significantly increased the fraction of ifosfamide metabolized to 2-dechloro-
ethylifosfamide (F*2dce), whereas the elimination rate of 2-dechloroethylifosfamide (K2dce) was 
not changed. AUC2dce and UE2dce were slightly increased although the latter not significantly 
(figure 3, table 1). No changes in F*, K, AUC and UE were observed for 3-
dechloroethylifosfamide. For 4-hydroxyifosfamide decreased values for AUC, K and F* were 
observed with the latter reaching statistical significance. 
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CLini,ifo was doubled by rifampicin, resulting in a decreased AUC ifo and UEifo. A significant 
increase in F*2dce and K2dce was observed with the inducer, with the increase in elimination 
being the most pronounced (82%). Consequently, the AUC2dce decreased with rifampicin 
(figure 3). The decrease of AUC2dce did not, however, affect UE2dce, which increased slightly. 
Similar results were observed for 3-dechloroethylifosfamide. Both F*3dce and K3dce increased; 
the increase of the latter was significant. This resulted in a decrease of AUC3dce whereas 
UE3dce was not influenced. The changes in F
*
4ohif and K4ohif by rifampicin were 12-fold and 
14-fold, respectively. These changes were, however, not significant. The changes in F*4ohif 
and K4ohif were comparable; the AUC4ohif changed therefore only slightly. It should be noted 
that the estimates of F*4ohif and K4ohif were highly correlated. 
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Figure 3. Bayesian estimation of the areas under the concentration-time curves (AUC) of ifosfamide 
(IFO), 2-dechloroethylifosfamide (2DCE), 3-dechloroethylifosfamide (3DCE) and 4-hydroxyifosfamide 
(4OHIF) in 16 patients receiving 3 g/m²/24 hours ifosfamide i.v., either alone or in combination with 200 
mg ketoconazole bid (one day pre-treatment and three days concomitant administration) or 300 mg 
rifampicin bid (three days pre-treatment and three days concomitant administration). 
 
Discussion 
 
Although drug-drug interactions are generally avoided in pharmacotherapy, CYP interactions 
have also been used to increase therapeutic efficacy. For instance, the anti-retroviral drug 
ritonavir, an inhibitor of CYP3A4, is used to enhance efficacy of saquinavir anti-retroviral 
therapy by increasing the AUC of saquinavir 58-fold.[15] Cyclosporin is used to increase the 
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oral uptake of paclitaxel by CYP and P-glycoprotein interaction.[16] Modulation of ifosfamide 
metabolism may be used to decrease formation of the neurotoxic metabolite 
chloracetaldehyde and to increase exposure to 4-hydroxy-ifosfamide, which is a marker for 
anti-tumour activity. Modulation of the metabolism of ifosfamide in rats has been 
demonstrated with phenobarbital and dexamethasone, which are potent inducers of CYP2B 
and 3A in rats, respectively, and metyrapone, which is a potent inhibitor of CYP2B1 in rats.[17] 
Modulation of ifosfamide metabolism in humans has not yet been successful. In a study by 
Lokiec et al. modulation was not detected when ifosfamide was administered together with 
the inducer phenobarbital.[18] This failure could, however, be explained by the fact that 
enzyme induction by barbiturates typically requires several days to develop.[7] Therefore, the 
simultaneous administration of phenobarbital was not likely to result in hetero-induction of 
ifosfamide.  
In this study modulation of the CYP-mediated metabolism of ifosfamide was investigated by 
co-administration of ketoconazole and rifampicin in a double randomized, cross-over study in 
16 patients. In conventional schemes ifosfamide is administered as a continuous 24-hour 
infusion with a dosage  of 5 g/m².[1] In this study the dosage was decreased to 3 g/m² to 
prevent possible unacceptable neurotoxicity as a result from the co-administration of the 
modulators. A non-linear pharmacokinetic population model described the autoinducible 
pharmacokinetics of ifosfamide, 2- and 3-dechloroethyl-ifosfamide and 4-hydroxyifosfamide 
adequately. In this study conventional non-compartmental analysis of individual plasma 
concentration-time profiles did not allow accurate estimation of the metabolite elimination 
rates in all patients, due to insufficient data to accurately extrapolate the profiles to infinity. 
This was overcome by using a population pharmacokinetic approach, which allows the 
estimation of pharmacokinetic parameters when data are sparse.[19] 
In this study no ketoconazole or rifampicin concentrations were determined, but literature data 
suggested that co-administration at these dosages should have resulted in significant 
inhibition and induction of CYP3A4, respectively. Tsunoda et al. reported that after 200 mg 
ketoconazole orally twice daily for two days, plasma concentrations ranged between 0.15 and 
9.13 µM, which was well above the Ki of 0.01µM, thus resulting in complete inhibition of 
CYP3A4-mediated midazolam metabolism.[20] Administration of 300 mg rifampicin bid if given 
for at least 3 days, has been reported to produce CYP3A4 up-regulation in various clinical 
studies.[6] 
In our study ketoconazole decreased ifosfamide metabolism, as indicated by the decreased 
clearance and increased urinary excretion (table 1). Furthermore, it slightly decreased 
activation, as indicated by the decreased F*4ohif and AUC4ohif, and did not affect deactivation 
to 3-dechloroethylifosfamide. F*2dce and AUC2dce were slightly increased, which resulted in 
more urinary excretion (UE2dce). The latter difference was, however, not significant due to 
interindividual variability. Overall, only marginal influence of ketoconazole on exposure to 4-
hydroxyifosfamide and the dechloroethylated metabolites was observed. Rifampicin 
increased ifosfamide metabolism as indicated by an increased CLini,ifo and decreased AUC ifo 
and UEifo. For all metabolites both the fraction metabolized and elimination rates were 
increased. Exposure to 4-hydroxyifosfamide was not changed whereas exposure to the 
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dechloroethylated metabolites decreased. Surprisingly, UE of 2- and 3-
dechloroethylifosfamide was not decreased. This may indicate that renal clearance of 2- and 
3-dechloroethylifosfamide may increase with concomitant administration of rifampicin. 
In a recent preclinical study with isolated cytochrome P450 isoenzymes (cDNA supersomes) 
Huang et al. indicated that hydroxylation of ifosfamide is performed by CYP3A4 only, but 
dechloroethylation is performed by both CYP3A4 (70%) and CYP2B6 (30%).[21] The observed 
effects of ketoconazole in our study are in accordance with these preclinical findings. The 
fraction metabolized to 4-hydroxyifosfamide is inhibited, whereas the fractions metabolized to 
2- and 3-dechloroethylifosfamide are uninfluenced or slightly increased. This may indicate that 
CYP2B6 acts as an escape-pathway for the dechloroethylation of ifosfamide. Accordingly, no 
qualitative differences were observed for the effect of rifampicin on the fractions metabolized 
to 4-hydroxyifosfamide, 2- and 3-dechloroethylifosfamide. All were increased with 
concomitant administration of the inducer. It should be noted that the effect of rifampicin on 
F*4ohif was difficult to quantitate due to the observed high correlation between F
*
4ohif and K4ohif 
in the estimation procedure. Since 4-hydroxyifosfamide spontaneously decomposes no effect 
of rifampicin was expected on K4ohif. However, a 14-fold increase was observed, which can 
be explained by the observed correlation. Despite the increase of the fractions metabolized to 
2- and 3-dechloroethylifosfamide, their exposures were decreased due to increased 
elimination rates. This may indicate that metabolism of 2- and 3-dechloroethylifosfamide is 
induced by rifampicin as well. 
From a clinical point of view, it should be noted that activation was not increased by either 
ketoconazole or rifampicin; corresponding fractions metabolized to 4-hydroxyifosfamide 
decreased or were unaffected and exposure was not influenced. Development of 
neurotoxicity, caused by the formation of chloroacetaldehyde, may be reflected by the fraction 
metabolized to 2- and 3-dechloroethylifosfamide. No decrease of the fractions was observed 
with either ketoconazole or rifampicin. As a result neither ketoconazole or rifampicin can be 
expected to produce a more favourable toxicity-efficacy profile. Co-administration of 
ketoconazole should even be avoided due to decreased activation.  
The presented double-randomized cross-over study succeeded in establishing the effects of 
modulation of ifosfamide metabolism. Rifampicin increased metabolism of ifosfamide without 
specifically favouring the activation or deactivation route of ifosfamide. Ketoconazole 
decreased activation to 4-hydroxyifosfamide. Therefore, both ketoconazole and rifampicin co-
administration may result in a possible decreased therapeutic benefit of ifosfamide therapy. In 
conclusion, our pharmacokinetic study indicated that no therapeutic benefit may be gained in 
humans by modulation of ifosfamide therapy with rifampicin or ketoconazole. 
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Chapter 4.4 
 
 
 
 
 
 
Phase I and pharmacokinetic study of the 
combination of topotecan and ifosfamide 
administered intravenously every 3 weeks 
-interim analysis- 
 
 
 
 
Summary 
 
Objectives were to determine the maximum tolerated dose (MTD), dose-limiting toxicities 
(DLT), and pharmacokinetics of topotecan administered as a 30-minute intravenous (IV) 
infusion over five days in combination with a 1-hour i.v. infusion of ifosfamide for three 
consecutive days every three weeks. Patients with advanced malignancies refractory to 
standard therapy were entered into the study. The starting dose of topotecan was 0.4 
mg/m²/day x 5 days. Ifosfamide was administered at a fixed dose of 1.2 g/m²/day x 3 days. 
After identification of the MTD at the starting dose level, the topotecan administration was 
reduced from 5 to 3 days. Twenty-three patients received 89 treatment courses at topotecan 
dosages ranging from 0.4-1.2 mg/m²/day. Due to toxicities the schedule of topotecan 
administration was reduced from 5 to 3 days. The MTD has not yet been reached at the 3-
day schedule, because DLT was observed only in one out of three patients of the highest 
dose-level. Haematological toxicities were dose limiting. Neutropenia was the major toxicity. 
Thrombocytopenia and anaemia were rare. Non-haematological toxicities were relatively mild. 
Pharmacokinetics of topotecan and ifosfamide and metabolites were similar to those 
observed after single agent administration. Modest interpatient variability (range: 14-23%) and 
minor interoccasion variability (range: 6-13%) in topotecan and ifosfamide clearance was 
observed. A sigmoidal Emax model could be fit to the relationship between the areas under the 
plasma concentration-time curve (AUC) of topotecan lactone and total topotecan and the 
decrease in absolute neutrophil count. Partial responses were documented in three patients 
with ovarian cancer. The combination of (up to) 1.2 mg/m²/day topotecan administered as a 
30-minute i.v. infusion daily times 3 with 1.2 g/m²/day ifosfamide administered as a 1-hour i.v. 
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infusion daily times 3 every three weeks is feasible, although no MTD has been established, 
yet. Thus, no recommendation for phase II dosing can be made, yet. Topotecan and 
ifosfamide did not exhibit interactions in pharmacokinetics. Possible clinical benefit of this 
combination needs to be evaluated  in phase II/III studies. 
 
Introduction 
 
Topotecan (HycamtinÒ) is a semi-synthetic analogue of the alkaloid camptothecin that acts 
as a specific inhibitor of the nuclear enzyme topoisomerase-I.[1] Inhibition of this enzyme 
results in lethal DNA damage during transcription and replication. The E-ring lactone in the 
basic structure of topotecan is considered essential for the interaction with topoisomerase-I.[1] 
In vivo, rapid conversion of the active lactone to the inactive carboxylate form occurs. 
Topotecan is indicated for second-line treatment of advanced ovarian cancer or refractory 
small cell lung cancer and has demonstrated anti-tumour efficacy in non-small cell lung 
cancer, prostate cancer and colorectal cancer.[1] 
Ifosfamide (HoloxanÒ, IfexÒ) is an alkylating agent, which is indicated as third-line agent in the 
treatment of germ cell testicular cancer in combination with other chemotherapeutic agents. It 
is also used to treat cancers of the head and neck, breast, cervix, ovaries, soft tissue 
sarcoma, Ewing´s sarcoma, osteosarcoma, both Hodgkin´s and non-Hodgkin´s lymphomas, 
non-small cell lung cancer, acute lymphocytic leukaemia and neuroblastoma.[2] Ifosfamide is 
a prodrug, which needs to undergo activation by cytochrome P450-3A4 (CYP3A4) to 4-
hydroxyifosfamide. Intracellular spontaneous decomposition of 4-hydroxyifosfamide yields the 
ultimate alkylating metabolite ifosforamide mustard. Ifosfamide is deactivated to the non-
cytotoxic metabolites 2- and 3-dechloroethylifosfamide, yielding an equimolar amount of 
neurotoxic chloroacetaldehyde.[3] Ifosfamide metabolism is autoinducible.[4] 
In a phase I study with the combination topotecan and cyclophosphamide, an isomer of 
ifosfamide, synergism was suggested between alkylating agents and topoisomerase-I 
inhibitors.[5] It was proposed that DNA alkylation triggers DNA repair mechanisms, which may 
depend on topoisomerase-I. Ifosfamide was chosen as representative alkylator because it is 
associated with less haematological toxicity than cyclophosphamide.[2] 
These data led us to evaluate a chemotherapeutic regimen of topotecan in combination with 
ifosfamide. Aims of this phase I trial were to determine the MTD, DLT and the safety profile of 
the combination of daily 30-minute infusions of topotecan on days 1-5 followed by 1.2 g/m² 
ifosfamide administered as a 1-hour infusion daily on days 1-3 every 3 weeks in patients with 
advanced malignancies. Secondary aims were the assessment of the pharmacokinetics of 
topotecan and ifosfamide and its main metabolites when given in combination and 
documentation of any anti-tumour activity of this regimen.  
 
Patients and methods 
 
Eligibility criteria 
 
Eligibility criteria were histologically confirmed metastatic or locally advanced cancer, no 
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proven benefit of existing anti-cancer therapy, age between 18 and 75 years, World Health 
Organization (WHO) performance status £ 2, adequate bone marrow function (white blood 
cells (WBC) ³ 3.5 x 109/L, granulocytes ³ 1.5 x 109/L, platelets ³ 100 x 109/L, haemoglobin ³ 
6 mmol/L), adequate hepatic function (serum bilirubin £ 20 µmol/L, alanine-aminotransferase 
(ALAT), aspartate-aminotransferase (ASAT) and alkaline phosphatase (AP) £ 2 x the upper 
limit of the reference range or £ 5 x the upper limit of the reference range if the elevation was 
directly contributed to the presence of metastatic disease), adequate renal function (serum 
creatinine £ 120 µmol/L or creatinine clearance ³ 60 ml/min), evaluable disease and a life 
expectancy ³ 3 months. Exclusion criteria were breast feeding, pregnancy or inadequate 
contraceptive protection, drug, medication or alcohol abuse, treatment with an investigational 
drug £ 1 month prior to the study-entry, surgery, radiotherapy (except for analgesic 
indications) or chemotherapy (mitomycin C or nitrosoureas £ 1.5) £ 1 month prior to the 
study-entry, other diseases altering procedures of the trial, history of seizures or central 
nervous system disorders, severe intercurrent infection, serious uncontrolled concurrent 
medical or psychiatric disease, known hypersensitivity to ifosfamide or topotecan, prior 
treatment with ifosfamide or topotecan. The study protocol was approved by the Ethics 
Review Boards of the Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute and 
University Medical Center Utrecht. The trial was conducted in these two centres according to 
Good Clinical Practice and the current edition of the Declaration of Helsinki. Written informed 
consent was obtained from all patients entering the study. 
  
Toxicity and response evaluation 
 
Pre-treatment evaluation included a complete medical history and complete physical 
examination. Before each course, blood chemistry and haematological profiles were checked 
and urinalysis was performed. Complete blood cell counts and blood chemistry were 
repeated weekly. Electrocardiograms and tumour measurements (by physical examination, 
chest x-ray, other radiological investigations, or ultrasound) were performed every other cycle. 
All toxicities were graded according to the National Cancer Institute Common Toxicity Criteria 
(NCI-CTC).[6] DLTs were defined as any of the following events occurring during the first 
treatment cycle and attributable to either ifosfamide or topotecan: (1) grade IV neutropenia 
lasting ³ 7 days or of any duration associated with severe systemic infection requiring 
parental treatment, (2) febrile neutropenia, (3) grade III or IV thrombocytopenia with or without 
haemorrhagic complications, or (4) grade III or IV non-haematological toxicity excluding 
nausea/vomiting responsive to treatment, anorexia and alopecia. The MTD was defined as 
the dose at which ³ two out of three or ³ two out of six patients experienced DLT. The next 
lower dose level below the MTD was the recommended dose for phase II studies. Responses 
were determined according to the WHO criteria.[7] 
 
Dose escalation 
 
Doses of topotecan were escalated during the study. Starting dose was 0.4 mg/m²/day 
topotecan for 5 days by means of a 30-minute infusion. Escalation was planned with 0.2 
4           Chapter 4.4 
mg/m²/day increments per dose level. Ifosfamide was administered at a fixed dose of 1.2 
g/m²/day for 3 days by means of a 1-hour infusion. Ifosfamide was administered directly after 
the topotecan infusion. Upon identification of the MTD, the protocol was amended to reduce 
topotecan dosing from 5 to 3 days. Treatment cycles were repeated every 21 days, provided 
patients had sufficiently recovered from any drug-related toxicity associated with the previous 
course (non-haematological toxicity ³ 1, alopecia excluded, haemoglobin ³ 6 mmol/L and 
return of blood cell counts to ³ 1.5 x 109/L neutrophils and ³ 100 x 109/L platelets). Dose 
modifications of both ifosfamide and topotecan were made if poor subjective tolerance to 
treatment occurred. Neutrophils < 0.5 x 109/L associated with temperature ³ 38.5 °C or 
lasting longer ³ 7 days, neutrophils < 1.0 x 109/L lasting longer ³ 21 days, platelets < 50 x 
109/L or any non-haematological toxicity requiring a delay in treatment resulted in dose 
reduction of 25% and platelets < 25 x 109/L resulted in dose reduction of 50%. 
 
Drug administration 
 
Topotecan (HycamtinÒ) was supplied by SmithKline Beecham Farma (Rijswijk, The 
Netherlands) in vials containing topotecan HCl, equivalent to 5 mg of free base. Inactive 
ingredients were 60 mg mannitol and 25 mg tartaric acid. The content of each vial was 
reconstituted with 2 ml sterile water for injection. The appropriate dosage of the drug was 
diluted in 50 ml of 0.9% NaCl solution. Topotecan was administered through a peripheral 
venous access device using a syringe pump. Ifosfamide (HoloxanÒ) was supplied by Asta 
Medica BV (Diemen, The Netherlands) in vials containing 0.5, 1 or 2 g without excipients. 
Ifosfamide was diluted in 0.9 % NaCl to approximately 1 l and administered through a 
peripheral venous access device using an ambulatory infusion pump. 
 
Pharmacokinetic sampling 
 
Pharmacokinetic studies were performed for topotecan (total and lactone form), and 
ifosfamide and metabolites (2- and 3-dechloroethylifosfamide, 4-hydroxyifosfamide and 
ifosforamide mustard) during the first two treatment courses. Intravenous samples were 
drawn from an indwelling intravenous cannula placed in the arm contralateral to the arm 
receiving chemotherapy prior to the topotecan infusion and at the following time-points after 
start of the topotecan infusion: 15, 30 (prior to the end of the topotecan infusion), 60 and 90 
min (prior to the end of the ifosfamide infusion), and 2, 3, 4.5, 7.5, 11 and 24 hours (prior to 
the start of the following topotecan infusion). Pharmacokinetic sampling was executed 
according to this schedule on days 1 and 3 of cycle 1 and day 1 of cycle 2. Blood samples 
were immediately placed on ice water. The plasma was immediately separated by 
centrifugation at 1,000 g for 5 min at 4°C. For the analysis of topotecan lactone plasma 
protein precipitation was performed by adding 1 ml plasma to 2 ml cold methanol (-20°C). 
The sample was mixed on a whirl mixer for 10 sec. and centrifuged for 3 min at 1,000 g at 
4°C. The clear supernatant was transferred to a polypropylene tube and immediately stored at 
-70°C pending analysis. Furthermore, plasma was aliquoted in three 1-ml volumes. Two 
aliquots were used for 4-hydroxyifosfamide analysis after stabilization with semicarbazide and 
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one aliquot was used for ifosforamide mustard analysis after stabilization with semicarbazide 
and sodium chloride. The remaining plasma was aliquoted to two 0.5-ml volumes for analysis 
of ifosfamide, 2- and 3-dechloroethylifosfamide, and total topotecan. Urine was collected 
during the first course for 96 hours after the start of the ifosfamide infusion and an aliquot was 
analysed for ifosfamide, 2- and 3-dechloroethylifosfamide. Both plasma and urine samples 
were immediately stored at -70°C, pending analysis. Total topotecan (lactone plus 
carboxylate form) and the lactone form were determined separately using a high-performance 
liquid chromatographic (HPLC) system with fluorometric detection.[8] Gas chromatography 
with selective nitrogen-phosphorous detection was used for the determination of ifosfamide, 
2- and 3-dechloroethylifosfamide in urine and plasma.[9] Two separate HPLC methods were 
used for the determination of 4-hydroxyifosfamide and ifosforamide mustard 
concentrations.[10,11] 
 
Pharmacokinetic evaluation 
 
The pharmacokinetics of lactone and total topotecan were described with a two-compartment 
model, yielding clearance (CL, L· h-1), volume of distribution (V, L), volume of distribution at 
steady-state (Vss, L) and intercompartmental clearance (Q, L· h-1). The pharmacokinetics of 
ifosfamide and its main metabolites were described using an integrated non-linear model with 
autoinduction.[4,12,13] This model described the pharmacokinetics of ifosfamide with an initial 
clearance of ifosfamide (CLinit, L· h
-1) and a volume of distribution (Vifo, L), and autoinduction 
with a first-order rate constant for enzyme degradation/inactivation (Kenz,out,  h
-1) and an 
ifosfamide concentration at 50% of the maximum inhibition of enzyme degradation (IC50, µM). 
The induction half-life of the enzyme (t½,enz, h) was calculated by the ratio of ln(2) and Kenz,out. 
The pharmacokinetics of the metabolites were described with a ratio of the fraction of 
ifosfamide metabolized and the volume of distribution of that metabolite (Fm/Vm=F
*, L-1), an 
elimination rate constant (K, h-1) and a rate constant (F**) from 4-hydroxyifosfamide to 
ifosforamide mustard.[13] The exposure to a compound was described by the area under the 
plasma concentration-time curve (AUC). All pharmacokinetic models were fitted to the data 
from the individuals using the population pharmacokinetic programme NONMEM (Non-linear 
Mixed Effects Modelling, Version V).[14] The residual or intraindividual variability of the 
pharmacokinetics were described separately with a combined proportional and additive term. 
The interindividual variability of each pharmacokinetic parameter was estimated using a 
proportional error model. 
 
Pharmacokinetic-pharmacodynamic relationships 
  
Relationships between the AUC of lactone and total topotecan and myelosuppression were 
explored using scatter plots of the AUC versus the percentage decrease in absolute 
neutrophil count (ANC). The percentage decrease in blood cells was defined as: 
%100
count baseline
count nadircount baseline
decrease % ´-=  
The data were fit to a sigmoidal maximum effect (Emax) model, as described by the modified 
Hill equation[15]: 
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where Emax denotes the maximal effect that can be elicited, DE is a measure of drug 
exposure (i.e. AUC), DE50 represents the drug exposure associated with 50% of Emax, and g 
is the Hill-coefficient describing the sigmoidicity of the curve. Modelling was performed using 
S-PLUS (Professional release 1, Mathsoft Inc.) 
 
Results 
 
Patients 
 
At the cut-off date for the interim analysis (11 August, 2000) 23 patients have received 89 
courses at six dose levels. Patient characteristics are listed in table 1. The medium number 
of courses administered per patient was 4 (range 1 to 9). In three patients only one treatment 
course was administered because of rapid progressive disease. Two of these patients 
developed an ileus, one with septic shock and one with lethal intestinal bleeding, which toxicity 
was considered disease-related. Two courses were delayed in one patient at dose level 5 
(1.0 mg/m²/day x3) due to the occurrence of an ileus. 
 
Dose escalation 
 
All patients were assessable for toxicity during the first treatment course. Doses of topotecan 
were escalated according to the scheme depicted in table 2. Myelosuppression was the 
dose-limiting toxicity for the combination of topotecan and ifosfamide in this schedule (table 
3). At dose level 2 (topotecan 0.6 mg/m²/day x 5) one patient developed dose-limiting grade III 
thrombocytopenia, grade IV neutropenia and grade IV anaemia (due to intestinal bleeding) 
resulting in toxic death. 
 
Table 1. Patient characteristics 
 
Characteristic Number % 
Number of patients 23  
Male/female 3/20  
Age, years   
    Median 58  
    Range 37-75  
Performance status   
    0 7 30 
    1 13 57 
    2 3 13 
Primary tumour site   
    Colon 1 4 
    Cervix 1 4 
    Melanoma 1 4 
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    Ovarian 15 65 
    Gastric 1 4 
    Renal 1 4 
    NSCLC 2 9 
    NSCLC+colon 1 4 
Prior palliative chemotherapy 21 91 
Number of previous regimens   
    Median 1  
    Range 1-3  
Prior radiotherapy 3 13 
 
NSCLC=non-small cell lung cancer. 
 
Table 2. Topotecan dose escalation 
 
Dose level Number of patients Topotecan dose Total topotecan dose 
1 5 0.4 mg/m²/day x 5days  2.0 mg/m²  
2 3 (DLT in 1 of 3) 0.6 mg/m²/day x 5days  3.0 mg/m² 
3 6 0.6 mg/m²/day x 3days  1.8 mg/m² 
4 3 0.8 mg/m²/day x 3days  2.4 mg/m² 
5 3 1.0 mg/m²/day x 3days  3.0 mg/m² 
6 3 (DLT in 1 of 3) 1.2 mg/m²/day x 3days  3.6 mg/m² 
 
Accrual at dose level 2 was stopped and two additional patients were treated at dose level 1; 
no DLT was observed in these patients. To investigate further dose-intensification topotecan 
dosing was reduced from 5 to 3 days, yielding a total dose at level 3 similar to level 1. At dose 
level 3 only 5 courses of chemotherapy could be evaluated in the first three patients, because 
of the development of progressive disease. Therefore, it was decided to include 3 additional 
patients at level 3.  
Table 3. Haematological toxicities in 70 of 89 courses. 
 
Dose  Topotecan Number of  Number Anaemia* Neutropenia* Thrombocytopenia* 
level dose patients of 
courses 
Grade III Grade IV Grade III Grade IV Grade III Grade IV 
1 0.4 mg/m²x5d 5 20 0/1 0/0 1/1 0/2 0/0 0/0 
2 0.6 mg/m²x5d 3 10 0/0 1/1 0/0 2/4 1/1 0/0 
3 0.6 mg/m²x3d 6 17 0/0 0/0 0/6 2/4 0/0 0/0 
4 0.8 mg/m²x3d 3 8(21)** 0/0 0/0 0/1 1/3 0/0 0/0 
5 1.0 mg/m²x3d 3 7(10)** 0/1 0/0 0/1 3/5 0/0 0/0 
6 1.2 mg/m²x3d 3 8(10)** 0/0 0/0 0/0 2/6 1/1 0/0 
 
*number of patients developing toxicity in the 1st course/number of courses causing toxicity, **number of courses evaluated of total. 
 
Table 4. Nadir blood counts in 70 of 89 courses. 
 
    ANC (x109/L) Haemoglobin (mmol/L) Platelets (x109/L) 
Dose Topotecan Number of  Number 1st course All courses 1st course All courses 1st course All courses 
level dose patients of 
courses 
Median (range) Median (range) Median (range) Median (range) Median (range) Median (range) 
1 0.4 mg/m² x 5d 5 20 1.9 (0.7-3.5) 2.0 (0.4-3.5) 6.4 (4.4-7.1) 6.5 (1.2-5.9) 230 (99-403) 165 (99-445) 
2 0.6 mg/m² x 5d 3 10 0.4 (0.2-1.3) 1.0 (0.2-2.4) 5.6 (3.4-5.7) 5.7 (3.4-6.6) 79 (25-231) 212 (25-282) 
3 0.6 mg/m² x 3d 6 17 1.4 (0.1-3.7) 0.7 (0.04-4.0) 6.2 (5.9-7.0) 5.9 (5.0-7.3) 190 (125-283) 175 (78-283) 
4 0.8 mg/m² x 3d 3 8(21)** 2.1 (0.3-3.5) 1.0 (0.3-3.5) 6.1 (5.7-7.5) 6.7 (5.7-7.5) 176 (129-230) 235 (129-261) 
5 1.0 mg/m² x 3d 3 7(10)** 0.2 (0.1-0.3) 0.3 (0.1-0.7) 6.2 (5.5-6.8) 5.6 (4.0-6.8) 267 (193-269) 269 (130-399) 
6 1.2 mg/m² x 3d 3 8(10)** 0.1 (0.02-2.1) 0.2 (0.02-2.1) 5.6 (5.5-6.1) 5.6 (5.3-6.1) 71 (44-117) 107 (44-419) 
 
**number of courses evaluated of total. 
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Dose levels 4 and 5 were uneventful. At level 6 dose-limiting grade IV neutropenia 
accompanied by neutropenic fever for more than 7 days was observed in one out of three 
patients. Therefore another 3 patients will be entered at this level. 
 
Haematological toxicity 
 
Myelosuppression was the principal toxicity. Table 3 lists the frequency of the grade III and IV 
haematological toxicities during treatment course 1 and during all courses. A total of 70 of 89 
courses were evaluated so far involving all 23 patients. Overall, grade III thrombocytopenia 
(3%) and grade III (3%) and IV (1%) anaemia were rare. Grade IV anaemia was considered 
not related to the study drugs. Neutropenia grade III and IV occurred in 9 (13%) and 24 (34%) 
of all courses, respectively. Nine (10%) of all evaluable treatment courses were delayed for 
one week. Three patients had unresolved neutropenia at day 21, one patient had two 
episodes of ileus, one patient had two episodes of severe ascitis, and two courses were 
postponed upon patients’ request. Dose reductions due to neutropenia were performed in 12 
(17%) of 70 treatment courses involving five patients. At dose level 2 (0.6 mg/m²/day x5) one 
patient received two courses at 75% of the intended dose and another patient received four 
courses with topotecan for 3 days instead of 5 days. At dose level 3 one patient received one 
course at 75% of the intended topotecan dose. At dose level 6 one patient developed grade IV 
neutropenia with fever, which was resolved before start of the second course. However, the 
fever reoccurred during the second day of the second course. This prompted an early 
infusion discontinuation after the first day of the second course. At the same dose level 
another patient experienced DLT (grade III thrombocytopenia, grade IV neutropenia with 
neutropenic fever). Consequently, the dose of topotecan and ifosfamide was reduced by 25% 
in all subsequent courses in this patient. 
There was no indication of cumulative myelosuppression on repeated dosing, evidenced by 
similar or less prominent haemoglobin, neutrophil and platelet nadirs in later courses 
compared with the first course (table 4). The neutrophil nadir typically occurred between days 
7 and 14. Absolute neutrophil counts at dose level 2 (dose intensity 3.0 mg/m²) were 
comparable to dose level 5 and 6 (dose intensities 3.0 and 3.6 mg/m², respectively). A similar 
pattern was observed with the haemoglobin and platelets levels of dose levels 2 and 6. Most 
patients in the study received infusions of packed cells due to anaemia. 
 
Non-haematological toxicity 
 
Non-haematological toxicities were relatively mild and not dose-related. Thus far, a total of 20 
patients with 61 courses were evaluated for non-haematological toxicities. Nausea and/or 
vomiting grade III was observed in four (7%) courses involving three patients. Transient 
nausea and/or vomiting grade I or II was observed in 67% of the assessable courses and 
responded well to standard anti-emetics. Other treatment related gastrointestinal side effects 
of grade I or II included abdominal cramps (3%), constipation (48%) and anorexia (5%). In 
addition, one patient suffered from grade III diarrhoea. Fatigue grade III was observed in two 
(3%) courses in one patient and grade I or II in 21 (34%) courses. Fatigue grade II in two 
patients resulted in delay of treatment at the patients’ request. Fever grade III was observed in 
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one patient and grade II in 7 (11%) courses involving five patients. Asthenia grade III was 
observed in 3 (5%) courses involving three patients and grade I and II in another 12 (20%) 
courses. Alopecia grade I and II was observed in 16 (70%) patients without influence of dose. 
Peripheral neuropathy grade I was observed in 9 (15%) courses involving four patients, of 
which one patient (6 courses) had pre-existing neuropathy due to cisplatin pre-treatment. In 
one patient an episode of neuropathy grade II was suspected to be treatment-related, but in 
another patient an episode of grade III was not considered to be related, because of confirmed 
CNS metastases. One patient complained of mild dizziness. All toxicities including 
neuropathy were reversible and rapidly disappeared after therapy was stopped. 
Blood chemistry prior to treatment did not exceed reference values. Median creatinine 
clearance prior to treatment was 85 ml/min and ranged between 48 and 136 ml/min; this was 
unaltered prior to the second course. In one patient increased levels of AP, ASAT and ALAT 
(946, 103 and 132 U/L, respectively) were observed after the first course. Later, this patient 
was found to have an obstructed biliary tract due to tumour growth. Between course 1 and 2 a 
total of three and two patients had calcium and magnesium levels below the reference values 
of 2.2 and 0.7 µmol/L, respectively.  
 
Pharmacokinetics 
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Figure 1. A typical plasma concentration-time profile of total topotecan (solid markers) and topotecan 
lactone (open markers) of a patient receiving a 30-minute administration of 1.2 mg/m²/day topotecan for 
three consecutive days. 
 
Complete pharmacokinetic data sets were obtained in the first course of all 23 patients and in 
the second course of 17 patients. Typical plasma profiles of topotecan lactone and total 
topotecan of a patient receiving 1.2 mg/m²/day topotecan are displayed in figure 1.  
The lactone form was the predominant form during the infusion, but approximately 30 minutes 
after the end of the infusion the open-ring (carboxylate) form concentrations exceeded lactone 
levels. The mean (±sem) lactone-to-total topotecan ratio at the end of the infusion was 
0.74±0.02 (n=23). After the end of the infusion, lactone curves exhibited a bi-exponential 
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decay. The population pharmacokinetic parameters of topotecan lactone and total topotecan 
are listed in table 5.  
 
Table 5. Pharmacokinetics of topotecan lactone and total topotecan (lactone and carboxylate form) with 
their relative standard error of the mean (sem), interindividual variability (IIV), interoccasion variability 
(IOV) and residual variability (RV). 
 
  topotecan lactone total topotecan 
 Mean (±sem) IIV IOV RV Mean (±sem) IIV IOV RV 
CL (L· h-1) 65.7±3.0 14% 9%  24.4±1.4 23% 13%  
V (L) 27.9±1.1 22% -  16.5±2.5 40% -  
Vss (L) 123±5 13% -  77.0±3.0 15% -  
Q (L· h-1) 65.3±2.6 - -  112±13 60% -  
PE    14.% PE   12.8% 
AE (µM)    0.143 AE (µM)   0.406 
 
CL=clearance, V=volume of distribution of ifosfamide, Vss=volume of distribution at steady-state, 
Q=intercompartmental clearance, PE=proportional error, AE=additive error. 
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Figure 2. The relationship between the total topotecan dose (mg) per course and the area under the 
plasma concentration-time curve (AUC) of total topotecan (upper graph) and topotecan lactone (lower 
graph) in course 1 (solid marker) and 2 (open marker).  
 
Interindividual variability was only modest (14-60%). For the intercompartmental clearance of 
topotecan lactone inclusion of the interindividual variability in the pharmacokinetic model did 
not improve the fit. This should not be interpreted as an absence of interindividual variability in 
this parameter, but only that the concentration-time data did not contain sufficient information 
for the model to estimate it. Interoccasion variability in clearance of topotecan lactone and 
total topotecan was small with 9 and 13%, respectively. No interoccasion variability could be 
estimated for the other parameters. The relationship between the AUC of lactone and total 
topotecan with the absolute topotecan dose is represented in figure 2. 
Plasma concentration-time profiles of ifosfamide and its metabolites of a typical patient 
receiving 1.2 g/m²/day ifosfamide are presented in figure 3. A decrease in elimination half-life 
of ifosfamide was observed when comparing the mono-exponential decays on day 1 and 3, 
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due to the autoinduction of the ifosfamide metabolism. This effect was reset at the start of the 
next course. The population pharmacokinetic parameters of ifosfamide and its metabolites 
are listed in table 6. The concentration-time data did not allow estimation of IC50 and it was 
therefore fixed at 0.001 µM, which was far below the lower limit of quantification. Fixation of 
IC50 resulted in an adequate description of the development of autoinduction of the ifosfamide 
metabolism. Interindividual variability in ifosfamide pharmacokinetics was modest (14-22%) 
and somewhat larger for the metabolites (29-76%). Interoccasion variability of the initial 
clearance of ifosfamide was small (6%) and could not be estimated for the other parameters. 
Mean (±sem) urinary excretion of ifosfamide was 34.7±2.7% of the administered dose with 
17.8±2.2% as unchanged ifosfamide, 5.6±0.5% as 2-dechloroethylifosfamide and 11.2±0.9% 
as 3-dechloroethylifosfamide. 
Course 1
0.01
0.1
1
10
100
1000
0 24 48 72
Time (h)
C
o
n
c
. (
µ
M
)
Course 2
0.01
0.1
1
10
100
1000
0 24 48 72
Time (h)
C
o
n
c
. (
µ
M
)
IFO
2DCE
3DCE
4OHIF
IFM
 
Figure 3. Typical plasma concentration-time profiles of ifosfamide (IFO) 2-dechloroethylifosfamide 
(2DCE), 3-dechloroethylifosfamide (3DCE), 4-hydroxyifosfamide (4OHIF) and ifosforamide mustard (IFM) 
of a patient receiving a 1-hour infusion of 1.2 g/m²/day ifosfamide for three consecutive days with a 3-
week interval. 
 
Pharmacodynamics 
 
The correlations between the AUC for the lactone and total topotecan and the percentage 
decrease in neutrophils could adequately be described by sigmoidal Emax models (figure 4). 
Estimations for Emax, AUC50 and the Hill-coefficient of the four models are depicted in table 7. 
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Figure 4. The percentage decrease in absolute neutrophil count (ANC) versus the area under plasma 
concentration-time curve (AUC) of total (upper graph) and lactone (lower graph) topotecan during course 
1 (solid markers) and course 2 (open markers). The lines indicate the best fit of the data to the 
sigmoidal maximum effect pharmacodynamic model in course 1 (solid line) and course 2 (dashed line). 
 
Responses 
 
Eighteen patients were assessable for therapeutic activity. Eleven patients demonstrated 
stable disease and four patients progressive disease during treatment. Partial responses 
were documented in three patients heavily pre-treated for ovarian cancer. 
 
Table 6. Pharmacokinetics of ifosfamide (IF), 2-dechloroethylifosfamide (2DCE), 3-dechloroethylifosfamide (3DCE), 4-hydroxyifosfamide (4OHIF) and 
ifosforamide mustard (IFM) with their relative standard error of the mean (sem), interindividual variability (IIV), interoccasion variability (IOV) and residual 
variability (RV). 
 
 Ifosfamide  Deactivated metabolites  Activated metabolites 
 Mean (±sem) IIV IOV RV  Mean (±sem) IIV RV  Mean ± RE IIV RV 
CLinit (L/h) 3.52±0.18 22% 6%  F
*
2DCE (L
-1) 0.00406±0.00077  70%  F*4OHIF (L
-1) 0.147±0.013 43%  
VIFO (L) 32.3±1.0 14% -  K2DCE (h
-1) 0.118±0.021 27%  K4OHIF (h
-1) 73.8  -  
Kenz,out (h
-1) 0.0137±0.0012 20% -  AUC2DCE (µM· h) 0.861±0.132   AUC4OHIF (µM· h) 0.0482±0.0044   
t½,enz (h) 50.6    PE   0% PE   23.0% 
AUCIFO (µM· h) 4.67±0.27    AE (µM)   5.10 AE (µM)   0.274 
PE    14.3% F*3DCE (L
-1) 0.00633±0.00044 29%  F**IFM (h
-1) 0.56±0.36 -  
AE (µM)    4.51 K3DCE (h
-1) 0.0752±0.0038 -  KIFM (h
-1) 4.0±1.5 76%  
     AUC3DCE (µM· h) 2.04±0.13   AUCIFM (µM· h) 0.399±0.089   
     PE   17.3% PE   10.7% 
     AE (µM)   3.22 AE (µM)   4.50 
 
CLinit=initial ifosfamide clearance, VIFO=volume of distribution of ifosfamide, Kenz,out=first-order rate constant for enzyme degradation/inactivation, t½,enz=induction half-
life of the enzyme, AUC=area under the plasma concentration-time curve during the first course, PE=proportional error, AE=additive error, F*=ratio of fraction 
metabolized and volume of distribution of metabolite, K=first-order rate constant for metabolite elimination, F**=formation rate constant. 
 
Table 7. The estimated parameters of the relationship between the area under the plasma concentration-time curve (AUC) of lactone and total topotecan 
and the percentage decrease in absolute neutrophil count (ANC) in course 1 and 2 of 23 patients. 
 
 topotecan lactone total topotecan 
 Mean (±sem) Mean (±sem) 
 Course 1 Course 2 Course 1 Course 2 
Emax (%) 101±20 95±16 105±25 97±20 
AUC50 (µM) 95±12 98±9 239±48 243±36 
g 2.8±2.0 6.3±4.1 2.3±1.4 3.8±2.7 
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Emax=maximum effect on ANC, AUC50=topotecan AUC associated with 50% of Emax, g=Hill-coefficient 
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Discussion 
 
There are few anticancer agents that have significant therapeutic impact when used alone, 
particularly in the treatment of solid tumours. The single agent and combination therapy 
activities of topotecan and ifosfamide have been extensively studied.[1,2] Murren et al. 
proposed a synergistic cytotoxicity between topoisomerase-I inhibitors and alkylating 
agents.[5] Bioactivation of ifosfamide leads to the alkylating compound ifosforamide mustard, 
which possesses a high affinity for macromolecules such as DNA. DNA alkylation leads to 
cross-link formation finally resulting in cytotoxicity and cell death through apoptosis. DNA 
alkylation initiates DNA repair mechanisms. Topoisomerase-I may be involved in this 
machinery through unwinding of the DNA. However, at present its direct relationship to the 
cytotoxic events of ifosfamide is unclear. The suggested synergism encouraged us to 
evaluate the feasibility and safety profile of the combination topotecan with ifosfamide in 
cancer patients. 
Haematological toxicity, especially neutropenia was the dose-limiting toxicity for this 
combination. Topotecan could not be safely administered in the approved single agent (1.5 
mg/m²) daily times five schedule. Severe neutropenia and thrombocytopenia occurred at a 
dose of 0.6 mg/m2/day for 5 days. To investigate further dose intensification, topotecan 
dosing was reduced from 5 to 3 days. With the adjusted schedule, topotecan doses could be 
escalated to 1.2 mg/m2/day. The currently tested daily dose of 1.2 mg/m²/day topotecan in 
combination with 1.2 g/m²/day ifosfamide for three days resulted in DLT in one of three 
patients. Therefore, another three patients need to be included. 
The neutropenia was correlated with the dose-intensity of topotecan (table 3), which was also 
observed in previous studies.[16] Neutropenia is the most frequently observed toxicity 
associated with single agent topotecan. In phase II trials of single agent topotecan in adult 
patients with solid tumours receiving 30-minute infusions of 1.5-2.0 mg/m²/day for 5 days 
every 3 or 4 weeks, grade III to IV neutropenia was observed in 71 to 75% of all courses.[17,18] 
The haematological toxicity was generally of short duration, non-cumulative and manageable. 
Ifosfamide’s principal toxicity is also haematological, albeit less severe than its isomer 
cyclophosphamide. A WBC count < 3 x 109/L is expected in approximately 50% of patients 
and platelet counts < 100 x 109/L in 20% of patients treated with single agent ifosfamide at a 
dose of 1.2 g/m²/day for 5 days.[19] Their over-lapping toxicity profiles prevented escalation of 
topotecan in combination with ifosfamide, to a dose near the single agent MTD of 1.5 
mg/m2/day for 5 consecutive days.  
Bone marrow colony-stimulating factors (G-CSF) could potentially improve the tolerance to 
the combination regimen. However, preliminary results presented by Bienvenu et al. suggest 
the impact of G-CSF to be limited.[20] They recommended a dose of 1.0 mg/m²/day topotecan 
in combination with 1.5 g/m²/day ifosfamide both daily for three consecutive days with G-CSF 
support from days 5 to 12. 
Two episodes of grade III anaemia were observed in all courses, which were considered 
related to the study drugs. This is in accordance with the observation that significant anaemia 
occurred in 2-14% of all courses of phase II studies in patients receiving single agent 
topotecan at 1.5-2.0 mg/m²/day for 5 days.[17,18] 
Only two episodes of grade III thrombocytopenia were observed in our study. 
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Thrombocytopenia associated with single agent topotecan is rare and mainly reported after 
prolonged infusion schedules.[21] Severe thrombocytopenia was observed in 2-10% of all 
courses in the above mentioned phase II studies of the daily times 5 schedule.[17,18] 
All non-haematological toxicities were relatively mild, not dose-related and transient with 
nausea and/or vomiting, fatigue, constipation and alopecia being the most observed. These 
have been described before in phase II studies of single agent topotecan with similar 
incidence rates.[18] Peripheral neuropathy or paresthesia occurred rarely with topotecan 
treatment and a causal relationship is uncertain. The relatively high incidence of neuropathy in 
our study may be related to prior treatment with paclitaxel in 3 and cisplatin in 1 of 5 
patients.[22] None of the specific ifosfamide toxicities have been observed in this study, such 
as renal tubular abnormalities, haemorrhagic cystitis and encephalopathy.[2] 
Population pharmacokinetic parameters of topotecan were similar to previously reported 
parameter estimates obtained using a population approach and a standard two stage analysis 
after single agent administration of 0.5-2.0 mg/m² topotecan in the daily times 5 
schedule.[23,16,24] Metabolic interactions of topotecan with concomitantly administered 
ifosfamide were not anticipated, because topotecan metabolism to N-desmethyl-topotecan is 
only 0.4-3% of the dose.[21]  
Nephrotoxicity is frequently encountered with ifosfamide treatment. Since approximately 40% 
of topotecan is eliminated by the kidneys, ifosfamide-induced renal tubular damage could 
potentially alter the renal clearance of topotecan. In the current study no episodes of renal 
toxicity were observed. Creatinine clearance, an indicator of renal function, did not exceed 
reference values. In agreement with these clinical findings, plasma profiles of topotecan on 
days 2 and 3 were similar to those on day 1 indicating that ifosfamide co-administration at the 
applied dose regimen most likely does not interfere with topotecan clearance. However, an 
assessment of the urinary excretion of topotecan will be made to exclude decreased renal 
clearance of topotecan by ifosfamide. 
Population pharmacokinetic parameters of ifosfamide and metabolites were similar to those 
reported in a previous pharmacokinetic study using an identical model.[13] In another study 
high doses of ifosfamide (9-12 g/m2) were administered as single agent by a 72-hour 
continuous infusion.[4] A four-fold higher value for t½,enz was obtained in the current study. 
Furthermore, no IC50 could be estimated. This may be explained by the fact that estimation of 
autoinduction in a 1-hour infusion is inherently less feasible than in a 72-hour continuous 
infusion of ifosfamide. In conclusion, although the analysis is not fully complete topotecan and 
ifosfamide do not appear to interact pharmacokinetically in the studied combination regimen. 
The estimates for the parameters used to describe the sigmoidal Emax relationship of the 
pharmacokinetics and the myelosuppression were similar to previously reported values.[1] 
Warmerdam et al. reported an AUC50 and Hill-coefficient for total topotecan of 173 nM· h and 
1.8, respectively, after single agent topotecan (0.5-1.5 mg/m²/day x5).[16,25] No differences 
were observed in the estimates for the first and second course in the current study. This is in 
accordance with the observation that neutropenia is not cumulative. So far, dose escalation of 
topotecan only reached approximately 50% of the MTD of single agent treatment with 
topotecan. This indicates a considerable additive myelosuppressive effect of ifosfamide. 
However, no clear relationship between the exposure to the activated metabolites of 
ifosfamide (4-hydroxyifosfamide and ifosforamide mustard) and the myelosuppression was 
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observed. Preliminary investigations indicated that combined modelling of topotecan and 
ifosfamide do not result in an increased goodness-of-fit of the relationship with 
myelosuppression.  
It is concluded that the combination of topotecan and ifosfamide is feasible, although for the 3-
day schedule no MTD has yet been established. Both drugs demonstrated single agent 
pharmacokinetics without apparent mutual interactions. Possible clinical benefit of this 
combination needs to be evaluated in future trials. 
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Summary and conclusions 
 
Introduction 
 
Ifosfamide is an alkylating agent, which is used in the treatment of various types of malignant 
diseases in adults and childeren. Its use, however, can be accompanied by severe 
haematological, neuro- and nephrotoxicities. Since its development in the middle of the 
1960’s, most of its extensive metabolism has been elucidated. Ifosfamide is a prodrug, which 
needs to undergo activation by cytochrome P450-3A4 (CYP3A4) to 4-hydroxyifosfamide. 
Intracellular spontaneous decomposition of 4-hydroxyifosfamide yields the ultimate alkylating 
metabolite ifosforamide mustard. Ifosforamide mustard binds to DNA causing cross-links 
followed by apoptosis. Ifosfamide is deactivated to the non-cytotoxic metabolites 2- and 3-
dechloroethylifosfamide, yielding an equimolar amount of neurotoxic chloroacetaldehyde. 
Ifosfamide metabolism is autoinducible. In chapter 1 a review of the literature is given 
addressing key issues in the clinical pharmacology of ifosfamide and its metabolites. 
Understanding the relationship between plasma concentrations (pharmacokinetics) and effect 
(pharmacodynamics) is important for the rational development and the safe and effective use 
of every therapeutic agent. Since the efficacy and specific toxicities of the treatment with 
ifosfamide may be linked to its extensive metabolism, pharmacokinetic assessment of 
ifosfamide and its metabolites is of special interest in helping to explain the unpredictable 
chances of success and failure in ifosfamide treatment. To characterize the pharmacokinetic-
pharmacodynamic relationships and their variability adequately, studies in a representative 
population using a relatively large number of patients, are needed. However, for practical and 
ethical reasons extensive pharmacokinetic and pharmacodynamic studies in a large number 
of often critically ill patients are not possible. Therefore, there was a need for an approach 
with the help of which description of the relevant pharmacokinetic and pharmacodynamic 
relationships and of their variability is possible on the basis of sparse data (few data-points 
per patient) collected under unbalanced designs. Such a population approach will also allow 
therapeutic drug monitoring of ifosfamide, which can help in further tailoring ifosfamide 
treatment to the specific needs of the individual patient.  
The aims of the research described in this thesis were to develop bioanalytical methods for 
determination of ifosfamide and its metabolites, to build population pharmacokinetic models 
for these compounds and to apply thee techniques in various clinical studies on ifosfamide. 
 
Bioanalysis of ifosfamide and metabolites 
 
Assessment of the pharmacokinetics of ifosfamide and metabolites has long been impaired 
by the lack of reliable bioanalytical assays. The availability of high through-put bioanalytical 
methods for all relevant metabolites of ifosfamide is a prerequisite for the pharmacological 
evaluation of the drug in cancer patients. In chapter 2 several new analytical methods are 
described for the determination of ifosfamide and its main metabolites. Gas chromatography 
was used to determine ifosfamide and its deactivated metabolites (chapter 2.1). Knowledge 
of the pharmacokinetics of the deactivated metabolites 2- and 3-dechloroethylifosfamide is 
crucial for insight into the risk of central neurotoxicity during ifosfamide treatment. In a 
2           Chapter 5.1 
comparison between nitrogen-phosphorous detection and positive ion electron-impact ion-
trap mass spectrometry, the former proved to be superior in sensitivity, accuracy and 
precision. The main activated metabolites 4-hydroxyifosfamide (chapter 2.2) and  
ifosforamide mustard (chapter 2.3) were determined using two high-performance liquid 
chromatography assays. The limitation of the highly unstable character of these metabolites 
was addressed by derivatization creating stabile, UV-absorbing derivatives. All analytical 
methods proved to be specific, sensitive, accurate and precise, and could be employed in the 
analysis of patient samples in a hospital setting.  
The choice of the matrix for the pharmacokinetic assessment might be of importance, as 
literature previously indicated possible differences in metabolite distribution between plasma 
and erythrocytes. Consequently, drug concentration-time profiles in whole blood and plasma 
could differ, thereby yielding different values for the pharmacokinetic parameters. These data 
led us to investigate the in vitro and in vivo distribution of ifosfamide and its metabolites. 
These studies indicated that ifosfamide and its metabolites rapidly reach distribution 
equilibrium between erythrocytes and plasma, with ifosforamide mustard being the slowest 
(chapter 2.4). A strong parallelism in the erythrocyte and plasma concentration profiles was 
observed for all compounds, which indicates that no differences will arise in the assessment 
of pharmacokinetic parameters using either matrix. Thus, pharmacokinetic assessment using 
only plasma sampling can yield direct, accurate and relevant relationships with efficacy and 
toxicity of ifosfamide treated patients. 
 
Development of population pharmacokinetic models 
 
The development of improved bioanalytical assays allowed extensive pharmacokinetic 
assessment of ifosfamide and its metabolites. Pharmacokinetic assessment can identify key 
issues like population differences in pharmacokinetic parameters and the influence of dose 
and schedule of administration. A review of clinical pharmacokinetic studies on ifosfamide 
demonstrates that in most studies autoinduction has been observed (chapter 1). Although the 
mechanism of autoinduction is currently not completely understood, this phenomenon needed 
to be taken into account when establishing a pharmacokinetic model for ifosfamide and its 
metabolites. Development of these models was accelerated by using rich data populations.  
In a population of 15 patients with soft tissue sarcoma who received a 72-hour continuous 
infusion of ifosfamide, a non-linear population pharmacokinetic model was developed using 
non-linear mixed effect modelling (NONMEM). This model allowed quantification of the effect 
of autoinduction on the concentration-time profiles of ifosfamide with correlations between the 
ifosfamide plasma concentrations and the extent of the autoinduction (chapter 3.1).  
In order to determine whether this population pharmacokinetic model was adequate in 
describing the pharmacokinetics of ifosfamide, a comparison was made with two other 
structural models: one without autoinduction and one with a time-dependent development of 
autoinduction of ifosfamide (chapter 3.2). The comparison was made in a population of 14 
patients with small cell lung cancer who received a 1-hour intravenous infusion of ifosfamide 
daily for one or two days in combination with paclitaxel and carboplatin. Again, the model 
presented in chapter 3.1 described the concentration-time profiles of ifosfamide best. The 
Bayesian estimates of the pharmacokinetic parameters were used to describe the 
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pharmacokinetics of 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide. Dose-
fractionation over two days compared to one day resulted in increased metabolite formation, 
especially for 2-dechloroethylifosfamide, probably due to increased autoinduction.  
This effect of schedule was investigated further in a population pharmacokinetic study of all 
quantifiable analytes (chapter 2) in 56 patients, who were divided in three groups according to 
the length of ifosfamide infusion (chapter 3.3). The rate by which the autoinduction developed 
and the fractions metabolized to 2- and 3-dechloroethyl-ifosfamide were found to be 
significantly dependent on the infusion schedule. The observed differences in the parameters 
were, however, comparable to their interindividual variability and were, therefore, considered 
to be of minor clinical importance. Autoinduction caused a less than proportional increase in 
the area under the ifosfamide plasma concentration-time curve (measurement of exposure) 
and more than proportional increase in metabolite exposure with increasing ifosfamide dose. 
This study demonstrated that the duration of ifosfamide infusion influences the exposure to 
the parent and its metabolite 3-dechloroethylifosfamide. The observed dose and infusion 
duration dependency should be taken into account when the pharmacodynamics of different 
infusion schedules are evaluated. 
 
Clinical applications 
 
The developed pharmacokinetic population models (chapter 3) were valuable tools in the 
determination of the pharmacokinetic profiles of ifosfamide and its metabolites in various 
clinical studies on ifosfamide (chapter 4). Responses to ifosfamide treatment and toxicities 
vary to a great degree among patients. This variability might be explained by differences in 
pharmacokinetics. Characterising covariates which contribute to the variation in the 
pharmacokinetics is therefore of paramount importance. Therefore, the pharmacokinetics, 
relations between the pharmacokinetics and covariates and pharmacodynamics of ifosfamide 
and 2- and 3-dechloroethylifosfamide and 4-hydroxyifosfamide were assessed in a population 
of 20 patients with soft tissue sarcoma, who received ifosfamide administered as a 72-hour 
continuous intravenous infusion (chapter 4.1). The population pharmacokinetic model 
(according to chapter 3.1) was built in a sequential manner, starting with a covariate-free 
model and progressing to a covariate model with the aid of generalized additive modelling. 
The addition of the covariates weight, body surface area, albumin, serum creatinine, serum 
urea, alkaline phosphatase and lactate dehydrogenase improved the prediction errors of the 
model. Significant pharmacokinetic-pharmacodynamic relationships were observed between 
the exposure to 2- and 3-dechloroethylifosfamide and orientational disorder, a neurotoxic side-
effect. No pharmacokinetic-pharmacodynamic relationships between exposure to 4-
hydroxyifosfamide and haematological toxicities could be observed in this population.  
Children are a special population within the field of oncology. Only limited information is 
available on the pharmacokinetics of ifosfamide and its metabolites in paediatric patients, due 
to the ethical problems involved in these studies. We assessed the feasibility of a sparse data 
approach for the determination of the population pharmacokinetics of ifosfamide, 2- and 3-
dechloroethylifosfamide and 4-hydroxyifosfamide in 32 children treated with various 
schedules of single agent ifosfamide therapy against various malignant tumours (chapter 
4.2). A non-linear population pharmacokinetic model with linear development of autoinduction 
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was implemented. In chapter 3.2 this model proved less accurate in the description of the 
ifosfamide concentration-time profiles than the model presented in chapters 3.1 and 3.3. 
However, the more elaborate ifosfamide concentration dependent autoinduction model could 
not be applied in this sparse data population. Cross-validation by bootstrapping the data 
indicated accurate description of the population pharmacokinetic parameter without bias.  
Specific isoenzymes are responsible for ifosfamide metabolism; activation is mediated by 
CYP3A4 and deactivation by CYP3A4 and CYP2B6. Therefore, modulation of the metabolism 
of ifosfamide may lead to an improved efficacy/toxicity ratio. Modulation was investigated by 
co-administrating ketoconazole and rifampicin, a potent inhibitor of CYP3A4 and inducer of 
CYP3A4/2B6, respectively (chapter 4.3). In a double randomized, two-way cross-over study a 
total of 16 patients received ifosfamide either alone or in combination with ketoconazole or 
rifampicin. Pharmacokinetics were assessed using the models developed in chapter 3. 
Rifampicin increased metabolism of ifosfamide without specifically favouring the activation or 
deactivation route of ifosfamide. Ketoconazole decreased activation to 4-hydroxyifosfamide. 
Thus, disappointingly this pharmacokinetic study indicated that no therapeutic benefit may be 
gained by modulation of ifosfamide therapy with rifampicin or ketoconazole in humans.  
Commonly, chemotherapeutic agents are applied in combination-schedules in order to 
maximize the efficacy. The novel combination of ifosfamide and the topoisomerase I inhibitor 
topotecan was investigated in a phase I trial (chapter 4.4). Preliminary results indicate that the 
combination of topotecan administered as a 30-minute infusion daily times 3 with ifosfamide 
administered as a 1-hour infusion daily times 3 every three weeks to patients with advanced 
malignancies was feasible. Haematological toxicities were dose limiting. The maximum 
tolerated dose of topotecan has not yet been reached. The pharmacokinetics of topotecan 
and ifosfamide and its metabolites were similar to those observed after single agent 
administration suggesting that the drugs did not interact pharmacokinetically. Sigmoidal Emax 
models could be fit to the relationship between the areas under the plasma concentration-
time curve of topotecan lactone and total topotecan, and the decrease in absolute neutrophil 
count. Partial responses were documented in three patients with ovarian cancer. Possible 
clinical benefit of this combination needs to be evaluated  in phase II/III studies. 
 
Perspectives and final remarks 
 
Although ifosfamide has successfully been used for over 30 years in the treatment of various 
malignant diseases, there is still a need for understanding its variability in success and failure 
of treatment. Now that satisfactory bioanalytical methods and population pharmacokinetic 
models have been developed, the underlying mechanisms of this varibility may be better 
understood and a superior ifosfamide therapy may be developed, tailored to dosing-
requirements of the individual patient. Furthermore, as individuals differ from each other in 
their concentration-effect relationships, the implication of schedule dependence is that varying 
the administration pattern, for example the infusion duration, between individuals may prove to 
be as important as individualising the dose-size of ifosfamide. 
One of the remaining issues in the clinical pharmacology of ifosfamide is the firm 
establishment of pharmacokinetic-pharmacodynamic relationships that provide enough 
information for precise predictions of the clinical outcome of therapy based on the 
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pharmacokinetics of ifosfamide. Only if this requirement is met the further development of 
therapeutic drug monitoring and dose individualization of ifosfamide treatment will be possible. 
This thesis is the first step in that direction, but many more pieces of the puzzle need to be 
put together to achieve complete understanding of the extent and limitations of the clinical 
activity and toxicity of ifosfamide therapy. 
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Samenvatting en conclusies 
 
Introductie 
 
Ifosfamide is een alkylerend middel, dat toegepast wordt bij verschillende maligne 
aandoeningen bij zowel volwassenen als kinderen. Het gebruik van ifosfamide kan echter 
gepaard gaan met hematologische, neurologische en nefrologische neveneffecten. Ifosfamide 
is zelf niet actief en dient eerst door het cytochroom P450 (CYP) te worden omgezet in 4-
hydroxyifosfamide. Spontane intracellulaire degradatie van 4-hydroxyifosfamide levert de 
uiteindelijke alkylerende metaboliet: ifosforamide mosterd. Ifosforamide mosterd is in staat om 
covalent aan het DNA van de tumorcel te binden, resulterend in verstoring van de functies van 
het DNA en uiteindelijk celdood. Naast deze activatieroute wordt ifosfamide ook gedeactiveerd 
tot de metabolieten 2- and 3-dechloorethylifosfamide. Hierbij komt een equimolaire 
hoeveelheid neurotoxisch chlooracetaldehyde vrij. Het metabolisme van ifosfamide is 
autoinduceerbaar, hetgeen inhoudt dat het metabolisme toeneemt met toenemende 
ifosfamide blootstelling. In hoofdstuk 1 wordt een overzicht gegeven van de klinische 
farmacologie van ifosfamide en metabolieten.  
Kennis van het verband tussen de plasmaconcentraties (farmacokinetiek) en het effect 
(farmacodynamiek) is van belang voor een rationele ontwikkeling en een veilig en effectief 
gebruik van een chemotherapeuticum. De effectiviteit en specifieke bijwerkingen van de 
behandeling met ifosfamide kunnen worden teruggevoerd op het uitgebreide metabolisme. De 
beschrijving van de farmacokinetiek van ifosfamide en de metabolieten kan helpen de nu nog 
onvoorspelbare succeskans van ifosfamidebehandeling te verklaren. Hiervoor zijn studies 
met relatief grote aantallen patiënten nodig om de farmacokinetisch-farmacodynamische 
relaties en de variabiliteit daarin in kaart te brengen. Praktische en ethische bezwaren 
verhinderen echter dat er uitgebreid farmacologisch onderzoek kan worden gedaan in relatief 
grote populaties van vaak ernstig zieke patiënten. Daarom is er een dringende behoefte aan 
een methodiek die met slechts beperkte experimentele data per patiënt (een zogenaamde 
“sparse data approach”), verzameld onder ongecontroleerde omstandigheden, toch valide 
uitspraken kan doen over de relevante farmacokinetische en farmacodynamische relaties.  
Doelstellingen van het onderzoek beschreven in dit proefschrift waren de ontwikkeling van 
bioanalytische methodes voor de bepaling van ifosfamide en metabolieten, de ontwikkeling 
van populatie farmacokinetische modellen voor ifosfamide en metabolieten en het toepassen 
van de technieken in verschillende klinische studies.  
 
Bioanalyse van ifosfamide en metabolieten 
 
Bepaling van de farmacokinetiek van ifosfamide en metabolieten is lange tijd belemmerd door 
een gebrek aan betrouwbare bioanalytische methodes. Klinische evaluatie vereist dat in een 
korte tijd een grote hoeveelheid monsters kan worden bepaald. In het tweede hoofdstuk 
worden verschillende bioanalytische methodes gepresenteerd voor ifosfamide en haar 
belangrijkste metabolieten. Gaschromatografie werd gebruikt voor de bepaling van ifosfamide 
en de gedeactiveerde metabolieten 2- en 3-dechloorethylifosfamide (hoofdstuk 2.1). Kennis 
van de farmacokinetiek van de gedeactiveerde metabolieten is cruciaal in de vaststelling van 
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het risico op de ontwikkeling van neurotoxiciteit tijdens de behandeling met ifosfamide. In een 
vergelijking tussen selectieve stikstof-fosfordetectie en “positive ion electron-impact ion-trap” 
massaspectrometrie, bleek de eerste detectiemethode gevoeliger, nauwkeuriger en 
preciezer. De belangrijkste geactiveerde metabolieten 4-hydroxyifosfamide (hoofdstuk 2.2) en 
ifosforamide mosterd (hoofdstuk 2.3) werden bepaald met twee hoge-druk-
vloeistofchromatografische methodes. De beperkingen in kwantificeerbaarheid van deze 
instabiele verbindingen werden overwonnen door een derivatiseringsstap in te bouwen, 
waardoor een stabiel, UV-absorberend derivaat ontstond. Validatie van de drie methodes 
wees uit dat ze specifiek, gevoelig, nauwkeurig, precies en toepasbaar zijn voor de analyse 
van patiënten-monsters.  
Uit literatuurgegevens blijkt dat de keuze van de matrix waarin de farmacokinetiek bepaald 
wordt, mogelijkerwijs van belang kan zijn. Verschillen in de verdeling van de metabolieten 
tussen plasma en rode bloedcellen zouden als gevolg kunnen hebben dat de concentratie-tijd 
profielen van een therapeuticum verschillen in volbloed en plasma. Daarom onderzochten wij 
de in vitro en in vivo distributie van ifosfamide en metabolieten (hoofdstuk 2.4). Uit deze 
studies bleek dat ifosfamide en metabolieten zich snel verdelen tussen de rode bloedcellen 
en het plasma, waarbij ifosforamide mosterd de langzaamste bleek te zijn. De 
farmacokinetische profielen van alle verbindingen vertoonden sterk parallellisme in rode 
bloedcellen en plasma. Dit geeft aan dat er geen verschillen worden verwacht in de 
kwantificering van de farmacokinetische parameters met behulp van plasma of rode 
bloedcellen. 
 
Ontwikkeling van populatie farmacokinetische modellen  
 
De ontwikkeling van de bioanalytische assays stelt ons in staat om belangrijke onderwerpen 
te onderzoeken als populatieverschillen in farmacokinetiek en de invloed van het 
toedieningsschema. Uit de literatuur blijkt dat in de meeste farmacokinetische studies met 
ifosfamide het fenomeen autoinductie werd geobserveerd (hoofdstuk 1). Het 
werkingsmechanisme van autoinductie van ifosfamide is op dit moment nog niet volledig 
duidelijk. Door de grote invloed van dit fenomeen op de farmacokinetiek dient het echter wel 
opgenomen te worden in de ontwikkeling van een populatie farmacokinetisch model voor 
ifosfamide. De ontwikkeling van dit model kon versneld worden door gebruik te maken van 
groepen patiënten waarbij veel monsters per patiënt afgenomen waren. Dientengevolge werd 
een niet-lineair populatie farmacokinetisch model ontwikkeld in een groep van 15 patiënten 
met weke delen tumoren, die een 72-uurs continu infuus van ifosfamide ontvingen (hoofdstuk 
3.1). Met dit model kon het effect van de autoinductie op de concentratie-tijd profielen van 
ifosfamide worden bepaald. Hierbij werd gebruik gemaakt van het programma “non-linear 
mixed effect modelling” (NONMEM). Het model beschreef de autoinductie door de mate van 
ontwikkeling van de autoinductie af te laten hangen van de hoogte van de ifosfamide 
concentraties. 
Om de geschiktheid van dit model verder te valideren werd het vergeleken met twee andere 
modellen waarbij farmacokinetiek werd beschreven zonder autoinductie of met een 
tijdsafhankelijke ontwikkeling van autoinductie (hoofdstuk 3.2). De vergelijking werd gemaakt 
in een populatie van 14 patiënten met kleincellige longcarcinoom, die een 1-uurs intraveneus 
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infuus van ifosfamide ontvingen over 1 of 2 dagen in combinatie met paclitaxel en 
carboplatine. Opnieuw beschreef het model van hoofdstuk 3.1 de concentratie-tijd profielen 
van ifosfamide het beste. Bayesiaanse schattingen van de farmacokinetische parameters van 
ifosfamide werden gebruikt bij de beschrijving van de farmacokinetiek van 2- en 3-
dechloorethylifosfamide en 4-hydroxyifosfamide. Fractionering van de ifosfamide dosis over 2 
dagen in plaats van 1 dag resulteerde in toegenomen metabolietvorming. Dit was vooral het 
geval voor 2-dechloorethyl-ifosfamide. De toename kan verklaard worden door toegenomen 
autoinductie.  
Het effect van het toedieningsschema werd verder onderzocht in een populatie 
farmacokinetische studie van alle kwantificeerbare verbindingen (hoofdstuk 2) in drie groepen 
van in totaal 56 patiënten (hoofdstuk 3.3). De groepen waren ingedeeld naar lengte van de 
infuusduur: 1-4 uur, 24-72 uur en 96-240 uur. De snelheid waarmee de autoinductie zich 
ontwikkelde en de fracties van ifosfamide die tot 2- en 3-dechloorethylifosfamide werden 
omgezet waren significant afhankelijk van de infuusduur. De relatie werd echter als minder 
klinisch relevant beoordeeld, omdat de verschillen in dezelfde orde van grootte lagen als de 
interindividuele variabiliteit in deze parameters. Autoinductie resulteerde in een minder dan 
proportionele toename in de oppervlakte onder de plasma concentratie-tijd curve (een maat 
voor blootstelling) van ifosfamide en een meer dan proportionele toename aan metaboliet 
blootstelling bij hogere ifosfamide doseringen. Deze studie toonde verder aan dat de duur van 
het ifosfamide infuus de blootstelling aan ifosfamide en 3-dechloorethylifosfamide beïnvloedt. 
Bij de bestudering van de farmacodynamiek van ifosfamide moet rekening worden gehouden 
met deze dosis- en infuusduurafhankelijkheid van de farmacokinetiek.  
 
Klinische toepassingen 
 
De ontwikkelde populatie farmacokinetische modellen (hoofdstuk 3) waren waardevolle 
technieken bij de bepaling van de farmacokinetische profielen van ifosfamide en metabolieten 
in verschillende klinische studies (hoofdstuk 4). De kans op respons op de behandeling met 
ifosfamide, maar ook de kans op ernstige bijwerkingen verschilt enorm per patiënt. Deze 
variabiliteit zou verklaard kunnen worden door verschillen in de farmacokinetiek. Het is 
daarom van belang om mogelijke covariaten in kaart te brengen, die bijdragen aan de 
variabiliteit in farmacokinetiek. Derhalve werden de farmacokinetiek, de relaties tussen 
farmacokinetiek en covariaten en farmacodynamiek van ifosfamide, 2- en 3-
dechloorethylifosfamide en 4-hydroxyifosfamide bepaald in een populatie van 20 patiënten 
met weke delen tumoren, die een 72-uurs continue infuus van ifosfamide ontvingen 
(hoofdstuk 4.1). Het populatie farmacokinetisch model van hoofdstuk 3.1 werd verder 
uitgebreid door stapsgewijze toevoeging van covariaten tot een volledig covariatenmodel met 
behulp van de techniek “generalized additive modelling”. De toevoeging van de covariaten 
lichaamsgewicht, lichaamsoppervlakte, albumine, serum creatinine, serum ureum, alkalische 
fosfatase en lactaat dehydrogenase verbeterde de voorspelbaarheid van het model. Er 
werden significante farmacokinetisch-farmacodynamische relaties waargenomen tussen 2- 
en 3-dechloorethylifosfamide en oriëntatievermogen (een neurologische bijwerking). Er 
werden geen relaties gezien tussen 4-hydroxyifosfamide en de beenmergdepressie in deze 
populatie. 
Samenvatting en Conclusies  4 
Kinderen zijn een aparte groep binnen de oncologie. Door de praktische en ethische 
bezwaren tegen uitgebreide farmacokinetische bemonstering, is er slechts beperkte kennis 
over de farmacokinetiek van ifosfamide en metabolieten in de pediatrische populatie. Deze 
kennis is zeer gewenst voor de optimalisering van de ifosfamidebehandeling bij kinderen. 
Daarom onderzochten wij de mogelijkheid van een “sparse data approach” in de bepaling van 
de populatie farmacokinetiek van ifosfamide, 2- en 3-dechloorethylifosfamide en 4-
hydroxyifosfamide in 32 kinderen met verschillende typen maligne tumoren, die een grote 
verscheidenheid aan infuusschemata met ifosfamide ontvingen (hoofdstuk 4.2). Er werd een 
niet-lineair populatie farmacokinetisch model met een lineaire tijdafhankelijke ontwikkeling 
toegepast. Dit model bleek voorheen (hoofdstuk 3.2) inferieur aan een model met een 
ifosfamide concentratie-afhankelijke ontwikkeling van autoinductie (hoofdstuk 3.1). Dit laatste, 
meer complexe model kon echter niet worden gebruikt in deze populatie met beperkte 
informatie per individu. Kruisvalidatie met behulp van een zogenaamde “bootstrap” methode 
gaf aan dat de beschrijving van de farmacokinetische parameters adequaat en zonder bias 
was.  
Specifieke isoenzymen zijn verantwoordelijk voor de verschillende routes in het metabolisme 
van ifosfamide; CYP3A4 is verantwoordelijk voor de activatie- en CYP3A4 en 2B6 voor de 
deactivatieroute. Specifieke modulatie van het metabolisme zou kunnen leiden tot een 
verbetering van de verhouding tussen de effectiviteit en bijwerkingen van de behandeling. Een 
farmacokinetische evaluatie kan inzicht verschaffen in mogelijke metabole verschuivingen als 
gevolg van de modulatie. Modulatie werd onderzocht met behulp van het CYP3A4-remmende 
ketoconazol en de CYP3A4/2B6-inducerende rifampicine in een dubbel gerandomiseerde, 
cross-over studie in 16 patiënten, die ifosfamide monotherapie of in combinatie met 
ketoconazol of rifampicine ontvingen. Rifampicine verhoogde het metabolisme van ifosfamide 
zonder onderscheid te maken tussen de activatie- en deactivatieroute. Ketoconazol 
daarentegen verlaagde de activatie tot 4-hydroxyifosfamide. Dit impliceert derhalve dat de 
toediening van ketoconazol of rifampicine aan de ifosfamide behandeling mogelijk niet zal 
leiden tot een therapeutisch voordeel. 
Chemotherapeutica worden vaak gecombineerd om maximalisatie van de effectiviteit te 
bereiken. De nieuwe combinatie van ifosfamide met de topoisomerase I remmer topotecan 
werd onderzocht in een fase I studie (hoofdstuk 4.4). Uit voorlopige resultaten blijkt dat de 
combinatie van topotecan toegediend als 30-minuten infuus gedurende 3 dagen, met 
ifosfamide toegediend als 1-uurs infuus gedurende dezelfde 3 dagen, aan patiënten met 
vergevorderde maligniteiten haalbaar was. Hematologische bijwerkingen bleken dosis-
limiterend te zijn. De maximaal verdraagbare dosering van topotecan is echter nog niet 
vastgesteld. De farmacokinetiek van topotecan, ifosfamide en metabolieten was gelijk aan de 
farmacokinetiek na enkelvoudige toediening. Dit duidde op de afwezigheid van een 
farmacokinetische interactie van deze combinatie. De relatie tussen de blootstelling aan 
lacton en totaal topotecan en de afname in neutrofielen kon beschreven worden met 
sigmoïdale Emax modellen. Partiële responsen werden geobserveerd in drie patiënten met 
een ovariumcarcinoom. Mogelijke klinisch voordeel van deze combinatie dient nader te 
worden onderzocht in fase II en III studies. 
 
Perspectieven en afsluitende opmerkingen 
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Ondanks dat ifosfamide al meer dan dertig jaar succesvol wordt ingezet tegen verscheidene 
maligne aandoeningen, is er nog steeds behoefte aan kennis over de variabiliteit van het 
slagen of mislukken van de behandeling. Nu er afdoende bioanalytische methoden en 
populatie farmacokinetische modellen beschikbaar zijn kunnen de onderliggende 
mechanismen van deze variabiliteit beter begrepen worden. Dit kan resulteren in een 
verbeterde therapie van ifosfamide, die beter aansluit op de specifiek doseringsbehoefte van 
de individuele patiënt. Omdat patiënten verschillen in hun concentratie-effectrelaties, zullen de 
implicaties van de schema-afhankelijkheid van het metabolisme van ifosfamide misschien 
even belangrijk worden als de absolute doseringshoeveelheid.  
Op dit moment zijn de farmacokinetisch-farmacodynamische relaties van ifosfamide en 
metabolieten nog niet onomstotelijk vastgesteld. Daarnaast zullen deze relaties ook een 
voldoende mate van voorspelbaarheid moeten bevatten. Alleen dan kan de 
geneesmiddelbewaking en dosisindividualisatie van ifosfamide verder worden ontwikkeld. Dit 
proefschrift is de eerste stap in die richting, maar er zijn er nog vele nodig om alle 
mogelijkheden en onmogelijkheden van de behandeling met ifosfamide te begrijpen. 
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Het proefschrift: een eenvoudig verhaal 
 
Ifosfamide is een antikankermiddel dat reeds sinds de jaren ‘70 succesvol wordt ingezet 
in de strijd tegen diverse vormen van kanker bij zowel volwassenen als kinderen. 
Remming van de aanmaak van bloedcellen en bijwerkingen op het centrale zenuwstelsel 
en de nieren blijven echter ernstig beperkende factoren van de behandeling met 
ifosfamide. Het belang van een goede dosering is groot. Overdosering kan leiden tot 
ernstige bijwerkingen, maar onderdosering kan leiden tot falen van de therapie. De 
balans tussen bijwerkingen en succesvolle behandeling is moeilijk te bepalen en 
verschilt tussen patiënten enorm. Deze verschillen tussen de patiënten zijn deels te 
verklaren door verschillen in afbraak van het geneesmiddel in het lichaam. De ene 
patiënt breekt een geneesmiddel sneller af dan de andere patiënt. De verschillende 
afbraakprodukten van ifosfamide zijn verantwoordelijk voor de ernstige bijwerkingen, 
maar ook voor het kankerceldodend effect. Kennis van de afbraak van ifosfamide in het 
lichaam is van belang om tot een beter begrip te komen van de effecten van het 
kankerceldodend middel in het lichaam. Dit kan door zogenaamde bloedspiegel-
effectrelaties te beschrijven. Deze relaties kunnen de behandeld arts in staat stellen om 
aan de hand van de bloedspiegels van ifosfamide, uitspraken te doen over de te 
verwachten bijwerkingen, maar ook het mogelijke slagen van de therapie. Op basis van 
de bloedspiegels kan de dosis en het behandelschema meer op de individuele patiënt 
worden toegespitst. Het afnemen van veel bloedmonsters om deze relaties te 
beschrijven stuit echter op ethische bezwaren, want het is belastend en vermindert de 
kwaliteit van leven van de patiënt.  
In dit proefschrift zijn nieuwe methoden beschreven voor het meten en beschrijven van 
het bloedspiegelverloop van ifosfamide en metabolieten. Deze technieken zijn 
vervolgens gebruikt om o.a. het effect van de dosis en duur van het infuus, 
patiënteigenschappen als gewicht, lichaamsgrootte, lever- en nierfunctie en het effect 
van andere geneesmiddelen op het bloedspiegelverloop van ifosfamide en metabolieten 
vast te stellen. Het bloedspiegel-verloop in kinderen is vastgesteld met behulp van een 
zogenaamde groepsbenadering, waarbij slechts enkele bloedafnames per kind nodig 
waren. De optimale dosering van een combinatie van ifosfamide met een ander 
cytostaticum is onderzocht. De verworven kennis van het bloedspiegelverloop van 
ifosfamide en metabolieten kan bijdragen tot een beter op maat gemaakte therapie voor 
kankerpatiënten met minder kans op ernstige bijwerkingen en meer kans op een 
succesvolle behandeling. 
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Nawoord 
 
Als laatste een dankwoord gericht aan alle mensen die hebben bijgedragen aan het onderzoek 
beschreven in dit proefschrift. Dit werk was niet tot stand gekomen zonder de onbaatzuchtige 
bijdrage van de patiënten die hebben geparticipeerd in het onderzoek.  
Ik ben veel dank verschuldigd aan de toegewijde wetenschappers, laboranten, artsen, 
verpleegkundigen en andere medewerkers met wie ik in de afgelopen jaren heb 
samengewerkt. Jos Beijnen heeft als promotor mijn onderzoeksproject van a tot z begeleid en 
gedurende die periode mij altijd met raad en daad terzijde gestaan. Jouw feedback op het 
gebied van bioanalyse en farmacokinetiek heb ik altijd zeer gewaardeerd. Jan Schellens vervulde 
diezelfde rol in de kliniek. Jouw uitgebreide kennis van zaken heeft zeker tot de uiteindelijke 
kwaliteit van het klinisch onderzoek bijgedragen. Gedurende de tweede helft van mijn 
promotie werd dit begeleidingsteam uitgebreid met Ron Mathôt. Jouw eindeloze geduld voor 
het blijven schaven en bijvijlen van de populatiekinetiek-artikelen is bewonderenswaardig. Jij 
hebt de kwaliteit van deze artikelen naar een hoger niveau getild. Je hebt me geleerd dat er 
voor ieder NONMEM-probleem een oplossing is: simuleren! 
Naast mijn vaste begeleiders heb ik veel samengewerkt met een aantal artsen verspreid over 
Nederland. Deze samenwerking, het Dutch Ifosfamide Study Committee (DISC) werd 
geïnitieerd vanuit ASTA Medica met als drijvende kracht Pieter van Niel samen met Adri Knol 
en Edwin Klumper. Jullie niet aflatend enthousiasme voor de DISC heeft altijd zeer 
aanstekelijk gewerkt op de andere DISCers. De halfjaarlijkse overleggen waren dan ook van 
een hoog (culinair) gehalte. 
De andere DISCers wil ik bedanken voor jullie enthousiasme voor het mee opzetten en 
uitvoeren van de klinische studies. In willekeurige volgorde, noem ik Jan Keizer en Jan 
Ouwerkerk van het Leiden University Medical Center. Vanaf het begin af aan hebben jullie je 
vol ingezet om de klinische studie vlekkeloos te laten verlopen. Ik heb er veel van geleerd. De 
inzet van Jan de Kraker van het AMC/Emma Kinderziekenhuis wordt zeer gewaardeerd. De 
samenwerking met jou heeft ertoe geleid dat er baanbrekend onderzoek gedaan kon worden 
in een heel bijzondere populatie van patiënten. In het Academisch Ziekenhuis Maastricht werd 
een complexe cross-over studie verricht die opgezet was door Ruud van Rijswijk en 
uitgevoerd werd door Rob Jansen. Ik wil natuurlijk Myra Jansen niet vergeten, want jij was het 
logistieke wonder achter deze studie. Daarnaast wil ik John van Putten en Harry Groen van het 
Academisch Ziekenhuis Groningen bedanken voor hun bijdrage. Jullie nuchtere kijk op de zaken 
was vaak verhelderend. Ook in het Antoni van Leeuwenhoekhuis werden er studies verricht. De 
fase I studie van topotecan en ifosfamide loopt zelfs nu nog. Dit gebeurt in samenwerking met 
Gerard Groenewegen van het UMCU en de research-verpleegkundigen Martha Swart, Ria 
Dubbelman en Betty Ambaum. Ik bewonder jullie inzet voor de patiënten. Daarnaast ben ik 
dank verschuldigd aan alle verpleegkundigen en andere medewerkers van de 4de en 8ste 
etage van het AvL. Ze waren altijd bereid om te helpen, maar ook gewoon even te kletsen. 
“Zou jij een monster willen overnemen? Is het veel werk? Ja! Geen probleem, komt voor 
elkaar.” En dan kwam het ook voor elkaar. Jullie zijn de drijvende kracht achter de hoge 
kwaliteit van de zorg in het AvL. Uit al dat onderzoek kwam natuurlijk een stroom van data. De 
medewerkers van het trialbureau voelden zich daarin helemaal thuis. Jullie zijn nog niet van 
me af, maar alvast bedankt voor jullie inzet en toewijding. 
3 
Een groot gedeelte van mijn promotietijd heb ik op het Lab van de apotheek van het 
Slotervaart Ziekenhuis doorgebracht. Ik heb het altijd als een bijzonder prettige werkomgeving 
ervaren. Dit is volledig terug te voeren op de groep enthousiaste labgenoten. Iedereen heeft 
bijgedragen aan de prettige werksfeer, maar Roel, Hilde, Eric, Sindy en Matthijs wil ik speciaal 
noemen, omdat ze mij in mijn werk hebben bijgestaan. Niet alleen hadden jullie tips en wijze 
raad op het gebied van de bioanalyse ook waren jullie altijd bereid, al dan niet vrijwillig, naar 
mijn geklaag te luisteren als er weer eens een validatie-run was mislukt. De prettige 
werksfeer heb ik ook ervaren met de stagiaires Marie-José en Jamila. Ik hoop dat jullie net 
zoveel hebben geleerd als ik van onze samenwerking.  
Dan is er natuurlijk de onderzoeksvleugel. In de loop der jaren bestond de groep uit vele gezichten, maar 
altijd was de sfeer optimaal. Vier jaren van hard werken, maar toch netjes uitgebalanceerd met 
vermaak. Bedankt Agnes, Alwin, Astrid, Bastiaan, Bregt, Charlotte, Daniëlle, Desirée, Ellen, Esther, Carin, 
Jetske, Kristel, Liesbeth, Marjan, Marjolein, Mirjam, Mirte, Monique, Monique, Nadja, Richard, Rolf, Vinodh, 
Virginie en alle anderen die tijdelijk deze groep hebben aangevuld.  
Verder wil ik alle vrienden bedanken die zich tijdens het onderzoek persoonlijk betrokken 
voelden bij de daarmee gepaard gaande ups en downs. Mijn paranimfen Eric Verbeek en Dick Tulp 
bedank ik voor het telkens weer vragen of ze al iets moeten doen. Ik wil mijn zusje Alison en mijn moeder 
bedanken, die mij altijd gesteund hebben in wat ik wilde bereiken. Mijn vader was mijn 
inspirator, maar jullie mijn dagelijkse houvast. Het moederlijke advies heeft zich zelfs 
uitgestrekt tot het correcte taalgebruik in dit boekje.  
De meeste promovendi eindigen met het bedanken van hun “significant other”. Virginie, om 
jou voldoende te bedanken zou ik je ook bij de co-promotores, onderzoekers, labgenoten, 
kamergenoten en co-auteurs moeten bedanken. Je bent dit en nog veel meer voor mij geweest. 
Samen prikken in de kliniek, samen zondagmiddagen vortexen op het lab, samen artikelen nakijken en 
bediscussiëren: een unieke samenwerking met een uniek meisje, voor alles bedankt. 
 
